Intra-arterial treatment with 90Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital

International Nuclear Information System (INIS)

Lambert, Bieke; Mertens, Jeroen; Oltenfreiter, Ruth; Sturm, Emiel; Defreyne, Luc; Smeets, Peter; Troisi, Roberto; Vlierberghe, Hans van

2011-01-01

We report on our experience in terms of eligibility, safety, response and survival for treatment of hepatocellular carcinoma (HCC) with 90 Y microspheres. Secondly, we investigated the urinary excretion of 90 Y following treatment. We retrospectively reviewed all HCC patients referred to our department for 90 Y microsphere treatment. We recorded reasons for not proceeding to actual treatment. In case treatment was performed, we assessed the tolerance (Common Terminology Criteria for Adverse Events v3.0, CTCAE v3.0), the response [modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria] and long-term survival (Kaplan-Meier). The urinary excretion was estimated by 12-h urine collections post-injection for analysis in a gamma counter. Forty-three HCC patients were referred for radioembolization. Fourteen patients were excluded, mainly due to unfavourable 99m Tc-macroaggregated albumin (MAA) distribution. Twenty-nine patients were treated with 90 Y microspheres (TheraSphere, mean activity 2.17 GBq). In four patients severe clinical adverse events were encountered, however only in one case clearly related to the therapy. Twenty patients were assessable by mRECIST: complete response in 15%, partial response in 35%, stable disease in 30% and progression in 20% were observed. A median survival of 12.3 months (95% confidence interval 9.4-15.2) was estimated. Concerning the substudy on urinary excretion, only 0.0025% of the administered activity was excreted in the urine within the first 12 h following TheraSphere. Following a strict workup before admitting patients to radioembolization with TheraSphere, we found good clinical tolerance in the vast majority of patients. Radiological response assessment yielded an overall response rate of 50%, when evaluated early following treatment. Urine analysis showed consistently only low activities of 90 Y excreted in the urine. (orig.)

Intra-arterial treatment with {sup 90}Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital

Energy Technology Data Exchange (ETDEWEB)

Lambert, Bieke; Mertens, Jeroen; Oltenfreiter, Ruth [Ghent University Hospital, Department of Nuclear Medicine, Ghent (Belgium); Sturm, Emiel; Defreyne, Luc [Ghent University Hospital, Department of Vascular and Interventional Radiology, Ghent (Belgium); Smeets, Peter [Ghent University Hospital, Department of Radiology, Ghent (Belgium); Troisi, Roberto [Ghent University Hospital, Department of Hepatobiliary Surgery and Liver Transplantation, Ghent (Belgium); Vlierberghe, Hans van [Ghent University Hospital, Department of Gastroenterology and Hepatology, Ghent (Belgium)

2011-12-15

We report on our experience in terms of eligibility, safety, response and survival for treatment of hepatocellular carcinoma (HCC) with {sup 90}Y microspheres. Secondly, we investigated the urinary excretion of {sup 90}Y following treatment. We retrospectively reviewed all HCC patients referred to our department for {sup 90}Y microsphere treatment. We recorded reasons for not proceeding to actual treatment. In case treatment was performed, we assessed the tolerance (Common Terminology Criteria for Adverse Events v3.0, CTCAE v3.0), the response [modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria] and long-term survival (Kaplan-Meier). The urinary excretion was estimated by 12-h urine collections post-injection for analysis in a gamma counter. Forty-three HCC patients were referred for radioembolization. Fourteen patients were excluded, mainly due to unfavourable {sup 99m}Tc-macroaggregated albumin (MAA) distribution. Twenty-nine patients were treated with {sup 90}Y microspheres (TheraSphere, mean activity 2.17 GBq). In four patients severe clinical adverse events were encountered, however only in one case clearly related to the therapy. Twenty patients were assessable by mRECIST: complete response in 15%, partial response in 35%, stable disease in 30% and progression in 20% were observed. A median survival of 12.3 months (95% confidence interval 9.4-15.2) was estimated. Concerning the substudy on urinary excretion, only 0.0025% of the administered activity was excreted in the urine within the first 12 h following TheraSphere. Following a strict workup before admitting patients to radioembolization with TheraSphere, we found good clinical tolerance in the vast majority of patients. Radiological response assessment yielded an overall response rate of 50%, when evaluated early following treatment. Urine analysis showed consistently only low activities of {sup 90}Y excreted in the urine. (orig.)

Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review

Energy Technology Data Exchange (ETDEWEB)

Lee, Edward Wolfgang; Alanis, Lourdes [Division of Interventional Radiology, Department of Radiology, UCLA Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 (United States); Cho, Sung-Ki [Division of Interventional Radiology, Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351 (Korea, Republic of); Saab, Sammy [Division of Hepatology, Department of Medicine, Pfleger Liver Institute, University of California at Los Angeles, Los Angeles, CA 90024 (United States)

2016-11-01

Hepatocellular carcinoma is the most common primary liver cancer and it represents the majority of cancer-related deaths in the world. More than 70% of patients present at an advanced stage, beyond potentially curative options. Ytrrium-90 selective internal radiation therapy (Y90-SIRT) with glass microspheres is rapidly gaining acceptance as a potential therapy for intermediate and advanced stage primary hepatocellular carcinoma and liver metastases. The technique involves delivery of Y90 infused glass microspheres via the hepatic arterial blood flow to the appropriate tumor. The liver tumor receives a highly concentrated radiation dose while sparing the healthy liver parenchyma due to its preferential blood supply from portal venous blood. There are two commercially available devices: TheraSphere® and SIR-Spheres®. Although, Y90-SIRT with glass microspheres improves median survival in patients with intermediate and advanced hepatocellular carcinoma and has the potential to downstage hepatocellular carcinoma so that the selected candidates meet the transplantable criteria, it has not gained widespread acceptance due to the lack of large randomized controlled trials. Currently, there are various clinical trials investigating the use of Y90-SIRT with glass microspheres for treatment of hepatocellular carcinoma and the outcomes of these trials may result in the incorporation of Y90-SIRT with glass microspheres into the treatment guidelines as a standard therapy option for patients with intermediate and advanced stage hepatocellular carcinoma.

Yttrium-90 selective internal radiation therapy with glass microspheres for hepatocellular carcinoma: Current and updated literature review

International Nuclear Information System (INIS)

Lee, Edward Wolfgang; Alanic, Lourdes; Cho, Sung Ki; Saab, Sammy

2016-01-01

Hepatocellular carcinoma is the most common primary liver cancer and it represents the majority of cancer-related deaths in the world. More than 70% of patients present at an advanced stage, beyond potentially curative options. Ytrrium-90 selective internal radiation therapy (Y90-SIRT) with glass microspheres is rapidly gaining acceptance as a potential therapy for intermediate and advanced stage primary hepatocellular carcinoma and liver metastases. The technique involves delivery of Y90 infused glass microspheres via the hepatic arterial blood flow to the appropriate tumor. The liver tumor receives a highly concentrated radiation dose while sparing the healthy liver parenchyma due to its preferential blood supply from portal venous blood. There are two commercially available devices: TheraSphere® and SIR-Spheres®. Although, Y90-SIRT with glass microspheres improves median survival in patients with intermediate and advanced hepatocellular carcinoma and has the potential to downstage hepatocellular carcinoma so that the selected candidates meet the transplantable criteria, it has not gained widespread acceptance due to the lack of large randomized controlled trials. Currently, there are various clinical trials investigating the use of Y90-SIRT with glass microspheres for treatment of hepatocellular carcinoma and the outcomes of these trials may result in the incorporation of Y90-SIRT with glass microspheres into the treatment guidelines as a standard therapy option for patients with intermediate and advanced stage hepatocellular carcinoma

Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review

International Nuclear Information System (INIS)

Lee, Edward Wolfgang; Alanis, Lourdes; Cho, Sung-Ki; Saab, Sammy

2016-01-01

Hepatocellular carcinoma is the most common primary liver cancer and it represents the majority of cancer-related deaths in the world. More than 70% of patients present at an advanced stage, beyond potentially curative options. Ytrrium-90 selective internal radiation therapy (Y90-SIRT) with glass microspheres is rapidly gaining acceptance as a potential therapy for intermediate and advanced stage primary hepatocellular carcinoma and liver metastases. The technique involves delivery of Y90 infused glass microspheres via the hepatic arterial blood flow to the appropriate tumor. The liver tumor receives a highly concentrated radiation dose while sparing the healthy liver parenchyma due to its preferential blood supply from portal venous blood. There are two commercially available devices: TheraSphere® and SIR-Spheres®. Although, Y90-SIRT with glass microspheres improves median survival in patients with intermediate and advanced hepatocellular carcinoma and has the potential to downstage hepatocellular carcinoma so that the selected candidates meet the transplantable criteria, it has not gained widespread acceptance due to the lack of large randomized controlled trials. Currently, there are various clinical trials investigating the use of Y90-SIRT with glass microspheres for treatment of hepatocellular carcinoma and the outcomes of these trials may result in the incorporation of Y90-SIRT with glass microspheres into the treatment guidelines as a standard therapy option for patients with intermediate and advanced stage hepatocellular carcinoma

Yttrium-90 selective internal radiation therapy with glass microspheres for hepatocellular carcinoma: Current and updated literature review

Energy Technology Data Exchange (ETDEWEB)

Lee, Edward Wolfgang; Alanic, Lourdes [Div. of Interventional Radiology, Dept. of Radiology, UCLA Medical Center, David Geffen School of Medicine at UCLA, Los Angeles (United States); Cho, Sung Ki [Div. of Interventional Radiology, Dept. of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul (Korea, Republic of); Saab, Sammy [Div. of Hepatology, Dept. of Medicine, Pfleger Liver Institute, University of California at Los Angeles, Los Angeles (United States)

2016-07-15

Hepatocellular carcinoma is the most common primary liver cancer and it represents the majority of cancer-related deaths in the world. More than 70% of patients present at an advanced stage, beyond potentially curative options. Ytrrium-90 selective internal radiation therapy (Y90-SIRT) with glass microspheres is rapidly gaining acceptance as a potential therapy for intermediate and advanced stage primary hepatocellular carcinoma and liver metastases. The technique involves delivery of Y90 infused glass microspheres via the hepatic arterial blood flow to the appropriate tumor. The liver tumor receives a highly concentrated radiation dose while sparing the healthy liver parenchyma due to its preferential blood supply from portal venous blood. There are two commercially available devices: TheraSphere® and SIR-Spheres®. Although, Y90-SIRT with glass microspheres improves median survival in patients with intermediate and advanced hepatocellular carcinoma and has the potential to downstage hepatocellular carcinoma so that the selected candidates meet the transplantable criteria, it has not gained widespread acceptance due to the lack of large randomized controlled trials. Currently, there are various clinical trials investigating the use of Y90-SIRT with glass microspheres for treatment of hepatocellular carcinoma and the outcomes of these trials may result in the incorporation of Y90-SIRT with glass microspheres into the treatment guidelines as a standard therapy option for patients with intermediate and advanced stage hepatocellular carcinoma.

Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review.

Science.gov (United States)

Lee, Edward Wolfgang; Alanis, Lourdes; Cho, Sung-Ki; Saab, Sammy

2016-01-01

Hepatocellular carcinoma is the most common primary liver cancer and it represents the majority of cancer-related deaths in the world. More than 70% of patients present at an advanced stage, beyond potentially curative options. Ytrrium-90 selective internal radiation therapy (Y90-SIRT) with glass microspheres is rapidly gaining acceptance as a potential therapy for intermediate and advanced stage primary hepatocellular carcinoma and liver metastases. The technique involves delivery of Y90 infused glass microspheres via the hepatic arterial blood flow to the appropriate tumor. The liver tumor receives a highly concentrated radiation dose while sparing the healthy liver parenchyma due to its preferential blood supply from portal venous blood. There are two commercially available devices: TheraSphere® and SIR-Spheres®. Although, Y90-SIRT with glass microspheres improves median survival in patients with intermediate and advanced hepatocellular carcinoma and has the potential to downstage hepatocellular carcinoma so that the selected candidates meet the transplantable criteria, it has not gained widespread acceptance due to the lack of large randomized controlled trials. Currently, there are various clinical trials investigating the use of Y90-SIRT with glass microspheres for treatment of hepatocellular carcinoma and the outcomes of these trials may result in the incorporation of Y90-SIRT with glass microspheres into the treatment guidelines as a standard therapy option for patients with intermediate and advanced stage hepatocellular carcinoma.

Yttrium 90 microspheres for the treatment of hepatocellular carcinoma.

Science.gov (United States)

Memon, Khairuddin; Lewandowski, Robert J; Riaz, Ahsun; Salem, Riad

2013-01-01

Yttrium-90 microspheres are radioactive particles which are increasingly being employed for treating patients with unresectable hepatocellular carcinoma (HCC). The procedure is called radioembolization. It involves the injection of micron-sized embolic particles loaded with a radioisotope by use of transarterial techniques. Because of the sensitivity of liver parenchyma and relative insensitivity of tumor, external radiation has played a limited role in treating HCC. (90)Y administered via arterial route directs the highly concentrated radiation to the tumor while healthy liver parenchyma is relatively spared due to its preferential blood supply from portal venous blood. This technique has proven useful for the majority of patients with HCC as most of them present in advanced stage, beyond potentially curative options (resection/liver transplantation). (90)Y microspheres can be used in downstaging large tumors to bring within transplantable criteria, in patients with portal venous thrombosis due to tumor invasion and as palliative therapy. There are two available devices for (90)Y administration; TheraSphere® (glass based) and SIR-Spheres® (resin based). The procedure is performed on an outpatient basis. The incidence of complications is comparatively less and may include nausea, fatigue, abdominal pain, hepatic dysfunction, biliary injury, fibrosis, radiation pneumonitis, GI ulcers, and vascular injury; however, these can be avoided by meticulous pretreatment assessment, careful patient selection, and adequate dosimetry. This article explores the technical and clinical aspects of (90)Y radioembolization with keeping emphasis on patient selection, uses, and complications.

Yttrium-90 resin microspheres and their use in the treatment of intrahepatic cholangiocarcinoma.

Science.gov (United States)

Filippi, Luca; Schillaci, Orazio; Cianni, Roberto; Bagni, Oreste

2018-04-01

Intrahepatic cholangiocarcinoma (ICC) is a severe and rapidly progressive hepatic tumor. Surgery is often impracticable due to locally advanced presentation. On the other hand, chemotherapy has demonstrated only limited effectiveness. For these reasons, liver-directed therapies have been successfully applied for treating ICC. In particular, radioembolization with Yttrium-90 ( 90 Y)-labeled spheres has been reported to be a promising therapeutic approach for this neoplasia. Two commercial forms of 90 Y-labeled spheres are available: glass (TheraSphere ® ) and resin (SIR-Spheres ® ) microspheres. The aim of the present paper is to review the existing literature on the use of the resin microspheres for the treatment of unresectable and chemorefractory ICC, focusing on the methodology, clinical applications and side effects.

Personnel dose reduction in 90Y microspheres liver-directed radioembolization: from interventional radiology suite to patient ward.

Science.gov (United States)

Law, Martin; Wong, K K; Tso, W K; Lee, Victor; Luk, M Y; Tong, C C; Chu, Ferdinand

2017-03-01

To describe a method to reduce the external radiation exposure emitted from the patient after liver-directed radioembolization using 90 Y glass microspheres, to quantitatively estimate the occupational dose of medical personnel providing patient care to the patient radioembolized with the use of the method and to discuss radiation exposure to patients who are adjacent if the patient radioembolized needs hospitalization. A lead-lined blanket of lead equivalence of 0.5 mm was used to cover the patient abdomen immediately after the 90 Y radioembolization procedure, in order to reduce the radiation emitted from the patient. The interventional radiologist used a rod-type puncture site compressor for haemostasis to avoid direct contact with possible residual radioactivity at the puncture site. Dose rates were measured at the interventional radiologist chest and hand positions during puncture site pressing for haemostasis with and without the use of the blanket. The measurement results were applied to estimate the occupational dose of colleagues performing patient care to the patient radioembolized. The exposure to patients adjacent in the ward was estimated if the patient radioembolized was hospitalized. The radiation exposures measured at the radiologist chest and hand positions have been significantly reduced with the lead-lined blanket in place. The radiologist, performing puncture site pressing at the end of radioembolization procedure, would receive an average hand dose of 1.95 μSv and body dose under his own lead apron of 0.30 μSv for an average 90 Y microsphere radioactivity of 2.54 GBq. Other medical personnel, nurses and porters, would receive occupational doses corresponding to an hour of background radiation. If the patient radioembolized using 90 Y needs hospitalization in a common ward, using the lead-lined blanket to cover the abdomen of the patient and keeping a distance of 2 m from the patient who is adjacent would reduce the exposure by 0

Therapy with {sup 90}Y microspheres: radiation protection in new medical therapies; Terapia con microesferas de {sup 90}Y: proteccion radiologica en nuevas terapias medicas

Energy Technology Data Exchange (ETDEWEB)

Rojo, Ana; Puerta, Nancy, E-mail: arojo@arn.gob.ar [Autoridad Regulatoria Nuclear (ARN), Buenos Aires (Argentina)

2013-07-01

Primary liver cancer is one of the most frequent in the world and with a low cure rate. Radioembolization using 90y spheres is a promising treatment of this pathology and involves the percutaneous vascular application of radioisotope-labeled the order of Micron size particles. The advantages of this technique include the permit administered high doses of radiation to small volumes with low relative toxicity, offer the possibility of treating all the liver including microscopic tumors, and finally, the feasibility of combined with other therapies. Radiation protection in new medical therapies requires justification and optimization, as requirements for their implementation. The application of the principle of optimization in the context of the protection of the patient must be the minimum that it can be reasonably reached compatible with the required doses of treatment dose to healthy tissue. With {sup 90}Y microspheres therapy this optimization applies to the activity of 90y which is administered to the patient, and estimation methods are postulated. in this work are analyzed comparatively these methods, described the early physicists, equations and the limitations of each. Finally, it is concluded that the optimal method to be implemented for the evaluation of the activity of {sup 90}Y manage must be based in a voxel dosimetric model specific for each patient, however, the partitional method may be a good alternative if you don't have the tools to apply the method.

Process improvement for the safe delivery of multidisciplinary-executed treatments-A case in Y-90 microspheres therapy.

Science.gov (United States)

Cai, Bin; Altman, Michael B; Garcia-Ramirez, Jose; LaBrash, Jason; Goddu, S Murty; Mutic, Sasa; Parikh, Parag J; Olsen, Jeffrey R; Saad, Nael; Zoberi, Jacqueline E

To develop a safe and robust workflow for yttrium-90 (Y-90) radioembolization procedures in a multidisciplinary team environment. A generalized Define-Measure-Analyze-Improve-Control (DMAIC)-based approach to process improvement was applied to a Y-90 radioembolization workflow. In the first DMAIC cycle, events with the Y-90 workflow were defined and analyzed. To improve the workflow, a web-based interactive electronic white board (EWB) system was adopted as the central communication platform and information processing hub. The EWB-based Y-90 workflow then underwent a second DMAIC cycle. Out of 245 treatments, three misses that went undetected until treatment initiation were recorded over a period of 21 months, and root-cause-analysis was performed to determine causes of each incident and opportunities for improvement. The EWB-based Y-90 process was further improved via new rules to define reliable sources of information as inputs into the planning process, as well as new check points to ensure this information was communicated correctly throughout the process flow. After implementation of the revised EWB-based Y-90 workflow, after two DMAIC-like cycles, there were zero misses out of 153 patient treatments in 1 year. The DMAIC-based approach adopted here allowed the iterative development of a robust workflow to achieve an adaptable, event-minimizing planning process despite a complex setting which requires the participation of multiple teams for Y-90 microspheres therapy. Implementation of such a workflow using the EWB or similar platform with a DMAIC-based process improvement approach could be expanded to other treatment procedures, especially those requiring multidisciplinary management. Copyright © 2016 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Model-Based Radiation Dose Correction for Yttrium-90 Microsphere Treatment of Liver Tumors With Central Necrosis

International Nuclear Information System (INIS)

Liu, Ching-Sheng; Lin, Ko-Han; Lee, Rheun-Chuan; Tseng, Hsiou-Shan; Wang, Ling-Wei; Huang, Pin-I; Chao, Liung-Sheau; Chang, Cheng-Yen; Yen, Sang-Hue; Tung, Chuan-Jong; Wang, Syh-Jen; Oliver Wong, Ching-yee; Liu, Ren-Shyan

2011-01-01

Purpose: The objectives of this study were to model and calculate the absorbed fraction φ of energy emitted from yttrium-90 ( 90 Y) microsphere treatment of necrotic liver tumors. Methods and Materials: The tumor necrosis model was proposed for the calculation of φ over the spherical shell region. Two approaches, the semianalytic method and the probabilistic method, were adopted. In the former method, the range--energy relationship and the sampling of electron paths were applied to calculate the energy deposition within the target region, using the straight-ahead and continuous-slowing-down approximation (CSDA) method. In the latter method, the Monte Carlo PENELOPE code was used to verify results from the first method. Results: The fraction of energy, φ, absorbed from 90 Y by 1-cm thickness of tumor shell from microsphere distribution by CSDA with complete beta spectrum was 0.832 ± 0.001 and 0.833 ± 0.001 for smaller (r T = 5 cm) and larger (r T = 10 cm) tumors (where r is the radii of the tumor [T] and necrosis [N]). The fraction absorbed depended mainly on the thickness of the tumor necrosis configuration, rather than on tumor necrosis size. The maximal absorbed fraction φ that occurred in tumors without central necrosis for each size of tumor was different: 0.950 ± 0.000, and 0.975 ± 0.000 for smaller (r T = 5 cm) and larger (r T = 10 cm) tumors, respectively (p 90 Y microsphere treatment of hepatic tumors with central necrosis. With this model, important information is provided regarding the absorbed fraction applicable to clinical 90 Y microsphere treatment.

90Sr content in 90Y-labeled SIR-spheres and Zevalin.

Science.gov (United States)

Metyko, John; Erwin, William; Poston, John; Jimenez, Sandra

2014-11-01

Three different 90Y internally administered radionuclide therapies are currently used in both standard-of-care and clinical trial procedures atMD Anderson Cancer Center. TheraSphere and SIR-Spheres therapies utilize 90Y-labeled microspheres, while Zevalin is an 90Y-labeled radioimmunotherapeutic agent. Several publications have indicated radionuclidic impurities resulting from 90Y production methods. The 90Y in SIR-Spheres and Zevalin are produced from a 90Sr/90Y generator, which leaves measurable quantities of 90Sr in the final product. TheraSphere 90Y is produced in a nuclear reactor which results in a large number of impurities, most notably 88Y and 91Y. Product information sheets reference these impurities with specific limits given. These limits represent a tiny fraction of the total product activity, and in the case of TheraSphere and SIR-Spheres gamma-emitting impurities, this has been verified in the literature. An analysis of 90Sr impurities in SIR-Spheres and Zevalin is presented in this paper. Impurity quantities were found to be within the vendors’ documented limits.

Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival.

Science.gov (United States)

Salem, Riad; Lewandowski, Robert J; Atassi, Bassel; Gordon, Stuart C; Gates, Vanessa L; Barakat, Omar; Sergie, Ziad; Wong, Ching-Yee O; Thurston, Kenneth G

2005-12-01

To present safety and efficacy results obtained in treatment of a cohort of patients with unresectable hepatocellular carcinoma (HCC) with use of 90Y microspheres (TheraSphere). Forty-three consecutive patients with HCC were treated with 90Y microspheres over a 4-year period. Patients were treated by liver segment or lobe on one or more occasions based on tumor distribution, liver function, and vascular flow dynamics. Patients were followed for adverse events, objective tumor response, and survival. Patients were stratified into three risk groups according to method of treatment and risk stratification (group 0, segmental; group 1, lobar low-risk; group 2, lobar high-risk) and Okuda and Child-Pugh scoring systems. Based on follow-up data from 43 treated patients, 20 patients (47%) had an objective tumor response based on percent reduction in tumor size and 34 patients (79%) had a tumor response when percent reduction and/or tumor necrosis were used as a composite measure of tumor response. There was no statistical difference among the three risk groups with respect to tumor response. Survival times from date of diagnosis were different among the risk groups (P TheraSpheres) provides a safe and effective method of treatment for a broad spectrum of patients presenting with unresectable HCC. Further investigation is warranted.

Effects of hepatic arterial yttrium 90 glass microspheres in dogs.

Science.gov (United States)

Wollner, I; Knutsen, C; Smith, P; Prieskorn, D; Chrisp, C; Andrews, J; Juni, J; Warber, S; Klevering, J; Crudup, J

1988-04-01

A 22-micron glass microsphere called TheraSphere (Theragenics Corp., Atlanta, GA) has been developed in which yttrium 89 oxide is incorporated into the glass matrix and is activated by neutron bombardment to form the beta-emitting isotope yttrium 90 (Y 90) before using the spheres as radiotherapeutic vehicles. The injection of up to 12 times (on a liver weight basis) the anticipated human dose of nonradioactive TheraSphere into the hepatic arteries of dogs was well tolerated and produced clinically silent alterations within centrolobular areas. The hepatic arterial (HA) injection of radioactive TheraSphere also produced portal changes similar to those observed in humans after external beam therapy. While the extent of damage increased with the delivered dose, radiation exposures in excess of 30,000 cGy did not cause total hepatic necrosis and were compatible with survival. No microspheres distributed to the bone marrow and absolutely no myelosuppression was encountered in any animal. Proposed hepatic exposures to humans of 5000 to 10,000 cGy by means of these microspheres, therefore, would appear to be feasible and tolerable. Radiotherapeutic microsphere administration preceded by regional infusion of a radiosensitizing agent and/or immediately following the redistribution of blood flow toward intrahepatic tumor by vasoactive agents can potentially yield a synergistic, highly selective attack on tumors confined to the liver.

Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma

International Nuclear Information System (INIS)

Sangro, Bruno; Bilbao, Jose I.; Boan, Jose; Martinez-Cuesta, Antonio; Benito, Alberto; Rodriguez, Javier; Panizo, Angel; Gil, Belen; Inarrairaegui, Mercedes; Herrero, Ignacio; Quiroga, Jorge; Prieto, Jesus

2006-01-01

Purpose: To investigate the antitumor effect of resin microspheres loaded with 90-yttrium against hepatocellular carcinoma and their safety in the setting of liver cirrhosis. Patients and Methods: Data from 24 consecutive patients with hepatocellular carcinoma (HCC) treated by radioembolization in the period from September 2003 to February 2005 were reviewed. Patients received no further antineoplastic therapy. A comprehensive evaluation was performed to prevent the risk of damage due to microsphere misplacing. Patients were discharged the day after microspheres injection. Results: Serious liver toxicity observed among cirrhotic patients in a first period was subsequently prevented by modifying the selection criteria and the method for calculating the activity to be administered. Among 21 patients evaluable for response using Response Evaluation Criteria in Solid Tumors (RECIST) criteria, a reduction in size of target lesions was observed in all but 1 patient. When considering only target lesions, disease control rate and response rate were 100% and 23.8%, respectively. However, 43% of patients progressed in the liver in the form of new lesions appearing a median time of 3 months after radioembolization. Conclusion: Our experience in these series of patients indicates that radioembolization using resin microspheres has a significant antitumor effect against HCC and that using stringent selection criteria and conservative models for calculating Radiation activity to be administered, radioembolization can be performed safely even in cirrhotic patients

3D inpatient dose reconstruction from the PET-CT imaging of 90Y microspheres for metastatic cancer to the liver: feasibility study.

Science.gov (United States)

Fourkal, E; Veltchev, I; Lin, M; Koren, S; Meyer, J; Doss, M; Yu, J Q

2013-08-01

The introduction of radioembolization with microspheres represents a significant step forward in the treatment of patients with metastatic disease to the liver. This technique uses semiempirical formulae based on body surface area or liver and target volumes to calculate the required total activity for a given patient. However, this treatment modality lacks extremely important information, which is the three-dimensional (3D) dose delivered by microspheres to different organs after their administration. The absence of this information dramatically limits the clinical efficacy of this modality, specifically the predictive power of the treatment. Therefore, the aim of this study is to develop a 3D dose calculation technique that is based on the PET imaging of the infused microspheres. The Fluka Monte Carlo code was used to calculate the voxel dose kernel for 90Y source with voxel size equal to that of the PET scan. The measured PET activity distribution was converted to total activity distribution for the subsequent convolution with the voxel dose kernel to obtain the 3D dose distribution. In addition, dose-volume histograms were generated to analyze the dose to the tumor and critical structures. The 3D inpatient dose distribution can be reconstructed from the PET data of a patient scanned after the infusion of microspheres. A total of seven patients have been analyzed so far using the proposed reconstruction method. Four patients underwent treatment with SIR-Spheres for liver metastases from colorectal cancer and three patients were treated with Therasphere for hepatocellular cancer. A total of 14 target tumors were contoured on post-treatment PET-CT scans for dosimetric evaluation. Mean prescription activity was 1.7 GBq (range: 0.58-3.8 GBq). The resulting mean maximum measured dose to targets was 167 Gy (range: 71-311 Gy). Mean minimum dose to 70% of target (D70) was 68 Gy (range: 25-155 Gy). Mean minimum dose to 90% of target (D90) was 53 Gy (range: 13-125 Gy). A

Semi-quantitative analysis of post-transarterial radioembolization 90Y Microsphere position emission tomography combined with computed tomography (PET/CT) images in advance liver malignancy: Comparison with 99mTc macroaggregated albumin (MAA) single photon emission computed tomography (SPECT)

International Nuclear Information System (INIS)

Rhee, Seung Hong; Kim, Sung Eun; Cho, Jae Hyuk; Park, Ju Kyung; Kim, Yun Hwan; Choe, Jae Gol; Eo, Jae Seon; Park, So Yeon; Lee, Eun Sub

2016-01-01

The purpose of this study is to evaluate the correlation between pretreatment planning technetium-99m ( 99 mTc) macroaggregated albumin (MAA) SPECT images and posttreatment transarterial radioembolization (TARE) yttirum-90 ( 90 Y) PET/CT images by comparing the ratios of tumor-to-normal liver counts. Fifty-two patients with advanced hepatic malignancy who underwent 90 Y microsphere radioembolization from January 2010 to December 2012 were retrospectively reviewed. Patients had undergone 99 mTc MAA intraarterial injection SPECT for a pretreatment evaluation of microsphere distribution and therapy planning. After the administration of 90 Y microspheres, the patients underwent posttreatment 90 Y PET/CT within 24 h. For semiquantitative analysis, the tumor-to-normal uptake ratios in 90 Y PET/CT (TNR-yp) and 99 mTc MAA SPECT (TNR-ms) as well as the tumor volumes measured in angiographic CT were obtained and analyzed. The relationship of TNR-yp and TNR-ms was evaluated by Spearman's rank correlation and Wilcoxon's matched pairs test. In a total of 79 lesions of 52 patients, the distribution of microspheres was well demonstrated in both the SPECT and PET/CT images. A good correlation was observed of between TNR-ms and TNR-yp (rho value = 0.648, p < 0.001). The TNR-yp (median 2.78, interquartile range 2.43) tend to show significantly higher values than TNR-ms (median 2.49, interquartile range of 1.55) (p = 0.012). The TNR-yp showed weak correlation with tumor volume (rho = 0.230, p = 0.041). The 99mTc MAA SPECT showed a good correlation with 90 Y PET/CT in TNR values, suggesting that 99 mTc MAA can be used as an adequate pretreatment evaluation method. However, the 99 mTc MAA SPECT image consistently shows lower TNR values compared to 90Y PET/CT, which means the possibility of underestimation of tumorous uptake in the partition dosimetry model using 99 mTc MAA SPECT. Considering that 99 mTc MAA is the only clinically available surrogate marker

Yttrium-90 microspheres for the treatment of hepatocellular carcinoma.

Science.gov (United States)

Geschwind, Jean Francois H; Salem, Riad; Carr, Brian I; Soulen, Michael C; Thurston, Kenneth G; Goin, Kathleen A; Van Buskirk, Mark; Roberts, Carol A; Goin, James E

2004-11-01

Unresectable hepatocellular carcinoma is extremely difficult to treat. TheraSphere consists of yttrium-90 (a pure beta emitter) microspheres, which are injected into the hepatic arteries. This article reviews the safety and survival of patients with hepatocellular carcinoma who were treated with yttrium-90 microspheres. Eighty patients were selected from a database of 108 yttrium-90 microsphere-treated patients and were staged by using Child-Pugh, Okuda, and Cancer of the Liver Italian Program scoring systems. Patients were treated with local, regional, and whole-liver approaches. Survival from first treatment was analyzed with Kaplan-Meier and Cox regression methods. Adverse events and complications of treatment were coded by using the Southwest Oncology Group toxicity scoring system. Patients received liver doses ranging from 47 to 270 Gy. Thirty-two patients (40%) received more than 1 treatment. Survival correlated with pretreatment Cancer of the Liver Italian Program scores ( P = .002), as well as with the individual Cancer of the Liver Italian Program components, Child-Pugh class, alpha-fetoprotein levels, and percentage of tumor replacement. Patients classified as Okuda stage I (n = 54) and II (n = 26) had median survival durations and 1-year survival rates of 628 days and 63%, and 384 days and 51%, respectively ( P = .02). One patient died of liver failure judged as possibly related to treatment. Thus, in selected patients with hepatocellular carcinoma, yttrium-90 microsphere treatment is safe and well tolerated. On the basis of these results, a randomized controlled trial is warranted comparing yttrium-90 microsphere treatment with transarterial chemoembolization by using the Cancer of the Liver Italian Program system for prospective stratified randomization.

3D inpatient dose reconstruction from the PET-CT imaging of 90Y microspheres for metastatic cancer to the liver: Feasibility study

International Nuclear Information System (INIS)

Fourkal, E.; Veltchev, I.; Lin, M.; Meyer, J.; Koren, S.; Doss, M.; Yu, J. Q.

2013-01-01

Purpose: The introduction of radioembolization with microspheres represents a significant step forward in the treatment of patients with metastatic disease to the liver. This technique uses semiempirical formulae based on body surface area or liver and target volumes to calculate the required total activity for a given patient. However, this treatment modality lacks extremely important information, which is the three-dimensional (3D) dose delivered by microspheres to different organs after their administration. The absence of this information dramatically limits the clinical efficacy of this modality, specifically the predictive power of the treatment. Therefore, the aim of this study is to develop a 3D dose calculation technique that is based on the PET imaging of the infused microspheres.Methods: The Fluka Monte Carlo code was used to calculate the voxel dose kernel for 90 Y source with voxel size equal to that of the PET scan. The measured PET activity distribution was converted to total activity distribution for the subsequent convolution with the voxel dose kernel to obtain the 3D dose distribution. In addition, dose-volume histograms were generated to analyze the dose to the tumor and critical structures.Results: The 3D inpatient dose distribution can be reconstructed from the PET data of a patient scanned after the infusion of microspheres. A total of seven patients have been analyzed so far using the proposed reconstruction method. Four patients underwent treatment with SIR-Spheres for liver metastases from colorectal cancer and three patients were treated with Therasphere for hepatocellular cancer. A total of 14 target tumors were contoured on post-treatment PET-CT scans for dosimetric evaluation. Mean prescription activity was 1.7 GBq (range: 0.58–3.8 GBq). The resulting mean maximum measured dose to targets was 167 Gy (range: 71–311 Gy). Mean minimum dose to 70% of target (D70) was 68 Gy (range: 25–155 Gy). Mean minimum dose to 90% of target (D90

Radioactive impurities in radiopharmaceuticals with Y-90. Consequences for waste disposal; Radioaktive Verunreinigungen in Radiopharmazeutika mit Y-90. Konsequenzen fuer die Entsorgung von Reststoffen

Energy Technology Data Exchange (ETDEWEB)

Wanke, C.; Solle, A.; Geworski, L. [Medizinische Hochschule Hannover (Germany). Stabsstelle Strahlenschutz und Abt. Medizinische Physik

2016-07-01

Y-90 plays an important role in nuclear medicine and is of particular interest in radiation synovectomy (RSO) and in Selective internal radiation therapy (SIRT). Longer-lived impurities were investigated in a pharmaceutical used in RSO and in glass microspheres applied for SIRT. For this, measurements were carried out to identify gamma-emitting impurities. Especially in the late measurements, after decay of Y-90, impurities such as Y-88 and Y-91, Zn-65, Eu-152, Gd-153, Tb-160 und Yb-169 were identified, which accounted for less than 0,01 % of the total radioactivity at the calibration date, so that all pharmaceutical requirements were met. The impurities, however, have to be taken into account in waste management and clearance. Assuming typical masses, waste from RSO can undergo unrestricted clearance based on the clearance values tabulated in the German Radiation Protection Ordinance, provided sufficient decay storage. For waste from SIRT with glass microspheres, however, other clearance or disposal options have to be found.

3D inpatient dose reconstruction from the PET-CT imaging of {sup 90}Y microspheres for metastatic cancer to the liver: Feasibility study

Energy Technology Data Exchange (ETDEWEB)

Fourkal, E.; Veltchev, I.; Lin, M.; Meyer, J. [Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 (United States); Koren, S. [Department of Radiation Oncology, Beth Israel Comprehensive Cancer Center, New York, New York 10011 (United States); Doss, M.; Yu, J. Q. [Department of Diagnostic Imaging, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 (United States)

2013-08-15

Purpose: The introduction of radioembolization with microspheres represents a significant step forward in the treatment of patients with metastatic disease to the liver. This technique uses semiempirical formulae based on body surface area or liver and target volumes to calculate the required total activity for a given patient. However, this treatment modality lacks extremely important information, which is the three-dimensional (3D) dose delivered by microspheres to different organs after their administration. The absence of this information dramatically limits the clinical efficacy of this modality, specifically the predictive power of the treatment. Therefore, the aim of this study is to develop a 3D dose calculation technique that is based on the PET imaging of the infused microspheres.Methods: The Fluka Monte Carlo code was used to calculate the voxel dose kernel for {sup 90}Y source with voxel size equal to that of the PET scan. The measured PET activity distribution was converted to total activity distribution for the subsequent convolution with the voxel dose kernel to obtain the 3D dose distribution. In addition, dose-volume histograms were generated to analyze the dose to the tumor and critical structures.Results: The 3D inpatient dose distribution can be reconstructed from the PET data of a patient scanned after the infusion of microspheres. A total of seven patients have been analyzed so far using the proposed reconstruction method. Four patients underwent treatment with SIR-Spheres for liver metastases from colorectal cancer and three patients were treated with Therasphere for hepatocellular cancer. A total of 14 target tumors were contoured on post-treatment PET-CT scans for dosimetric evaluation. Mean prescription activity was 1.7 GBq (range: 0.58–3.8 GBq). The resulting mean maximum measured dose to targets was 167 Gy (range: 71–311 Gy). Mean minimum dose to 70% of target (D70) was 68 Gy (range: 25–155 Gy). Mean minimum dose to 90% of target

Semi-quantitative analysis of post-transarterial radioembolization {sup 90}Y Microsphere position emission tomography combined with computed tomography (PET/CT) images in advance liver malignancy: Comparison with {sup 99m}Tc macroaggregated albumin (MAA) single photon emission computed tomography (SPECT)

Energy Technology Data Exchange (ETDEWEB)

Rhee, Seung Hong; Kim, Sung Eun; Cho, Jae Hyuk; Park, Ju Kyung; Kim, Yun Hwan; Choe, Jae Gol [Korea University Anam Hospital, Seoul (Korea, Republic of); Eo, Jae Seon; Park, So Yeon; Lee, Eun Sub [Dept. of Nuclear Medicine, Korea University Guro Hospital, Seoul (Korea, Republic of)

2016-03-15

The purpose of this study is to evaluate the correlation between pretreatment planning technetium-99m ({sup 99}mTc) macroaggregated albumin (MAA) SPECT images and posttreatment transarterial radioembolization (TARE) yttirum-90 ({sup 90}Y) PET/CT images by comparing the ratios of tumor-to-normal liver counts. Fifty-two patients with advanced hepatic malignancy who underwent {sup 90}Y microsphere radioembolization from January 2010 to December 2012 were retrospectively reviewed. Patients had undergone {sup 99}mTc MAA intraarterial injection SPECT for a pretreatment evaluation of microsphere distribution and therapy planning. After the administration of {sup 90}Y microspheres, the patients underwent posttreatment {sup 90}Y PET/CT within 24 h. For semiquantitative analysis, the tumor-to-normal uptake ratios in {sup 90}Y PET/CT (TNR-yp) and {sup 99}mTc MAA SPECT (TNR-ms) as well as the tumor volumes measured in angiographic CT were obtained and analyzed. The relationship of TNR-yp and TNR-ms was evaluated by Spearman's rank correlation and Wilcoxon's matched pairs test. In a total of 79 lesions of 52 patients, the distribution of microspheres was well demonstrated in both the SPECT and PET/CT images. A good correlation was observed of between TNR-ms and TNR-yp (rho value = 0.648, p < 0.001). The TNR-yp (median 2.78, interquartile range 2.43) tend to show significantly higher values than TNR-ms (median 2.49, interquartile range of 1.55) (p = 0.012). The TNR-yp showed weak correlation with tumor volume (rho = 0.230, p = 0.041). The 99mTc MAA SPECT showed a good correlation with {sup 90}Y PET/CT in TNR values, suggesting that {sup 99}mTc MAA can be used as an adequate pretreatment evaluation method. However, the {sup 99}mTc MAA SPECT image consistently shows lower TNR values compared to 90Y PET/CT, which means the possibility of underestimation of tumorous uptake in the partition dosimetry model using {sup 99}mTc MAA SPECT. Considering that

Long-lived impurities of 90Y-labeled microspheres, TheraSphere and SIR-spheres, and the impact on patient dose and waste management.

Science.gov (United States)

Metyko, John; Williford, John M; Erwin, William; Poston, John; Jimenez, Sandra

2012-11-01

Yittrium-90 microsphere brachytherapy procedures have increased in number due to their efficacy in treating some unresectable metastatic liver tumors. The discovery of long-lived impurities in two microsphere products, first reported between 2006 and 2007, has resulted in some radiation safety concerns. Since then, microsphere production processes have been refined, which reportedly lead to a reduction in detectable by-products. In this study unused vials of TheraSphere and SIR-Spheres, manufactured in early January 2011, were analyzed to identify and quantify the low-level radioactive impurities. Absorbed dose calculations were performed to assess the potential increased dose to the patient due to long-lived impurities. Results showed that while the SIR-Spheres vials contained no detectable impurities (contrary to other published results in the literature), the TheraSphere vials contained 17 radionuclides in one sample and 15 in the other. The dominant impurities were Y and Y, with specific activities ranging from 0.99 ± 3.40 × 10 kBq mg to 6.30 ± 0.40 kBq mg at vendor assay date. Other impurities were on the order of Bq mg. Based on Medical Internal Radiation Dose (MIRD) liver and lung dose estimates, the long-lived impurities would be expected to increase an administered dose by less than 0.1% from the prescribed dose.

Patent hepatic falciform artery detected after Tc-99m-macroaggregated albumin injection on SPECT/CT prior to Yttrium-90 microsphere radioembolization: a case report

International Nuclear Information System (INIS)

Karaman, B.; Aslan, A.; Hamcan, S.; Ugurel, M.

2012-01-01

Full text: Introduction: Yttrium-90 (Y-90) microsphere radioembolization is increasingly used for the treatment of unresectable hepatocellular carcinoma and liver metastasis. Objectives and tasks: We aim to present the upper abdominal wall skin involvement detected during routine pre-therapy Technetium-99m-macroaggregated albumin (Tc-99m-MAA) on SPECT/CT due to patent hepatic falciform artery and the precautions to avoid this potential complication. Material and methods: 38-year-old male with colon cancer and multiple liver metastasis was evaluated prior to radioembolization and Tc-99 MAA was slowly hand injected at the bifurcation of the proper hepatic artery. Then, the SPECT/CT scan was performed in order to investigate the systemic shunt or gastric involvement. Results: On SPECT/CT scan, involvement of the upper abdominal wall through falciform ligament was seen. Re-evaluation of the hepatic angiogram identified a patent hepatic falciform artery arising from the left hepatic artery. Y-90 microspheres were slowly hand injected to the left hepatic artery superselectively and no extra-hepatic activity was seen on SPECT/CT scan. Conclusion: Upper abdominal pain and dermatitis are uncommon findings after radioembolization and may occur due to inadvertent delivery of Y-90 microspheres into patent hepatic falciform artery. To prevent these complications, either patent hepatic falciform artery must be embolized by coil or Y-90 injection must be performed superselectively

Temporary balloon occlusion of the common hepatic artery for administration of yttrium-90 resin microspheres in a patient with patent hepatoenteric collaterals.

Science.gov (United States)

Mahvash, Armeen; Zaer, Navid; Shaw, Colette; Chasen, Beth; Avritscher, Rony; Murthy, Ravi

2012-02-01

The most common serious complication of yttrium-90 ((90)Y) therapy is gastrointestinal ulceration caused by extrahepatic microsphere dispersion. The authors describe the use of a balloon catheter for temporary occlusion of the common hepatic artery to reverse hepatoenteric flow for lobar administration of resin microspheres when coil embolization of a retroportal artery was impossible. At 9 months after treatment, the patient had no gastrointestinal side effects and showed a partial response. Copyright © 2012 SIR. Published by Elsevier Inc. All rights reserved.

Comparison of the stability of Y-90-, Lu-177- and Ga-68- labeled human serum albumin microspheres (DOTA-HSAM)

Energy Technology Data Exchange (ETDEWEB)

Wunderlich, Gerd [Department of Nuclear Medicine, University Hospital, 01307 Dresden (Germany); Schiller, Eik, E-mail: eisc@rotop-pharmaka.d [ROTOP Pharmaka AG, 01454 Radeberg (Germany); Bergmann, Ralf; Pietzsch, Hans-Juergen [Forschungszentrum Dresden-Rossendorf, Institute of Radiopharmacy, P.O. Box 510119, 01314 Dresden (Germany)

2010-11-15

Introduction: Microparticles derived from denatured human serum albumin (DOTA-derivatized human serum albumin microspheres, or DOTA-HSAM) are attractive carriers of radionuclides for both therapeutic and diagnostic purposes. In this article, we describe a labeling procedure for diagnostic (Ga-68) and therapeutic (Y-90, Lu-177) radionuclides and report on the results of stability studies of these products. Methods: DOTA-HSAM was labeled in 0.5 M ammonium acetate buffer, pH 5.0, containing 0.02 mg/ml detergent. After adding the radionuclide, the mixture was shaken for 15 min at 90{sup o}C. Labeling yields and in vitro stability were determined by thin-layer chromatography. For determination of the in vivo stability of Ga-68 and Y-90 DOTA-HSAM, the particles were injected intravenously in Wistar rats. Results: Labeling yields up to 95% in the case of Ga-68 and Lu-177 were achieved. Ga-68-labeled DOTA-HSAM showed high in vitro and in vivo stability. The amount of particle-bound radioactivity of Lu-177 DOTA-HSAM declines slowly in a linear manner to approximately 72% after 13 days. For Y-90, the labeling yield decreased with increasing radioactivity level. We presume radiolysis as the reason for these findings. Conclusion: The labeling of DOTA-HSAM with different radionuclides is easy to perform. The radiation-induced cleavage of the labeled chelator together with the rather short half-life of radioactivity fixation in vivo (3.7 days) is, in our opinion, opposed to therapeutic applications of DOTA-HSAM. On the other hand, the high stability of Ga-68 DOTA-HSAM makes them an attractive candidate for the measurement of regional perfusion by PET.

Comparison of the stability of Y-90-, Lu-177- and Ga-68- labeled human serum albumin microspheres (DOTA-HSAM)

International Nuclear Information System (INIS)

Wunderlich, Gerd; Schiller, Eik; Bergmann, Ralf; Pietzsch, Hans-Juergen

2010-01-01

Introduction: Microparticles derived from denatured human serum albumin (DOTA-derivatized human serum albumin microspheres, or DOTA-HSAM) are attractive carriers of radionuclides for both therapeutic and diagnostic purposes. In this article, we describe a labeling procedure for diagnostic (Ga-68) and therapeutic (Y-90, Lu-177) radionuclides and report on the results of stability studies of these products. Methods: DOTA-HSAM was labeled in 0.5 M ammonium acetate buffer, pH 5.0, containing 0.02 mg/ml detergent. After adding the radionuclide, the mixture was shaken for 15 min at 90 o C. Labeling yields and in vitro stability were determined by thin-layer chromatography. For determination of the in vivo stability of Ga-68 and Y-90 DOTA-HSAM, the particles were injected intravenously in Wistar rats. Results: Labeling yields up to 95% in the case of Ga-68 and Lu-177 were achieved. Ga-68-labeled DOTA-HSAM showed high in vitro and in vivo stability. The amount of particle-bound radioactivity of Lu-177 DOTA-HSAM declines slowly in a linear manner to approximately 72% after 13 days. For Y-90, the labeling yield decreased with increasing radioactivity level. We presume radiolysis as the reason for these findings. Conclusion: The labeling of DOTA-HSAM with different radionuclides is easy to perform. The radiation-induced cleavage of the labeled chelator together with the rather short half-life of radioactivity fixation in vivo (3.7 days) is, in our opinion, opposed to therapeutic applications of DOTA-HSAM. On the other hand, the high stability of Ga-68 DOTA-HSAM makes them an attractive candidate for the measurement of regional perfusion by PET.

Booted selective internal radiation therapy (B-SIRT) using 90Y-loaded glass microspheres induces prolonged overall survival for PVT patients

International Nuclear Information System (INIS)

Garin, E.; Lenoir, L.; Edeline, J.; Laffont, S.; Mesbah, H.; Poree, P.; Boucher, E.; Rolland, Y.

2015-01-01

Full text of publication follows. Goal: evaluation of the response rate and survival of hepatocellular carcinoma PVT patients treated with Therasphere using the boost concept. Material and methods: Therasphere was administered in 40 PVT hepatocellular carcinoma patients (main = 11, lobar = 23, segmental = 6). MAA SPECT/CT quantitative analysis was used for the calculation of the tumour dose (TD), the healthy injected liver dose (HLD) and the injected liver dose (LD). Response was evaluated at 3 months using EASL criterion. OS was evaluated using Kaplan and Meyer tests. Results: Mean 90 Y-loaded microspheres injected activity was 3.1 ± 1.5 GBq. Mean LD was 143 ± 49 Gy. Median TD was 316 Gy for responding lesions versus 133 Gy for non responding lesion (p<0.0001). With a threshold TD of 205 Gy, MAA-SPECT/CT was predictive of response with a sensibility of 100%, and an overall accuracy of 90% (0FN, 4FP). Knowing the TD and the HLD, 40% of the patients received an intensification of the treatment (increase of the injected activity with the goal to achieve a TD> 205 Gy with a LD > 150 Gy and a HLD<120 Gy) with a good response rate (81%) and without increased liver grade III toxicity (6.2% as against 12.5% in the non boosted patients, ns). 6 patients were put aside, 5 received a lobar hepatectomy. Median OS was 18.2 months [12-27]. It was 4 m [12-27] for patients with a TD < 205 Gy versus 21.5 m [12-28.5] for patients with a TD > 205 Gy. OS was 12 m [3-∞] for patients with main PVT versus 21.5 m [12-28.7] for patients segmental or lobar PVT (ns). Finally Os was 23.2 m for patients with a TD > 205 Gy and a good PVT targeting (n = 34). Conclusion: boosted selective internal radiation therapy using 90 Y-loaded glass microspheres induces prolonged overall survival for PVT patients without increasing liver toxicity. (authors)

Gastric injury from 90Y to left hepatic lobe tumors adjacent to the stomach: fact or fiction?

International Nuclear Information System (INIS)

Gates, Vanessa L.; Hickey, Ryan; Marshall, Karen; Williams, Melissa; Salzig, Krystina; Lewandowski, Robert J.; Salem, Riad

2015-01-01

Radioembolization with 90 Y microspheres is a locoregional radiation therapy for unresectable hepatic neoplasm. Non-target delivery of 90 Y microspheres resulting in gastrointestinal (GI) symptoms is a recognized complication; there is minimal knowledge regarding the radiation effect to the gastric wall from left hepatic lobe 90 Y treatments. Our aim was to study the incidence of GI complications when the target tissue (hepatic parenchyma ± tumor) is in close proximity to the gastric wall. We hypothesized that liver (tumor) to stomach proximity does not correlate with increased toxicity. Between November 2011 and September 2013, we studied all patients who underwent left lobe radioembolization with 90 Y glass microspheres. With Institutional Review Board (IRB) approval, we retrospectively reviewed MRI/CT images of these patients, identifying a subset of patients with the left hepatic lobe <1 cm from the gastric wall. Patients were seen in clinic 1 month posttreatment and subsequently at 3-month intervals. Short- and long-term gastric adverse events were tabulated. Ninety-seven patients successfully underwent left hepatic lobe 90 Y microsphere radioembolization in which the average distance from the liver to the stomach wall was 1.0 ± 2.8 mm. The average dose for patients who received radioembolization to the left hepatic lobe was 109 ± 57 Gy. Fifty patients had tumor within 1 cm of the gastric wall. The average dose for patients who received radioembolization to the left hepatic lobe with tumor within 1 cm of the gastric wall was 121 ± 41 Gy. There were no reportable or recordable medical events. Of the patients, 34 % reported abdominal pain that was grade 1-2; 65 % of the patients reported no abdominal pain. None of the 97 patients developed a clinically evident GI ulcer. Patients with left lobe tumors adjacent to or abutting the stomach do not exhibit acute or chronic radiation effects following radioembolization with glass microspheres. (orig.)

Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver.

Science.gov (United States)

Lewandowski, Robert J; Salem, Riad

2006-03-01

Yttrium-90 ((90)Y) radioembolization is a catheter-based therapy that delivers internal radiation to hepatic tumors in the form of microspheres. (90)Y can be delivered to the hepatic tumor as either a constituent of a glass microsphere, TheraSphere(®), or as a biocompatible resin-based microsphere, SIR-Spheres(®). Once embedded within the tumor microcirculation, these microspheres emit β-radiation at therapeutic levels. While the technical aspects of radioembolization are quite complex, the collective clinical experience presented in the literature supports the use of (90)Y radioembolization for unresectable hepatic malignancies.

Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation.

Science.gov (United States)

Kulik, Laura M; Atassi, Bassel; van Holsbeeck, Lodewijk; Souman, Tameem; Lewandowski, Robert J; Mulcahy, Mary F; Hunter, Russell D; Nemcek, Albert A; Abecassis, Michael M; Haines, Kenneth G; Salem, Riad

2006-12-01

To present the clinical data of 35 patients with T3 unresectable hepatocellular carcinoma (HCC) that were treated with (90)Y with the specific intent of downstaging to resection, radiofrequency ablation (RFA) candidate, United Network for Organ Sharing (UNOS) stage T2 or liver transplantation. One hundred fifty patients with unresectable HCC were treated with (90)Y microspheres. Of these, 35 patients were UNOS stage T3 at the time of treatment. Patients were followed for clinical toxicities, alterations in model for end-stage-liver disease (MELD) score, tumor response, downstaging to RFA, resection, transplantation, and survival. Nineteen of 34 patients (56%) were successfully downstaged from T3 to T2 following treatment. 11 of 34 (32%) patients treated were downstaged to target lesions measuring 3.0 cm or less. Twenty-three of 35 (66%) were downstaged to either T2 status, lesion < 3.0 cm (RFA candidate), or resection. Seventeen of 34 (50%) had an objective tumor response by WHO criteria. Eight patients (23%) were successfully downstaged and underwent OLT following treatment. 1, 2, and 3-year survival was 84%, 54%, and 27%, respectively. Median survival by Kaplan-Meier analysis for the entire cohort was 800 days. These data suggest that intra-arterial (90)Y microspheres can be used as a bridge to transplantation, surgical resection, or RFA. (c) 2006 Wiley-Liss, Inc.

Collimator and energy window optimization for 90Y bremsstrahlung SPECT imaging: A SIMIND Monte Carlo study

International Nuclear Information System (INIS)

Roshan, Hoda Rezaei; Mahmoudian, Babak; Gharepapagh, Esmaeil; Azarm, Ahmadreza; Pirayesh Islamian, Jalil

2016-01-01

Treatment efficacy of radioembolization using Yttrium-90 ( 90 Y) microspheres is assessed by the 90 Y bremsstrahlung single photon emission computed tomography (SPECT) imaging following radioembolization. The radioisotopic image has the potential of providing reliable activity map of 90 Y microspheres distribution. One of the main reasons of the poor image quality in 90 Y bremsstrahlung SPECT imaging is the continuous and broad energy spectrum of the related bremsstrahlung photons. Furthermore, collimator geometry plays an impressive role in the spatial resolution, sensitivity and image contrast. Due to the relatively poor quality of the 90 Y bremsstrahlung SPECT images, we intend to optimize the medium-energy (ME) parallel-hole collimator and energy window. The Siemens e.cam gamma camera equipped with a ME collimator and a voxelized phantom was simulated by the SImulating Medical Imaging Nuclear Detectors (SIMIND) program. We used the SIMIND Monte Carlo program to generate the 90 Y bremsstrahlung SPECT projection of the digital Jaszczak phantom. The phantom consist of the six hot spheres ranging from 9.5 to 31.8 mm in diameter, which are used to evaluate the image contrast. In order to assess the effect of the energy window on the image contrast, three energy windows ranging from 60 to 160 KeV, 160 to 400 KeV, and 60 to 400 KeV were set on a 90 Y bremsstrahlung spectrum. As well, the effect of the hole diameter of a ME collimator on the image contrast and bremsstrahlung spectrum were investigated. For the fixed collimator and septa thickness values (3.28 cm and 1.14 mm, respectively), a hole diameter range (2.35–3.3 mm) was chosen based on the appropriate balance between the spatial resolution and sensitivity. The optimal energy window for 90 Y bremsstrahlung SPECT imaging was extended energy window from 60 to 400 KeV. Besides, The optimal value of the hole diameter of ME collimator was obtained 3.3 mm. Geometry of the ME parallel-hole collimator and energy

Gastric injury from {sup 90}Y to left hepatic lobe tumors adjacent to the stomach: fact or fiction?

Energy Technology Data Exchange (ETDEWEB)

Gates, Vanessa L.; Hickey, Ryan; Marshall, Karen; Williams, Melissa; Salzig, Krystina; Lewandowski, Robert J. [Robert H. Lurie Comprehensive Cancer Center, Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Chicago, IL (United States); Salem, Riad [Robert H. Lurie Comprehensive Cancer Center, Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Chicago, IL (United States); Northwestern University, Department of Medicine, Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL (United States)

2015-12-15

Radioembolization with {sup 90}Y microspheres is a locoregional radiation therapy for unresectable hepatic neoplasm. Non-target delivery of {sup 90}Y microspheres resulting in gastrointestinal (GI) symptoms is a recognized complication; there is minimal knowledge regarding the radiation effect to the gastric wall from left hepatic lobe {sup 90}Y treatments. Our aim was to study the incidence of GI complications when the target tissue (hepatic parenchyma ± tumor) is in close proximity to the gastric wall. We hypothesized that liver (tumor) to stomach proximity does not correlate with increased toxicity. Between November 2011 and September 2013, we studied all patients who underwent left lobe radioembolization with {sup 90}Y glass microspheres. With Institutional Review Board (IRB) approval, we retrospectively reviewed MRI/CT images of these patients, identifying a subset of patients with the left hepatic lobe <1 cm from the gastric wall. Patients were seen in clinic 1 month posttreatment and subsequently at 3-month intervals. Short- and long-term gastric adverse events were tabulated. Ninety-seven patients successfully underwent left hepatic lobe {sup 90}Y microsphere radioembolization in which the average distance from the liver to the stomach wall was 1.0 ± 2.8 mm. The average dose for patients who received radioembolization to the left hepatic lobe was 109 ± 57 Gy. Fifty patients had tumor within 1 cm of the gastric wall. The average dose for patients who received radioembolization to the left hepatic lobe with tumor within 1 cm of the gastric wall was 121 ± 41 Gy. There were no reportable or recordable medical events. Of the patients, 34 % reported abdominal pain that was grade 1-2; 65 % of the patients reported no abdominal pain. None of the 97 patients developed a clinically evident GI ulcer. Patients with left lobe tumors adjacent to or abutting the stomach do not exhibit acute or chronic radiation effects following radioembolization with glass

Trisacryl Gelatin Microspheres Versus Polyvinyl Alcohol Particles in the Preoperative Embolization of Bone Neoplasms

International Nuclear Information System (INIS)

Basile, Antonio; Rand, Thomas; Lomoschitz, Fritz; Toma, Cyril; Lupattelli, Tommaso; Kettenbach, Joachim; Lammer, Johannes

2004-01-01

The aim of this study was to compare the efficacy of trisacryl gelatin microspheres versus polyvinyl alcohol particles (PVA) in the preoperative embolization of bone neoplasms, on the basis of intraoperative blood loss quantified by the differences in preoperative and postoperative hematic levels of hemoglobin, hematocrit and erythrocytes count. From January 1997 to December 2002, preoperative embolization of bone tumors (either primary or secondary) was carried out in 49 patients (age range 12/78), 20 of whom were treated with trysacril gelatin microspheres (group A) and 29 with PVA particles (group B). The delay between embolization and surgery ranged from 1 to 13 days in group A and 1 to 4 days in group B. As used in international protocols, we considered hematic levels of hemoglobin, hematocrit and erythrocytes count for the measurement of intraoperative blood loss then the differences in pre- and postoperative levels were used as statistical comparative parameters. We compared the values of patients treated with embospheres (n = 10) and PVA (n = 18) alone, and patients treated with (group A = 10; group B = 11) versus patients treated without other additional embolic materials in each group (group A = 10; group B = 18). According to the Student's t-test (p < 0.05), the difference of hematic parameters between patients treated by embospheres and PVA alone were significant; otherwise there was no significant difference between patients treated with only one embolic material (embospheres and PVA) versus those treated with other additional embolic agents in each group. The patients treated with microspheres had a minor quantification of intraoperative blood loss compared to those who received PVA particles. Furthermore, they had a minor increase of bleeding related to the delay time between embolization and surgery. The use of additional embolic material did not improve the efficacy of the procedure in either group of patients

Clinical impact of 99mTc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with 90Y-loaded microspheres

International Nuclear Information System (INIS)

Garin, Etienne; Rolland, Yan; Laffont, Sophie; Edeline, Julien

2016-01-01

Radioembolization with 90 Y-loaded microspheres is increasingly used in the treatment of primary and secondary liver cancer. Technetium-99 m macroaggregated albumin (MAA) scintigraphy is used as a surrogate of microsphere distribution to assess lung or digestive shunting prior to therapy, based on tumoral targeting and dosimetry. To date, this has been the sole pre-therapeutic tool available for such evaluation. Several dosimetric approaches have been described using both glass and resin microspheres in hepatocellular carcinoma (HCC) and liver metastasis. Given that each product offers different specific activities and numbers of spheres injected, their radiobiological properties are believed to lightly differ. This paper summarizes and discusses the available studies focused on MAA-based dosimetry, particularly concentrating on potential confounding factors like clinical context, tumor size, cirrhosis, previous or concomitant therapy, and product used. In terms of the impact of tumoral dose in HCC, the results were concordant and a response relationship and tumoral threshold dose was clearly identified, especially in studies using glass microspheres. Tumoral dose has also been found to influence survival. The concept of treatment intensification has recently been introduced, yet despite several studies publishing interesting findings on the tumor dose-metastasis relationship, no consensus has been reached, and further clarification is thus required. Nor has the maximal tolerated dose to the liver been well documented, requiring more accurate evaluation. Lung dose was well described, despite recently identified factors influencing its evaluation, requiring further assessment. MAA SPECT/CT dosimetry is accurate in HCC and can now be used in order to achieve a fully customized approach, including treatment intensification. Yet further studies are warranted for the metastasis setting and evaluating the maximal tolerated liver dose. (orig.)

Intra-arterial treatment with ⁹⁰Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital.

Science.gov (United States)

Lambert, Bieke; Sturm, Emiel; Mertens, Jeroen; Oltenfreiter, Ruth; Smeets, Peter; Troisi, Roberto; Van Vlierberghe, Hans; Defreyne, Luc

2011-12-01

We report on our experience in terms of eligibility, safety, response and survival for treatment of hepatocellular carcinoma (HCC) with (90)Y microspheres. Secondly, we investigated the urinary excretion of (90)Y following treatment. We retrospectively reviewed all HCC patients referred to our department for (90)Y microsphere treatment. We recorded reasons for not proceeding to actual treatment. In case treatment was performed, we assessed the tolerance (Common Terminology Criteria for Adverse Events v3.0, CTCAE v3.0), the response [modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria] and long-term survival (Kaplan-Meier). The urinary excretion was estimated by 12-h urine collections post-injection for analysis in a gamma counter. Forty-three HCC patients were referred for radioembolization. Fourteen patients were excluded, mainly due to unfavourable (99m)Tc-macroaggregated albumin (MAA) distribution. Twenty-nine patients were treated with (90)Y microspheres (TheraSphere, mean activity 2.17 GBq). In four patients severe clinical adverse events were encountered, however only in one case clearly related to the therapy. Twenty patients were assessable by mRECIST: complete response in 15%, partial response in 35%, stable disease in 30% and progression in 20% were observed. A median survival of 12.3 months (95% confidence interval 9.4-15.2) was estimated. Concerning the substudy on urinary excretion, only 0.0025% of the administered activity was excreted in the urine within the first 12 h following TheraSphere. Following a strict workup before admitting patients to radioembolization with TheraSphere, we found good clinical tolerance in the vast majority of patients. Radiological response assessment yielded an overall response rate of 50%, when evaluated early following treatment. Urine analysis showed consistently only low activities of (90)Y excreted in the urine.

Dose-response evaluation after Yttrium-90 resin microsphere radio-embolization of breast cancer liver metastases

International Nuclear Information System (INIS)

Gnesin, S.; Verdun, F.R.; Baechler, S.; Boubacker, A.; Adib, S.; Cherbuin, N.; Prior, J.O.; Bize, P.; Denys, A.

2015-01-01

Full text of publication follows. Aim: Yttrium-90 resin microsphere radio-embolization is a valuable therapeutic option in metastatic breast cancer patients with progressive disease refractory to chemotherapy. The goal of this study was to evaluate the dose-response relationship of liver metastasis based on a 3D voxelized 90 Y PET dosimetry. Materials and methods: we studied the dose-response relationship of twelve hepatic lesions in four selected patients with metastatic breast cancer who underwent 90 Y radio-embolization (Sirtex SIR-Spheres Pty Ltd.). The administered activity ranged from 1 to 1.3 GBq. Ten days before treatment, patients underwent a baseline 18 F-FDG PET/CT. The determination of the 90 Y-microsphere activity to administer for treatment was based on the BSA method refined with the partition model derived from a 99m Tc-MAA SPECT/CT performed a week prior to radio-embolization. Within 24 hours after treatment, 90 Y TOF PET/CT imaging was performed. A follow-up 18 F-FDG PET/CT was performed 1 month after the treatment to evaluate the response to radio-embolization. For each patient, 3D voxelized dose-maps were obtained from the post-treatment 90 Y TOF PET/CT. A volume of interest (VOI) was drawn for each selected hepatic lesion using the baseline 18 F-FDG PET/CT. To obtain dose-volume histogram (DVH) for each lesion, image co-registration and VOI masks were generated using the PMOD 3.4 software and then exported in Matlab for dose calculation. Furthermore, the average absorbed dose in lesions was corrected for PVE effects by multiplication for appropriate (phantom-based) recovery coefficients according to the lesion size. Early metabolic lesion response was assessed in terms of variation in the maximum standard uptake value (ΔSUVmax) between baseline and follow-up 18 F-FDG PET/CT. The average absorbed dose for each lesion was associated with the respective metabolic response. Results: for the 12 selected lesions, the average volume was 35 cm 3

WE-AB-BRA-05: PET-Guided Delivery Quality Evaluation of Yttrium-90 Microsphere Radioembolizaton for Hepatocellular Carcinoma Patients: The Optimal Sequence of Radioembolizaton and Chemoembolization Treatments

Energy Technology Data Exchange (ETDEWEB)

Lin, M [The University of Texas Southwestern Medical Ctr, Dallas, TX (United States); Saboury, B [University of Maryland School of Medicine, Baltimore, MD (United States)

2016-06-15

Purpose: Selective-internal-radiation-therapy (SIRT) and transarterial-chemoembolization (TACE) are commonly used for treatment of liver tumors. The use of TACE, which is macroembolic, prior to SIRT may cause hemodynamic changes in tumor vasculature that impair yttrium-90 (90Y) microsphere delivery to the targeted lesions. This work aims to quantify dosimetric tumor coverage using 90Y positron emission tomography (PET) dosimetry after SIRT alone compared to TACE followed by SIRT. Methods: A total of 40 consecutive hepatocellular carcinoma (HCC) SIRT patients who had a post-SIRT 90Y PET/CT scan were evaluated. The patient-specific-3D-dose was reconstructed from the PET images. Patients were categorized into two groups: patients received TACE prior SIRT procedure (n=18) and patient received SIRT alone (n=22). The lesions and liver were delineated by a senior radiologist. We evaluated both the lesion-specific dose-volume-histogram (DVH) and the selectivity index (SI) defined as the ratio of the average dose inside the total lesion(s) and the average dose of the normal liver. The SI values of patients were compared based on whether TACE was previously used. Results: A wide spectrum was observed in the lesion-specific DVH-evaluation and SI appeared to be suitable of evaluating the quality of each SIRT infusion. The average SI of the entire patient group was 3.0, i.e. targeted lesion receiving three times higher dose than normal liver. The average SI was 1.8 for patients who had prior TACE and 3.9 for patients who did not have prior TACE (p=0.008). 85% of the patients with prior TACE demonstrated poor 90Y-microsphere delivery (SI <2) while none demonstrated excellent delivery (SI >4). On the other hand, the incidence SI >4 among patients with no prior TACE was 37%. Conclusion: 3D dose evaluation using post-SIRT PET suggests that 90Y microsphere delivery to liver tumors is impaired among patients who received prior TACE compared to those who receive SIRT alone.

Clinical impact of {sup 99m}Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with {sup 90}Y-loaded microspheres

Energy Technology Data Exchange (ETDEWEB)

Garin, Etienne [Cancer Institute Eugene Marquis, Department of Nuclear Medicine, Rennes (France); University of Rennes 1, Rennes (France); INSERM, U-991, Liver Metabolisms and Cancer, Rennes (France); Rolland, Yan [Cancer Institute Eugene Marquis, Department of Medical Imaging, Rennes (France); Laffont, Sophie [University of Rennes 1, Rennes (France); Edeline, Julien [University of Rennes 1, Rennes (France); INSERM, U-991, Liver Metabolisms and Cancer, Rennes (France); Cancer Institute Eugene Marquis, Department of Medical Oncology, Rennes (France)

2016-03-15

Radioembolization with {sup 90}Y-loaded microspheres is increasingly used in the treatment of primary and secondary liver cancer. Technetium-99 m macroaggregated albumin (MAA) scintigraphy is used as a surrogate of microsphere distribution to assess lung or digestive shunting prior to therapy, based on tumoral targeting and dosimetry. To date, this has been the sole pre-therapeutic tool available for such evaluation. Several dosimetric approaches have been described using both glass and resin microspheres in hepatocellular carcinoma (HCC) and liver metastasis. Given that each product offers different specific activities and numbers of spheres injected, their radiobiological properties are believed to lightly differ. This paper summarizes and discusses the available studies focused on MAA-based dosimetry, particularly concentrating on potential confounding factors like clinical context, tumor size, cirrhosis, previous or concomitant therapy, and product used. In terms of the impact of tumoral dose in HCC, the results were concordant and a response relationship and tumoral threshold dose was clearly identified, especially in studies using glass microspheres. Tumoral dose has also been found to influence survival. The concept of treatment intensification has recently been introduced, yet despite several studies publishing interesting findings on the tumor dose-metastasis relationship, no consensus has been reached, and further clarification is thus required. Nor has the maximal tolerated dose to the liver been well documented, requiring more accurate evaluation. Lung dose was well described, despite recently identified factors influencing its evaluation, requiring further assessment. MAA SPECT/CT dosimetry is accurate in HCC and can now be used in order to achieve a fully customized approach, including treatment intensification. Yet further studies are warranted for the metastasis setting and evaluating the maximal tolerated liver dose. (orig.)

Recommendations for radioembolisation after liver surgery using yttrium-90 resin microspheres based on a survey of an international expert panel

International Nuclear Information System (INIS)

Samim, Morsal; Veenendaal, Linde M. van; Braat, Manon N.G.J.A.; Hoven, Andor F. van den; Bosch, Maurice A.A.J. van den; Lam, Marnix G.E.H.; Hillegersberg, Richard van; Sangro, Bruno; Kao, Yung Hsiang; Liu, Dave; Louie, John D.; Sze, Daniel Y.; Rose, Steven C.; Brown, Daniel B.; Ahmadzadehfar, Hojjat; Kim, Edward

2017-01-01

Guidelines on how to adjust activity in patients with a history of liver surgery who are undergoing yttrium-90 radioembolisation ( 90 Y-RE) are lacking. The aim was to study the variability in activity prescription in these patients, between centres with extensive experience using resin microspheres 90 Y-RE, and to draw recommendations on activity prescription based on an expert consensus. The variability in activity prescription between centres was investigated by a survey of international experts in the field of 90 Y-RE. Six representative post-surgical patients (i.e. comparable activity prescription, different outcome) were selected. Information on patients' disease characteristics and data needed for activity calculation was presented to the expert panel. Reported was the used method for activity prescription and whether, how and why activity reduction was found indicated. Ten experts took part in the survey. Recommendations on activity reduction were highly variable between the expert panel. The median intra-patient range was 44 Gy (range 18-55 Gy). Reductions in prescribed activity were recommended in 68% of the cases. In consensus, a maximum D Target of 50 Gy was recommended. With a current lack of guidelines, large variability in activity prescription in post-surgical patients undergoing 90 Y-RE exists. In consensus, D Target ≤50 Gy is recommended. (orig.)

Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept

International Nuclear Information System (INIS)

Garin, E.; Lenoir, L.; Edeline, J.; Laffont, S.; Mesbah, H.; Poree, P.; Sulpice, L.; Boudjema, K.; Mesbah, M.; Guillygomarc'h, A.; Quehen, E.; Pracht, M.; Raoul, J.L.; Clement, B.; Rolland, Y.; Boucher, E.

2013-01-01

To evaluate the impact of dosimetry based on MAA SPECT/CT for the prediction of response, toxicity and survival, and for treatment planning in patients with hepatocellular carcinoma (HCC) treated with 90 Y-loaded glass microspheres (TheraSphere registered). TheraSphere registered was administered to 71 patients with inoperable HCC. MAA SPECT/CT quantitative analysis was used for the calculation of the tumour dose (TD), healthy injected liver dose (HILD), and total injected liver dose. Response was evaluated at 3 months using EASL criteria. Time to progression (TTP) and overall survival (OS) were evaluated using the Kaplan-Meier method. Factors potentially associated with liver toxicity were combined to construct a liver toxicity score (LTS). The response rate was 78.8 %. Median TD were 342 Gy for responding lesions and 191 Gy for nonresponding lesions (p 205 Gy (p = 0.0015 and not significant). Among patients with portal vein thrombosis (PVT) (n = 33), the median TTP and OS were 4.5 months (2-7 months) and 5 months (2-8 months), respectively, in patients with TD 205 Gy (p = 0.039 and 0.005). The median OS was 24.5 months (18-28.5 months) in PVT patients with TD >205 Gy and good PVT targeting on MAA SPECT/CT. The LTS was able to detect severe liver toxicity (n = 6) with a sensitivity of 83 % and overall accuracy of 97 %. Dosimetry based on MAA SPECT/CT was able to accurately predict response and survival in patients treated with glass microspheres. This method can be used to adapt the injected activity without increasing liver toxicity, thus defining a new concept of boosted selective internal radiation therapy (B-SIRT). This new concept and LTS enable fully personalized treatment planning with glass microspheres to be achieved. (orig.)

Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept.

Science.gov (United States)

Garin, E; Lenoir, L; Edeline, J; Laffont, S; Mesbah, H; Porée, P; Sulpice, L; Boudjema, K; Mesbah, M; Guillygomarc'h, A; Quehen, E; Pracht, M; Raoul, J L; Clement, B; Rolland, Y; Boucher, E

2013-07-01

To evaluate the impact of dosimetry based on MAA SPECT/CT for the prediction of response, toxicity and survival, and for treatment planning in patients with hepatocellular carcinoma (HCC) treated with (90)Y-loaded glass microspheres (TheraSphere®). TheraSphere® was administered to 71 patients with inoperable HCC. MAA SPECT/CT quantitative analysis was used for the calculation of the tumour dose (TD), healthy injected liver dose (HILD), and total injected liver dose. Response was evaluated at 3 months using EASL criteria. Time to progression (TTP) and overall survival (OS) were evaluated using the Kaplan-Meier method. Factors potentially associated with liver toxicity were combined to construct a liver toxicity score (LTS). The response rate was 78.8%. Median TD were 342 Gy for responding lesions and 191 Gy for nonresponding lesions (p 205 Gy (p = 0.0015 and not significant). Among patients with portal vein thrombosis (PVT) (n = 33), the median TTP and OS were 4.5 months (2-7 months) and 5 months (2-8 months), respectively, in patients with TD 205 Gy (p = 0.039 and 0.005). The median OS was 24.5 months (18-28.5 months) in PVT patients with TD >205 Gy and good PVT targeting on MAA SPECT/CT. The LTS was able to detect severe liver toxicity (n = 6) with a sensitivity of 83% and overall accuracy of 97%. Dosimetry based on MAA SPECT/CT was able to accurately predict response and survival in patients treated with glass microspheres. This method can be used to adapt the injected activity without increasing liver toxicity, thus defining a new concept of boosted selective internal radiation therapy (B-SIRT). This new concept and LTS enable fully personalized treatment planning with glass microspheres to be achieved.

Country report: Syria. Development of 90Y/90Sr Generator and 90Y Radiopharmaceuticals

International Nuclear Information System (INIS)

Yassine, Taufik; Mukhallalati, Ch. Heyam

2010-01-01

The aim of this project is to develop a technique for preparation of 90 Sr- 90 Y generator, we have developed a separation technique for isolation of 90 Y from 90 Sr based on using Sr – Spec resin packed in three columns for separation and purification of 90 Sr- 90 Y .The resulting Y90 is used for therapeutic applications. The first part of this project describe a prototype design for the 90 Sr- 90 Y generator in order to get a very accurate method to obtain the minimum possible 90 Sr Breakthrough. 25 mci of 90 Sr was used in the generator 90 Sr- 90 Y and we obtained the elution yield of 90 Y higher than 88%, Also the eluate was used for preparation of several 90 Y radiopharmaceuticals such as 90 YEDTMP and 90 Y-DOTA-HR 3 . And the work is continues to investigate more radiopharmaceuticals applications in the second part of this project such as 90 Y– FHMA. In this part of the co-coordination research programmer, A protocol based on results of this studies was developed to prepare and operate a higher activity generator (50-100mci), the resulting elution yield was approximately 94% of 90 Y . The elute was used in preparation of new 90 Y radiopharmaceuticals. The monoclonal antibodies is still evolving by conjugate Rituximab to The macrocyclic bifunctional chelating agent,(p-SCN-Bn-DOTA)S-2-(4-Isothiocyanatobenzyle)-1,4,7,10- tetraazacyclododecane-tetraaceticacid to obtain the inmunoconjugate DOTA-Rituximub in simple way and then investigating the radio labeling conditions with 90 Y. (author)

Complexation studies with 90Y from a novel 90Sr-90Y generator

International Nuclear Information System (INIS)

Venkatesh, M.; Pandey, U.; Banerjee, S.; Samuel, G.; Pillai, M.R.A.; Dhami, P.S.; Kannan, R.; Achuthan, P.V.; Chitnis, R.R.; Gopalakrishnan, V.; Ramanujam, A.

2001-01-01

Some features of a novel 90 Sr- 90 Y generator which employs supported liquid membrane (SLM) to separate carrier-free 90 Y from 90 Sr present in the high level waste of the spent fuel of reactor are described. After ascertaining the purity of 90 Y particularly with respect to 90 Sr breakthrough, its complexation was studied with a few oxo/aza donor ligands, such as DTPA, EDTMP, DOTA, TETA and a cyclic phosphonate, CTMP. These studies were primarily carried out to adjudge the quality of the 90 Y obtained from a novel 90 Sr- 90 Y generator and ascertain its usability for labelling biomolecules such as antibodies and peptides. The DOTA complexes are most stable at 37 C in human serum; they appear to be ideal bifunctional chelating agent for use in radioimmunotherapy with 90 Y. (orig.)

Development and evaluation of holmium doped phosphate glass microspheres for selective internal radiotherapy

International Nuclear Information System (INIS)

Barros Filho, Eraldo C.; Martinelli, Jose Roberto; Squair, Peterson L; Osso Junior, Joao A.; Sene, Frank Ferrer

2013-01-01

Selective Internal Radiotherapy is used to treat hepatocellular carcinoma. In this treatment 90 Y -doped aluminosilicate glass microspheres are introduced in the hepatic artery and they migrate to the liver near to the tumor where they are trapped in the arterioles. The radiation β- emitted by the decay of 90 Y annihilates the cancer cells. A macroaggregate of albumin containing technetium is previously used to monitor the lung shunt and to prevent the spreading of 90 Y during the treatment. In the present work, 165 Ho- doped phosphate glass microspheres were developed aiming that application. 165 Ho has high cross section for neutron capture (64 bars) and 166 Ho decays emitting β- radiation with appropriate energy for killing cancer cells, and gamma rays with low energy which can be used to obtain images of the microspheres location and to check possible occurrence of lung shunt. Holmium also is highly paramagnetic and can be used to obtain images whereby NMR. The glass matrix consists of (P 2 O 5 ) tetrahedrons and can be produced by a relatively lower melting temperature of chemical compounds. The 31 P decays by emitting β- radiation and contributes to the absorbed dose, helping to annihilate the cancer cells. The microspheres were produced by using two methods: the flame and the gravitation falling methods to obtain microspheres with appropriate properties. (author)

Recommendations for radioembolisation after liver surgery using yttrium-90 resin microspheres based on a survey of an international expert panel

Energy Technology Data Exchange (ETDEWEB)

Samim, Morsal [University Medical Center Utrecht, Department of Surgery, Utrecht (Netherlands); University Medical Center Utrecht, Department of Radiology and Nuclear Medicine, Utrecht (Netherlands); Veenendaal, Linde M. van; Braat, Manon N.G.J.A.; Hoven, Andor F. van den; Bosch, Maurice A.A.J. van den; Lam, Marnix G.E.H. [University Medical Center Utrecht, Department of Radiology and Nuclear Medicine, Utrecht (Netherlands); Hillegersberg, Richard van [University Medical Center Utrecht, Department of Surgery, Utrecht (Netherlands); Sangro, Bruno [Clinica Universidad de Navarra-IDISNA and CIBEREHD, Liver Unit, Pamplona (Spain); Kao, Yung Hsiang [Cabrini Hospital, Department of Nuclear Medicine, Melbourne (Australia); Liu, Dave [Vancouver General Hospital, University of British Columbia, Department of Radiology, Vancouver, British Columbia (Canada); Louie, John D.; Sze, Daniel Y. [Stanford University Medical Center, Division of Interventional Radiology, Stanford (United States); Rose, Steven C. [University of California, Department of Radiology, San Diego (United States); Brown, Daniel B. [Vanderbilt University, Medical Center North, Department of Radiology, Nashville (United States); Ahmadzadehfar, Hojjat [University Hospital Bonn, Department of Nuclear Medicine, Bonn (Germany); Kim, Edward [Icahn School of Medicine at Mount Sinai, Division of Vascular and Interventional Radiology, New York (United States)

2017-12-15

Guidelines on how to adjust activity in patients with a history of liver surgery who are undergoing yttrium-90 radioembolisation ({sup 90}Y-RE) are lacking. The aim was to study the variability in activity prescription in these patients, between centres with extensive experience using resin microspheres {sup 90}Y-RE, and to draw recommendations on activity prescription based on an expert consensus. The variability in activity prescription between centres was investigated by a survey of international experts in the field of {sup 90}Y-RE. Six representative post-surgical patients (i.e. comparable activity prescription, different outcome) were selected. Information on patients' disease characteristics and data needed for activity calculation was presented to the expert panel. Reported was the used method for activity prescription and whether, how and why activity reduction was found indicated. Ten experts took part in the survey. Recommendations on activity reduction were highly variable between the expert panel. The median intra-patient range was 44 Gy (range 18-55 Gy). Reductions in prescribed activity were recommended in 68% of the cases. In consensus, a maximum D{sub Target} of 50 Gy was recommended. With a current lack of guidelines, large variability in activity prescription in post-surgical patients undergoing {sup 90}Y-RE exists. In consensus, D{sub Target} ≤50 Gy is recommended. (orig.)

Determination of Radiation Absorbed Dose to Primary Liver Tumors and Normal Liver Tissue Using Post Radioembolization 90Y PET

Directory of Open Access Journals (Sweden)

Shyam Mohan Srinivas

2014-10-01

Full Text Available Background: Radioembolization with Yttrium-90 (90Y microspheres is becoming a more widely used transcatheter treatment for unresectable hepatocellular carcinoma (HCC. Using post-treatment 90Y PET/CT scans,the distribution of microspheres within the liver can be determined and quantitatively assessesed . We studied the radiation dose of 90Y delivered to liver and treated tumors.Methods: This retrospective study of 56 patients with HCC, including analysis of 98 liver tumors, measured and correlated the dose of radiation delivered to liver tumors and normal liver tissue using glass microspheres (TheraSpheres® to the frequency of complications with mRECIST. 90Y PET/CT and triphasic liver CT scans were used to contour treated tumor and normal liver regions and determine their respective activity concentrations. An absorbed dose factor was used to convert the measured activity concentration (Bq/mL to an absorbed dose (Gy.Results: The 98 studied tumors received a mean dose of 169 Gy (mode 90-120 Gy;range 0-570 Gy. Tumor response by mRECIST criteria was performed for 48 tumors that had follow up scans. There were 21 responders (mean dose 215 Gy and 27 nonresponders (mean dose 167 Gy. The association between mean tumor absorbed dose and response suggests a trend but did not reach statistical significance (p=0.099. Normal liver tissue received a mean dose of 67 Gy (mode 60-70 Gy; range 10-120 Gy. There was a statistically significant association between absorbed dose to normal liver and the presence of two or more severe complications (p=0.036.Conclusion: Our cohort of patients showed a possible dose response trend for the tumors. Collateral dose to normal liver is nontrivial and can have clinical implications. These methods help us understand whether patient adverse events, treatment success, or treatment failure can be attributed to the dose which the tumor or normal liver received.

SU-D-201-05: Phantom Study to Determine Optimal PET Reconstruction Parameters for PET/MR Imaging of Y-90 Microspheres Following Radioembolization

Energy Technology Data Exchange (ETDEWEB)

Maughan, N [Washington University in Saint Louis, Saint Louis, MO (United States); Conti, M [Siemens Healthcare Molecular Imaging, Knoxville, TN (United States); Parikh, P [Washington Univ. School of Medicine, Saint Louis, MO (United States); Faul, D [Siemens Healthcare, New York, NY (United States); Laforest, R [Washington University School of Medicine, Saint Louis, MO (United States)

2015-06-15

Purpose: Imaging Y-90 microspheres with PET/MRI following hepatic radioembolization has the potential for predicting treatment outcome and, in turn, improving patient care. The positron decay branching ratio, however, is very small (32 ppm), yielding images with poor statistics even when therapy doses are used. Our purpose is to find PET reconstruction parameters that maximize the PET recovery coefficients and minimize noise. Methods: An initial 7.5 GBq of Y-90 chloride solution was used to fill an ACR phantom for measurements with a PET/MRI scanner (Siemens Biograph mMR). Four hot cylinders and a warm background activity volume of the phantom were filled with a 10:1 ratio. Phantom attenuation maps were derived from scaled CT images of the phantom and included the MR phased array coil. The phantom was imaged at six time points between 7.5–1.0 GBq total activity over a period of eight days. PET images were reconstructed via OP-OSEM with 21 subsets and varying iteration number (1–5), post-reconstruction filter size (5–10 mm), and either absolute or relative scatter correction. Recovery coefficients, SNR, and noise were measured as well as total activity in the phantom. Results: For the 120 different reconstructions, recovery coefficients ranged from 0.1–0.6 and improved with increasing iteration number and reduced post-reconstruction filter size. SNR, however, improved substantially with lower iteration numbers and larger post-reconstruction filters. From the phantom data, we found that performing 2 iterations, 21 subsets, and applying a 5 mm Gaussian post-reconstruction filter provided optimal recovery coefficients at a moderate noise level for a wide range of activity levels. Conclusion: The choice of reconstruction parameters for Y-90 PET images greatly influences both the accuracy of measurements and image quality. We have found reconstruction parameters that provide optimal recovery coefficients with minimized noise. Future work will include the effects

Y-90 microspheres in the treatment of unresectable hepatocellularcarcinoma

International Nuclear Information System (INIS)

Al-Kalbani, A.; Kamel, Y.

2008-01-01

A small percentage of patients with hepatocellular carcinoma (HCC) arecandidates for curative treatment in form of resection or transplantation.There are different treatment options for unresectable HCC-like localablative therapies and recently systemic therapy with Sorafenib. All of thesehave variable response rate and had been proven to improve survival. In thelast few years, there is a growing interest in TheraSphere radioembolization.It consists of yttrium (Y-90) embedded into nonbiodegradeable glassmicrospheres. It is selectively administered by intraarterial hepaticinjection giving high doses of radiation to the tumor and sparing the liverparenchyma. It has been shown to improve survival and used as a bridge totransplantation and to downstage tumors for resection. Therasphere seems tohave favorable safety profile and has been used in patients with portal veinthrombosis with successful outcome. (author)

Preparation of 90Sr-90Y generator

International Nuclear Information System (INIS)

Jin Xiaohai; Yu Haibin; Zhang Jinming; Zhang Peixin; Lin Qiongfang

1990-01-01

In recent years, 90 Y has been considered as one of the best radionuclides for tumor radioimmunotherapy when chelated to tumor-associated antibodies. This evaluation is based on the superior properties of this radionuclide (suitable half-life, pure β-ray emitter of intermediate energy, stable daughters, and suitable chemical properties) and because it is available as a radionuclide generator product by decay of its 28a parent 90 Sr. The experimental conditions of 90 Sr- 90 Y generator are described. The elution efficiency of 90 Sr- 90 Y generator reaches 98%. One of the most important problems is the 90 Sr contamination breakthrough from the generator. The level of 90 Sr contamination must be controlled to the clinical standard. The cation exchange resin 732 (100-150 mesh) was successfully used for the separation of 90 Y from 90 Sr. The method used by the authors provides a 90 Y-HAc solution which is very simple and safe for administration to the patients. 90 Y was separated from 90 Sr almost completely, the level of the 90 Sr contamination per 740 MBq 90 Y product was only 0.74 kBq. However the toxicity of 90 Sr is extremely high, the human life-time permissible dose is 74 kBq, then 740 MBq of 90 Y is allowed to be administrated to a patient for 50-100 times

Radioembolization of hepatocarcinoma with 90Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology

International Nuclear Information System (INIS)

Chiesa, C.; Maccauro, M.; Aliberti, G.; Padovano, B.; Seregni, E.; Crippa, F.; Mira, M.; Negri, A.; Spreafico, C.; Morosi, C.; Civelli, E.; Lanocita, R.; Marchiano, A.; Romito, R.; Sposito, C.; Bhoori, S.; Facciorusso, A.; Mazzaferro, V.; Camerini, T.; Carrara, M.; Pellizzari, S.; Migliorisi, M.; De Nile, M.C.

2015-01-01

The aim of this study was to optimize the dosimetric approach and to review the absorbed doses delivered, taking into account radiobiology, in order to identify the optimal methodology for an individualized treatment planning strategy based on 99m Tc-macroaggregated albumin (MAA) single photon emission computed tomography (SPECT) images. We performed retrospective dosimetry of the standard TheraSphere registered treatment on 52 intermediate (n = 17) and advanced (i.e. portal vein thrombosis, n = 35) hepatocarcinoma patients with tumour burden < 50 % and without obstruction of the main portal vein trunk. Response was monitored with the densitometric radiological criterion (European Association for the Study of the Liver) and treatment-related liver decompensation was defined ad hoc with a time cut-off of 6 months. Adverse events clearly attributable to disease progression or other causes were not attributed to treatment. Voxel dosimetry was performed with the local deposition method on 99m Tc-MAA SPECT images. The reconstruction protocol was optimized. Concordance of 99m Tc-MAA and 90 Y bremsstrahlung microsphere biodistributions was studied in 35 sequential patients. Two segmentation methods were used, based on SPECT alone (home-made code) or on coregistered SPECT/CT images (IMALYTICS trademark by Philips). STRATOS trademark absorbed dose calculation was validated for 90 Y with a single time point. Radiobiology was used introducing other dosimetric variables besides the mean absorbed dose D: equivalent uniform dose (EUD), biologically effective dose averaged over voxel values (BED ave ) and equivalent uniform biologically effective dose (EUBED). Two sets of radiobiological parameters, the first derived from microsphere irradiation and the second from external beam radiotherapy (EBRT), were used. A total of 16 possible methodologies were compared. Tumour control probability (TCP) and normal tissue complication probability (NTCP) were derived. The area under the

Country report: Syria. Development of {sup 90}Y/{sup 90}Sr Generator and {sup 90}Y Radiopharmaceuticals

Energy Technology Data Exchange (ETDEWEB)

Yassine, Taufik; Mukhallalati, Ch. Heyam, E-mail: atomic@aec.org.sy [Atomic Energy Commission of Syria, Damascus (Syrian Arab Republic)

2010-07-01

The aim of this project is to develop a technique for preparation of {sup 90}Sr-{sup 90}Y generator, we have developed a separation technique for isolation of {sup 90}Y from {sup 90}Sr based on using Sr – Spec resin packed in three columns for separation and purification of {sup 90}Sr-{sup 90}Y .The resulting Y90 is used for therapeutic applications. The first part of this project describe a prototype design for the {sup 90}Sr- {sup 90}Y generator in order to get a very accurate method to obtain the minimum possible {sup 90}Sr Breakthrough. 25 mci of {sup 90}Sr was used in the generator {sup 90}Sr-{sup 90}Y and we obtained the elution yield of {sup 90}Y higher than 88%, Also the eluate was used for preparation of several {sup 90}Y radiopharmaceuticals such as {sup 90}YEDTMP and {sup 90}Y-DOTA-HR{sub 3}. And the work is continues to investigate more radiopharmaceuticals applications in the second part of this project such as {sup 90}Y– FHMA. In this part of the co-coordination research programmer, A protocol based on results of this studies was developed to prepare and operate a higher activity generator (50-100mci), the resulting elution yield was approximately 94% of {sup 90}Y . The elute was used in preparation of new {sup 90}Y radiopharmaceuticals. The monoclonal antibodies is still evolving by conjugate Rituximab to The macrocyclic bifunctional chelating agent,(p-SCN-Bn-DOTA)S-2-(4-Isothiocyanatobenzyle)-1,4,7,10- tetraazacyclododecane-tetraaceticacid to obtain the inmunoconjugate DOTA-Rituximub in simple way and then investigating the radio labeling conditions with {sup 90}Y. (author)

Occupational exposure following Yttrium-90 microspheres SIR therapy

International Nuclear Information System (INIS)

Fontaine, P.; Boirie, G.; Dieudonne, A.; Leguludec, D.; Lebtahi, R.; Ben Reguiga, M.

2015-01-01

Full text of publication follows. Introduction: Selective Internal Radiation Therapy (SIRT) is a promising technique for solid hepatic neoplasms treatment. SIRT consists in implanting radioactive microspheres (RMS) in targeted hepatic lesions via femoral artery. Two RMS-Therapsheres [glass-microspheres/TSR] and Sir-Spheres [resin-spheres/SSR]- are marketed in the European market, both radiolabeled with Yttrium-90. The objective of this study is to assess occupational exposure for nuclear medicine, radiology and clinical staff involved in Y 90 -RMS preparation and implantation. Materials and methods: The study was conducted on 20 patients treated for Hepato-Cellular Carcinoma: 10 treated with TSR and 10 with SSR. Dose rate (DR, mSv/h) or absorbed doses (mSv) measurements were made during all steps of TSR and SSR handling: sources receipt and unpacking, preparation, transport to radiology, implantation, and patient care. Measurements were made with portable ionization chamber(Babyline/Nardeux), spectrometer(FieldSpect/Aries), digital dosimeter (NED/Unfors) and operational dosimeter (Mk2/Siemens). Values were expressed as mean±SD. Results: patients received of 1.8 GBq to 3.1 GBq of TSR and 0.55 GBq to 2.4 GBq of SSR. TSR were delivered ready-to-use with the prescribed activity. For SSR only one activity was commercially available and shipped (3 GBq at calibration-time)requiring a preparation step to adjust needed activity. DR measured during RMS was 1723 ± 157 μSv/h SSR and 1189 ± 92 μSv/h for TSR. When preparing spheres in radiopharmacy, fingers and whole body doses were respectively 8326 ± 2360 μSv and 12.3 ± 5,2 μSv for Sir-Spheres vs. 33.5 ± 7.8 μSv and 1.1 ± 0.3 μSv for TSR. DR in contact with carrying case during RMS transfer to radiology were 299 ± 102 μSv/h for SSR and 5.3 ± 1.2 μSv/h for TSR. During RMS infusion, radiologist's finger doses were limited to 3.6 ± 1 μSv for SSR and 0.7± 0.3 μSv for TSR. Finally, following RMS

A collimator optimization method for quantitative imaging: application to Y-90 bremsstrahlung SPECT.

Science.gov (United States)

Rong, Xing; Frey, Eric C

2013-08-01

Post-therapy quantitative 90Y bremsstrahlung single photon emission computed tomography (SPECT) has shown great potential to provide reliable activity estimates, which are essential for dose verification. Typically 90Y imaging is performed with high- or medium-energy collimators. However, the energy spectrum of 90Y bremsstrahlung photons is substantially different than typical for these collimators. In addition, dosimetry requires quantitative images, and collimators are not typically optimized for such tasks. Optimizing a collimator for 90Y imaging is both novel and potentially important. Conventional optimization methods are not appropriate for 90Y bremsstrahlung photons, which have a continuous and broad energy distribution. In this work, the authors developed a parallel-hole collimator optimization method for quantitative tasks that is particularly applicable to radionuclides with complex emission energy spectra. The authors applied the proposed method to develop an optimal collimator for quantitative 90Y bremsstrahlung SPECT in the context of microsphere radioembolization. To account for the effects of the collimator on both the bias and the variance of the activity estimates, the authors used the root mean squared error (RMSE) of the volume of interest activity estimates as the figure of merit (FOM). In the FOM, the bias due to the null space of the image formation process was taken in account. The RMSE was weighted by the inverse mass to reflect the application to dosimetry; for a different application, more relevant weighting could easily be adopted. The authors proposed a parameterization for the collimator that facilitates the incorporation of the important factors (geometric sensitivity, geometric resolution, and septal penetration fraction) determining collimator performance, while keeping the number of free parameters describing the collimator small (i.e., two parameters). To make the optimization results for quantitative 90Y bremsstrahlung SPECT more

A gate evaluation of the sources of error in quantitative90 Y PET.

Science.gov (United States)

Strydhorst, Jared; Carlier, Thomas; Dieudonné, Arnaud; Conti, Maurizio; Buvat, Irène

2016-10-01

Accurate reconstruction of the dose delivered by 90 Y microspheres using a postembolization PET scan would permit the establishment of more accurate dose-response relationships for treatment of hepatocellular carcinoma with 90 Y. However, the quality of the PET data obtained is compromised by several factors, including poor count statistics and a very high random fraction. This work uses Monte Carlo simulations to investigate what impact factors other than low count statistics have on the quantification of 90 Y PET. PET acquisitions of two phantoms-a NEMA PET phantom and the NEMA IEC PET body phantom-containing either 90 Y or 18 F were simulated using gate. Simulated projections were created with subsets of the simulation data allowing the contributions of random, scatter, and LSO background to be independently evaluated. The simulated projections were reconstructed using the commercial software for the simulated scanner, and the quantitative accuracy of the reconstruction and the contrast recovery of the reconstructed images were evaluated. The quantitative accuracy of the 90 Y reconstructions were not strongly influenced by the high random fraction present in the projection data, and the activity concentration was recovered to within 5% of the known value. The contrast recovery measured for simulated 90 Y data was slightly poorer than that for simulated 18 F data with similar count statistics. However, the degradation was not strongly linked to any particular factor. Using a more restricted energy range to reduce the random fraction in the projections had no significant effect. Simulations of 90 Y PET confirm that quantitative 90 Y is achievable with the same approach as that used for 18 F, and that there is likely very little margin for improvement by attempting to model aspects unique to 90 Y, such as the much higher random fraction or the presence of bremsstrahlung in the singles data. © 2016 American Association of Physicists in Medicine.

Radioembolization of hepatocarcinoma with {sup 90}Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology

Energy Technology Data Exchange (ETDEWEB)

Chiesa, C.; Maccauro, M.; Aliberti, G.; Padovano, B.; Seregni, E.; Crippa, F. [Foundation IRCCS Istituto Nazionale Tumori, Nuclear Medicine Division, Milan (Italy); Mira, M.; Negri, A. [University of Milan, Postgraduate Health Physics School, Milan (Italy); Spreafico, C.; Morosi, C.; Civelli, E.; Lanocita, R.; Marchiano, A. [Foundation IRCCS Istituto Nazionale Tumori, Radiology 2, Milan (Italy); Romito, R.; Sposito, C.; Bhoori, S.; Facciorusso, A.; Mazzaferro, V. [Foundation IRCCS Istituto Nazionale Tumori, Surgery 1, Milan (Italy); Camerini, T. [Foundation IRCCS Istituto Nazionale Tumori, Scientific Direction, Milan (Italy); Carrara, M. [Foundation IRCCS Istituto Nazionale Tumori, Health Physics, Milan (Italy); Pellizzari, S. [University La Sapienza, Engineering Faculty, Rome (Italy); Migliorisi, M. [Foundation IRCCS Istituto Nazionale Tumori, Nuclear Medicine Division, Milan (Italy); Foundation IRCCS Istituto Nazionale Tumori, Clinical Engineering, Milan (Italy); De Nile, M.C. [University of Pavia, Physics Faculty, Pavia, Lombardy (Italy)

2015-10-15

The aim of this study was to optimize the dosimetric approach and to review the absorbed doses delivered, taking into account radiobiology, in order to identify the optimal methodology for an individualized treatment planning strategy based on {sup 99m}Tc-macroaggregated albumin (MAA) single photon emission computed tomography (SPECT) images. We performed retrospective dosimetry of the standard TheraSphere registered treatment on 52 intermediate (n = 17) and advanced (i.e. portal vein thrombosis, n = 35) hepatocarcinoma patients with tumour burden < 50 % and without obstruction of the main portal vein trunk. Response was monitored with the densitometric radiological criterion (European Association for the Study of the Liver) and treatment-related liver decompensation was defined ad hoc with a time cut-off of 6 months. Adverse events clearly attributable to disease progression or other causes were not attributed to treatment. Voxel dosimetry was performed with the local deposition method on {sup 99m}Tc-MAA SPECT images. The reconstruction protocol was optimized. Concordance of {sup 99m}Tc-MAA and {sup 90}Y bremsstrahlung microsphere biodistributions was studied in 35 sequential patients. Two segmentation methods were used, based on SPECT alone (home-made code) or on coregistered SPECT/CT images (IMALYTICS trademark by Philips). STRATOS trademark absorbed dose calculation was validated for {sup 90}Y with a single time point. Radiobiology was used introducing other dosimetric variables besides the mean absorbed dose D: equivalent uniform dose (EUD), biologically effective dose averaged over voxel values (BED{sub ave}) and equivalent uniform biologically effective dose (EUBED). Two sets of radiobiological parameters, the first derived from microsphere irradiation and the second from external beam radiotherapy (EBRT), were used. A total of 16 possible methodologies were compared. Tumour control probability (TCP) and normal tissue complication probability (NTCP) were

Country report: Thailand. Development of Sr-90/ Y-90 Generator and Development of Radiopharmaceuticals Using Y-90

International Nuclear Information System (INIS)

Nipavan, Poramatikul

2010-01-01

The research project has been conducted at Thailand Institute of Nuclear Technology in accordance to the 1st RCM plan during the IAEA meeting in Warsaw. The objectives of the project include the following 5 specific aims: 1. Development of Sr-90/Y-90 ion-exchange chromatography generator 2. Development of Sr-90/Y-90 extraction chromatography generator 3. Development of quality control technique 4. Development of herapeutic radiopharmaceuticals Y-90 particulates/colloids 5. Development of Re-188 DMSA–bis-phosphonates Currently we have achieved specific aims 1 to 3. The specific aims 4 and 5 are during investigation. For specific aim 4, we are during the process to extract high purity 90 Y from 90 Sr/ 90 Y generator that will yield the starting 90 Y for the production of Y-90 particulates and colloids. For the 5 th specific aim, we are on hold to receive the starting agent, bis- Phosphonates, from Dr. Blower group. Therefore, this progress report will cover our work focusing on specific aims 1 to 3

Country report: Thailand. Development of Sr-90/ Y-90 Generator and Development of Radiopharmaceuticals Using Y-90

Energy Technology Data Exchange (ETDEWEB)

Nipavan, Poramatikul [Nuclear Research and Development Group, Thailand Institute of Nuclear Technology (Public Organization), Bangkok (Thailand)

2010-07-01

The research project has been conducted at Thailand Institute of Nuclear Technology in accordance to the 1st RCM plan during the IAEA meeting in Warsaw. The objectives of the project include the following 5 specific aims: 1. Development of Sr-90/Y-90 ion-exchange chromatography generator 2. Development of Sr-90/Y-90 extraction chromatography generator 3. Development of quality control technique 4. Development of herapeutic radiopharmaceuticals Y-90 particulates/colloids 5. Development of Re-188 DMSA–bis-phosphonates Currently we have achieved specific aims 1 to 3. The specific aims 4 and 5 are during investigation. For specific aim 4, we are during the process to extract high purity {sup 90}Y from {sup 90}Sr/{sup 90}Y generator that will yield the starting {sup 90}Y for the production of Y-90 particulates and colloids. For the 5{sup th} specific aim, we are on hold to receive the starting agent, bis- Phosphonates, from Dr. Blower group. Therefore, this progress report will cover our work focusing on specific aims 1 to 3.

Y-90 microshperes in the treatment of unresectable hepatocellular carcinoma.

Science.gov (United States)

Al-Kalbani, Abdullah; Kamel, Yasser

2008-04-01

A small percentage of patients with hepatocellular carcinoma (HCC) are candidates for curative treatment in form of resection or transplantation. There are different treatment options for unresectable HCC-like local ablative therapies and recently systemic therapy with Sorafenib. All of these have variable response rate and had been proven to improve survival. In the last few years, there is a growing interest in TheraSphere radioembolization. It consists of yttrium90 (Y-90) embedded into nonbiodegradable glass microspheres. It is selectively administered by intraarterial hepatic injection giving high doses of radiation to the tumor and sparing the liver parenchyma. It has been shown to improve survival and used as a bridge to transplantation and to downstage tumors for resection. Therasphere seems to have favorable safety profile and has been used in patients with portal vein thrombosis with successful outcome.

Development of an electrochemical 90Sr-90Y generator for separation of 90Y suitable for targeted therapy

International Nuclear Information System (INIS)

Chakravarty, Rubel; Pandey, Usha; Manolkar, Remani B.; Dash, Ashutosh; Venkatesh, Meera; Pillai, M.R. Ambikalmajan

2008-01-01

90 Y of high specific activity and very high radionuclidic purity (>99.998%) is essential for targeted therapy. Since the current methods used for the preparation of 90 Y from 90 Sr are not adaptable for use in a central/hospital radiopharmacy, a simple 90 Sr- 90 Y generator system based on electrochemical separation technique was developed. Methods: Two-cycle electrolysis procedure was developed for separation of 90 Y from 90 Sr in nitrate solution. The first electrolysis was performed for 90 min in 90 Sr(NO 3 ) 2 feed solution at pH 2-3 at a potential of -2.5V with 100-200 mA current using platinum electrodes. The second electrolysis was performed for 45 min in 3 mM HNO 3 at a potential of -2.5V with 100 mA current. In this step, the cathode from the first electrolysis containing 90 Y was used as anode along with a fresh circular platinum electrode as cathode. The 90 Y deposited on the circular cathode after the second electrolysis was dissolved in acetate buffer to obtain 90 Y acetate, suitable for radiolabeling. Results: >96% recovery of 90 Y could be achieved in each cycle, with an overall decay corrected yield of >90%. The recovered 90 Y had high radionuclidic purity with barely 30.2±15.2 kBq (817±411 nCi) of 90 Sr per 37 GBq (1 Ci) of 90 Y (0.817±0.411 ppm). Consistent and repeated separation could be demonstrated using up to 1.85 GBq (50 mCi) of 90 Sr. The generator was named 'Kamadhenu,' the eternally milk-yielding Indian mythological cow. Conclusions: A technique suitable for adaptation at central radiopharmacies for obtaining therapeutic quantities of pure 90 Y has been developed

Boosted selective internal radiation therapy with {sup 90}Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept

Energy Technology Data Exchange (ETDEWEB)

Garin, E.; Lenoir, L. [Comprehensive Cancer Center, Institute Eugene Marquis, Department of Nuclear Medicine, CS 44229, Rennes (France); University of Rennes 1, Rennes (France); INSERM, U-991, Liver Metabolisms and Cancer, Rennes (France); Edeline, J. [University of Rennes 1, Rennes (France); Comprehensive Cancer Center, Institute Eugene Marquis, Department of Medical Oncology, CS 44229, Rennes (France); Laffont, S. [Comprehensive Cancer Center, Institute Eugene Marquis, Department of Nuclear Medicine, CS 44229, Rennes (France); Mesbah, H.; Poree, P. [Comprehensive Cancer Center, Institute Eugene Marquis, Department of Medical Informatics, CS 44229, Rennes (France); Sulpice, L. [INSERM, U-991, Liver Metabolisms and Cancer, Rennes (France); Centre Hospitalier Universitaire Pontchaillou, Department of Digestive Surgery, Rennes (France); Boudjema, K. [University of Rennes 1, Rennes (France); INSERM, U-991, Liver Metabolisms and Cancer, Rennes (France); Centre Hospitalier Universitaire Pontchaillou, Department of Digestive Surgery, Rennes (France); Mesbah, M. [University of Pierre et Marie Curie, Paris (France); Guillygomarc' h, A. [Centre Hospitalier Universitaire Pontchaillou, Department of Hepatology, Rennes (France); Quehen, E. [Centre Hospitalier Universitaire Pontchaillou, Department of Radiology, Rennes (France); Pracht, M. [Comprehensive Cancer Center, Institute Eugene Marquis, Department of Medical Oncology, CS 44229, Rennes (France); Raoul, J.L. [Comprehensive Cancer Center, Institute Paoli Calmette, Department of Medical Oncology, Marseille (France); Clement, B. [INSERM, U-991, Liver Metabolisms and Cancer, Rennes (France); Rolland, Y. [Comprehensive Cancer Center, Institute Eugene Marquis, Department of Medical Imaging, CS 44229, Rennes (France); Boucher, E. [INSERM, U-991, Liver Metabolisms and Cancer, Rennes (France); Comprehensive Cancer Center, Institute Eugene Marquis, Department of Medical Oncology, CS 44229, Rennes (France)

2013-07-15

To evaluate the impact of dosimetry based on MAA SPECT/CT for the prediction of response, toxicity and survival, and for treatment planning in patients with hepatocellular carcinoma (HCC) treated with {sup 90}Y-loaded glass microspheres (TheraSphere registered). TheraSphere registered was administered to 71 patients with inoperable HCC. MAA SPECT/CT quantitative analysis was used for the calculation of the tumour dose (TD), healthy injected liver dose (HILD), and total injected liver dose. Response was evaluated at 3 months using EASL criteria. Time to progression (TTP) and overall survival (OS) were evaluated using the Kaplan-Meier method. Factors potentially associated with liver toxicity were combined to construct a liver toxicity score (LTS). The response rate was 78.8 %. Median TD were 342 Gy for responding lesions and 191 Gy for nonresponding lesions (p < 0.001). With a threshold TD of 205 Gy, MAA SPECT/CT predicted response with a sensitivity of 100 % and overall accuracy of 90 %. Based on TD and HILD, 17 patients underwent treatment intensification resulting in a good response rate (76.4 %), without increased grade III liver toxicity. The median TTP and OS were 5.5 months (2-9.5 months) and 11.5 months (2-31 months), respectively, in patients with TD <205 Gy and 13 months (10-16 months) and 23.2 months (17.5-28.5 months), respectively, in those with TD >205 Gy (p = 0.0015 and not significant). Among patients with portal vein thrombosis (PVT) (n = 33), the median TTP and OS were 4.5 months (2-7 months) and 5 months (2-8 months), respectively, in patients with TD <205 Gy and 10 months (6-15.2 months) and 21.5 months (12-28.5 months), respectively, in those with TD >205 Gy (p = 0.039 and 0.005). The median OS was 24.5 months (18-28.5 months) in PVT patients with TD >205 Gy and good PVT targeting on MAA SPECT/CT. The LTS was able to detect severe liver toxicity (n = 6) with a sensitivity of 83 % and overall accuracy of 97 %. Dosimetry based on MAA SPECT/CT was

Development of 90Sr-90Y generators

International Nuclear Information System (INIS)

Barrio, Graciela

2007-01-01

Yttrium-90 is a radioisotope of great interest in the field of Nuclear Medicine. It is considered one of the most important and most used radionuclides for radioimmunotherapeutical applications, especially promising for the treatment of certain types of cancer. Another important application of 90 Y is radio synovectomy. This radionuclide has a half-life of 64 hours, emits long range beta particles (maximum energy of 2.3 MeV) and decays, without intermediate nuclides, to a stable daughter. 90 Y may be obtained carrier-free, generated by the decay of its parent 90 Sr (half-life=28 years). 90 Sr is a product from uranium fission, and due to its long half-life, can be indefinitely used, which is certainly advantageous. It is present in great amounts, and needs to be processed and purified in order to be used as raw material for the generators. Generators of 90 Sr- 90 Y may thus be used during various months, due to 90 Sr long half-life. Several methods for the separation of 90 Y from 90 Sr by solvent extraction and ion exchange have been reported in literature. Thanks to its simplicity, ion exchange techniques have been more commonly used for this generator system. The main objective of this work was to develop a methodology for the preparation of 90 Sr- 90 Y generators, using cationic exchange resins. In such method, 90 Sr is strongly adsorbed in the resin and 90 Y is eluted by a 0.003 M EDTA solution. According to the quality control carried out, results showed that elution yields are greater than 65%, thus confirming the efficiency of the separation method used.

Absorbed dose kernel and self-shielding calculations for a novel radiopaque glass microsphere for transarterial radioembolization.

Science.gov (United States)

Church, Cody; Mawko, George; Archambault, John Paul; Lewandowski, Robert; Liu, David; Kehoe, Sharon; Boyd, Daniel; Abraham, Robert; Syme, Alasdair

2018-02-01

Radiopaque microspheres may provide intraprocedural and postprocedural feedback during transarterial radioembolization (TARE). Furthermore, the potential to use higher resolution x-ray imaging techniques as opposed to nuclear medicine imaging suggests that significant improvements in the accuracy and precision of radiation dosimetry calculations could be realized for this type of therapy. This study investigates the absorbed dose kernel for novel radiopaque microspheres including contributions of both short and long-lived contaminant radionuclides while concurrently quantifying the self-shielding of the glass network. Monte Carlo simulations using EGSnrc were performed to determine the dose kernels for all monoenergetic electron emissions and all beta spectra for radionuclides reported in a neutron activation study of the microspheres. Simulations were benchmarked against an accepted 90 Y dose point kernel. Self-shielding was quantified for the microspheres by simulating an isotropically emitting, uniformly distributed source, in glass and in water. The ratio of the absorbed doses was scored as a function of distance from a microsphere. The absorbed dose kernel for the microspheres was calculated for (a) two bead formulations following (b) two different durations of neutron activation, at (c) various time points following activation. Self-shielding varies with time postremoval from the reactor. At early time points, it is less pronounced due to the higher energies of the emissions. It is on the order of 0.4-2.8% at a radial distance of 5.43 mm with increased size from 10 to 50 μm in diameter during the time that the microspheres would be administered to a patient. At long time points, self-shielding is more pronounced and can reach values in excess of 20% near the end of the range of the emissions. Absorbed dose kernels for 90 Y, 90m Y, 85m Sr, 85 Sr, 87m Sr, 89 Sr, 70 Ga, 72 Ga, and 31 Si are presented and used to determine an overall kernel for the

A GATE evaluation of the sources of error in quantitative {sup 90}Y PET

Energy Technology Data Exchange (ETDEWEB)

Strydhorst, Jared, E-mail: jared.strydhorst@gmail.com; Buvat, Irène [IMIV, U1023 Inserm/CEA/Université Paris-Sud and ERL 9218 CNRS, Université Paris-Saclay, CEA/SHFJ, Orsay 91401 (France); Carlier, Thomas [Department of Nuclear Medicine, Centre Hospitalier Universitaire de Nantes and CRCNA, Inserm U892, Nantes 44000 (France); Dieudonné, Arnaud [Department of Nuclear Medicine, Hôpital Beaujon, HUPNVS, APHP and Inserm U1149, Clichy 92110 (France); Conti, Maurizio [Siemens Healthcare Molecular Imaging, Knoxville, Tennessee, 37932 (United States)

2016-10-15

Purpose: Accurate reconstruction of the dose delivered by {sup 90}Y microspheres using a postembolization PET scan would permit the establishment of more accurate dose–response relationships for treatment of hepatocellular carcinoma with {sup 90}Y. However, the quality of the PET data obtained is compromised by several factors, including poor count statistics and a very high random fraction. This work uses Monte Carlo simulations to investigate what impact factors other than low count statistics have on the quantification of {sup 90}Y PET. Methods: PET acquisitions of two phantoms—a NEMA PET phantom and the NEMA IEC PET body phantom-containing either {sup 90}Y or {sup 18}F were simulated using GATE. Simulated projections were created with subsets of the simulation data allowing the contributions of random, scatter, and LSO background to be independently evaluated. The simulated projections were reconstructed using the commercial software for the simulated scanner, and the quantitative accuracy of the reconstruction and the contrast recovery of the reconstructed images were evaluated. Results: The quantitative accuracy of the {sup 90}Y reconstructions were not strongly influenced by the high random fraction present in the projection data, and the activity concentration was recovered to within 5% of the known value. The contrast recovery measured for simulated {sup 90}Y data was slightly poorer than that for simulated {sup 18}F data with similar count statistics. However, the degradation was not strongly linked to any particular factor. Using a more restricted energy range to reduce the random fraction in the projections had no significant effect. Conclusions: Simulations of {sup 90}Y PET confirm that quantitative {sup 90}Y is achievable with the same approach as that used for {sup 18}F, and that there is likely very little margin for improvement by attempting to model aspects unique to {sup 90}Y, such as the much higher random fraction or the presence of

First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation

International Nuclear Information System (INIS)

Garin, Etienne; Bourguet, Patrick; Rolland, Yan; Boucher, Eveline; Ardisson, Valerie; Laffont, Sophie; Boudjema, Karim; Raoul, Jean-Luc

2010-01-01

We report a first experience involving the use of 90 Y radiolabelled microspheres (TheraSphere) for the treatment of mainly primary hepatic tumours. Treatment using TheraSphere microspheres was planned in 15 patients (13 with hepatocellular carcinoma, 2 with neuroendocrine tumour metastases). The treatment was preceded by a first angiography aimed at embolizing the vascularizing arterial branches of other structures outside the liver and evaluating the percentage of pulmonary shunt by scintiscanning after perfusion with 99m Tc-MAA. The objective of the treatment carried out during a second angiography was to deliver a dose of 120±20 Gy (mean±SD) to the target hepatic volume. Technical difficulties were encountered in embolizing gastroduodenal or gastric branches in two patients and in one patient these led to cancellation of the treatment. A total of 14 patients were treated with an average activity of 3.18 GBq. In one patient, the injection was defective (stagnation of microspheres at the outlet of the catheter). SPECT/CT acquisitions provided important information in four patients (visualization of the gallbladder in three; visualization of the stomach in one, leading to a new coiling). The average exposure of the nuclear medicine physician carrying out the injections was 64±80μSv at the fingers. A partial response was seen in six patients, stabilization in five and progression in three. One patient presented with a gastric ulcer and two showed an increase in their hepatocellular insufficiency. Although sometimes technically difficult, the use of TheraSphere microspheres is a worthwhile therapeutic approach because of the low level exposure of operators and the encouraging rate of response or stabilization. The use of SPECT/CT contributes greatly to helping therapeutic planning, especially in the learning curve or when the angiographic procedure is difficult. (orig.)

First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation.

Science.gov (United States)

Garin, Etienne; Rolland, Yan; Boucher, Eveline; Ardisson, Valérie; Laffont, Sophie; Boudjema, Karim; Bourguet, Patrick; Raoul, Jean-Luc

2010-03-01

We report a first experience involving the use of (90)Y radiolabelled microspheres (TheraSphere) for the treatment of mainly primary hepatic tumours. Treatment using TheraSphere microspheres was planned in 15 patients (13 with hepatocellular carcinoma, 2 with neuroendocrine tumour metastases). The treatment was preceded by a first angiography aimed at embolizing the vascularizing arterial branches of other structures outside the liver and evaluating the percentage of pulmonary shunt by scintiscanning after perfusion with (99m)Tc-MAA. The objective of the treatment carried out during a second angiography was to deliver a dose of 120+/-20 Gy (mean+/-SD) to the target hepatic volume. Technical difficulties were encountered in embolizing gastroduodenal or gastric branches in two patients and in one patient these led to cancellation of the treatment. A total of 14 patients were treated with an average activity of 3.18 GBq. In one patient, the injection was defective (stagnation of microspheres at the outlet of the catheter). SPECT/CT acquisitions provided important information in four patients (visualization of the gallbladder in three; visualization of the stomach in one, leading to a new coiling). The average exposure of the nuclear medicine physician carrying out the injections was 64+/-80 microSv at the fingers. A partial response was seen in six patients, stabilization in five and progression in three. One patient presented with a gastric ulcer and two showed an increase in their hepatocellular insufficiency. Although sometimes technically difficult, the use of TheraSphere microspheres is a worthwhile therapeutic approach because of the low level exposure of operators and the encouraging rate of response or stabilization. The use of SPECT/CT contributes greatly to helping therapeutic planning, especially in the learning curve or when the angiographic procedure is difficult.

First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation

Energy Technology Data Exchange (ETDEWEB)

Garin, Etienne; Bourguet, Patrick [Comprehensive Cancer Center Eugene Marquis, Department of Nuclear Medicine, Rennes (France); University of Rennes 1, European University of Brittany/EA MDC, Rennes (France); Rolland, Yan [Comprehensive Cancer Center Eugene Marquis, Department of Medical Imaging, Rennes (France); Boucher, Eveline [Comprehensive Cancer Center Eugene Marquis, Department of Medical Oncology, Rennes (France); Ardisson, Valerie; Laffont, Sophie [Comprehensive Cancer Center Eugene Marquis, Department of Nuclear Medicine, Rennes (France); Boudjema, Karim [University of Rennes 1, European University of Brittany/EA MDC, Rennes (France); CHU Pontchaillou, Department of Digestive Surgery, Rennes (France); Raoul, Jean-Luc [University of Rennes 1, European University of Brittany/EA MDC, Rennes (France); Comprehensive Cancer Center Eugene Marquis, Department of Medical Oncology, Rennes (France)

2010-03-15

We report a first experience involving the use of {sup 90}Y radiolabelled microspheres (TheraSphere) for the treatment of mainly primary hepatic tumours. Treatment using TheraSphere microspheres was planned in 15 patients (13 with hepatocellular carcinoma, 2 with neuroendocrine tumour metastases). The treatment was preceded by a first angiography aimed at embolizing the vascularizing arterial branches of other structures outside the liver and evaluating the percentage of pulmonary shunt by scintiscanning after perfusion with {sup 99m}Tc-MAA. The objective of the treatment carried out during a second angiography was to deliver a dose of 120{+-}20 Gy (mean{+-}SD) to the target hepatic volume. Technical difficulties were encountered in embolizing gastroduodenal or gastric branches in two patients and in one patient these led to cancellation of the treatment. A total of 14 patients were treated with an average activity of 3.18 GBq. In one patient, the injection was defective (stagnation of microspheres at the outlet of the catheter). SPECT/CT acquisitions provided important information in four patients (visualization of the gallbladder in three; visualization of the stomach in one, leading to a new coiling). The average exposure of the nuclear medicine physician carrying out the injections was 64{+-}80{mu}Sv at the fingers. A partial response was seen in six patients, stabilization in five and progression in three. One patient presented with a gastric ulcer and two showed an increase in their hepatocellular insufficiency. Although sometimes technically difficult, the use of TheraSphere microspheres is a worthwhile therapeutic approach because of the low level exposure of operators and the encouraging rate of response or stabilization. The use of SPECT/CT contributes greatly to helping therapeutic planning, especially in the learning curve or when the angiographic procedure is difficult. (orig.)

Development of {sup 90}Sr-{sup 90}Y generators; Desenvolvimento de geradores de {sup 90}Sr-{sup 90}Y

Energy Technology Data Exchange (ETDEWEB)

Barrio, Graciela, E-mail: gracielabarrio@gmail.co [Pontificia Univ. Catolica de Sao Paulo (PUC-SP), SP (Brazil). Dept. de Fisica; Osso Junior, Joao Alberto, E-mail: jaossoj@ipen.b [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil)

2007-07-01

Yttrium-90 is a radioisotope of great interest in the field of Nuclear Medicine. It is considered one of the most important and most used radionuclides for radioimmunotherapeutical applications, especially promising for the treatment of certain types of cancer. Another important application of {sup 90}Y is radio synovectomy. This radionuclide has a half-life of 64 hours, emits long range beta particles (maximum energy of 2.3 MeV) and decays, without intermediate nuclides, to a stable daughter. {sup 90}Y may be obtained carrier-free, generated by the decay of its parent {sup 90}Sr (half-life=28 years). {sup 90}Sr is a product from uranium fission, and due to its long half-life, can be indefinitely used, which is certainly advantageous. It is present in great amounts, and needs to be processed and purified in order to be used as raw material for the generators. Generators of {sup 90}Sr-{sup 90}Y may thus be used during various months, due to {sup 90}Sr long half-life. Several methods for the separation of {sup 90}Y from {sup 90}Sr by solvent extraction and ion exchange have been reported in literature. Thanks to its simplicity, ion exchange techniques have been more commonly used for this generator system. The main objective of this work was to develop a methodology for the preparation of {sup 90}Sr-{sup 90}Y generators, using cationic exchange resins. In such method, {sup 90}Sr is strongly adsorbed in the resin and {sup 90}Y is eluted by a 0.003 M EDTA solution. According to the quality control carried out, results showed that elution yields are greater than 65%, thus confirming the efficiency of the separation method used.

Improved quantitative 90 Y bremsstrahlung SPECT/CT reconstruction with Monte Carlo scatter modeling.

Science.gov (United States)

Dewaraja, Yuni K; Chun, Se Young; Srinivasa, Ravi N; Kaza, Ravi K; Cuneo, Kyle C; Majdalany, Bill S; Novelli, Paula M; Ljungberg, Michael; Fessler, Jeffrey A

2017-12-01

In 90 Y microsphere radioembolization (RE), accurate post-therapy imaging-based dosimetry is important for establishing absorbed dose versus outcome relationships for developing future treatment planning strategies. Additionally, accurately assessing microsphere distributions is important because of concerns for unexpected activity deposition outside the liver. Quantitative 90 Y imaging by either SPECT or PET is challenging. In 90 Y SPECT model based methods are necessary for scatter correction because energy window-based methods are not feasible with the continuous bremsstrahlung energy spectrum. The objective of this work was to implement and evaluate a scatter estimation method for accurate 90 Y bremsstrahlung SPECT/CT imaging. Since a fully Monte Carlo (MC) approach to 90 Y SPECT reconstruction is computationally very demanding, in the present study the scatter estimate generated by a MC simulator was combined with an analytical projector in the 3D OS-EM reconstruction model. A single window (105 to 195-keV) was used for both the acquisition and the projector modeling. A liver/lung torso phantom with intrahepatic lesions and low-uptake extrahepatic objects was imaged to evaluate SPECT/CT reconstruction without and with scatter correction. Clinical application was demonstrated by applying the reconstruction approach to five patients treated with RE to determine lesion and normal liver activity concentrations using a (liver) relative calibration. There was convergence of the scatter estimate after just two updates, greatly reducing computational requirements. In the phantom study, compared with reconstruction without scatter correction, with MC scatter modeling there was substantial improvement in activity recovery in intrahepatic lesions (from > 55% to > 86%), normal liver (from 113% to 104%), and lungs (from 227% to 104%) with only a small degradation in noise (13% vs. 17%). Similarly, with scatter modeling contrast improved substantially both visually and in

Quantitative and Qualitative Assessment of Yttrium-90 PET/CT Imaging

OpenAIRE

Attarwala, Ali Asgar; Molina-Duran, Flavia; Büsing, Karen-Anett; Schönberg, Stefan O.; Bailey, Dale L.; Willowson, Kathy; Glatting, Gerhard

2014-01-01

Yttrium-90 is known to have a low positron emission decay of 32 ppm that may allow for personalized dosimetry of liver cancer therapy with (90)Y labeled microspheres. The aim of this work was to image and quantify (90)Y so that accurate predictions of the absorbed dose can be made. The measurements were performed within the QUEST study (University of Sydney, and Sirtex Medical, Australia). A NEMA IEC body phantom containing 6 fillable spheres (10-37 mm ∅) was used to measure the 90Y distribut...

radio embolization of yttrium 90 glass microspheres in treatment of hepatocellular carcinoma

International Nuclear Information System (INIS)

El Fouly, A.H.A.

2010-01-01

Hepatocellular carcinoma (HCC) is a common cancer that typically occurs in the setting of cirrhosis and chronic hepatitis virus infections. HCC is considered currently as global problem; its incidence is expected to increase dramatically by the next few decades. More than 90 % of the accidentally diagnosed patients have non resectable tumor. Portal vein thrombosis, diffuse multifocal liver infiltration and large tumor burden are considered to be a great obstacle in front of the modern lines of treatment, even with Child A liver cirrhosis. Transarterial intrahepatic application of Yttrium-90 glass microspheres may allow effective local ablative treatment of patients with intrahepatic advanced hepatocellular carcinoma (HCC) with or without portal vein thrombosis. The aim of this open-label phase II study was to validate evidence on the safety and efficacy of this treatment in an European cohort of patients with locally advanced HCC such as (large tumor burden, multifocal distribution, portal vein thrombosis). And to assess the response rate according to different approved response assessment guidelines (WHO, RECIST and EASL). Patients and Methods Starting from November 2006 till March 2009, one hundred and eight advanced unresectable HCC patients with and without portal vein thrombosis were included in this prospective study. Yttrium-90 microspheres radiotherapy was performed in a lobar fashion through the right or left hepatic artery. In bilobar disease, right and left liver lobe were treated with 4-6 weeks intervals in between. Response rate was assessed according to different international response assessment criteria (WHO, RECIST and EASL) with sequential computed tomography scans till the last clinical visit or death. The safety of this technique was assessed according to the Common Toxicity Criteria version 3

Development of techniques for rapid analysis of 90Sr breakthrough and 90Y activity from a 90Sr-90Y generator

International Nuclear Information System (INIS)

Chism, S.E.; Goodwin, D.A.; Meares, C.F.

1986-01-01

Recently there has been interest in labelling monoclonal antibodies with therapeutic amounts of a pure beta emitting isotope. 90 Y offers many desirable features and may be conveniently and economically obtained from a 90 Sr- 90 Y generator. A potential hazard with this system is breakthrough of the parent 90 Sr which has a half life of 28 years and is an extremely toxic bone seeking isotope. Therefore it is essential that the daughter be completely separated from its parent. We have devised two simple techniques which allow us to monitor rapidly the amount of 90 Sr breakthrough and quantitate the 90 Y activity over a 5 log range. (author)

Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis.

Science.gov (United States)

Salem, Riad; Lewandowski, Robert; Roberts, Carol; Goin, James; Thurston, Kenneth; Abouljoud, Marwan; Courtney, Angi

2004-04-01

Intra-arterial injection of Yttrium-90 glass microspheres ((90)Y- microS; TheraSphere, MDS Nordion, Ottawa, Canada) is indicated for treatment of unresectable hepatocellular carcinoma (HCC) in the presence of acceptable liver function. This study presents hepatic toxicity results after unilobar and bilobar intra-arterial administration of (90)Y- microS in patients with unresectable HCC who had known portal vein thrombosis (PVT) without evidence of cavernous transformation. Fifteen patients with unresectable HCC and PVT of one or both first order and related segmental portal venous branches received a total of 29 infusions of (90)Y- microS for treatment of HCC. All patients had pretreatment evaluation including: computed tomography (CT) imaging, alpha-fetoprotein (AFP) levels, liver function tests, technetium-99m macroaggregated albumin ((99)Tc-MAA) scan for evaluation of lung and visceral shunting, and angiography with visualization into the portal venous phase. (90)Y- micro S dose was based on lobar hepatic volume with adjustment for lung shunt activity. Liver toxicity was assessed by serum total bilirubin graded for severity according to the NIH NCI Clinical Toxicity Criteria (CTC version 2.0). Other adverse events were reported according to the standards established by the Society of Interventional Radiology. There were no procedural complications with delivery of (90)Y- microS, and treatment was well tolerated by all patients. Increased post-treatment bilirubin levels were observed across all treatments in five patients, four of whom had CT or AFP evidence of intrahepatic disease progression. After initial treatment, two patients developed bilirubin toxicity (grades 1 and 2); one patient demonstrated an increment in bilirubin toxicity grade (grade 1 to grade 3) and one patient had an improvement in grade after initial treatment. There were no new treatment-related toxicities in nine patients after a second treatment. (90)Y- microS treatment was well tolerated

Progress of 90Y generator preparation

International Nuclear Information System (INIS)

Yin Bangshun; Li Mingqi; Deng Qimin; Cheng Zuoyong

2009-01-01

90 Y is an important radionuclide in radioimmunotherapy. The medical 90 Y is mainly obtained from 90 Y generator through methods of precipitation,coprecipitation, electrodeposition, solvent extraction, chromatography and so on. The progress of 90 Y generator, the advantages and disadvantages of different types of 90 Y generator, and the tendency of 90 Y generator preparation were described respectively. Comprehensive analysis showed that inorganic ion-exchange chromatography will be the main tendency of future 90 Y generator preparation. (authors)

Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer

International Nuclear Information System (INIS)

Ho, S.; Lau, W.Y.; Leung, T.W.T.; Chan, M.; Johnson, P.J.; Li, A.K.C.

1997-01-01

Radiation doses to the tumour and non-tumorous liver compartments from yttrium-90 microspheres in the treatment of hepatic cancer, as estimated by a partition model, have been verified by correlation with the actual doses measured with a beta probe at open surgery. The validity of the doses to the lungs, the tumour and non-tumours liver compartment as estimated by the partition model was further evaluated in clinical settings. On the basis of the observation that one of three patients who received more than 30 Gy from a single treatment and one of two patients who received more than 50 Gy from multiple treatments developed radiation pneumonitis, it was deduced that an estimated lung dose 30 Gy as estimated by the partition model and were predicted to develop radiation pneumonitis, did so despite the use of partial hepatic embolization to reduce the degree of lung shunting. Furthermore, a higher radiological response rate and prolonged survival were found in the group of patients who received higher tumour doses, as estimated by the partition model, than in the group with lower estimated tumour doses. Thus the radiation doses estimated by the partition model can be used to predict (a) complication rate, (b) response rate and (c) duration of survival in the same manner as the actual radiation doses measured with a beta probe at open surgery. The partition model has made selective internal radiation therapy using 90 Y microspheres safe and repeatable without laparotomy. (orig.)

Hanford isotope project strategic business analysis yttrium-90 (Y-90)

International Nuclear Information System (INIS)

1995-10-01

The purpose of this analysis is to address the short-term direction for the Hanford yttrium-90 (Y-90) project. Hanford is the sole DOE producer of Y-90, and is the largest repository for its source in this country. The production of Y-90 is part of the DOE Isotope Production and Distribution (IP and D) mission. The Y-90 is ''milked'' from strontium-90 (Sr-90), a byproduct of the previous Hanford missions. The use of Sr-90 to produce Y-90 could help reduce the amount of waste material processed and the related costs incurred by the clean-up mission, while providing medical and economic benefits. The cost of producing Y-90 is being subsidized by DOE-IP and D due to its use for research, and resultant low production level. It is possible that the sales of Y-90 could produce full cost recovery within two to three years, at two curies per week. Preliminary projections place the demand at between 20,000 and 50,000 curies per year within the next ten years, assuming FDA approval of one or more of the current therapies now in clinical trials. This level of production would incentivize private firms to commercialize the operation, and allow the government to recover some of its sunk costs. There are a number of potential barriers to the success of the Y-90 project, outside the control of the Hanford Site. The key issues include: efficacy, Food and Drug Administration (FDA) approval and medical community acceptance. There are at least three other sources for Y-90 available to the US users, but they appear to have limited resources to produce the isotope. Several companies have communicated interest in entering into agreements with Hanford for the processing and distribution of Y-90, including some of the major pharmaceutical firms in this country

Hanford isotope project strategic business analysis yttrium-90 (Y-90)

Energy Technology Data Exchange (ETDEWEB)

NONE

1995-10-01

The purpose of this analysis is to address the short-term direction for the Hanford yttrium-90 (Y-90) project. Hanford is the sole DOE producer of Y-90, and is the largest repository for its source in this country. The production of Y-90 is part of the DOE Isotope Production and Distribution (IP and D) mission. The Y-90 is ``milked`` from strontium-90 (Sr-90), a byproduct of the previous Hanford missions. The use of Sr-90 to produce Y-90 could help reduce the amount of waste material processed and the related costs incurred by the clean-up mission, while providing medical and economic benefits. The cost of producing Y-90 is being subsidized by DOE-IP and D due to its use for research, and resultant low production level. It is possible that the sales of Y-90 could produce full cost recovery within two to three years, at two curies per week. Preliminary projections place the demand at between 20,000 and 50,000 curies per year within the next ten years, assuming FDA approval of one or more of the current therapies now in clinical trials. This level of production would incentivize private firms to commercialize the operation, and allow the government to recover some of its sunk costs. There are a number of potential barriers to the success of the Y-90 project, outside the control of the Hanford Site. The key issues include: efficacy, Food and Drug Administration (FDA) approval and medical community acceptance. There are at least three other sources for Y-90 available to the US users, but they appear to have limited resources to produce the isotope. Several companies have communicated interest in entering into agreements with Hanford for the processing and distribution of Y-90, including some of the major pharmaceutical firms in this country.

Phase transformation, morphology evolution and luminescence property variation in Y2O3: Eu hollow microspheres

International Nuclear Information System (INIS)

Wang, Qin; Guo, Jing; Jia, Wenjing; Liu, Baocang; Zhang, Jun

2012-01-01

Highlights: ► We report a general and facile method for the synthesis of Y 2 O 3 : Eu hollow microspheres. ► This method may be of great significance in the synthesis of many other hollow spherical materials. ► Phase, morphology and luminescence property were found to be strongly dependent on temperature and pH. ► The evolution process under various temperatures and pH values were discussed. ► The sample shows a strong red emission under short UV irradiation, and the lifetime is determined to be 7.0 ms. - Abstract: Y 2 O 3 : Eu hollow microspheres with average size of 500–600 nm have been successfully synthesized via a solvothermal method in the presence of sodium citrate as surfactant followed by a subsequent heat treatment process. High polymer F127(EO 106 PO 70 EO 106 ) served as a soft template in the formation of as prepared hollow microspheres. It is found that the pH values and the reaction temperature are two crucial factors in determining the phase, morphology and luminescence properties of the Y 2 O 3 : Eu hollow microspheres. Morphology evolution can be achieved by changing the pH and the reaction temperature. The properties of the Eu 3+ -doped Y 2 O 3 : Eu nanocrystals were characterized by XRD, FE-SEM, HR-TEM and UV–vis spectroscopy.

Dosimetry and prescription in liver radioembolization with 90Y microspheres: 3D calculation of tumor-to-liver ratio from global 99mTc-MAA SPECT information

Science.gov (United States)

Mañeru, Fernando; Abós, Dolores; Bragado, Laura; Fuentemilla, Naiara; Caudepón, Fernando; Pellejero, Santiago; Miquelez, Santiago; Rubio, Anastasio; Goñi, Elena; Hernández-Vitoria, Araceli

2017-12-01

Dosimetry in liver radioembolization with 90Y microspheres is a fundamental tool, both for the optimization of each treatment and for improving knowledge of the treatment effects in the tissues. Different options are available for estimating the administered activity and the tumor/organ dose, among them the so-called partition method. The key factor in the partition method is the tumor/normal tissue activity uptake ratio (T/N), which is obtained by a single-photon emission computed tomography (SPECT) scan during a pre-treatment simulation. The less clear the distinction between healthy and tumor parenchyma within the liver, the more difficult it becomes to estimate the T/N ratio; therefore the use of the method is limited. This study presents a methodology to calculate the T/N ratio using global information from the SPECT. The T/N ratio is estimated by establishing uptake thresholds consistent with previously performed volumetry. This dose calculation method was validated against 3D voxel dosimetry, and was also compared with the standard partition method based on freehand regions of interest (ROI) outlining on SPECT slices. Both comparisons were done on a sample of 20 actual cases of hepatocellular carcinoma treated with resin microspheres. The proposed method and the voxel dosimetry method yield similar results, while the ROI-based method tends to over-estimate the dose to normal tissues. In addition, the variability associated with the ROI-based method is more extreme than the other methods. The proposed method is simpler than either the ROI or voxel dosimetry approaches and avoids the subjectivity associated with the manual selection of regions.

Development of 90Sr/90Y Generator Systems Based on SLM Techniques for Radiolabelling of Therapeutic Biomolecules with 90Y. Chapter 14

International Nuclear Information System (INIS)

Thu, N.T.; Van Dong, D.; Van Cuong, B.; Van Khoa, C.; Cam Hoa, V.T.

2015-01-01

Yttrium-90 is one of the most useful radionuclides for radioimmunotherapeutic applications, especially for labelling peptides and antibodies. Studies were carried out to develop a 90 Sr/ 90 Y generator system based on the SLM technique. Two stages of 90 Sr/ 90 Y generator systems were developed at different activity levels of 5, 20, 50 and 100 mCi and operated with semiautomation in sequential mode. In the first stage of the system, PC88A based SLM was used, which transported 90 Y from a nitric acid medium containing 0.01–4M HNO 3 . In the second stage, the 90 Y from the first stage was transferred to the first compartment of the second stage using carbamoylmethyl phosphine oxide (CMPO) based SLM where 1M acetic acid was used as the receiving phase for 90 Y. Quality control was carried out for the products of 90 Y using EPC with paper chromatography and Tec control chromatography. Peptides and antibodies were labelled using the 90 Y product obtained from the generator developed in house. (author)

A method for energy window optimization for quantitative tasks that includes the effects of model-mismatch on bias: application to Y-90 bremsstrahlung SPECT imaging

International Nuclear Information System (INIS)

Rong Xing; Du Yong; Frey, Eric C

2012-01-01

Quantitative Yttrium-90 ( 90 Y) bremsstrahlung single photon emission computed tomography (SPECT) imaging has shown great potential to provide reliable estimates of 90 Y activity distribution for targeted radionuclide therapy dosimetry applications. One factor that potentially affects the reliability of the activity estimates is the choice of the acquisition energy window. In contrast to imaging conventional gamma photon emitters where the acquisition energy windows are usually placed around photopeaks, there has been great variation in the choice of the acquisition energy window for 90 Y imaging due to the continuous and broad energy distribution of the bremsstrahlung photons. In quantitative imaging of conventional gamma photon emitters, previous methods for optimizing the acquisition energy window assumed unbiased estimators and used the variance in the estimates as a figure of merit (FOM). However, for situations, such as 90 Y imaging, where there are errors in the modeling of the image formation process used in the reconstruction there will be bias in the activity estimates. In 90 Y bremsstrahlung imaging this will be especially important due to the high levels of scatter, multiple scatter, and collimator septal penetration and scatter. Thus variance will not be a complete measure of reliability of the estimates and thus is not a complete FOM. To address this, we first aimed to develop a new method to optimize the energy window that accounts for both the bias due to model-mismatch and the variance of the activity estimates. We applied this method to optimize the acquisition energy window for quantitative 90 Y bremsstrahlung SPECT imaging in microsphere brachytherapy. Since absorbed dose is defined as the absorbed energy from the radiation per unit mass of tissues in this new method we proposed a mass-weighted root mean squared error of the volume of interest (VOI) activity estimates as the FOM. To calculate this FOM, two analytical expressions were derived for

A method for energy window optimization for quantitative tasks that includes the effects of model-mismatch on bias: application to Y-90 bremsstrahlung SPECT imaging.

Science.gov (United States)

Rong, Xing; Du, Yong; Frey, Eric C

2012-06-21

Quantitative Yttrium-90 ((90)Y) bremsstrahlung single photon emission computed tomography (SPECT) imaging has shown great potential to provide reliable estimates of (90)Y activity distribution for targeted radionuclide therapy dosimetry applications. One factor that potentially affects the reliability of the activity estimates is the choice of the acquisition energy window. In contrast to imaging conventional gamma photon emitters where the acquisition energy windows are usually placed around photopeaks, there has been great variation in the choice of the acquisition energy window for (90)Y imaging due to the continuous and broad energy distribution of the bremsstrahlung photons. In quantitative imaging of conventional gamma photon emitters, previous methods for optimizing the acquisition energy window assumed unbiased estimators and used the variance in the estimates as a figure of merit (FOM). However, for situations, such as (90)Y imaging, where there are errors in the modeling of the image formation process used in the reconstruction there will be bias in the activity estimates. In (90)Y bremsstrahlung imaging this will be especially important due to the high levels of scatter, multiple scatter, and collimator septal penetration and scatter. Thus variance will not be a complete measure of reliability of the estimates and thus is not a complete FOM. To address this, we first aimed to develop a new method to optimize the energy window that accounts for both the bias due to model-mismatch and the variance of the activity estimates. We applied this method to optimize the acquisition energy window for quantitative (90)Y bremsstrahlung SPECT imaging in microsphere brachytherapy. Since absorbed dose is defined as the absorbed energy from the radiation per unit mass of tissues in this new method we proposed a mass-weighted root mean squared error of the volume of interest (VOI) activity estimates as the FOM. To calculate this FOM, two analytical expressions were

A Woman with Black Beads in Her Stomach: Severe Gastric Ulceration Caused by Yttrium-90 Radioembolization

Directory of Open Access Journals (Sweden)

Indu S. Voruganti

2018-01-01

Full Text Available Radioembolization (RE is a selective internal radiation therapy (SIRT delivering targeted, high-dose, intra-arterial radiation directly to the vascular supply of liver tumors. Complications can occur due to aberrant deposition or migration of radiation microspheres into nontarget locations, including normal hepatic parenchyma, lungs, pancreas, and upper gastrointestinal (UGI tract. We report a case of gastric ulcers due to yttrium-90 (90Y seed migration to the stomach to alert clinicians to this rare cause of gastric injury. A 57-year-old woman with stage IV breast cancer with liver and lung metastases presented to the hospital with 2 months of worsening nausea and vomiting. Two months prior, she had received SIRT with 90Y microspheres without complications. Upper GI endoscopy showed diffuse gastritis and extensive antral ulceration. Biopsies revealed black, spherical foreign bodies, consistent with 90Y microspheres, documenting radiation injury. Radiation-induced UGI ulceration is caused by direct radiation injury from beta-radiation. Delay in diagnosis may be due to the nonspecificity of symptoms and temporal delay of symptom onset from SIRT, which was 2 months in our patient. Also, complaints may be attributed erroneously to adjuvant chemotherapy or widespread metastatic disease. Clinicians must consider radiation-associated toxicity in any SIRT-treated patient developing abdominal symptoms.

Validation of an extraction paper chromatography (EPC) technique for estimation of trace levels of 90Sr in 90Y solutions obtained from 90Sr/90Y generator systems

International Nuclear Information System (INIS)

Usha Pandey; Yogendra Kumar; Ashutosh Dash

2014-01-01

While the extraction paper chromatography (EPC) technique constitutes a novel paradigm for the determination of few Becquerels of 90 Sr in MBq quantities of 90 Y obtained from 90 Sr/ 90 Y generator, validation of the technique is essential to ensure its usefulness as a real time analytical tool. With a view to explore the relevance and applicability of EPC technique as a real time quality control (QC) technique for the routine estimation of 90 Sr content in generator produced 90 Y, a systematic validation study was carried out diligently not only to establish its worthiness but also to broaden its horizon. The ability of the EPC technique to separate trace amounts of Sr 2+ in the presence of large amounts of Y 3+ was verified. The specificity of the technique for Y 3+ was demonstrated with 90 Y obtained by neutron irradiation. The method was validated under real experimental conditions and compared with a QC method described in US Pharmacopeia for detection of 90 Sr levels in 90 Y radiopharmaceuticals. (author)

Treatment of primary liver tumors with Yttrium-90 microspheres (TheraSphere) in high risk patients: analysis of survival and toxicities.

Science.gov (United States)

Reardon, Kelli A; McIntosh, Alyson F; Shilling, A Tanner; Hagspiel, Klaus D; Al-Osaimi, Abdullah; Berg, Carl; Caldwell, Stephen H; Northup, Patrick G; Angle, Fritz; Mulder, Robert; Rich, Tyvin A

2009-02-01

This retrospective study was undertaken to obtain information regarding the survival and toxicities after Yttrium-90 microspheres treatment in patients with primary liver malignancies. Baseline, treatment, and follow-up data were collected and analyzed for 21 patients treated with Yttrium-90 microspheres. Survival analysis was then performed. The results of this study showed that median survival for all the patients was 120 days. Twenty of 21 patients were categorized as high-risk with a median survival of 114 days. It was also found that one high-risk patient has survived 858 days with no recurrence of disease. Acute grade 3-5 toxicities were recorded for nine patients and consisted of elevations in AST and bilirubin, thrombocytopenia, abdominal pain, ascites, nausea, fatigue, and death. This study concluded that Yttrium-90 is a low-toxicity, outpatient alternative for individuals with liver cancer and without many options. The maximal value, however, may lie in the treatment of low-risk patients.

Extractive {sup 90}Y generator

Energy Technology Data Exchange (ETDEWEB)

Kodina, G.E. [State Scientific Center, Moscow (Russian Federation). Institute of Giophysics; Korpusov, G.V.; Filyanin, A.T. [Russian Academy of Sciences, Moscow (Russian Federation). Institute of Physical Chemistry

1997-10-01

The generator for {sup 90}Y production is made up of two units - an extractive unit and a unit for deep purification. Contrary to the well-known methods of {sup 90}Y separation two mineral acids are used in the developed technology. The solutions of nitric acid are used for preliminary separation of {sup 90}Y and the solutions of hydrochloric acid are used for the deep purification of {sup 90}Y from {sup 90}Sr and stripping. The optimum conditions for carrying out this technology were found. The following results are reported: the carry-over of the stationary phase is excluded in this generator; the separation time is 30-60 minutes; the yield of the final product is not less than 95%; impurity of {sup 90}Sr is not more than 10{sup -9-}-{sup -10}%; the content of the chemical (nonactive) impurities is not more than the allowed one for radiopharmaceuticals 4 refs., 4 tabs., 5 figs.

Early post-treatment FDG PET predicts survival after {sup 90}Y microsphere radioembolization in liver-dominant metastatic colorectal cancer

Energy Technology Data Exchange (ETDEWEB)

Sabet, Amir; Aouf, Anas; Sabet, Amin; Ghamari, Shahab; Biersack, Hans-Juergen [University Hospital, Department of Nuclear Medicine, Bonn (Germany); Meyer, Carsten; Pieper, Claus C. [University Hospital, Department of Radiology, Bonn (Germany); Mayer, Karin [University Hospital, Department of Medicine and Oncology, Bonn (Germany); Ezziddin, Samer [University Hospital, Department of Nuclear Medicine, Bonn (Germany); Saarland University, Department of Nuclear Medicine, Homburg (Germany)

2014-10-29

The aim of this study was to evaluate the predictive value of early metabolic response 4 weeks post-treatment using {sup 18}F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT in patients with unresectable hepatic metastases of colorectal cancer (CRC) undergoing radioembolization (RE) with {sup 90}Y-labelled microspheres. A total of 51 consecutive patients with liver-dominant metastases of CRC were treated with RE and underwent {sup 18}F-FDG PET/CT at baseline and 4 weeks after RE. In each patient, three hepatic metastases with the highest maximum standardized uptake value (SUV{sub max}) were selected as target lesions. Metabolic response was defined as >50 % reduction of tumour to liver ratios. Survival analyses using Kaplan-Meier and multivariate analyses were performed to identify prognostic factors for overall survival (OS). Investigated baseline characteristics included age (>60 years), performance status (Eastern Cooperative Oncology Group >1), bilirubin (>1.0 mg/dl), hepatic tumour burden (>25 %) and presence of extrahepatic disease. The median OS after RE was 7 months [95 % confidence interval (CI) 5-8]; early metabolic responders (n = 33) survived longer than non-responders (p < 0.001) with a median OS of 10 months (95 % CI 3-16) versus 4 months (95 % CI 2-6). Hepatic tumour burden also had significant impact on treatment outcome (p < 0.001) with a median OS of 5 months (95 % CI, 3-7) for patients with >25 % metastatic liver replacement vs 14 months (95 % CI 6-22) for the less advanced patients. Both factors (early metabolic response and low hepatic tumour burden) remained as independent predictors of improved survival on multivariate analysis. These are the first findings to show that molecular response assessment in CRC using {sup 18}F-FDG PET/CT appears feasible as early as 4 weeks post-RE, allowing risk stratification and potentially facilitating early response-adapted treatment strategies. (orig.)

Experimental autoabsorption curve 90Sr in SrCO3. Efficiency calculation to detection of 90Sr, 90Y and 90Sr + 90Y in a beta gas proportional counter

International Nuclear Information System (INIS)

Gasco, C.; Alvarez, A.

1987-01-01

Strontium-90 has been determined by radiochemical separation techniques in environmental samples. These techniques, of course, cannot separate the two strontium radionuclides from each other of from stable strontium. Consequently the end product of the chemical separation contains all strontium isotopes in SrCO 3 . The beta particules emitted by 90 Sr are absorbed by the SrCO 3 precipitate. This is the main source of error in the activity measurement. It has been prepared sources of 90 Sr in SrCO 3 in order to determinate the counting efficiency and autoabsorption curve. Also detection efficiencies have been calibrated using known activities of 90 Y and equilibrium mixture of 90 Sr+ 90 Y in the same geometry than our samples. The activity of 90 Sr by ingrowth of 90 Y has been calculated by our computer program. (author). 2 figs., 3 refs

90Sr-90Y radionuclide generator based on ionex chromatography. Part 1 - project

International Nuclear Information System (INIS)

Miler, V.; Budsky, F.; Malek, Z.

2003-09-01

This part contains a proposal for the generator column design, materials to be used (chemicals, ionexes) and technological procedures. The proposal was inspired by the 90 Sr- 90 Y generator operated by Zfk Rossendorf. The aim was to develop and launch a generator for the preparation of carrier-free 90 Y in the form of [ 90 Y] chloride solution in dilute hydrochloric acid. The separation of Y from Sr is based on ionex chromatography by sorbing the two radionuclides on a catex. While Sr remains sorbed, 90 Y is eluted with lithium citrate. During this process, 90 Y is bonded in a citrate complex which, having a negative charge, is subsequently trapped by an anex. A guard column is inserted before the anex column to trap any traces of 90 Sr. 90 Y is eluted from the anex in the yttrium chloride form by using dilute hydrochloric acid. The product from the generator can be used for the preparation of [ 90 Y] - Fe colloid injection or [ 90 Y] - yttrium citrate injection for intra-articular application or for the development of monoclonal antibodies and peptides

Peripheral Blood Lymphocyte Depletion After Hepatic Arterial {sup 90}Yttrium Microsphere Therapy for Hepatocellular Carcinoma

Energy Technology Data Exchange (ETDEWEB)

Carr, Brian I., E-mail: brianicarr@hotmail.com [Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA and Department of Nutrition and Exptl Biology, Saverio De Bellis Medical Research Institute, Castellana Grotte, Bari (Italy); Metes, Diana M. [Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA and Department of Nutrition and Exptl Biology, Saverio De Bellis Medical Research Institute, Castellana Grotte, Bari (Italy)

2012-03-01

Purpose: The short- and long-term effects of {sup 90}Yttrium microspheres therapy for hepatocellular carcinoma (HCC) on peripheral blood lymphocytes are unknown and were therefore examined. Methods and Materials: Ninety-two HCC patients were enrolled in a {sup 90}Yttrium therapy study and routine blood counts were examined as part of standard clinical monitoring. Results: We found an early, profound, and prolonged lymphopenia. In a subsequent cohort of 25 additional HCC patients, prospective flow cytometric immune-monitoring analysis was performed to identify specific changes on distinct lymphocyte subsets (i.e., CD3, CD4, CD8 T, and CD19 B lymphocytes) and NK cells absolute numbers, in addition to the granulocytes and platelets subsets. We found that the pretreatment lymphocyte subset absolute numbers (with the exception of NK cells) had a tendency to be lower compared with healthy control values, but no significant differences were detected between groups. Posttherapy follow-up revealed that overall, all lymphocyte subsets, except for NK cells, were significantly (>50% from pretherapy values), promptly (as early as 24 h) and persistently (up to 30 months) depleted post-{sup 90}Yttrium microspheres therapy. In contrast, granulocytes increased rapidly (24 h) to compensate for lymphocyte depletion, and remained increased at 1-year after therapy. We further stratified patients into two groups, according to survival at 1 year. We found that lack of recovery of CD19, CD3, CD8, and especially CD4 T cells was linked to poor patient survival. No fungal or bacterial infections were noted during the 30-month follow-up period. Conclusions: The results show that lymphocytes (and not granulocytes, platelets, or NK cells) are sensitive to hepatic arterial {sup 90}Yttrium without associated clinical toxicity, and lack of lymphocyte recovery (possibly leading to dysregulation of adaptive cellular immunity) posttherapy indicates poor survival.

Development of methodology for the preparation of 90Sr-90Y generators

International Nuclear Information System (INIS)

Barrio, Graciela; Osso, Joao A.

2008-01-01

Among the more attractive radionuclides for therapeutic applications is yttrium-90. Its relatively short half-life (64.0h), maximum beta energy (2.28 MeV) make it well suited for a variety of applications, ranging from the radiolabeling of antibodies for tumor therapy to the production of radiolabeled particles for the treatment of liver malignancies. Yttrium-90 results from the decay of strontium-90 (28y) and decays to a stable daughter ( 90 Zr) and has no γ-ray, what makes this nuclide very attractive for therapeutic applications. 90 Y is produced through a generator system, from the decay of 90 Sr. Before it can safely employed in clinical applications, the 90 Y must be made essentially free of 90 Sr, an isotope known to cause bone marrow suppression. The objective of this work is to develop 90 Sr- 90 Y generator using a cation exchange method resin. This method was the most effects for the separation of 90 Y and 90 Sr. 90 Sr is strongly adsorbed in the resin and 90 Y is eluted in 0.003M EDTA. The generator efficiency and radionuclide control results were also evaluated using 85 Sr (γ-ray emitter). The generator was developed, using AG 50WX8 exchange resin converted to the Na+ form and then conditioned with 0.003M EDTA solution (pH=4.8). The quality control showed that 90 Y had no 8 '5Sr impurities, inside the detection limits of the detector. The results presented here are very promising, showing that the methodology is able to separate the two nuclides, with low quantities of 90 Sr impurity and satisfactory elution yields. (author)

Yttrium-90 Resin Microsphere Radioembolization Using an Antireflux Catheter: An Alternative to Traditional Coil Embolization for Nontarget Protection

International Nuclear Information System (INIS)

Morshedi, Maud M.; Bauman, Michael; Rose, Steven C.; Kikolski, Steven G.

2015-01-01

PurposeSerious complications can result from nontarget embolization during yttrium-90 (Y-90) transarterial radioembolization. Hepatoenteric artery coil embolization has been traditionally performed to prevent nontarget radioembolization. The U.S. Food and Drug Administration–approved Surefire Infusion System (SIS) catheter, designed to prevent reflux, is an alternative to coils. The hypothesis that quantifiable SIS procedural parameters are comparable to coil embolization was tested.MethodsFourteen patients aged 36–79 years with colorectal, neuroendocrine, hepatocellular, and other predominantly bilobar hepatic tumors who underwent resin microsphere Y-90 radioembolization using only the SIS catheter (n = 7) versus only detachable coils (n = 7) for nontarget protection were reviewed retrospectively. Procedure time, fluoroscopy time, contrast dose, radiation dose, and cost were evaluated.ResultsMultivariate analysis identified significant cohort differences in the procedural parameters evaluated (F(10, 3) = 10.39, p = 0.04). Between-group comparisons of the pretreatment planning procedure in the SIS catheter group compared to the coil embolization group demonstrated a significant reduction in procedure time (102.6 vs. 192.1 min, respectively, p = 0.0004), fluoroscopy time (14.3 vs. 49.7 min, respectively, p = 0.0016), and contrast material dose (mean dose of 174.3 vs. 265.0 mL, respectively, p = 0.0098). Procedural parameters were not significantly different between the two groups during subsequent dose delivery procedures. Overall cost of combined first-time radioembolization procedures was significantly less in the SIS group ($4252) compared to retrievable coil embolization ($11,123; p = 0.001).ConclusionThe SIS catheter results in a reduction in procedure time, fluoroscopy time, and contrast material dose and may be an attractive cost-effective alternative to detachable coil embolization for prevention of nontarget radioembolization

Yttrium-90 Resin Microsphere Radioembolization Using an Antireflux Catheter: An Alternative to Traditional Coil Embolization for Nontarget Protection

Energy Technology Data Exchange (ETDEWEB)

Morshedi, Maud M., E-mail: maud.morshedi@my.rfums.org; Bauman, Michael, E-mail: mbauman@ucsd.edu; Rose, Steven C., E-mail: scrose@ucsd.edu; Kikolski, Steven G., E-mail: skikolski@gmail.com [University of California San Diego Health Sciences, Radiology Department, University of California San Diego Medical Center (United States)

2015-04-15

PurposeSerious complications can result from nontarget embolization during yttrium-90 (Y-90) transarterial radioembolization. Hepatoenteric artery coil embolization has been traditionally performed to prevent nontarget radioembolization. The U.S. Food and Drug Administration–approved Surefire Infusion System (SIS) catheter, designed to prevent reflux, is an alternative to coils. The hypothesis that quantifiable SIS procedural parameters are comparable to coil embolization was tested.MethodsFourteen patients aged 36–79 years with colorectal, neuroendocrine, hepatocellular, and other predominantly bilobar hepatic tumors who underwent resin microsphere Y-90 radioembolization using only the SIS catheter (n = 7) versus only detachable coils (n = 7) for nontarget protection were reviewed retrospectively. Procedure time, fluoroscopy time, contrast dose, radiation dose, and cost were evaluated.ResultsMultivariate analysis identified significant cohort differences in the procedural parameters evaluated (F(10, 3) = 10.39, p = 0.04). Between-group comparisons of the pretreatment planning procedure in the SIS catheter group compared to the coil embolization group demonstrated a significant reduction in procedure time (102.6 vs. 192.1 min, respectively, p = 0.0004), fluoroscopy time (14.3 vs. 49.7 min, respectively, p = 0.0016), and contrast material dose (mean dose of 174.3 vs. 265.0 mL, respectively, p = 0.0098). Procedural parameters were not significantly different between the two groups during subsequent dose delivery procedures. Overall cost of combined first-time radioembolization procedures was significantly less in the SIS group ($4252) compared to retrievable coil embolization ($11,123; p = 0.001).ConclusionThe SIS catheter results in a reduction in procedure time, fluoroscopy time, and contrast material dose and may be an attractive cost-effective alternative to detachable coil embolization for prevention of nontarget radioembolization.

SU-C-204-01: A Dosimetric Investigation Into the Effects of Yttrium-90 Radioembolization On the GI Tract: In-Vivo and Histological Analysis in An Animal Model

Energy Technology Data Exchange (ETDEWEB)

Pasciak, A [University of Tennessee Medical Center, Knoxville, TN (United States); The University of Tennessee Graduate School of Medicine, Knoxville, TN (United States); Nodit, L; Bourgeois, A; Bradley, Y [The University of Tennessee Graduate School of Medicine, Knoxville, TN (United States); Paxton, B [Duke university medical center, Durham, NC (United States); Arepally, A [Vanderbilt University Medical Center, Nashville, TN (United States)

2016-06-15

Purpose: In Yttrium-90 (90Y) radioembolization, non-target embolization (NTE) to the stomach or small bowel can result in ulceration, a rare but difficult to manage clinical complication. However, dosimetric thresholds for toxicity to these tissues from radioembolization have never been evaluated in a controlled setting. We performed an analysis of the effect of 90Y radioembolization in a porcine model at different absorbed-dose endpoints. Methods: Under approval of the University of Tennessee IACUC, 6 female pigs were included in this study. Animals underwent transfemoral angiography and infusion of calibrated dosages of 90Y resin microspheres into arteries supplying part of the gastric wall. A 99mTc-MAA simulation study was performed first to determine perfused tissue volume for treatment planning along with contrast-enhanced CT. The pigs were monitored for side effects for 9 weeks, after which time they were euthanized and their upper gastrointestinal tracts were harvested for analysis. Results: 90Y radioembolization was infused resulting in average absorbed doses of between 35.5 and 91.9 Gy to the gastric wall. No animal exhibited any signs of pain or gastrointestinal distress through the duration of the study. Excised tissue showed 1–2 small (<3.0 cm2) healed or healing superficial gastric lesions in 5 out of 6 animals. Histologic analysis demonstrated that lesion location was superficial to areas of abnormally high microsphere deposition. An analysis of microsphere deposition patterns within the gastric wall indicated a high preference for submucosal deposition. Dosimetric evaluation at the luminal mucosa performed based on microsphere deposition patterns confirmed that 90Y dosimetry techniques conventionally used in hepatic dosimetry provide a reasonable estimate of absorbed dose. Conclusion: The upper gastrointestinal tract may be less sensitive to 90Y radioembolization than previously thought. Lack of charged-particle equilibrium at the luminal mucosa

Phase transformation, morphology evolution and luminescence property variation in Y{sub 2}O{sub 3}: Eu hollow microspheres

Energy Technology Data Exchange (ETDEWEB)

Wang, Qin; Guo, Jing; Jia, Wenjing; Liu, Baocang [College of Chemistry and Chemical Engineering, Inner Mongolia University, Hohhot (China); Zhang, Jun, E-mail: cejzhang@sina.com [College of Chemistry and Chemical Engineering, Inner Mongolia University, Hohhot (China)

2012-11-25

Highlights: Black-Right-Pointing-Pointer We report a general and facile method for the synthesis of Y{sub 2}O{sub 3}: Eu hollow microspheres. Black-Right-Pointing-Pointer This method may be of great significance in the synthesis of many other hollow spherical materials. Black-Right-Pointing-Pointer Phase, morphology and luminescence property were found to be strongly dependent on temperature and pH. Black-Right-Pointing-Pointer The evolution process under various temperatures and pH values were discussed. Black-Right-Pointing-Pointer The sample shows a strong red emission under short UV irradiation, and the lifetime is determined to be 7.0 ms. - Abstract: Y{sub 2}O{sub 3}: Eu hollow microspheres with average size of 500-600 nm have been successfully synthesized via a solvothermal method in the presence of sodium citrate as surfactant followed by a subsequent heat treatment process. High polymer F127(EO{sub 106}PO{sub 70}EO{sub 106}) served as a soft template in the formation of as prepared hollow microspheres. It is found that the pH values and the reaction temperature are two crucial factors in determining the phase, morphology and luminescence properties of the Y{sub 2}O{sub 3}: Eu hollow microspheres. Morphology evolution can be achieved by changing the pH and the reaction temperature. The properties of the Eu{sup 3+}-doped Y{sub 2}O{sub 3}: Eu nanocrystals were characterized by XRD, FE-SEM, HR-TEM and UV-vis spectroscopy.

SU-E-T-02: 90Y Microspheres Dosimetry Calculation with Voxel-S-Value Method: A Simple Use in the Clinic

International Nuclear Information System (INIS)

Maneru, F; Gracia, M; Gallardo, N; Olasolo, J; Fuentemilla, N; Bragado, L; Martin-Albina, M; Lozares, S; Pellejero, S; Miquelez, S; Rubio, A; Otal, A

2015-01-01

Purpose: To present a simple and feasible method of voxel-S-value (VSV) dosimetry calculation for daily clinical use in radioembolization (RE) with 90 Y microspheres. Dose distributions are obtained and visualized over CT images. Methods: Spatial dose distributions and dose in liver and tumor are calculated for RE patients treated with Sirtex Medical miscrospheres at our center. Data obtained from the previous simulation of treatment were the basis for calculations: Tc-99m maggregated albumin SPECT-CT study in a gammacamera (Infinia, General Electric Healthcare.). Attenuation correction and ordered-subsets expectation maximization (OSEM) algorithm were applied.For VSV calculations, both SPECT and CT were exported from the gammacamera workstation and registered with the radiotherapy treatment planning system (Eclipse, Varian Medical systems). Convolution of activity matrix and local dose deposition kernel (S values) was implemented with an in-house developed software based on Python code. The kernel was downloaded from www.medphys.it. Final dose distribution was evaluated with the free software Dicompyler. Results: Liver mean dose is consistent with Partition method calculations (accepted as a good standard). Tumor dose has not been evaluated due to the high dependence on its contouring. Small lesion size, hot spots in health tissue and blurred limits can affect a lot the dose distribution in tumors. Extra work includes: export and import of images and other dicom files, create and calculate a dummy plan of external radiotherapy, convolution calculation and evaluation of the dose distribution with dicompyler. Total time spent is less than 2 hours. Conclusion: VSV calculations do not require any extra appointment or any uncomfortable process for patient. The total process is short enough to carry it out the same day of simulation and to contribute to prescription decisions prior to treatment. Three-dimensional dose knowledge provides much more information than other

SU-E-T-02: 90Y Microspheres Dosimetry Calculation with Voxel-S-Value Method: A Simple Use in the Clinic

Energy Technology Data Exchange (ETDEWEB)

Maneru, F; Gracia, M; Gallardo, N; Olasolo, J; Fuentemilla, N; Bragado, L; Martin-Albina, M; Lozares, S; Pellejero, S; Miquelez, S; Rubio, A [Complejo Hospitalario de Navarra, Pamplona, Navarra (Spain); Otal, A [Hospital Clinica Benidorm, Benidorm, Alicante (Spain)

2015-06-15

Purpose: To present a simple and feasible method of voxel-S-value (VSV) dosimetry calculation for daily clinical use in radioembolization (RE) with {sup 90}Y microspheres. Dose distributions are obtained and visualized over CT images. Methods: Spatial dose distributions and dose in liver and tumor are calculated for RE patients treated with Sirtex Medical miscrospheres at our center. Data obtained from the previous simulation of treatment were the basis for calculations: Tc-99m maggregated albumin SPECT-CT study in a gammacamera (Infinia, General Electric Healthcare.). Attenuation correction and ordered-subsets expectation maximization (OSEM) algorithm were applied.For VSV calculations, both SPECT and CT were exported from the gammacamera workstation and registered with the radiotherapy treatment planning system (Eclipse, Varian Medical systems). Convolution of activity matrix and local dose deposition kernel (S values) was implemented with an in-house developed software based on Python code. The kernel was downloaded from www.medphys.it. Final dose distribution was evaluated with the free software Dicompyler. Results: Liver mean dose is consistent with Partition method calculations (accepted as a good standard). Tumor dose has not been evaluated due to the high dependence on its contouring. Small lesion size, hot spots in health tissue and blurred limits can affect a lot the dose distribution in tumors. Extra work includes: export and import of images and other dicom files, create and calculate a dummy plan of external radiotherapy, convolution calculation and evaluation of the dose distribution with dicompyler. Total time spent is less than 2 hours. Conclusion: VSV calculations do not require any extra appointment or any uncomfortable process for patient. The total process is short enough to carry it out the same day of simulation and to contribute to prescription decisions prior to treatment. Three-dimensional dose knowledge provides much more information than

The prognostic value of functional and anatomical parameters for the selection of patients receiving yttrium-90 microspheres for the treatment of liver cancer

Science.gov (United States)

Mesoloras, Geraldine

Yttrium-90 (90Y) microsphere therapy is being utilized as a treatment option for patients with primary and metastatic liver cancer due to its ability to target tumors within the liver. The success of this treatment is dependent on many factors, including the extent and type of disease and the nature of prior treatments received. Metabolic activity, as determined by PET imaging, may correlate with the number of viable cancer cells and reflect changes in viable cancer cell volume. However, contouring of PET images by hand is labor intensive and introduces an element of irreproducibility into the determination of functional target/tumor volume (FTV). A computer-assisted method to aid in the automatic contouring of FTV has the potential to substantially improve treatment individualization and outcome assessment. Commercial software to determine FTV in FDG-avid primary and metastatic liver tumors has been evaluated and optimized. Volumes determined using the automated technique were compared to those from manually drawn contours identified using the same cutoff in the standard uptake value (SUV). The reproducibility of FTV is improved through the introduction of an optimal threshold value determined from phantom experiments. Application of the optimal threshold value from the phantom experiments to patient scans was in good agreement with hand-drawn determinations of the FTV. It is concluded that computer-assisted contouring of the FTV for primary and metastatic liver tumors improves reproducibility and increases accuracy, especially when combined with the selection of an optimal SUV threshold determined from phantom experiments. A method to link the pre-treatment assessment of functional (PET based) and anatomical (CT based) parameters to post-treatment survival and time to progression was evaluated in 22 patients with colorectal cancer liver metastases treated using 90Y microspheres and chemotherapy. The values for pre-treatment parameters that were the best

90Y of high purity for medical applications

International Nuclear Information System (INIS)

Castillo, A.X.; Alvarez, E.O.; Olive, K.I.

2001-01-01

Several 90 Sr/ 90 Y-generator systems have been developed and used to produce 90 Y. The most important parameter of the 90 Y to be assayed is 90 Sr content. In addition, when labelling monoclonal antibodies for therapy trace metal quantities accompanying 90 Y (Fe 3+ , Zn 2+ , Cu 2+ , ZrO 2+ , etc.) are to be kept as low as possible in order to obtain high labelling efficiencies. Generally generators' lifetime is limited due to the 90 Sr breakthrough which increases in eluates as a result of the radiolytic degradation of the resin used as support. In the study a described procedure for 90 Y purification from metal contamination is modified in order to lower the amount of 90 Sr present in eluates from generators. As a result a very low 90 Sr content is always assured ( 90 Sr/ 90 Y -6 ). (author)

Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: The tumor selectivity of the treatment as a function of tumor to liver flow ratio

Directory of Open Access Journals (Sweden)

Dezarn William A

2007-03-01

Full Text Available Abstract Background Treatment records and follow-up data on 40 patients with primary and metastatic liver malignancies who underwent a single whole-liver treatment with Y-90 resin microspheres (SIR-Spheres® Sirtex Medical, Lake Forest, IL were retrospectively reviewed. The objective of the study was to evaluate the anatomic and physiologic determinants of radiation dose distribution, and the dose response of tumor and liver toxicity in patients with liver malignancies who underwent hepatic arterial Y-90 resin microsphere treatment. Methods Liver and tumor volume calculations were performed on pre-treatment CT scans. Fractional tumor and liver flow characteristics and lung shunt fractions were determined using hepatic arterial Tc-99m MAA imaging. Absorbed dose calculations were performed using the MIRD equations. Liver toxicity was assessed clinically and by liver function tests. Tumor response to therapy was assessed by CT and/or tumor markers. Results Of the 40 patients, 5 had hepatocellular cancer (HCC, and 35 had metastatic liver tumors (15 colorectal cancer, 10 neuroendocrine tumors, 4 breast cancer, 2 lung cancer, 1 ovarian cancer, 1 endometrial cancer, and 2 unknown primary adenocarcinoma. All patients were treated in a salvage setting with a 3 to 80 week follow-up (mean: 19 weeks. Tumor volumes ranged from 15.0 to 984.2 cc (mean: 294.9 cc and tumor to normal liver uptake ratios ranged from 2.8 to 15.4 (mean: 5.4. Average administered activity was 1.2 GBq (0.4 to 2.4 GBq. Liver absorbed doses ranged from 0.7 to 99.5 Gy (mean: 17.2 Gy. Tumor absorbed doses ranged from 40.1 to 494.8 Gy (mean: 121.5 Gy. None of the patients had clinical venoocclusive disease or therapy-induced liver failure. Seven patients (17.5 % had transient and 7 patients (17.5 % had persistent LFT abnormalities. There were 27 (67.5% responders (complete response, partial response, and stable disease. Tumor response correlated with higher tumor flow ratio as measured by

Yttrium-90 radioembolization using TheraSphere in the management of primary and secondary liver tumors.

Science.gov (United States)

Riaz, A; Lewandowski, R J; Kulik, L; Salem, R

2009-06-01

Locoregional therapies, such as transarterial chemoembolization, radioembolization and thermal ablation (e.g., radiofrequency ablation) are establishing their roles in the management of liver malignancies. With yYttrium-90 radioembolization therapy (90Y) radionuclide labeled microspheres are injected into the tumor feeding artery. This allows the delivery of a high radioactive dose to the tumor with minimal toxicity to normal tissues. 90Y has demonstrated to be safe and effective in the management of liver tumors. Authors present a review of the literature available for the use of TheraSphere for radioembolization in the management of liver tumors.

Preparation and characterization of composite microspheres for brachytherapy and hyperthermia treatment of cancer

International Nuclear Information System (INIS)

Zhao Di; Huang Wenhai; Rahaman, Mohamed N.; Day, Delbert E.; Wang Deping; Gu Yifei

2012-01-01

Composite microspheres were prepared by coating yttrium–aluminum–silicate (YAS) glass microspheres (20–30 μm) with a layer of Fe 3 O 4 nanoparticles and evaluated for potential use in brachytherapy and hyperthermia treatment of cancer. After neutron activation to form the β-emitting 90 Y radionuclide, the composite microspheres can be injected into a patient to destroy cancerous tumors; at the same time, the composite microspheres can generate heat upon application of a magnetic field to also destroy the tumors. The results showed that the composite microspheres were chemically durable when immersed in a simulated body fluid (SBF), with ∼ 0.25% weight loss and ∼ 3.2% yttrium dissolved into the SBF after 30 days at 37 °C. The composite microspheres also showed ferromagnetic properties as a result of the Fe 3 O 4 coating; when immersed in water at 20 °C (20 mg in 1 mL of water), the application of an alternating magnetic field produced a temperature increase from 20 °C to 38−46 °C depending on the thickness of the Fe 3 O 4 coating. The results indicate that these composite microspheres have promising potential in combined brachytherapy and hyperthermia treatment of cancerous tumors. - Highlights: ► Composite microspheres for brachytherapy and hyperthermia treatment of cancer. ► Fe 3 O 4 nanoparticles coated on the yttrium–aluminum–silicate glass microspheres. ► Microspheres are chemically stable in SBF. ► Microspheres can generate heat for hyperthermia under an alternating magnetic field. ► Microspheres can emit β-rays for brachytherapy after neutron activation.

Treatment of diffuse large B-cell lymphoma of the liver with yttrium-90 microsphere embolization.

Science.gov (United States)

Fenske, Timothy S; Benjamin, Heather; Kroft, Steven H; Hohenwalter, Eric J; Rilling, William S

2008-11-01

A 41-year-old male with a 4-year history of chronic hepatitis C presented with a 1-month history of abdominal pain, fatigue, weight loss, and night sweats. Laboratory examinations, chest, abdomen, and pelvic CT scans, PET-CT scans, ultrasound-guided needle biopsies of liver lesions, bone-marrow biopsy, flow cytometry, and immunohistochemical staining for B-cell markers including CD20. Chemoresistant diffuse large B-cell lymphoma, with gradual loss of CD20 antigen expression. Embolization of hepatic tumors using yttrium-90 microspheres (Therasphere, Theragenics Corporation, Buford, GA).

Review: microspheres for radioembolization therapy

International Nuclear Information System (INIS)

Zhao Mingqiang; Xu Shuhe

2007-12-01

Radioembolization of liver cancer has been proven to be an effective therapy in nuclear medicine. The yttrium-90 glass microspheres has been used to treat both primary and metastatic liver tumors in clinic which shown encouraging results. The preparation, stability, degradation and application for medical purpose of radioactive microspheres are reviewed. At first, the theory of radioem- bolization treating cancer is discussed; and then three major radiolabled micro- sphere materials are expounded: viz. glass, resin-based and polymer-based; Future improvements in the preparation and use of radioactive microspheres are prospected at last. (authors)

Review: microspheres for radioembolization therapy

Energy Technology Data Exchange (ETDEWEB)

Mingqiang, Zhao; Shuhe, Xu [China Inst. of Atomic Energy, Beijing (China)

2007-12-15

Radioembolization of liver cancer has been proven to be an effective therapy in nuclear medicine. The yttrium-90 glass microspheres has been used to treat both primary and metastatic liver tumors in clinic which shown encouraging results. The preparation, stability, degradation and application for medical purpose of radioactive microspheres are reviewed. At first, the theory of radioem- bolization treating cancer is discussed; and then three major radiolabled micro- sphere materials are expounded: viz. glass, resin-based and polymer-based; Future improvements in the preparation and use of radioactive microspheres are prospected at last. (authors)

Synthesis of plastic scintillation microspheres: Evaluation of scintillators

International Nuclear Information System (INIS)

Santiago, L.M.; Bagán, H.; Tarancón, A.; Garcia, J.F.

2013-01-01

The use of plastic scintillation microspheres (PSm) appear to be an alternative to liquid scintillation for the quantification of alpha and beta emitters because it does not generate mixed wastes after the measurement (organic and radioactive). In addition to routine radionuclide determinations, PSm can be used for further applications, e.g. for usage in a continuous monitoring equipment, for measurements of samples with a high salt concentration and for an extractive scintillation support which permits the separation, pre-concentration and measurement of the radionuclides without additional steps of elution and sample preparation. However, only a few manufacturers provide PSm, and the low number of regular suppliers reduces its availability and restricts the compositions and sizes available. In this article, a synthesis method based on the extraction/evaporation methodology has been developed and successfully used for the synthesis of plastic scintillation microspheres. Seven different compositions of plastic scintillation microspheres have been synthesised; PSm1 with polystyrene, PSm2 with 2,5-Diphenyloxazol(PPO), PSm3 with p-terphenyl (pT), PSm4 with PPO and 1,4-bis(5-phenyloxazol-2-yl) (POPOP), PSm5 pT and (1,4-bis [2-methylstyryl] benzene) (Bis-MSB), PSm6 with PPO, POPOP and naphthalene and PSm7 with pT, Bis-MSB and naphthalene. The synthesised plastic scintillation microspheres have been characterised in terms of their morphology, detection capabilities and alpha/beta separation capacity. The microspheres had a median diameter of approximately 130 μm. Maximum detection efficiency values were obtained for the PSm4 composition as follows 1.18% for 3 H, 51.2% for 14 C, 180.6% for 90 Sr/ 90 Y and 76.7% for 241 Am. Values of the SQP(E) parameter were approximately 790 for PSm4 and PSm5. These values show that the synthesised PSm exhibit good scintillation properties and that the spectra are at channel numbers higher than in commercial PSm. Finally, the addition

Country report: Vietnam. Setting Up of a 90Sr/90Y Generator System Based on Supported Liquid Membrane (SLM) Technique and Radiolabeling of Eluted 90Y with Biomolecules

International Nuclear Information System (INIS)

Nguyen Thi Thu; Duong Van Dong; Bui Van Cuong; Chu Van Khoa

2010-01-01

In the course of participating in the IAEA-CRP during the last two years, Vietnam has achieved the goal of setting up a 90 Sr/ 90 Y generator system based on Supported Liquid Membrane (SLM) technique and also radiolabeling of the eluted 90 Y with antibody, peptides and albumin. A two stage SLM based 90 Sr- 90 Y generator was set up in-house to generate carrier-free 90 Y at different activity levels viz. 5, 20, 50 mCi. The generator system was operated in sequential mode in which 2-ethylhexyl 2-ethylhexyl phosphonic acid (PC88A) based SLM was used in the first stage for the transport 90 Y in 4.0 M nitric acid from source phase where 90 Sr- 90 Y equilibrium mixture is placed in nitric acid medium at pH to 1-2. In the second stage, octyl (phenyl)-N,N-diisobutylcarbamoylmethyl phosphine oxide (CMPO) based SLM was used for the transport of 90 Y selectively to 1.0 M acetic acid which is the best medium for radiolebeling. The eluted 90 Y from the generator was tested for the presence of any traces of 90 Sr using the Extraction Paper Chromatography (EPC) and was found suitable for radiolabeling. The generator system could be upgraded to 100 mCi level successfully due to an expert mission from India through IAEA. The 90 Y product obtained from the generator system was used for radiolabeling of antibody and peptides viz. Rituximab, DOTATATE and albumin particles under different experimental conditions. A new chromatography system could be developed for analyzing 90 Y labeled albumin using the TAE buffer as mobile phase in PC and ITLC

Photoluminescence and lasing in whispering gallery mode glass microspherical resonators

Energy Technology Data Exchange (ETDEWEB)

Ristić, D. [Ruđer Bošković Institute, Division of Materials Physics, Laboratory for Molecular Physics, Bijenička c. 54, Zagreb (Croatia); Center of Excellence for Advanced Materials and Sensing Devices, Research unit New Functional Materials, Bijenička c. 54, Zagreb (Croatia); Berneschi, S.; Camerini, M. [IFAC-CNR Istituto di Fisica Applicata, Via Madonna del Piano 10, 50019 Sesto Fiorentino (Italy); Farnesi, D.; Pelli, S. [IFAC-CNR Istituto di Fisica Applicata, Via Madonna del Piano 10, 50019 Sesto Fiorentino (Italy); Centro Studi e Ricerche ' E. Fermi' , Piazza del Viminale 2, 00184 Roma (Italy); Trono, C. [IFAC-CNR Istituto di Fisica Applicata, Via Madonna del Piano 10, 50019 Sesto Fiorentino (Italy); Chiappini, A.; Chiasera, A.; Ferrari, M. [CSMFO Group, Istituto di Fotonica e Nanotecnologie, IFN-CNR, Via alla Cascata 56/C, 38050 Povo-Trento (Italy); Lukowiak, A. [Institute of Low Temperature and Structure Research, PAS, ul. Okolna 2, Wroclaw 50-950 (Poland); Dumeige, Y.; Féron, P. [Laboratoire d' Optronique, (CNRS-UMR 6082-Foton), ENSSAT, 6 rue de Kérampont, 22300 Lannion (France); Righini, G.C. [IFAC-CNR Istituto di Fisica Applicata, Via Madonna del Piano 10, 50019 Sesto Fiorentino (Italy); Centro Studi e Ricerche ' E. Fermi' , Piazza del Viminale 2, 00184 Roma (Italy); Soria, S., E-mail: s.soria@ifac.cnr.it [IFAC-CNR Istituto di Fisica Applicata, Via Madonna del Piano 10, 50019 Sesto Fiorentino (Italy); Conti, G. Nunzi [IFAC-CNR Istituto di Fisica Applicata, Via Madonna del Piano 10, 50019 Sesto Fiorentino (Italy); Centro Studi e Ricerche ' E. Fermi' , Piazza del Viminale 2, 00184 Roma (Italy)

2016-02-15

We report experimental results regarding the development of Er{sup 3+}-doped glass microspherical cavities for the fabrication of compact sources at 1.55 μm. We investigate several different approaches in order to fabricate the microspheres including direct melting of Er{sup 3+}-doped glass powders, synthesis of Er{sup 3+}-doped monolithic microspheres by drawing Er{sup 3+}-doped glass, and coating of silica microspheres with an Er{sup 3+}-doped sol–gel layer. Details of the different fabrication processes are presented together with the photoluminescence characterization in free space configuration of the microspheres and of the glass precursor. We have analyzed the photoluminescence spectra of the whispering gallery modes of the microspheres excited using evanescent coupling and we demonstrate tunable laser action in a wide range of wavelengths around 1.55 μm. As much as 90 μW of laser output power was measured in Er{sup 3+}-doped glass microspheres. - Highlights: • Different approaches in microsphere fabrication and various types of post-processing. • Trimming of photorefractive glass microsphere lasers with UV light. • Peak power record of 90 μW by pumping at 1480 nm.

Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma.

Science.gov (United States)

Bhangoo, Munveer Singh; Karnani, Diraj R; Hein, Paul N; Giap, Huan; Knowles, Harry; Issa, Chris; Steuterman, Steve; Pockros, Paul; Frenette, Catherine

2015-10-01

Hepatocellular carcinoma (HCC) is aggressive primary malignancy of the liver that most commonly presents late in the disease course. As a result, the majority of patients are not candidates for curative therapies. Locoregional therapies including Yttrium-90 (Y-90) radioembolization play an important role in management of the vast majority of patients with HCC. Patients with unnresectable HCC (n=17) treated with Y-90 radioembolization from 2005 to 2014 were evaluated retrospectively. Data was abstracted from medical records including patient charts, laboratory data, and imaging. Toxicities were recorded using Common Terminology Criteria 3.0. Response was recorded according to modified RECIST (mRECIST) criteria. Seventeen patients received 33 treatments with Y-90 radioembolization. A majority (65%) received TheraSphere with a minority (35%) receiving SIR-Spheres. The median treatment activity delivered was 1.725 gBq (range, 1.4-2.5 gBq). The median treatment dose delivered was 100 Gy (range, 90-120 Gy). The median lung shunt fraction was 2.02% (range, 1.5-4.1%). The most common clinical toxicity among all patients was nausea and vomiting (59%), primarily grade 1 and 2. Other post-treatment findings included abdominal pain (29%), fatigue (53%), and weight loss (18%). One patient developed a grade 5 gastric ulcer after the treatment. A clinical benefit, defined as patients achieving complete response (CR), partial response (PR) or stable disease (SD), was seen in 48% of patients. PR was seen in 24% of cases; progressive disease (PD) was noted in 35%. Patients survived for a median of 8.4 months (range, 1.3 to 21.1 months) after the first radioembolization treatment. Median survival after Y-90 treatment was 8.4 months among patients treated TheraSphere as compared with 7.8 months in patients treated with SIR-Spheres. The mean overall survival from the time of diagnosis was 11.7 months (range, 3.4 to 43.2 months). For patients with unresectable HCC, Y-90

Treatment of metastasis localizations by intratumoral injection of radionuclide microsphere

International Nuclear Information System (INIS)

Tuo Peiyu; Pang Yan; Zhu Dianqing; Chang Keli; Zhu Yanjia

2001-01-01

Objective: To evaluate the therapeutic effects of radionuclide-labeled microsphere by intratumoral injection into 18 patients with superficial metastasis tumor for treatment. Methods: 18 patients with superficial metastasis were treated with radionuclide-labeled microsphere ( 90 Y-GTMS and 32 P-GTMS) by multi-point intratumoral injection. Each injection dose was 11.1-18.5 MBq/g (tumor). Results: 1 patient was relieved completely, 9 were relieved partly, 5 were improved and 3 kept stable. The total rate of relief and virtual value were 55.6% and 83.3% respectively. Conclusion: Topical treatment by using radionuclide may help diminish the tumor, control its progress and ease the symptoms. Thus it can be used as a supplement of routine treatment of tumors and it should do some work in therapy of malignant tumors in late stages

Hepatic Toxicity After Radioembolization of the Liver Using {sup 90}Y-Microspheres: Sequential Lobar Versus Whole Liver Approach

Energy Technology Data Exchange (ETDEWEB)

Seidensticker, Ricarda; Seidensticker, Max; Damm, Robert; Mohnike, Konrad [Universitaetsklinikum Magdeburg, Klinik fuer Radiologie and Nuklearmedizin (Germany); Schuette, Kerstin; Malfertheiner, Peter [Universitaetsklinikum Magdeburg, Klinik fuer Gastroenterologie, Hepatologie und Infektiologie (Germany); Buskirk, Mark Van [Data Reduction (United States); Pech, Maciej; Amthauer, Holger; Ricke, Jens, E-mail: jens.ricke@med.ovgu.de [Universitaetsklinikum Magdeburg, Klinik fuer Radiologie and Nuklearmedizin (Germany)

2012-10-15

Purpose: {sup 90}Y-radioembolization (RE) is a promising technique for delivering high doses of radiation to liver tumors but may result in compromise of liver function. To gain further perspective, we evaluated the toxicity rates of sequential lobar versus 'whole liver' {sup 90}Y-radioembolization. Methods: Thirty-four patients with liver malignancy in noncirrhotic livers were included; {sup 90}Y-radioembolization was performed as either whole liver or sequential lobar treatment in 17 patients each. Standard clinical and liver specific laboratory parameters as well as MR imaging before treatment and at follow-up (6 and 12 weeks) after radioembolization were evaluated for toxicity using the Common Terminology Criteria for Adverse Events (CTCAE). Volumetry of the liver, tumor, and spleen and measurement of portal vein diameter also were performed. Results: Three months after whole liver RE, 14 liver-related grade 3/4 events were recorded versus 2 events after sequential lobar treatment (P < 0.05). Three patients treated with whole liver RE suffered from radioembolization-induced liver disease (REILD). Pathological increases in bilirubin at 3 months were observed for the whole liver group only (52.3 vs. 18.7 {mu}mol/l, P = 0.012). Total liver volume did not change significantly in either group, but shrinkage of the initially treated hepatic lobe with compensatory hypertrophy of the subsequently treated lobe was observed in the sequential lobar group (P < 0.05). Portal vein diameter increased significantly in whole liver-treated patients only (+17% vs. +6.6%, P = 0.043). Conclusions: Noncirrhotic patients undergoing sequential lobar radioembolization had less hepatic toxicity compared to whole liver embolization. The sequential approach should be the preferred strategy.

Labeling of monoclonal antibody conjugates with 90Y

International Nuclear Information System (INIS)

Motta-Hennessy, Cecilia; Sharkey, R.M.; Goldenberg, D.M.

1991-01-01

An anti-carcinoembryonic antigen (CEA) antibody, NP-4, was labeled with 90 Y using p-isothiocyanatobenzyl DTPA (SCN-Bz-DTPA) and its derivatives 1-(p-isothiocyanatobenzyl)-3-methyl-DTPA (1B3M), 2-(p-isothiocyanatobenzyl)-4-methyl-DTPA (1M3B), 1-(2)-methyl-4-isothiocyanatobenzyl-DTPA (MX-DTPA) as the chelating agents. The 90 Y conjugates were purified from unbound 90 Y by two different methods, HPLC or acrylamide size exclusion gel chromatography, in order to evaluate the best purification method. Labeling efficiency, reaction kinetics and immunoreactivity were compared to the same antibodies labeled with [ 111 In]citrate. Labeling efficiency, as determined by either HPLC or ITLC (instant thin layer chromatography), was consistently higher by ITLC than HPLC for 90 Y-labeled MAb, but equal for 111 In-labeled MAbs. Discrepancies between the 2 methods were linked to impurities in the 90 Y that remained at the origin of ITLC plates. After purification by acrylamide gel filtration, recovery was 50-60% of loaded 90 Y activity, but was more than 87% for the 111 In compounds. Using HPLC, the recovery measured 85% for 90 Y-labeled MAb and more than 93% for 111 In-labeled conjugates. Immunoreactivity of the [ 90 Y]MAb was comparable to the 111 In-labeled conjugates. These studies indicate that HPLC purification of the [ 90 Y] MAbs improves recovery of activity, and suggests that impurities found in the 90 Y and metal-binding properties of acrylamide may have contributed to the poor recoveries from acrylamide gels. (author)

Non-target activity detection by post-radioembolization yttrium-90 PET/CT: Image assessment technique and case examples

Directory of Open Access Journals (Sweden)

Yung Hsiang eKao

2014-02-01

Full Text Available High-resolution yttrium-90 (90Y imaging of post-radioembolization microsphere biodistribution may be achieved by conventional positron emission tomography with integrated computed tomography (PET/CT scanners that have time-of-flight capability. However, reconstructed 90Y PET/CT images have high background noise, making non-target activity detection technically challenging. This educational article describes our image assessment technique for non-target activity detection by 90Y PET/CT which qualitatively overcomes the problem of background noise. We present selected case examples of non-target activity in untargeted liver, stomach, gallbladder, chest wall and kidney, supported by angiography and 90Y bremsstrahlung single photon emission computed tomography with integrated computed tomography (SPECT/CT or technetium-99m macroaggregated albumin SPECT/CT.

Molecular response assessed by {sup 68}Ga-DOTANOC and survival after {sup 90}Y microsphere therapy in patients with liver metastases from neuroendocrine tumours

Energy Technology Data Exchange (ETDEWEB)

Filippi, Luca; Salvatori, Rita; Bagni, Oreste [Santa Maria Goretti Hospital, Department of Nuclear Medicine, Latina (Italy); Scopinaro, Francesco [Sant' Andrea Hospital, Department of Nuclear Medicine, Rome (Italy); Pelle, Giuseppe; Cianni, Roberto [Santa Maria Goretti Hospital, Department of Interventional Radiology, Latina (Italy); Schillaci, Orazio [University Tor Vergata, Department of Biomedicine and Prevention, Rome (Italy)

2016-03-15

We investigated the prognostic role of {sup 68}Ga-DOTANOC in patients affected by hepatic metastases from neuroendocrine tumours (NET) undergoing {sup 90}Y radioembolization ({sup 90}Y-RE). A group of 15 consecutive patients with unresectable NET liver metastases underwent {sup 68}Ga-DOTANOC PET at baseline and 6 weeks after {sup 90}Y-RE. Molecular response was defined as a reduction of >50 % in the tumour-to-spleen ratio (ΔT/S). The patients were divided into two groups (responders with ΔT/S >50 % and nonresponders with ΔT/S <50 %) Patients were followed up by imaging and laboratory tests every 3 months until death or for at least 36 months following {sup 90}Y-RE. Statistical analysis was performed to identify factors predicting overall survival (OS) and progression-free survival (PFS). A decrease in T/S ratio was seen in all patients on {sup 68}Ga-DOTANOC PET scans performed after {sup 90}Y-RE. Nine patients were classified as responders and six as nonresponders. The mean OS in all patients was 31.0 months. Responders had a significantly (p < 0.001) longer OS (mean 36.0 ± 2.5 months) and PFS (mean 29.7 ± 3.4 months) than nonresponders. In a multivariate analysis, none of the other examined variables including age, unilobar vs. bilobar locations, bilirubin levels, radiological response or the presence of extrahepatic disease significantly predicted patient outcome. Molecular response assessed with {sup 68}Ga-DOTANOC PET might be a useful predictor of survival in patients affected by NET liver metastases treated with {sup 90}Y-RE. (orig.)

Silicon microspheres for near-IR communication applications

International Nuclear Information System (INIS)

Serpengüzel, Ali; Demir, Abdullah

2008-01-01

We have performed transverse electric and transverse magnetic polarized elastic light scattering calculations at 90° and 0° in the o-band at 1.3 µm for a 15 µm radius silicon microsphere with a refractive index of 3.5. The quality factors are on the order of 10 7 and the mode/channel spacing is 7 nm, which correlate well with the refractive index and the optical size of the microsphere. The 90° elastic light scattering can be used to monitor a dropped channel (drop port), whereas the 0° elastic scattering can be used to monitor the transmission channel (through port). The optical resonances of the silicon microspheres provide the necessary narrow linewidths that are needed for high-resolution optical communication applications. Potential telecommunication applications include filters, modulators, switches, wavelength converters, detectors, amplifiers and light sources. Silicon microspheres show promise as potential building blocks for silicon-based electrophotonic integration

Separation of 90Sr from Purex high level waste and development of a 90Sr-90Y generator

International Nuclear Information System (INIS)

Ramanujam, A.; Dhami, P.S.; Chitnis, R.R.; Achuthan, P.V.; Kannan, R.; Gopalakrishnan, V.; Balu, K.

2000-04-01

90 Y (T 1/2 =64.2 h) finds several applications in nuclear medicine. It is formed from the decay of 90 Sr which has a long half-life of 28.8 years. 90 Sr can be used as a long-lasting source for the production of carrier-free 90 Y. 90 Sr itself is abundantly available in high level waste (HLW) of PUREX origin. The present studies deal with the separation of pure 90 Sr from HLW and the subsequent separation of 90 Y from 90 Sr. Actinides and some of the fission products like lanthanides, zirconium, molybdenum and cesium were first removed from the HLW using methods based on solvent extraction and ion-exchange studied earlier in our laboratory. The resulting waste solution was used as a feed for the present process. The separation of 90 Sr from HLW was based on radiochemical method which involved a repeated scavenging with ferric hydroxide followed by strontium carbonate precipitation. The separation of 90 Y from 90 Sr was achieved by membrane separation technique. A compact generator is developed for this separation using a commercially available polytetrafluoroethylene (PTFE) membrane, impregnated with indigenously synthesised 2-ethylhexyl 2-ethylhexyl phosphonic acid (KSM-17). Generator system overcomes the drawbacks associated with conventional solvent extraction and ion-exchange based generators. The product is in chloride form and is suitable for complexation studies. After gaining an operating experience of ∼3 years in generating carrier-free 90 Y at 2 mCi level for initial studies in radiotherapeutic applications, the process was scaled up for the production of about 12 mCi of 90 Y to be used for animal studies before its application to patients. Radiochemical and chemical purity of the product was critically assayed by radiometry, ICP-AES, etc. The process is amenable for further scaling up. (author)

Interstitial pituitary irradiation with 90Y for the treatment of acromomegaly

International Nuclear Information System (INIS)

Cassar, J.; Doyle, F.H.; Banks, L.M.; Jadresic, A.; Mashiter, K.; Joplin, G.F.

1981-01-01

The management of 54 acromegalics referred to us between 1974 and 1978 has been analysed. Twenty-two patients were treated with pituitary implants of yttrium-90 ( 90 Y). Eleven are in complete remission (mean growth hormone (GH) < 11 mlU/l), 8 had improved (mean GH 11-20 mlU/l or 50% less than preoperatively) and 3 were poor responders. Two patients had temporary 6th nerve paresis. Seven patients are on replacement therapy. Thirty- one patients were not implanted for the following reasons with a number of patients having more than one: extension of the tumour into the spehnoid sinus 10, or above the sella 3, partially empty sella 9, internal carotids too close to midline 2, invisible landmarks 1, mild acromegaly 6, poor general health 3, declined investigations or operation 6. It is concluded that pituitary implant of yttrium is an effective and safe form of treatment on carefully selected patients. (author)

{sup 90}Y Production and Its Biodistribution in Mice; Pembuatan {sup 90}Y dan Biodistribusinya ke Mencit

Energy Technology Data Exchange (ETDEWEB)

Tri-Murni,; Cahyana,; Triyanto,; Djoharly,; Abidin,; Dede-K,; Karyadi, [Center for Development of Radioisotope and Radiopharmacentical(Indonesia)

2001-11-15

Yttrium - 90 is radioisotope emitting pure {beta} with maximum energy of 2.27 MeV while its average {beta} energy is 0.93 MeV. {sup 90}Y radioisotope was produced utilizing G.A Siwabessy reactor employing thermal neutron capture process. In nuclear medicine this radioisotope is utilized for bone mettastase palliative and curative therapies. Parameters in this research were the weight of natural Y{sub 2}O{sub 3} target, irradiation time in the reactor, radiochemical purity and specific activity. The end product of the process is YCl{sub 3}, in saline solution. Then sterility of the {sup 90}Y radioisotope so produced is tested and its biodistribution analysis results in mice organs show that the percentage of this radioisotope in the liver is much higher than the ones in heart, kidneys, lung and intestine. Therefore it is concluded that {sup 90}Y radioisotope in the form of YCl{sub 3} can be utilized as a radiopharmaceutical in nuclear medicine. (author)

Radiolabeling Of Albumin Particles With Yttrium-90

International Nuclear Information System (INIS)

Nguyen Thi Thu; Nguyen Thi Khanh Giang; Bui Van Cuong, Vo Thi Cam Hoa

2011-01-01

This paper presents the process of the radiolabeling of microaggregated albumin particles with radionuclide Yttrium-90 using the directed method. The albumin microsphere kit was prepared in sodium phosphate buffer. The original solution includes 2 mg albumin particle and 0.5 mg stannous chloride dihydrate. The albumin particles size was ranged from 5 ?m to 30 ?m. The mixture was washed three times with phosphate buffer saline, pH 7.2 by centrifugation and suspended in 0.5 M sodium acetate buffer, pH 6. Yttrium - 90 in 1.0 M acetic acid was collected from 90 Sr/ 90 Y generator. The labeling of the particles with Y-90 (185 MBq) was performed at pH 5.5 in acetate buffer with agitating for 60 min at room temperature. The labeled albumin suspensions were centrifuged at 3000 rpm for 15 min. Labeling yields was calculated using centrifugation, filtration and compared with paper chromatography, which is developed in the Tris Acetic EDTA. In this system, the unbound of Y-90 migrates to an R f of 0.9-1.0 and the radiolabeled albumin particles remains at the point of origin (R f = 0). The size of 90 Y-albumin particles was compared with the albumin particles in the original solution to be sure that they did not change during the labeling treatment. The radiolabeling yields were more than 80%. The labeled compound was dialysis in phosphate buffer. The radiochemical purity was 98%. The 90 Y- albumin is an ideal radiopharmaceutical for potential use in malignant cancer treatment as brachytherapy. (author)

Simulation Model of Microsphere Distribution for Selective Internal Radiation Therapy Agrees With Observations

Energy Technology Data Exchange (ETDEWEB)

Högberg, Jonas, E-mail: jonas.hogberg@radfys.gu.se [Department of Radiation Physics, Sahlgrenska Academy, University of Gothenburg, Gothenburg (Sweden); Rizell, Magnus [Department of Surgery, Sahlgrenska University Hospital, Gothenburg (Sweden); Hultborn, Ragnar; Svensson, Johanna [Department of Oncology, Sahlgrenska University Hospital, Gothenburg (Sweden); Henrikson, Olof [Department of Radiology, Sahlgrenska University Hospital, Gothenburg (Sweden); Mölne, Johan [Department of Pathology, Sahlgrenska University Hospital, Gothenburg (Sweden); Gjertsson, Peter [Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg (Sweden); Bernhardt, Peter [Department of Radiation Physics, Sahlgrenska Academy, University of Gothenburg, Gothenburg (Sweden); Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg (Sweden)

2016-10-01

Purpose: To perform a detailed analysis of microsphere distribution in biopsy material from a patient treated with {sup 90}Y-labeled resin spheres and characterize microsphere distribution in the hepatic artery tree, and to construct a novel dichotomous bifurcation model for microsphere deposits and evaluate its accuracy in simulating the observed microsphere deposits. Methods and Materials: Our virtual model consisted of arteries that successively branched into 2 new generations of arteries at 20 nodes. The artery diameter exponentially decreased from the lowest generation to the highest generation. Three variable parameters were optimized to obtain concordance between simulations and measure microsphere distributions: an artery coefficient of variation (ACV) for the diameter of all artery generations and the microsphere flow distribution at the nodes; a hepatic tree distribution volume (HDV) for the artery tree; and an artery diameter reduction (ADR) parameter. The model was tested against previously measured activity concentrations in 84 biopsies from the liver of 1 patient. In 16 of 84 biopsies, the microsphere distribution regarding cluster size and localization in the artery tree was determined via light microscopy of 30-μm sections (mean concentration, 14 microspheres/mg; distributions divided into 3 groups with mean microsphere concentrations of 4.6, 14, and 28 microspheres/mg). Results: Single spheres and small clusters were observed in terminal arterioles, whereas large clusters, up to 450 microspheres, were observed in larger arterioles. For 14 microspheres/mg, the optimized parameter values were ACV=0.35, HDV = 50 cm{sup 3}, and ADR=6 μm. For 4.6 microspheres/mg, ACV and ADR decreased to 0.26 and 0 μm, respectively, whereas HDV increased to 130 cm{sup 3}. The opposite trend was observed for 28 microspheres/mg: ACV = 0.49, HDV = 20 cm{sup 3}, and ADR = 8 μm. Conclusion: Simulations and measurements reveal that microsphere clusters are

Using Cherenkov Counting For Fast Determination of 90Sr/90Y Activity in Milk

International Nuclear Information System (INIS)

Tsroya, S.; Dolgin, B.; German, U.; Pelled, O.; Alfassi, Z. B.

2014-01-01

90Sr is one of the main long-lived fission products, and it is transferred into human body primarily by food, with milk being a substantial contributor. Due to its biochemical similarity to calcium, most strontium is efficiently incorporated into bone tissues. 90Sr is characterized by a long physical half life (28.8 y) and decays by beta particles with an Emax of 0.546 MeV to 90Y. This daughter isotope has a half life of 64 h and decays into 90Zr by beta particles with an Emax of 2.284 MeV. The milk components produce a high turbidity and light attenuation, causing a significant decrease of the counting efficiency in liquid scintillation counting (LSC) systems, mostly used for beta emitters detection. Most methods proposed in the past are time-consuming, as they are based on several stages of chemical and physical treatments, including precipitation, ashing, ion exchange and extraction (Wikins et al., 1984, Porter et al, 1961, Kimura et al., 1979). When measuring 90Sr/90Y activity by Cherenkov counting, most of the Cherenkov radiation is produced by 90Y (about 98.6%), due to the much higher energy of its beta particles relative to these from 90Sr. The counting efficiency varies strongly with color quenching, at a greater extent than in standard liquid scintillation counting (L'Annunziata, 2012), and therefore the quench correction is critical. The ‘‘external source area ratio’’ (ESAR) quench correction method was applied to measure 90Sr/90Y activities in aqueous samples with a wide range of quenching levels (Tsroya et al., 2009). This method was proved to be superior to all other quench correction methods (Tsroya et al., 2012) and is applicable also for determination of 90Sr/90Y in human urine (Tsroya et al., 2013). In the present work the applicability of the ESAR method to measurement of 90Sr/90Y activities in milk and some of its products was investigated

Utilization of a novel electrochemical {sup 90}Sr/{sup 90}Y generator for the preparation of {sup 90}Y-labeled RGD peptide dimer in clinically relevant dose

Energy Technology Data Exchange (ETDEWEB)

Chakraborty, Sudipta; Chakravarty, Rubel; Pillai, Maroor Raghavan Ambikalmajan; Dash, Ashutosh [Bhabha Atomic Research Centre, Mumbai (India). Radiopharmaceuticals Div.; Sarma, Haladhar Dev [Bhabha Atomic Research Centre, Mumbai (India). Radiation Biology and Health Sciences Div.

2014-09-01

The work reported in this paper provides a systematic study towards the development of an optimized strategy for preparation of a clinically relevant dose of {sup 90}Y-labeled dimeric RGD peptide derivative, DOTA-E[c(RGDfK)]{sub 2} [DOTA-(RGD){sub 2}] for in vivo targeted therapy utilizing {sup 90}Y obtained from a novel electrochemical {sup 90}Sr/{sup 90}Y generator. The performance of the generator was evaluated to ensure its suitability for providing {sup 90}Y in adequate quantity and purity required for formulation of clinically relevant dose for PRRT. {sup 90}Y-DOTA-(RGD){sub 2} was synthesized in high yield (86.2 ± 2.5%) and radiochemical purity (98.4 ± 0.5%) using clinically relevant dose (∝ 3.8 GBq) of {sup 90}Y. In vitro stability studies revealed that the radiolabeled conjugate retained its radiochemical purity in normal saline and human serum. Preliminary biodistribution studies carried out in C57/BL6 mice bearing melanoma tumors showed that the preparation exhibited significant tumor uptake (5.30 ± 0.78% of injected activity at 30 min post-injection) with good tumor to background ratio. The optimized radiolabeling protocol seems to be an attractive strategy which is largely viewed as a springboard to realize scope of developing {sup 90}Y labeled cyclic RGD peptides for targeted therapy of tumors over-expressing integrin-α{sub ν}β{sub 3} receptors. (orig.)

Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.

Science.gov (United States)

Demirelli, Serkan; Erkilic, Metin; Oner, Ali Ozan; Budak, Evrim Surer; Gunduz, Seyda; Ozgur, Ozhan; Bozcuk, Hakan; Sindel, Hakki Timur; Boz, Adil

2015-04-01

Radioembolization with the yttrium-90 (Y-90) microspheres is being used increasingly more often in the treatment of patients with primary or metastatic liver cancer. Although technetium-99m macroaggregated albumin (Tc-99m MAA) scintigraphy performed following diagnostic angiography has an important role in predicting the effectiveness of treatment and in dose estimation, the number of studies using quantitative assessment of Tc-99m MAA scintigraphy is limited in this field. In the present study, the aim was to assess whether a tumor dose is required to obtain objective tumor response and to check whether this threshold value is predictive in terms of tumor response, survival, and liver toxicity by using Tc-99m MAA single-photon emission computed tomography (SPECT) images. Overall, 54 patients (20 women and 34 men; median age: 60 years) who underwent Y-90 Resin (SIR-Spheres) and Glass (TheraSphere) microsphere treatment with a diagnosis of unresectable liver cancer between August 2010 and April 2013 were included in the study. The mean doses to normal liver and tumor were estimated for each patient using Tc-99m MAA SPECT images and the medical internal radiation dosimetry method. The responses were assessed according to Response Evaluation Criteria In Solid Tumors (RECIST) and European Organisation for Research and Treatment of Cancer (EORTC) criteria. Kaplan-Meier survival curves and univariate Cox regression analysis were used in survival analysis. The relationship between treatment response and other parameters included was assessed using logistic regression analysis. The variables with a P value less than 0.01 in univariate analysis were assessed with multivariate analysis. Fifty-four Y-90 microsphere treatments (eight by using a Y-90 glass microsphere and 46 by using a Y-90 resin microsphere) were performed. In the multivariate analysis, the only parameter related to response was tumor dose (P<0.01). With a tumor dose of 280 Gy or higher, objective tumor

A special mini-extrapolation chamber for calibration of 90Sr+90Y sources

International Nuclear Information System (INIS)

Oliveira, Mercia L; Caldas, Linda V E

2005-01-01

90 Sr+ 90 Y applicators are commonly utilized in brachytherapy, including ophthalmic procedures. The recommended instruments for the calibration of these applicators are extrapolation chambers, which are ionization chambers that allow the variation of their sensitive volume. Using the extrapolation method, the absorbed dose rate at the applicator surface can be determined. The aim of the present work was to develop a mini-extrapolation chamber for the calibration of 90 Sr+ 90 Y beta ray applicators. The developed mini-chamber has a 3.0 cm outer diameter and is 11.3 cm in length. An aluminized polyester foil is used as the entrance window while the collecting electrode is made of graphited polymethylmethacrylate. This mini-chamber was tested in 90 Sr+ 90 Y radiation beams from a beta particle check source and with a plane ophthalmic applicator, showing adequate results

Verification dosimetry of intravascular 90Sr/90Y source trains

International Nuclear Information System (INIS)

Sharma, S.D.; Shanta, A.; Tripathi, U.B.; Bhatt, B.C.

2001-01-01

90 Sr/ 90 Y source trains (Novoste Beta-Cath System) are currently under clinical trials in India and abroad for intracoronary brachytherapy for prevention of restenosis. Each source train of the Beta-Cath system is supplied with a source certificate giving dose rate at the reference distance of 2 mm from the centerline of the source train. It is essential that the user should check dose rates of brachytherapy sources before its application on the patients. Dose rates and depth dose measurements for 90 Sr/ 90 Y source trains of active length 40 mm using radiochromic films in a tissue equivalent phantom have been carried out. The objectives of these measurements were (1) to verify the dose rates stated in the source certificate, and (2) to obtain relative depth dose data for treatment planning. This paper presents the results of these measurements

Country report: Vietnam. Setting Up of a {sup 90}Sr/{sup 90}Y Generator System Based on Supported Liquid Membrane (SLM) Technique and Radiolabeling of Eluted {sup 90}Y with Biomolecules

Energy Technology Data Exchange (ETDEWEB)

Thu, Nguyen Thi; Dong, Duong Van; Cuong, Bui Van; Khoa, Chu Van [Vietnam Atomic Energy Commission (VAEC), Nuclear Research Institute, Dalat (Viet Nam)

2010-07-01

In the course of participating in the IAEA-CRP during the last two years, Vietnam has achieved the goal of setting up a {sup 90}Sr/{sup 90}Y generator system based on Supported Liquid Membrane (SLM) technique and also radiolabeling of the eluted {sup 90}Y with antibody, peptides and albumin. A two stage SLM based {sup 90}Sr-{sup 90}Y generator was set up in-house to generate carrier-free {sup 90}Y at different activity levels viz. 5, 20, 50 mCi. The generator system was operated in sequential mode in which 2-ethylhexyl 2-ethylhexyl phosphonic acid (PC88A) based SLM was used in the first stage for the transport {sup 90}Y in 4.0 M nitric acid from source phase where {sup 90}Sr-{sup 90}Y equilibrium mixture is placed in nitric acid medium at pH to 1-2. In the second stage, octyl (phenyl)-N,N-diisobutylcarbamoylmethyl phosphine oxide (CMPO) based SLM was used for the transport of {sup 90}Y selectively to 1.0 M acetic acid which is the best medium for radiolebeling. The eluted {sup 90}Y from the generator was tested for the presence of any traces of {sup 90}Sr using the Extraction Paper Chromatography (EPC) and was found suitable for radiolabeling. The generator system could be upgraded to 100 mCi level successfully due to an expert mission from India through IAEA. The {sup 90}Y product obtained from the generator system was used for radiolabeling of antibody and peptides viz. Rituximab, DOTATATE and albumin particles under different experimental conditions. A new chromatography system could be developed for analyzing {sup 90}Y labeled albumin using the TAE buffer as mobile phase in PC and ITLC.

Labeling of monoclonal antibody conjugates with sup 90 Y

Energy Technology Data Exchange (ETDEWEB)

Motta-Hennessy, Cecilia; Sharkey, R.M.; Goldenberg, D.M. (Center for Molecular Medicine and Immunology, Newark, NJ (USA))

1991-01-01

An anti-carcinoembryonic antigen (CEA) antibody, NP-4, was labeled with {sup 90}Y using p-isothiocyanatobenzyl DTPA (SCN-Bz-DTPA) and its derivatives 1-(p-isothiocyanatobenzyl)-3-methyl-DTPA (1B3M), 2-(p-isothiocyanatobenzyl)-4-methyl-DTPA (1M3B), 1-(2)-methyl-4-isothiocyanatobenzyl-DTPA (MX-DTPA) as the chelating agents. The {sup 90}Y conjugates were purified from unbound {sup 90}Y by two different methods, HPLC or acrylamide size exclusion gel chromatography, in order to evaluate the best purification method. Labeling efficiency, reaction kinetics and immunoreactivity were compared to the same antibodies labeled with ({sup 111}In)citrate. Labeling efficiency, as determined by either HPLC or ITLC (instant thin layer chromatography), was consistently higher by ITLC than HPLC for {sup 90}Y-labeled MAb, but equal for {sup 111}In-labeled MAbs. Discrepancies between the 2 methods were linked to impurities in the {sup 90}Y that remained at the origin of ITLC plates. After purification by acrylamide gel filtration, recovery was 50-60% of loaded {sup 90}Y activity, but was more than 87% for the {sup 111}In compounds. Using HPLC, the recovery measured 85% for {sup 90}Y-labeled MAb and more than 93% for {sup 111}In-labeled conjugates. Immunoreactivity of the ({sup 90}Y)MAb was comparable to the {sup 111}In-labeled conjugates. These studies indicate that HPLC purification of the ({sup 90}Y) MAbs improves recovery of activity, and suggests that impurities found in the {sup 90}Y and metal-binding properties of acrylamide may have contributed to the poor recoveries from acrylamide gels. (author).

Radiochemistry, pre-clinical studies and first clinical investigation of 90Y-labeled hydroxyapatite (HA) particles prepared utilizing 90Y produced by (n,γ) route

International Nuclear Information System (INIS)

Vimalnath, K.V.; Chakraborty, Sudipta; Rajeswari, A.; Sarma, H.D.; Nuwad, Jitendra; Pandey, Usha; Kamaleshwaran, K.; Shinto, Ajit; Dash, Ashutosh

2015-01-01

Introduction: The scope of using no carrier added (NCA) 90 Y [T 1/2 = 64.1 h, E β(max) = 2.28 MeV] obtained from 90 Sr/ 90 Y generator in radiation synovectomy (RSV) is widely accepted. In the present study, the prospect of using 90 Y produced by (n,γ) route in a medium flux research reactor for use in RSV was explored. Methods: Yttrium-90 was produced by thermal neutron irradiation of Y 2 O 3 target at a neutron flux of ~ 1 × 10 14 n/cm 2 .s for 14 d. The influence of various experimental parameters were systematically investigated and optimized to arrive at the most favorable conditions for the formulation of 90 Y labeled hydroxyapatite (HA) using HA particles of 1–10 μm size range. An optimized kit formulation strategy was developed for convenient one-step compounding of 90 Y-HA, which is easily adaptable at hospital radiopharmacy. The pre-clinical biological evaluation of 90 Y-HA particles was studied by carrying out biodistribution and bioluminiscence imaging studies in Wistar rats. The first clinical investigation using the radiolabeled preparation was performed on a patient suffering from chronic arthritis in knee joint by administering 185 MBq 90 Y-HA formulated at the hospital radiopharmacy deploying the proposed strategy. Results: Yttrium-90 was produced with a specific activity of 851 ± 111 MBq/mg and radionuclidic purity of 99.95 ± 0.02%. 90 Y-labeled HA particles (185 ± 10 MBq doses) were formulated in high radiochemical purity (> 99%) and excellent in vitro stability. The preparation showed promising results in pre-clinical studies carried out in Wistar rats. The preliminary results of the first clinical investigation of 90 Y-HA preparation in a patient with rheumatoid arthritis in knee joints demonstrated the effectiveness of the formulation prepared using 90 Y produced via (n,γ) route in the management of the disease. Conclusion: The studies revealed that effective utilization of 90 Y produced via (n,γ) route in a medium flux research

Polymer based microspheres of aceclofenac as sustained release parenterals for prolonged anti-inflammatory effect

Energy Technology Data Exchange (ETDEWEB)

Kaur, Manpreet; Sharma, Sumit; Sinha, VR, E-mail: sinha_vr@rediffmail.com

2017-03-01

Poly(lactic-co-glycolic acid) (PLGA) (75:25) and polycaprolactone (PCL) microspheres were fabricated for prolonged release of aceclofenac by parenteral administration. Microspheres encapsulating aceclofenac were designed to release the drug at controlled rate for around one month. Biodegradable microspheres were prepared by solvent emulsification evaporation method in different polymer:drug ratios (1:1, 2:1 and 3:1). After drug loading, PLGA and PCL microspheres showed a controlled size distribution with an average size of 11.75 μm and 3.81 μm respectively and entrapment efficiency in the range of 90 ± 0.72% to 91.06 ± 4.01% with PLGA and 83.01 ± 2.13% to 90.4 ± 2.11% with PCL. Scanning electron microscopy has confirmed good spherical structures of microspheres. The percent yield of biodegradable polymeric microspheres ranged between 30.95 ± 10.14% to 92.84 ± 3.15% and 47.33 ± 4.72% to 80 ± 3.60% for PLGA and PCL microspheres respectively. PLGA microspheres followed Higuchi release pattern while Korsmeyer-Peppas explained the release pattern of PCL microspheres. Stability studies of microspheres were also carried out by storing the preparations at 2-8 °C for 30, 60 and 90 days and evaluating them for entrapment efficiency, residual drug content and polymer drug compatability. In-vivo studies showed significant anti-inflammatory activity of microspheres upto 48 hours using the carrageenan induced rat paw oedema model. - Highlights: • PLGA and PCL polymeric microspheres for parenteral prolonged drug delivery system were formulated. • Polymeric microspheres were characterized physically and drug excipient incompatability. • Three months accelerated stability studies were carried for drug loaded polymeric microspheres. • Pharmacodynamic studies prove the rationality of sustained therapeutic effect of designed drug delivery system.

Synthesis of Y2O2S:Eu3+, Mg2+, Ti4+ hollow microspheres via homogeneous precipitation route

Directory of Open Access Journals (Sweden)

Peng-Fei Ai, Ying-Liang Liu, Li-Yuan Xiao, Hou-Jin Wang and Jian-Xin Meng

2010-01-01

Full Text Available A phosphorescent material in the form of Y2O2S:Eu3+, Mg2+, Ti4+ hollow microspheres was prepared by homogeneous precipitation using monodispersed carbon spheres as hard templates. Y2O3:Eu3+ hollow microspheres were first synthesized to serve as the precursor. Y2O2S:Eu3+, Mg2+, Ti4+ powders were obtained by calcinating the precursor in a CS2 atmosphere. The crystal structure, morphology and optical properties of the composites were characterized. X-ray diffraction measurements confirmed the purity of the Y2O2S phase. Electron microscopy observations revealed that the Y2O2S:Eu3+, Mg2+, Ti4+ particles inherited the hollow spherical shape from the precursor after being calcined in a CS2 atmosphere and that they had a diameter of 350–450 nm and a wall thickness of about 50–80 nm. After ultraviolet radiation at 265 or 325 nm for 5 min, the particles emitted strong red long-lifetime phosphorescence originating from Eu3+ ions. This phosphorescence is associated with the trapping of charge carriers by Ti4+ and Mg2+ ions.

A model for dose estimation in therapy of liver with intraarterial microspheres

International Nuclear Information System (INIS)

Zavgorodni, S.F.

1996-01-01

Therapy with intraarterial microspheres is a technique which involves incorporation of radioisotope-labelled microspheres into a capillary bed of tumour and normal tissue. Beta-emitters such as 90 Y and 166 Ho are used for this purpose. This technique provides tumour to normal tissue (TNT) dose ratios in the range of 2-10 and demonstrates significant clinical benefit, which could potentially be increased with more accurate dose predictions and delivery. However, dose calculations in this modality face the difficulties associated with nonuniform and inhomogeneous activity distribution. Most of the dose calculations used clinically do not account for the nonuniformity and assume uniform activity distribution. This paper is devoted to the development of a model which would allow more accurate prediction of dose distributions from microspheres. The model calculates dose assuming that microspheres are aggregated into randomly distributed clusters, and using precomputed dose kernels for the clusters. The dose kernel due to a microsphere cluster was found by numerical integration of a point source dose kernel over the volume of the cluster. It is shown that a random distribution of clusters produces an intercluster distance distribution which agrees well with the one measured by Pillai et al in liver. Dose volume histograms (DVHs) predicted by the model agree closely with the results of Roberson et al for normal tissue and tumour. Dose distributions for different concentrations and types of radioisotope, as well as for tumours of different radii, have been calculated to demonstrate the model's possible applications. (author)

Study of radionuclide 90Sr-90Y on cell proliferation and apoptosis in benign prostatic hyperplasia

International Nuclear Information System (INIS)

Zhang Tong; Wei Wei; Zou Benjie; Liu Fang; Xu Zhishun

2003-01-01

Objective: To investigate the effect of 90 Sr- 90 Yon cell proliferation and apoptosis in benign prostatic hyperplasia. Methods: The apoptosis and expression of Ki-67 in benign prostatic hyperplasia (BPH) before and after irradiation 90 Sr- 90 Y were detected by transferase-mediated dUTP-biotin nick end labeling (TUNEL) method and immunohistochemical technique, respectively. Results: The proliferation index (PI) of BPH after 90 Sr- 90 Y irradiation was much lower than that before irradiation, but there was no significant change in apoptosis index (AI). Conclusion: Irradiation with 90 Sr- 90 Y could restrain cell proliferation of BPH, but could not induce apoptosis

Internal Dosimetry in therapy with 90Y

International Nuclear Information System (INIS)

Torres, Leonel; Vergara, Alex; García, Leonardo

2016-01-01

Introduction: 90 Y has shown satisfactory results in the therapy of multiple oncological diseases. This radionuclide has been widely used in therapy of diseases such as NHL (Zevalin), TNE ( 90 Y-DOTATOC), liver cancer, etc. Its safe and effective use presupposes the availability of accurate dosimetry methods and reproducible.El objective of this work is to standardize and optimize images use procedures that allow for dosimetric estimates braking during therapy of malignant diseases 90 Y. Materials and Methods: To quantify the activity in absolute units from scans correction methods that consider the peculiarities of the bremsstrahlung of 90 Y were proposed. acquisition parameters such as the selection of the collimator and the definition of energy windows as well as methods of scatter correction, attenuation, interactions of radiation with the collimator (septal penetration and degradation of information with distance) were considered and sensitivity or calibration factor was estimated. They were evaluated and calibrated parameters for dosimetry at the level of organ and estimates of distributions 3D dose, using experimental measurements with SPECT Mediso Nucline ™ Spirit DH-V system and simulations were performed using the Monte Carlo method, using the SIMIND v5 software .0. Results: The optimum position-energy window width and collimator to be used is determined from the relationship between total photons and primary photons (T / P), calculated with SIMIND. The results were favorable to employ HEGP collimator and energy window between 90-170kev. the sensitivity of the system for the selected collimator (HEGP for 90 Y) was estimated. He was evaluated and determined the MTF order to correct dispersive plane images, the source-detector and interactions of radiation with the collimator distance, using filtering methods (Wiener filter), including empirical estimates of the SNR component. Similarly the procedure for the use of transmission maps obtained from

Rapid determination of 90Sr impurities in freshly 'generator eluted'90Y for radiopharmaceutical preparation

International Nuclear Information System (INIS)

Bonardi, Mauro L.; Martano, Luigi; Groppi, Flavia; Chinol, Marco

2009-01-01

90 Y is one of the most useful radionuclides for radioimmunotherapeutic applications and has a half-life (t 1/2 =64.14 h) suitable for most therapeutic applications, beta particles of high energy and decays to a stable daughter. It is significant that 90 Y is available conveniently and inexpensively from a radionuclide 'generator' by decay of its parent, 90 Sr. Nevertheless, current and planned clinical applications with [ 90 Y] labelled compounds employ activity levels that cannot be readily obtained from an in-house generator, but from commercial sources. We have evaluated Eichrom's Sr-resin, either as an 'in-house' generator or as a fast QC method for analysis of 90 Y solutions. In particular, for the development as a generator, we investigated the percentage of the radio-Sr in the first 8 M HNO 3 eluate: in this fraction the concentration of 90 Sr must be smaller than 10 -5 % (recommendations of the International Commission on Radiological Protection). For evaluation as a rapid QC method, we analyzed the concentration of 90 Y in all the fractions containing 'only' radio-Sr: 90 Y should not be present in these eluates. After the collection of β - and γ spectra and analysis of them, we concluded that commercial Sr-resin minicolumn cannot give us the results expected; we developed an in-house system loaded with 4 mL of Sr-resin which gave better results as a generator and a rapid QC method.

Quantitative measurement of Y90 brehmmstrahlung images after of Y90 Sir-Spheres implantation to assess lung shunting

International Nuclear Information System (INIS)

Forwood, Nicholas J.; Pocock, Nicholas; Shin, Jane; Young, Andy M; Szeto, Edwin R.

2009-01-01

Full text: Background: In clinical practice the dose of Y 9 0 Sir-Spheres is calculated using a pre injection of Tc 9 9 m MAA. There is however a potential difference due to the different properties of Tc 9 9 m MAA and Y 9 0 Sir-Spheres. We assessed the concordance of lung shunting of Y 9 0 Sir-Spheres estimated using Y 9 0 Bremsstrahlung imaging, compared to shunting assessed using Tc 9 9 m MAA. Methods: 15 Patients were evaluated using 150-200 MBq of Tc 9 9 m MAA injected into the hepatic artery under angiographic guidance. Whole body images were acquired using a LEAP collimator (window of 140 kEv+/-10%). The patients were subsequently treated with Y 9 0 Sir-Spheres. After microspheres injection, whole body brehmsstrahlung images were acquired using a medium energy collimator (window settings of 75 kEv +/- 20%). Tc 9 9 m MAA images were paired with their corresponding bremsstrahlung image and lung shunting in the stu ides calculated simultaneously. Each paired dataset was analyzed by 5 operators. Results: The mean lung shunting for Tc 9 9 m MAA acquisition was 3.32% (SD 2.03) which was significantly lower than the lung shunting using the Y 9 0 acquisitions: mean 16.19% (SD of 6.43). The Pearson coefficient was r = 0.62 (p 9 0 Sir-Spheres bremsstrahlung imaging is higher than that calculated by Tc 9 9 m MAA imaging. The relationship is not sufficiently strong to use bremsstahlung imaging to retrospectively quantify the lung-to-liver shunting as indicated using Tc 9 9 M AA. Further studies are underway to assess the reliability of Tc 9 9 m MAA lung uptake calculations in determining the dose of Y 9 0 Sir-Spheres.

Electrochemical separation of 90-yttrium in the electrochemical 90Sr/90Y generator and its use for radiolabelling of DOTA-conjugated somatostatin analog [DOTA0, Tyr3] octreotate

Directory of Open Access Journals (Sweden)

Petrović Đorđe Ž.

2012-01-01

Full Text Available Radiopharmaceuticals based on 90Y are widely used in the treatment of malignant deseases. In order to meet the requirements for their future application, a 90Sr/90Y generator was developed and 90Y eluted from this locally produced generator was used for the radiolabelling of the DOTA-conjugated somatostatin analog [DOTA0,Tyr3] octreotate and the preparation of [90Y-DOTA0,Tyr3] octreotate (90Y-DOTATATE for peptide receptore radionuclide therapy. 90Sr/90Y generator was based on the electrochemical separation of 90Y from 90Sr in a two-cycle electrolysis procedure. Three electrode cells were used to perform both electrolyses. In both cycles, working electrodes were kept on constant potential. The pH of the solution was adjusted to 2.7 of the value before the electrolyses. The radionuclidic purity of the 90Y solution was analysed by ITLC and extraction paper chromatography. The labelling of peptide (100 mg DOTATATE with 90YCl3 was performed at 95°C for 30 minutes. Radiochemical purity was determined by HPLC and chromatographic separation, using a solid SepPak C-18 column. Results obtained confirmed the efficiency of our electrochemical separation technique and quality control methods for 90Y. The achieved efficiency of the 90Sr/90Y generator above 96% of the theoretical value represents a good basis for the further development of this generator. The labelling of the DOTATATE with 90Y exhibited a high efficiency, too: there was less than 1% of 90Y3+in the 90Y-DOTATATE.

Calibration of the 90Sr+90Y ophthalmic and dermatological applicators with an extrapolation ionization minichamber

International Nuclear Information System (INIS)

Antonio, Patrícia L.; Oliveira, Mércia L.; Caldas, Linda V.E.

2014-01-01

90 Sr+ 90 Y clinical applicators are used for brachytherapy in Brazilian clinics even though they are not manufactured anymore. Such sources must be calibrated periodically, and one of the calibration methods in use is ionometry with extrapolation ionization chambers. 90 Sr+ 90 Y clinical applicators were calibrated using an extrapolation minichamber developed at the Calibration Laboratory at IPEN. The obtained results agree satisfactorily with the data provided in calibration certificates of the sources. - Highlights: • 90 Sr+ 90 Y clinical applicators were calibrated using a mini-extrapolation chamber. • An extrapolation curve was obtained for each applicator during its calibration. • The results were compared with those provided by the calibration certificates. • All results of the dermatological applicators presented lower differences than 5%

Enrichment and determination of small amounts of 90Sr/90Y in water samples

International Nuclear Information System (INIS)

Mundschenk, H.

1979-01-01

Small amounts of 90 Sr/ 90 Y can be concentrated from large volumes of surface water (100 l) by precipitation of the phosphates, using bentonite as adsorber matrix. In the case of samples containing no or nearly no suspended matter (tap water, ground water, sea water), the daughter 90 Y can be extracted directly by using filter beds impregnated with HDEHP. The applicability of both techniques is demonstrated under realistic conditions. (orig.) 891 HP/orig. 892 MKO [de

Dosimetric comparison of electron beam and 90Sr+90Y applicator for keloids treatment

International Nuclear Information System (INIS)

Coelho, Talita S.; Tada, Ariane; Antonio, Patricia L.; Yoriyaz, Helio; Fernandes, Marco A.R.

2009-01-01

Studies have been shown that among several methods that have been used for the treatment of keloids the surgical excision followed by the adjuvant radiotherapy presents the lowest relapsed rate of the injury. In this work a comparative dosimetric study has been performed using a 4 MeV electron beam from a Varian Clinac 2100C linear accelerator at the radiotherapy service of the Hospital das Clinicas of UNESP-HC, Botucatu-SP and an Amershan 90 Sr+ 90 Y brachytherapy applicator with 1491 MBq of activity. Percentage depth dose curves from ionization chamber measurements and through Monte Carlo simulation have been obtained and compared. Dose measurements have been obtained using parallel plates ionization chamber (Esradin A12) and extrapolation mini-chamber developed at IPEN. The dose calculations have been obtained using the well-known Monte Carlo radiation transport code MCNP-4C. Maximum dose differences obtained between measured/calculated values for 90 Sr+ 90 Y applicator and for the electron beam were, respectively: 7.8 % and 8.0%. The profiles of the depth and superficial tissue dose distribution produced by the electron beam revealed themselves flatter and more homogeneous than those produced by the 90 Sr+ 90 Y applicator, especially to wider fields, which cannot be obtained with beta therapy applicators because of their geometric limitations. In conclusion this present work has shown that 90 Sr+ 90 Y applicators could be efficient for small and very superficial lesions but in most cases electron beam sources are more adequate especially for large and deeper lesions. (author)

Right Gastric Artery Embolization Prior to Treatment with Yttrium-90 Microspheres

International Nuclear Information System (INIS)

Cosin, Octavio; Bilbao, Jose Ignacio; Alvarez, Sergio; Luis, Esther de; Alonso, Alberto; Martinez-Cuesta, Antonio

2007-01-01

Purpose. Intra-arterial infusion of yttrium-90 microspheres is a form of radiation treatment for unresectable hepatic neoplasms. Misdeposition of particles in the gastroduodenal area such as the right gastric artery (RGA) may occur with serious consequences. We present a series of patients who underwent a detailed vascular study followed by RGA embolization. Special emphasis is placed on anatomic variations and technical considerations .Methods. In a 1 year period, 27 patients were treated. Initial vascular evaluation was performed, with careful attention to anatomic variants or extrahepatic arterial supply, especially to the gastroduodenal area. Embolization of such arteries was planned if needed. RGA embolization was performed antegradely from the hepatic artery or retrogradely via the left gastric artery (LGA). Postprocedural follow-up included clinical interview and gastroscopy if necessary. Results. RGA embolization was performed in 9 patients presenting with primary (n = 3) or metastatic liver tumors (n 6). Six patients underwent antegrade RGA embolization and 3 had embolization done retrogradely via the LGA. Retrograde access was chosen for anatomic reasons. None of the patients complained of gastroduodenal symptoms. Conclusion. RGA embolization can help minimize the gastroduodenal deposition of radioactive particles. RGA embolization should routinely be carried out. The procedure can be performed, with similar technical success, by both anterograde and retrograde approaches

Hepatobiliary effects of 90yttrium microsphere therapy for unresectable hepatocellular carcinoma.

Science.gov (United States)

Nalesnik, Michael A; Federle, Michael; Buck, David; Fontes, Paulo; Carr, Brian I

2009-01-01

(90)Yttrium (Therasphere) microspheres administered via hepatic artery are a valuable option for treatment of hepatocellular carcinoma. This therapy targets tumor nodules while largely sparing hepatic parenchyma. This retrospective study examines liver explants from 13 adult patients with hepatocellular carcinoma who received intrahepatic Theraspheres and subsequently underwent liver transplantation. Histopathologic and laboratory reviews are performed. Theraspheres preferentially migrated to the lobe(s) supplied by the injected artery branches and frequently localized to tumors. Tumors showed a chronology of changes beginning with confluent necrosis typically accompanied by hemorrhage and later by fibrinoid change. This was followed by fibrosis with regenerative activity at tumor peripheries. Adjacent hepatic parenchyma went through a similar sequence of injury and repair that could lead to markedly fibrotic cirrhotic nodules in the vicinity of treated tumors. No consistent pattern of thrombomodulin loss was seen in endothelial cells of the tumors or adjacent parenchyma, suggesting that direct endothelial cell injury was likely not a major contributor to the necrotic process. However, the pattern of injury and repair is suggestive of a localized and subclinical form of radiation-induced liver disease. The pathologist should be aware of these changes to distinguish them from the diffuse "radiation hepatitis" associated with older forms of radiotherapy.

Development of Technology for the Preparation of 90Sr/90Y Generators at the Radiopharmacy Directory of IPEN/CNEN-SP

International Nuclear Information System (INIS)

Barrio, Graciela

2010-01-01

90 Y (T /2 = 2,67 d; Eβmax = 2,28 MeV) is a radionuclide with efficacy established for various cancer therapies, labeling biomolecules and treating of radiosinovectomy. Due to its nuclear properties, is obtained through the decay of 90 Sr T /2 = 28 y in the form of a generator. Several types of 90 Sr/ 90 Y generators were developed, and the most employed are the cation exchange resins, where Sr and Y are adsorbed and 90 Y is selectively eluted with acetate or EDTA. The disadvantage of this type of generator is the radiolysis, which degrades its use. The electrochemical generator is a proposed solution because there is no significant effect of radiation. In this concept, the difference between the electrochemical potentials of the elements Sr and Y is used to obtain a rapid separation of 90 Y from 90 Sr. The production of 90 Y via colloid formation is the simplest method for the separation, based on the colloid formation of Y in high alkaline pH, which can be filtered and separated from Sr, and subsequently dissolved in HCl. The objective of this work was the development of technologies for the preparation of 90 Sr/ 90 Y generators, and three technologies were developed: generators using cation resins columns, generators through colloid formation and electrochemical generators. Radionuclidic quality control of 90 Y was also evaluated by liquid scintillation, radionuclide identity, extraction paper chromatography (EPC) using complexing agents for 90 Y and by Optical Emission Spectrometry with Inductively Coupled Plasma (ICP-OES). The results showed that generators using cation resins have the best results related to the elution efficiency (∼83%), the reproducibility and radionuclidic purity. The electrochemical generator showed a potential for development, having the advantage of not suffering the effects of radiolysis of the pair 90 Sr/ 90 Y as the resin. A comparison and evaluation of the methods of the radionuclidic quality control showed that the EPC is very

Synovectomy of the knee with 90Y

International Nuclear Information System (INIS)

Spooren, P.F.M.J.; Rasker, J.J.; Arens, R.P.J.H.; Ziekenhuis Ziekenzorg, Enschede

1985-01-01

In 33 patients with chronic arthritis of the knee, 48 knees were treated with an intra-articular injection of 5 mCi yttrium silicate 90 Y. There were 27 patients with rheumatoid arthritis (RA) and 6 with osteoarthrosis (OA); the mean follow-up period was 33 months. At clinical investigation after 1 year, no signs of pain or swelling were found in 15 knees. In most cases, pain and swelling improved subjectively, with a mean duration of 11 months; in 20 knees, the improvement lasted more than 22 months. When radiographs showed severse destruction, 90 Y treatment was unsuccessful, but an important new finding was that most patients with mild or moderate radiological abormalities appeared to have a long-lasting improvement. The result did not correlate with erythrocyte sedimentation rate (ESR), haemoglobin or Rose titre at the time of injection or at follow up, suggesting that the result of the treatment is more dependent on local factors than on the disease activity. The results of 90 Y treatment in 6 OA knees with persistent swelling were promising regarding swelling, even in patients with moderate radiological abnormalities. The main side-effect was a sometimes painful swelling of the knee, which was always successfully treated with an intra-articular corticosteroid injection. In 90 Y-treated knees, the incidence of unstable joints was not significantly higher than in non-treated knees. In conclusion, 90 Y synovectomy may be a succesful treatment for patients older than 50 years with chronic arthritis of the knee due to RA and probably also OA, even when moderate radiological abnormalities are present. (orig.)

Treatment of pains from bone metastases with 90Y

International Nuclear Information System (INIS)

Kutzner, J.; Daehnert, W.; Schreyer, T.; Grimm, W.; Brod, K.H.; Becker, M.

1981-01-01

For palliation of pain caused by bone metastases beta radiation isotope therapy was successful. As shown in experimental work on animals bone uptake of 90 Y with its shorter half-life is high when it is administered as a citrate complex. 90 Y can be eluted with high purity from a 90 Sr cow. The retention in man was found by whole-body counting to be higher than 80%. In preliminary trials on 16 patients the analgetic effect was the same as that of 89 Sr. The properties of 90 Y therapy are discussed. (orig.) [de

Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers.

Science.gov (United States)

Villard, Linda; Romer, Anna; Marincek, Nicolas; Brunner, Philippe; Koller, Michael T; Schindler, Christian; Ng, Quinn K T; Mäcke, Helmut R; Müller-Brand, Jan; Rochlitz, Christoph; Briel, Matthias; Walter, Martin A

2012-04-01

Radiopeptide therapy is commonly performed with a single radioisotope. We aimed to compare the effectiveness of somatostatin-based radiopeptide therapy with a single versus a combination of radioisotopes. In a cohort study, patients with metastasized neuroendocrine cancer were treated with repeated cycles of (90)yttrium-labeled tetraazacyclododecane-tetraacetic acid modified Tyr-octreotide ([(90)Y-DOTA]-TOC) or with cycles alternating between [(90)Y-DOTA]-TOC and (177)lutetium-labeled DOTA-TOC ([(177)Lu-DOTA]-TOC) until tumor progression or permanent toxicity. Multivariable Cox regression and competing risk regression were used to study predictors of survival and renal toxicity in patients completing three or more treatment cycles. A total of 486 patients completed three or more treatment cycles; 237 patients received [(90)Y-DOTA]-TOC and 249 patients received [(90)Y-DOTA]-TOC + [(177)Lu-DOTA]-TOC. Patients receiving [(90)Y-DOTA]-TOC + [(177)Lu-DOTA]-TOC had a significantly longer survival than patients receiving [(90)Y-DOTA]-TOC alone (5.51 v 3.96 years; hazard ratio, 0.64; 95% CI, 0.47 to 0.88; P = .006). The rates of severe hematologic toxicities (6.3% v 4.4%; P = .25) and severe renal toxicity (8.9% v 11.2%; P = .47) were comparable in both groups. [(90)Y-DOTA]-TOC + [(177)Lu-DOTA]-TOC was associated with improved overall survival compared with [(90)Y-DOTA]-TOC alone in patients completing three or more cycles of treatment. Contrary to the current practice in radiopeptide therapy, our results suggest an advantage of using a combination of radioisotopes.

[Preparation of citrulline microspheres by spray drying technique for colonic targeting].

Science.gov (United States)

Bahri, S; Zerrouk, N; Lassoued, M-A; Tsapis, N; Chaumeil, J-C; Sfar, S

2014-03-01

Citrulline is an amino acid that becomes essential in situations of intestinal insufficiency such as short bowel syndrome. It is therefore interesting to provide the patients with dosage forms for routing citrulline to the colon. The aim of this work is to formulate microspheres of citrulline for colonic targeting by the technique of spray drying. Eudragit(®) FS 30D was selected as polymer to encapsulate citrulline using the spray drying technique. Citrulline and Eudragit(®) FS 30D were dissolved in water and ethanol, respectively. The aqueous and the ethanolic solutions were then mixed in 1:2 (v/v) ratio. Microspheres were obtained by nebulizing the citrulline-Eudragit(®) FS 30D solution using a Mini spray dryer equipped with a 0.7mm nozzle. The microspheres have been formulated using citrulline and Eudragit(®) FS 30D. The size distribution of microspheres was determined by light diffraction. The morphology of the microspheres was studied by electron microscopy. Manufacturing yields, encapsulation rate and dissolution profiles were also studied. The microspheres obtained had a spherical shape with a smooth surface and a homogeneous size except for the microspheres containing the highest concentration of polymer (90 %). The formulation showed that the size and morphology of the microspheres are influenced by the polymer concentration. Manufacturing yields were about 51 % but encapsulation rate were always very high (above 90 %). The in vitro dissolution study showed that the use of the Eudragit(®) FS 30D under these conditions is not appropriate to change the dissolution profile of the citrulline. This technique has led to the formulation of microspheres with good physical properties in terms of morphology and size. The compression of the microspheres should help to control citrulline release for colonic targeting. Copyright © 2013 Elsevier Masson SAS. All rights reserved.

The behaviour of selected yttrium containing bioactive glass microspheres in simulated body environments.

Science.gov (United States)

Cacaina, D; Ylänen, H; Simon, S; Hupa, M

2008-03-01

The study aims at the manufacture and investigation of biodegradable glass microspheres incorporated with yttrium potentially useful for radionuclide therapy of cancer. The glass microspheres in the SiO2-Na2O-P2O5-CaO-K2O-MgO system containing yttrium were prepared by conventional melting and flame spheroidization. The behaviour of the yttrium silicate glass microspheres was investigated under in vitro conditions using simulated body fluid (SBF) and Tris buffer solution (TBS), for different periods of time, according to half-life time of the Y-90. The local structure of the glasses and the effect of yttrium on the biodegradability process were evaluated by Fourier Transform Infrared (FT-IR) spectroscopy and Back Scattered Electron Imaging of Scanning Electron Microscopy (BEI-SEM) equipped with Energy Dispersive X-ray (EDX) analysis. UV-VIS spectrometry and Inductively Coupled Plasma Mass Spectrometry (ICP-MS) was used for analyzing the release behaviour of silica and yttrium in the two used solutions. The results indicate that the addition of yttrium to a bioactive glass increases its structural stability which therefore, induced a different behaviour of the glasses in simulated body environments.

Microstructure and magnetic properties of yttrium alumina silicate glass microspheres containing iron oxide

International Nuclear Information System (INIS)

Sharma, K.; Basak, C.B.; Prajapat, C.L.; Singh, M.R.

2015-01-01

Yttrium alumino-silicate glass microspheres have been used for localized delivery of high radiation dose to tissues in the treatment of hepatocellular carcinoma (BCC) and synovitis. 90 Y is a pure beta emitter with beta emission energy of 0.9367 MeV, average penetration range in tissue 2.5 mm, physical half-life of 64.2 h, thus an effective radioisotope for delivering high radiation dose to the tumor. The efficacy of radiotherapy can further be improved if the glass microspheres are doped with magnetic particles for targeted delivery of high radiation dose. Magnetic glass microspheres can also be utilized for cancer treatment using the magnetic heating of tumor cell. The magnetic glass microspheres are obtained from the glasses with nominal composition (64-x) SiO 2 -17Y 2 O 3 -19 Al 2 O 3 -xFe 2 O 3 (x=4-16 mol %). Density of glasses increases from 3.5g/cc to 3.8g/cc as iron oxide content is increased from 4 to 16 mol %. The glass transition temperature and peak crystallization temperature decreases as the iron oxide content increases. T g values of glass samples decreases with increase of Fe 2 O 3 , while SiO 2 content is decreased. SiO 2 is a network forming oxide and a decrease in the network former in glass lead to decrease in thermo-physical properties like T g . The development of ferrimagnetic crystallites in glasses arise from the conversion of iron oxide into magnetite, magnemite and hematite, which is influenced by the structural and ordering of magnetic particles. The microstructure of glass-ceramic exhibited the formation of 50-100 nm size particles. The magnetite and hematite are formed as major crystalline phases. The magnetization values increased with an increase of iron oxide content and attributed to formation of magnetite phase. Results have shown that the glass microspheres with magnetic properties can be used as potential materials for cancer treatment. (author)

Adsorption of 90Sr and 90Y by bottom-set beds in the Atlantic ocean

International Nuclear Information System (INIS)

Gromov, V.V.; Shakhova, N.F.; Emel'yanov, E.M.

1978-01-01

The behaviour of 90 Sr and 90 Y has been studied in an adsorption system of sea water-bottom-set beds of the Atlantic ocean (red clay; pelitic silt). It has been shown that strontium is present in the sea water in one form, viz, Sr 2+ . Adsorption of 90 Sr with bottom-set beds follows the ion-exchange mechanism. Yttrium is present in the sea water at least three forms (two absorbable and one non-absorbable). Yttrium-90 adsorption is an irreversible process and only about 10% 90 Y is desorbed by the sea water from red clay and silt

Computed tomography hepatic arteriography has a hepatic falciform artery detection rate that is much higher than that of digital subtraction angiography and 99mTc-MAA SPECT/CT: Implications for planning 90Y radioembolization?

Energy Technology Data Exchange (ETDEWEB)

Burgmans, M.C., E-mail: mburgmans@hotmail.com [Department of Diagnostic Radiology, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Too, C.W., E-mail: too.chow.wei@singhealth.com.sg [Department of Diagnostic Radiology, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Kao, Y.H., E-mail: yung.h.kao@gmail.com [Department of Nuclear Medicine and PET, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Goh, A.S.W., E-mail: anthony.goh.s.w@sgh.com.sg [Department of Nuclear Medicine and PET, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Chow, P.K.H., E-mail: gsupc@singnet.com.sg [Department of General Surgery, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Office of Clinical Sciences, Duke-NUS Graduate Medical School Singapore, 8 College Road, Singapore 169857 (Singapore); Department of Surgical Oncology, National Cancer Center Singapore, 11 Hospital Drive, Singapore 169610 (Singapore); Tan, B.S., E-mail: tan.bien.soo@sgh.com.sg [Department of Diagnostic Radiology, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Tay, K.H., E-mail: tay.kiang.hiong@sgh.com.sg [Department of Diagnostic Radiology, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore); Lo, R.H.G., E-mail: richard.lo.h.g@sgh.com.sg [Department of Diagnostic Radiology, Singapore General Hospital, Outram Road, Singapore 169608 (Singapore)

2012-12-15

Purpose: To compare the hepatic falciform artery (HFA) detection rates of digital subtraction angiography (DSA), computed tomography hepatic arteriography (CTHA) and 99mTc-macroaggregated albumin (99mTc-MAA) single photon emission computed tomography with integrated CT (SPECT/CT) and to correlate HFA patency with complication rates of yttrium-90 (90Y) radioembolization. Material and methods: From August 2008 to November 2010, 79 patients (range 23–83 years, mean 62.3 years; 67 male) underwent pre-treatment DSA, CTHA and 99mTc-MAA scintigraphy (planar/SPECT/CT) to assess suitability for radioembolization with 90Y resin microspheres. Thirty-seven patients were excluded from the study, because CTHA was performed with a catheter position that did not result in opacification of the liver parenchyma adjacent to the falciform ligament. DSA, CTHA and 99mTc-MAA SPECT/CT images and medical records were retrospectively reviewed. Results: A patent HFA was detected in 22 of 42 patients (52.3%). The HFA detection rates of DSA, CTHA and 99mTc-MAA SPECT/CT were 11.9%, 52.3% and 13.3%, respectively (p < 0.0001). An origin from the segment 4 artery was seen in 51.7% of HFAs. Prophylactic HFA coil-embolization prior to 90Y microspheres infusion was performed in 2 patients. Of the patients who underwent radioembolization with a patent HFA, none developed supra-umbilical radiation dermatitis. One patient experienced epigastric pain attributed to post-embolization syndrome and was managed conservatively. Conclusion: The HFA detection rate of CTHA is superior to that of DSA and 99mTc-MAA SPECT/CT. Complications related to non-target radiation of the HFA vascular territory rarely occur, even in patients undergoing radioembolization with a patent HFA.

Computed tomography hepatic arteriography has a hepatic falciform artery detection rate that is much higher than that of digital subtraction angiography and 99mTc-MAA SPECT/CT: Implications for planning 90Y radioembolization?

International Nuclear Information System (INIS)

Burgmans, M.C.; Too, C.W.; Kao, Y.H.; Goh, A.S.W.; Chow, P.K.H.; Tan, B.S.; Tay, K.H.; Lo, R.H.G.

2012-01-01

Purpose: To compare the hepatic falciform artery (HFA) detection rates of digital subtraction angiography (DSA), computed tomography hepatic arteriography (CTHA) and 99mTc-macroaggregated albumin (99mTc-MAA) single photon emission computed tomography with integrated CT (SPECT/CT) and to correlate HFA patency with complication rates of yttrium-90 (90Y) radioembolization. Material and methods: From August 2008 to November 2010, 79 patients (range 23–83 years, mean 62.3 years; 67 male) underwent pre-treatment DSA, CTHA and 99mTc-MAA scintigraphy (planar/SPECT/CT) to assess suitability for radioembolization with 90Y resin microspheres. Thirty-seven patients were excluded from the study, because CTHA was performed with a catheter position that did not result in opacification of the liver parenchyma adjacent to the falciform ligament. DSA, CTHA and 99mTc-MAA SPECT/CT images and medical records were retrospectively reviewed. Results: A patent HFA was detected in 22 of 42 patients (52.3%). The HFA detection rates of DSA, CTHA and 99mTc-MAA SPECT/CT were 11.9%, 52.3% and 13.3%, respectively (p < 0.0001). An origin from the segment 4 artery was seen in 51.7% of HFAs. Prophylactic HFA coil-embolization prior to 90Y microspheres infusion was performed in 2 patients. Of the patients who underwent radioembolization with a patent HFA, none developed supra-umbilical radiation dermatitis. One patient experienced epigastric pain attributed to post-embolization syndrome and was managed conservatively. Conclusion: The HFA detection rate of CTHA is superior to that of DSA and 99mTc-MAA SPECT/CT. Complications related to non-target radiation of the HFA vascular territory rarely occur, even in patients undergoing radioembolization with a patent HFA.

Radioisotope generators for nuclear medicine based on Fajans adsorption on glass microspheres

International Nuclear Information System (INIS)

Ehrhardt, G.J.; Symes, S.; Guimon, R.K.; Zinn, K.R.

1992-01-01

Several radioisotope generator systems exist in which the carrier-free daughter product would precipitate if present in macro amounts at pH levels at which the parent is soluble. Included among these are the 68 Ge/ 68 Ga, 90 Sr/ 90 Y, and 47 Ca/ 47 Sc pairs. This paper reveals that in these systems, chemical separation can be achieved by Fajans adsorption of the radiocolloidal daughter products onto surfaces such as activated glass microspheres at an appropriate pH. This is followed by washing to remove the parent solution and desorption of the daughter crop by acid washes. Investigation of the Ge/Ga and Sr/Y systems demonstrated that this solid-phase extraction method is erratic, but can give daughter yields as high at 89% with separation factors up to ∼ 10,000 form parent isotope. This method has the potential for producing daughter isotopes with a minimum of metal and organic impurities for labeling cells, receptor binding ligands, and antibodies for diagnostic and radiotherapeutic purposes

90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging.

Science.gov (United States)

Lewandowski, Robert J; Thurston, Kenneth G; Goin, James E; Wong, Ching-Yee O; Gates, Vanessa L; Van Buskirk, Mark; Geschwind, Jean-Francois H; Salem, Riad

2005-12-01

The purpose of this phase II study was to determine the safety and efficacy of TheraSphere treatment (90Y microspheres) in patients with liver-dominant colorectal metastases in whom standard therapies had failed or were judged to be inappropriate. Twenty-seven patients with unresectable hepatic colorectal metastases were treated at a targeted absorbed dose of 135-150 Gy. Safety and toxicity were assessed according to the National Cancer Institute's Common Toxicity Criteria, version 3.0. Response was assessed with use of computed tomography (CT) and was correlated with response on [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET). Survival from first treatment was estimated with use of the Kaplan-Meier method. Tumor response measured by FDG PET imaging exceeded that measured by CT imaging for the first (88% vs 35%) and second (73% vs 36%) treated lobes. Tumor replacement of 25% or less (vs >25%) was associated with a statistically significant increase in median survival (339 days vs 162 days; P = .002). Treatment-related toxicities included mild fatigue (n = 13; 48%), nausea (n = 4; 15%), and vague abdominal pain (n = 5; 19%). There was one case of radiation-induced gastritis from inadvertent deposition of microspheres to the gastrointestinal tract (n = 1; 4%). Three patients (11%) experienced ascites/pleural effusion after treatment with TheraSphere as a consequence of liver failure in advanced-stage metastatic disease. With the exception of these three patients whose sequelae were not considered to be related to treatment, all observed toxicities were transient and resolved without medical intervention. TheraSphere administration appears to provide stabilization of liver disease with minimal toxicity in patients in whom standard systemic chemotherapy regimens have failed.

Radioembolization and the dynamic role of 90Y PET/CT

Directory of Open Access Journals (Sweden)

Alexander S Pasciak

2014-02-01

Full Text Available Before the advent of tomographic imaging, it was postulated that decay of 90Y to the 0+ excited state of 90Zr may result in emission of a positron-electron pair. While the branching ratio for pair production is small (~32x10-6, PET has been successfully used to image 90Y in numerous recent patient and phantom studies. 90Y PET imaging has been performed on a variety of PET/CT systems, with and without time-of-flight (TOF and/or resolution recovery capabilities as well as on both BGO and L(YSO based scanners. On all systems, resolution and contrast superior to bremsstrahlung SPECT has been reported. The intrinsic radioactivity present in L(YSO-based PET scanners is a potential limitation associated with accurate quantification of 90Y. However, intrinsic radioactivity has been shown to have a negligible effect at the high activity concentrations common in 90Y radioembolization. Accurate quantification is possible on a variety of PET scanner models, with or without TOF, although TOF improves accuracy at lower activity concentrations. Quantitative 90Y PET images can be transformed into 3D maps of absorbed dose based on the premise that the 90Y activity distribution does not change after infusion. This transformation has been accomplished primarily with the use of 3D dose point-kernel convolution. From a clinical standpoint, 90Y PET provides a superior post-infusion evaluation of treatment technical success owing to its improved resolution. Absorbed dose maps generated from quantitative PET data can be used to predict treatment efficacy and manage patient follow-up. For patients who receive multiple treatments, this information can also be used to provide patient-specific treatment planning for successive therapies, potentially improving response. The broad utilization of 90Y PET has the potential to provide a wealth of dose-response information, which may lead to development of improved radioembolization treatment-planning models in the future.

A retrospective review of Y90 synovectomy in Auckland

International Nuclear Information System (INIS)

Stamp, L.

2000-01-01

Full text: A retrospective review of Yttrium 90 synovectomies carried out from June 1997 to February 1999 in Auckland Hospital to determine outcome from the procedure. Methods: Patients were sent a questionnaire for each treated knee The principal outcome measures assessed in the month prior and the 6 months after the Y90 were pain, swelling, walking distance and overall disability score. Referring doctors were sent a questionnaire to provide information on duration of synovitis and treatment. Outcomes measured were presence of effusion 6 months after the Y90, requirement for intra-articular steroid in the 12 months prior to and after the yttrium and change of therapy due lo ongoing symptoms in the treated knee. Results: 29 patients and 40 knees had Y90 during the study period 86% patients with 87.5% knees responded. Referring doctors for 86% patients accounting for 87.5% knees responded. The procedure was well tolerated with the majority of patients reporting nil-mild discomfort during and in the 24 hours after Y90. 86% knees treated reported improvement with a reduction in pain and swelling Patient global assessment reduced from 3.8 to 2.0 while physician global assessment reduced from 3.9 to 3.0. There was an improvement in walking distance 6 months after Y90 with the number of knees able to walk >1km increasing from 2 to 17 14 of 25 patients required a change in treatment because of ongoing problems in the treated knee and one patient has undergone knee joint replacement One further patient is waiting knee joint replacement The need for intra-articular steroid was reduced with 83%, knees having an average of 2.4 steroid injections in the 12 months prior to Y90 compared to 38% knees having an average of 0.7 steroid injections in the 12 months after Y90. Of the 30 knees reporting Improvement 24 knees are at least 12 months post Y90. Of these 50% were Improved at 12 months. As a result of this audit we continue to offer this procedure in the Auckland area, and

Preparation & in vitro evaluation of 90Y-DOTA-rituximab

Science.gov (United States)

Kameswaran, Mythili; Pandey, Usha; Dash, Ashutosh; Samuel, Grace; Venkatesh, Meera

2016-01-01

Background & objectives: Radioimmunotherapy is extensively being used for the treatment of non-Hodgkin's lymphoma (NHL). Use of rituximab, a chimeric anti-CD20 antibody directed against the CD20 antigen in combination with suitable beta emitters is expected to result in good treatment response by its cross-fire and bystander effects. The present work involves the conjugation of p-isothiocyanatobenzyl DOTA (p-SCN-Bn-DOTA) to rituximab, its radiolabelling with 90Y and in vitro and in vivo evaluation to determine its potential as a radioimmunotherapeutic agent. Methods: Rituximab was conjugated with p-SCN-Bn-DOTA at 1:1 antibody: DOTA molar ratio. The number of DOTA molecules linked to one molecule of rituximab was determined by radioassay and spectroscopic assay. Radiolabelling of rituximab with 90Y was carried out and its in vitro stability was evaluated. In vitro cell binding studies were carried out in Raji cells expressing CD20 antigen. Biodistribution studies were carried out in normal Swiss mice. Results: Using both radioassay and spectroscopic method, it was determined that about five molecules of DOTA were linked to rituximab. Radiolabelling of the rituximab conjugate with 90Y and subsequent purification on PD-10 column gave a product with radiochemical purity (RCP) > 98 per cent which was retained at > 90 per cent up to 72 h when stored at 37°C. In vitro cell binding experiments of 90Y-DOTA-rituximab with Raji cells exhibited specific binding of 20.7 ± 0.1 per cent with 90Y-DOTA-rituximab which reduced to 15.5 ± 0.2 per cent when incubated with cold rituximab. The equilibrium constant Kd for 90Y-DOTA-Rituximab was determined to be 3.38 nM. Radiolabelled antibody showed clearance via hepatobiliary and renal routes and activity in tibia was found to be quite low indicating in vivo stability of 90Y-DOTA-rituximab. Interpretation & conclusions: p-SCN-Bn-DOTA was conjugated with rituximab and radiolabelling with 90Y was carried out. In vitro studies carried

Preparation of nano-hydroxyapatite/poly(l-lactide) biocomposite microspheres

International Nuclear Information System (INIS)

Qiu Xueyu; Han Yadong; Zhuang Xiuli; Chen Xuesi; Li Yuesheng; Jing Xiabin

2007-01-01

Nano-hydroxyapatite (HA)/poly(l-lactide) (PLLA) composite microspheres with relatively uniform size distribution were prepared by a solid-in-oil-in-water (s/o/w) emusion solvent evaporation method. The encapsulation of the HA nanopaticles in microshperes was significantly improved by grafting PLLA on the surface of the HA nanoparticles (p-HA) during emulsion process. This procedure gave a possibility to obtain p-HA/PLLA composite microspheres with uniform morphology and the encapsulated p-HA nanoparticle loading reached up to 40 wt% (33 wt% of pure HA) in the p-HA/PLLA composite microspheres. The microstructure of composite microspheres from core-shell to single phase changed with the variation of p-HA to PLLA ratios. p-HA/PLLA composite microspheres with the diameter range of 2-3 μm were obtained. The entrapment efficiency of p-HA in microspheres could high up to 90 wt% and that of HA was only 13 wt%. Surface and bulk characterizations of the composite microspheres were performed by measurements such as wide angle X-ray diffraction (WAXD), thermal gravimetric analysis (TGA), environmental scanning electron microscope (ESEM) and transmission electron microscopy (TEM)

Therapeutic result of radioactive nuclide 90Sr/90Y treatment in patients with benign prostatic hypertrophy (BPH)

International Nuclear Information System (INIS)

Chen Hanchao; Li Yuying

2008-01-01

Objective: To study the effect of radioactive nuclide 90 Sr/ 90 Y treatment in patients with benign prostatic hypertrophy (BPH). Methods: Sixty patients with BPH were treated with a course of transurethral radioactive nuclide 90 Sr/ 90 Y therapy. Results: The severity of BPH was assessed with four parameters: maximal flow rate (MFR), volume of residual urine (VRU), international prostatic symptom score (IPSS) and volume (size) of prostate. In this series, the total effective rate was 93.33% with no treatment- related mortality. Favorable changes of the parameters after a course of radioactive nuclide therapy were significant. Conclusion: Radioactive nuclide 90 Sr/ 90 Y therapy for patients with BPH was safe, easily performed and quite effective. This procedure is worth popularizing in appropriate patients. (authors)

The effect of 90Sr/90Y β-rays on benign prostatic hyperplasia

International Nuclear Information System (INIS)

Kong Xiangbo; Ma Qingjie; Gu Xinquan

2004-01-01

Objective: To investigate the effect of 90Sr/90Y β-rays on Benign prostatic hyperplasia (BPH). Methods: In order to carry out β intracavitary irradiation, the active area of the applicator was located into prostate gland section of urethra in 37 patients. The dose was controlled 30∼50Gy in each patient and the patients were observed for 3 months. Results: After two weeks 26 cases were remarkably improved, 7 cases were improved and 4 cases were ineffective. There was significant difference on MFR, PVR, I-PSS and volume of prostate gland before and after treatment (P<0.01=. Conclusion: Clinical tests indicate that the 90Sr/90Y prostatic hyperplasia applicators provide a safe, effective ,non-invasive and economical therapeutic method for BPH. It is especially applicable for old and high-risk patients. (authors)

Half-life evaluations for 3H, 90Sr, and 90Y

International Nuclear Information System (INIS)

MacMahon, Desmond

2006-01-01

A recent paper has reviewed methods for the evaluation of discrepant sets of data and demonstrated the results of applying these methods to the published half-life data of 90 Sr and 137 Cs [MacMahon, T.D., Pearce, A., Harris, P., 2004. Convergence of techniques for the evaluation of discrepant data. Appl. Radiat. Isot. 60, 275-281]. The half-life data for 3 H has been subject to a comprehensive review and critical evaluation by Lucas and Unterweger [2000. Comprehensive review and critical evaluation of the half-life of tritium. J. Res. Natl. Inst. Stand. Technol. 105, 541-549]. The current paper reports the results of applying the various evaluation procedures of MacMahon et al. Convergence of techniques for the evaluation of discrepant data. Appl. Radiat. Isot. 60, 275-281] to the data of Lucas and Unterweger [Comprehensive review and critical evaluation of the half-life of tritium. J. Res. Natl. Inst. Stand. Technol. 105, 541-549], resulting in a recommended half-life of 4497(4) days. MacMahon et al. [Convergence of techniques for the evaluation of discrepant data. Appl. Radiat. Isot. 60, 275-281] highlighted problems in the evaluation of the discrepant half-life data of 90 Sr, in particular the worrying upward trend in the data, where the weighted mean of all the measurements increases, on average, by 35 days each time a new measurement result is added. The current paper reports on further analyses of these data. New measurements of the half-life of 90 Y have been reported by Kossert and Schrader [2004. Standardization by liquid scintillation counting and half-life measurements of 90 Y. Appl. Radiat. Isot. 60, 741]. This has prompted a new evaluation of all available published 90 Y half-life data. The data are fairly consistent, and a value of 64.063(16) h is recommended

Determination of 90Sr in milk by solvent extraction of 90Y

International Nuclear Information System (INIS)

Mitsuhashi, Toshihiko; Sakanoue, Masanobu.

1977-01-01

In order to replace the conventional method using violent fuming nitric acid, a new method for the determination of 90 Sr in milk has been developed by using the solvent extraction with bis (2-ethylhexyl) phosphoric acid (HDEHP). The daughter nuclide 90 Y in a radiochemical equilibrium with its parent 90 Sr was extracted with 2:1 HDEHP-toluene from the acid solution (1M HCl) of milk ash sample prepared by dry-ashing. After stripping with 8M HCl, 90 Y, together with stable yttrium added as carrier, was precipitated as oxalate to prepare β-counting source. The radiochemical purity was confirmed by decay curve. The decontamination of strontium was checked by applying non-dispersive fluorescence x-ray analysis using 133 Ba as irradiating source. Bone samples of cow were also analyzed by the same method and the results were compared with those obtained by other methods. The duplicate crosschecking analyses of finely ground bone samples were carried out to examine the effectiveness of this method. This simple new method was found to be very effective for the routine analysis of 90 Sr in these samples. (auth.)

Validation of Extraction Paper Chromatography as a Quality Control Technique for Analysis of Sr-90 in Y-90 Product

International Nuclear Information System (INIS)

Nipavan, Poramatikul; Jatupol, Sangsuriyan; Wiranee, Sriweing

2009-07-01

Full text: Yttrium-90 (Y-90) is a daughter product of strontium-90 (Sr-90). It is specified that there should be less than 2 micro-curie of Sr-90 in Y-90 radiopharmaceuticals. Since both nuclides are beta emitting and there is always a contamination of Y-90 in Sr-90 sample, validation of the analytical method is necessary. In this study, commercial Y-90 and Sr-85 (a gamma emitting isotope of strontium) were used as daughter and mother nuclides, respectively. Extraction paper chromatography technique and its efficient validation method were investigated. Bis-(2-ethylhexyl) diphosphonate was dropped at the origin of chromatography paper and air dried prior to sample drops. Validation of the separation was done by radio-chromatography scanning of the chromatography paper. Their energy spectra were identified in the spectra mode of Packard Cobra II automatic gamma counter, which can differentiate a pure gamma, a pure beta and a mixture of beta and gamma nuclides. Results showed that yttrium acetate remained fixed at the origin of the chromatography paper while strontium acetate moved to the solvent front when developed in saline. In conclusion, the extraction paper chromatography technique can effectively separate Sr-90 from Y-90

The origin and reduction of spurious extrahepatic counts observed in 90Y non-TOF PET imaging post radioembolization

Science.gov (United States)

Walrand, Stephan; Hesse, Michel; Jamar, François; Lhommel, Renaud

2018-04-01

Our literature survey revealed a physical effect unknown to the nuclear medicine community, i.e. internal bremsstrahlung emission, and also the existence of long energy resolution tails in crystal scintillation. None of these effects has ever been modelled in PET Monte Carlo (MC) simulations. This study investigates whether these two effects could be at the origin of two unexplained observations in 90Y imaging by PET: the increasing tails in the radial profile of true coincidences, and the presence of spurious extrahepatic counts post radioembolization in non-TOF PET and their absence in TOF PET. These spurious extrahepatic counts hamper the microsphere delivery check in liver radioembolization. An acquisition of a 32P vial was performed on a GSO PET system. This is the ideal setup to study the impact of bremsstrahlung x-rays on the true coincidence rate when no positron emission and no crystal radioactivity are present. A MC simulation of the acquisition was performed using Gate-Geant4. MC simulations of non-TOF PET and TOF-PET imaging of a synthetic 90Y human liver radioembolization phantom were also performed. Internal bremsstrahlung and long energy resolution tails inclusion in MC simulations quantitatively predict the increasing tails in the radial profile. In addition, internal bremsstrahlung explains the discrepancy previously observed in bremsstrahlung SPECT between the measure of the 90Y bremsstrahlung spectrum and its simulation with Gate-Geant4. However the spurious extrahepatic counts in non-TOF PET mainly result from the failure of conventional random correction methods in such low count rate studies and poor robustness versus emission-transmission inconsistency. A novel proposed random correction method succeeds in cleaning the spurious extrahepatic counts in non-TOF PET. Two physical effects not considered up to now in nuclear medicine were identified to be at the origin of the unusual 90Y true coincidences radial profile. TOF reconstruction removing

Development of a dosimetric system for 90Sr + 90Y betatherapy applicators

International Nuclear Information System (INIS)

Coelho, Talita Salles

2010-01-01

The 90 Sr+ 90 Y applicators, used in betatherapy for prevention of keloids and pterigium, are imported and many times their dosimetric features are shown only in an illustrated form by the manufacturers. The exhaustive routine of the medical physicists in the clinic do not make possible the accomplishment of procedures for the confirmation of these parameters. This work presents the development of a methodology for the dosimetry of 90 Sr+ 90 Y betatherapy applicators. The Monte Carlo code MCNP5 was used for the simulation of the percentage depth dose curves and dose distribution profiles produced by these applicators. The experimental measurements of the radial and axial radiation attenuation, have been done with a mini-extrapolation chamber, thermoluminescent dosimeters and radiographic films. The experimental results have been compared with the simulated values. Both percentage depth dose curves and the radial dose profiles, the theoretical and the experimental ones, have presented good agreement, which may validate the use of the MCNP5 for these simulations, confirming the viability of the usage of this method in procedures of beta emitter sources dosimetry. (author)

(90)Y -PET imaging: Exploring limitations and accuracy under conditions of low counts and high random fraction.

Science.gov (United States)

Carlier, Thomas; Willowson, Kathy P; Fourkal, Eugene; Bailey, Dale L; Doss, Mohan; Conti, Maurizio

2015-07-01

(90)Y -positron emission tomography (PET) imaging is becoming a recognized modality for postinfusion quantitative assessment following radioembolization therapy. However, the extremely low counts and high random fraction associated with (90)Y -PET may significantly impair both qualitative and quantitative results. The aim of this work was to study image quality and noise level in relation to the quantification and bias performance of two types of Siemens PET scanners when imaging (90)Y and to compare experimental results with clinical data from two types of commercially available (90)Y microspheres. Data were acquired on both Siemens Biograph TruePoint [non-time-of-flight (TOF)] and Biograph microcomputed tomography (mCT) (TOF) PET/CT scanners. The study was conducted in three phases. The first aimed to assess quantification and bias for different reconstruction methods according to random fraction and number of true counts in the scan. The NEMA 1994 PET phantom was filled with water with one cylindrical insert left empty (air) and the other filled with a solution of (90)Y . The phantom was scanned for 60 min in the PET/CT scanner every one or two days. The second phase used the NEMA 2001 PET phantom to derive noise and image quality metrics. The spheres and the background were filled with a (90)Y solution in an 8:1 contrast ratio and four 30 min acquisitions were performed over a one week period. Finally, 32 patient data (8 treated with Therasphere(®) and 24 with SIR-Spheres(®)) were retrospectively reconstructed and activity in the whole field of view and the liver was compared to theoretical injected activity. The contribution of both bremsstrahlung and LSO trues was found to be negligible, allowing data to be decay corrected to obtain correct quantification. In general, the recovered activity for all reconstruction methods was stable over the range studied, with a small bias appearing at extremely high random fraction and low counts for iterative algorithms

90Y -PET imaging: Exploring limitations and accuracy under conditions of low counts and high random fraction

International Nuclear Information System (INIS)

Carlier, Thomas; Willowson, Kathy P.; Fourkal, Eugene; Bailey, Dale L.; Doss, Mohan; Conti, Maurizio

2015-01-01

Purpose: 90 Y -positron emission tomography (PET) imaging is becoming a recognized modality for postinfusion quantitative assessment following radioembolization therapy. However, the extremely low counts and high random fraction associated with 90 Y -PET may significantly impair both qualitative and quantitative results. The aim of this work was to study image quality and noise level in relation to the quantification and bias performance of two types of Siemens PET scanners when imaging 90 Y and to compare experimental results with clinical data from two types of commercially available 90 Y microspheres. Methods: Data were acquired on both Siemens Biograph TruePoint [non-time-of-flight (TOF)] and Biograph microcomputed tomography (mCT) (TOF) PET/CT scanners. The study was conducted in three phases. The first aimed to assess quantification and bias for different reconstruction methods according to random fraction and number of true counts in the scan. The NEMA 1994 PET phantom was filled with water with one cylindrical insert left empty (air) and the other filled with a solution of 90 Y . The phantom was scanned for 60 min in the PET/CT scanner every one or two days. The second phase used the NEMA 2001 PET phantom to derive noise and image quality metrics. The spheres and the background were filled with a 90 Y solution in an 8:1 contrast ratio and four 30 min acquisitions were performed over a one week period. Finally, 32 patient data (8 treated with Therasphere ® and 24 with SIR-Spheres ® ) were retrospectively reconstructed and activity in the whole field of view and the liver was compared to theoretical injected activity. Results: The contribution of both bremsstrahlung and LSO trues was found to be negligible, allowing data to be decay corrected to obtain correct quantification. In general, the recovered activity for all reconstruction methods was stable over the range studied, with a small bias appearing at extremely high random fraction and low counts for

Preparation and drug controlled release of porous octyl-dextran microspheres.

Science.gov (United States)

Hou, Xin; Liu, Yanfei

2015-01-01

In this work, porous octyl-dextran microspheres with excellent properties were prepared by two steps. Firstly, dextran microspheres were synthesized by reversed-phase suspension polymerization. Secondly, octyl-dextran microspheres were prepared by the reaction between dextran microspheres and ethylhexyl glycidyl ether and freezing-drying method. Porous structure of microspheres was formed through the interaction between octyl groups and organic solvents. The structure, morphology, dry density, porosity and equilibrium water content of porous octyl-dextran microspheres were systematically investigated. The octyl content affected the properties of microspheres. The results showed that the dry density of microspheres decreased from 2.35 to 1.21 g/ml, porosity increased from 80.68 to 95.05% with the octyl content increasing from 0.49 to 2.28 mmol/g. Meanwhile, the equilibrium water content presented a peak value (90.18%) when the octyl content was 2.25 mmol/g. Octyl-dextran microspheres showed high capacity. Naturally drug carriers play an important role in drug-delivery systems for their biodegradability, wide raw materials sources and nontoxicity. Doxorubicin (DOX) was used as a drug model to examine the drug-loading capacity of porous octyl-dextran microspheres. The drug-loading efficiency increased with the increase in microspheres/drug ratio, while the encapsulation efficiency decreased. When microspheres/drug mass ratio was 4/1, the drug-loading efficiency and encapsulation efficiency were 10.20 and 51.00%, respectively. The release rate of DOX increased as drug content and porosity increased. In conclusion, porous octyl-dextran microspheres were synthesized successfully and have the potential to serve as an effective delivery system in drug controlled release.

Carefully calibrated microsphere embolization of tumors and AVMs

International Nuclear Information System (INIS)

Laurent, A.; Wassef, M.; Beaujeux, R.; Hodes, J.E.; Gobin, P.Y.; Schenker, C.; Bouchez, B.; Brette, M.D.; Aymard, A.; Cophignon, J.; Merland, J.J.

1990-01-01

This paper evaluates the efficacy of a new type of uniformly calibrated microsphere for embolization of various pathologies. Fourteen tumors (five intracranial, eight extracranial, one spine), and seven facial arteriovenous malformations (AVMs) (nose, lip, and scalp) were embolized preoperatively. Angiographic, surgical devascularization, and histologic findings were correlated with the spheres' size. In the second part of the study, spinal cord (n = 22) and intracerbral (n = 14) AVM, Weber-Osler-Rendu disease (n = 2), and epistaxis (n = 1) embolization was angiographically evaluated

Yttrium-86-labelled human serum albumin microspheres: relation of surface structure with in vivo stability

International Nuclear Information System (INIS)

Schiller, Eik; Bergmann, Ralf; Pietzsch, Jens; Noll, Bernhard; Sterger, Antje; Johannsen, Bernd; Wunderlich, Gerd; Pietzsch, Hans-Juergen

2008-01-01

Introduction: Radiolabelled particles are an attractive tool in the therapy of malignancies of the liver. We consider particles manufactured from denatured human serum albumin (HSA) as useful carriers of therapeutic radionuclides. Covalent attachment of suitable chelators onto the surface of the spheres promises an easy access to radiolabelled HSA microspheres. Methods: We synthesized 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA) bearing smooth, medium-rough and rough surfaced HSA microspheres (mean diameter: 25 μm). In vitro stability of 86 Y-labelled particles was determined after incubation in human plasma and in a DTPA challenge experiment. In vivo stability of 86 Y DOTA-HSA microspheres was determined after single intravenous application in rats. Subsequently, the particles were completely trapped in the lung microvasculature. Thus, the lung serves in our experiments as target organ. Results: DOTA-HSA microspheres were 86 Y labelled in reproducible high yields (>95%). No differences between smooth and rough surfaced spheres were found for both DOTA coupling and 86 Y labelling. Labelled microspheres showed high in vitro stability in human plasma and in DTPA solution with only 8±1% and 2±0% loss of radioactivity from the surface, respectively, 48 h postinjection (pi). The three batches (smooth, medium-rough and rough surfaced microspheres) differed considerably in their radioactivity recovery in the lungs of rats 48 h pi. Smooth particles showed the highest in vivo stability of the radiolabel on the surface of the spheres, presumably because of slower proteolytic degradation. Conclusion: We found that for the preparation of HSA-derived microspheres for radiotherapeutic application, smooth surfaced spheres are superior to rough spheres due to their higher in vivo stability of the radionuclide fixation

Carboxyl-Functionalized Polymeric Microspheres Prepared by One-Stage Photoinitiated RAFT Dispersion Polymerization

Directory of Open Access Journals (Sweden)

Jianbo Tan

2017-12-01

Full Text Available Herein, we report a photoinitiated reversible addition-fragmentation chain transfer (RAFT dispersion copolymerization of methyl methacrylate (MMA and methyl methacrylic (MAA for the preparation of highly monodisperse carboxyl-functionalized polymeric microspheres. High rates of polymerization were observed, with more than 90% particle yields being achieved within 3 h of UV irradiation. Effects of reaction parameters (e.g., MAA concentration, RAFT agent concentration, photoinitiator concentration, and solvent composition were studied in detail, and highly monodisperse polymeric microspheres were obtained in most cases. Finally, silver (Ag composite microspheres were prepared by in situ reduction of AgNO3 using the carboxyl-functionalized polymeric microspheres as the template. The obtained Ag composite microspheres were able to catalyze the reduction of methylene blue (MB with NaBH4 as a reductant.

Power output and efficiency of beta-emitting microspheres

International Nuclear Information System (INIS)

Cheneler, David; Ward, Michael

2015-01-01

Current standard methods to calculate the dose of radiation emitted during medical applications by beta-minus emitting microspheres rely on an over-simplistic formalism. This formalism is a function of the average activity of the radioisotope used and the physiological dimensions of the patient only. It neglects the variation in energy of the emitted beta particle due to self-attenuation, or self-absorption, effects related to the finite size of the sphere. Here it is assumed the sphere is comprised of a pure radioisotope with beta particles being emitted isotropically throughout the material. The full initial possible kinetic energy distribution of a beta particle is taken into account as well as the energy losses due to scattering by other atoms in the microsphere and bremsstrahlung radiation. By combining Longmire’s theory of the mean forward range of charged particles and the Rayleigh distribution to take into account the statistical nature of scattering and energy straggling, the linear attenuation, or self-absorption, coefficient for beta-emitting radioisotopes has been deduced. By analogy with gamma radiation transport in spheres, this result was used to calculate the rate of energy emitted by a beta-emitting microsphere and its efficiency. Comparisons to standard point dose kernel formulations generated using Monte Carlo data show the efficacy of the proposed method. Yttrium-90 is used as a specific example throughout, as a medically significant radioisotope, frequently used in radiation therapy for treating cancer. - Highlights: • Range-energy relationship for the beta particles in yttrium-90 is calculated. • Formalism for the semi-analytical calculation of self-absorption coefficients. • Energy-dependent self-absorption coefficient calculated for yttrium-90. • Flux rate of beta particles from a self-attenuating radioactive sphere is shown. • The efficiency of beta particle emitting radioactive microspheres is calculated

Aspects of radiation protection during the treatment of liver cancer using yttrium-90 labelled microspheres

International Nuclear Information System (INIS)

Klemp, P.F.B.; Perry, A.M.; Fox, R.A.; Gray, B.N.; Burton, M.A.

1989-01-01

Twenty eight patients have received treatment for liver cancer by the intra-hepatic arterial injection of between 1 and 4 GBq of yttrium-90 labelled microspheres. The injection was performed at laparotomy. If 11.1 MBq of yttrium-90 are distributed evenly over 1 sq cm of tissue, the tissue surface will suffer an initial beta dose rate of 16.2 Gy h -1 . Special precautions are therefore essential during the injection procedure, subsequently in nursing the patient and if further intervention becomes necessary. A specially designed apparatus is used for the injection, glass spectacles are worn and if the active liver is to be handled, lead rubber gloves are used. The theatre is prepared so that contaminated items can be easily isolated and a 'spill pack' is readily available. At completion of the operation, the bremsstrahlung dose rate at 15 cm from the liver is initially 15 μSv h -1 GBq -1 . Contamination of urine is typically 20 to 50 kBq L -1 while the contamination of other body fluids is negligible. Finger doses to the surgeons has varied from 2 to 5 mSv GBq -1 injected while personnel film badges used to monitor the dose equivalent to the surgeons and ward staff have recorded maximum doses of 1.5 mSv and 300 μSv respectively. 11 refs., 1 fig., 3 tabs

Development of Poly Lactic/Glycolic Acid (PLGA Microspheres for Controlled Release of Rho-Associated Kinase Inhibitor

Directory of Open Access Journals (Sweden)

Sho Koda

2017-01-01

Full Text Available Purpose. The purpose of this study was to investigate the feasibility of poly lactic/glycolic acid (PLGA as a drug delivery carrier of Rho kinase (ROCK inhibitor for the treatment of corneal endothelial disease. Method. ROCK inhibitor Y-27632 and PLGA were dissolved in water with or without gelatin (W1, and a double emulsion [(W1/O/W2] was formed with dichloromethane (O and polyvinyl alcohol (W2. Drug release curve was obtained by evaluating the released Y-27632 by using high performance liquid chromatography. PLGA was injected into the anterior chamber or subconjunctiva in rabbit eyes, and ocular complication was evaluated by slitlamp microscope and histological analysis. Results. Y-27632 incorporated PLGA microspheres with different molecular weights, and different composition ratios of lactic acid and glycolic acid were fabricated. A high molecular weight and low content of glycolic acid produced a slower and longer release. The Y-27632 released from PLGA microspheres significantly promoted the cell proliferation of cultured corneal endothelial cells. The injection of PLGA did not induce any evident eye complication. Conclusions. ROCK inhibitor-incorporated PLGA microspheres were fabricated, and the microspheres achieved the sustained release of ROCK inhibitor over 7–10 days in vitro. Our data should encourage researchers to use PLGA microspheres for treating corneal endothelial diseases.

Evaluation of quantitative planar 90Y bremsstrahlung whole-body imaging

International Nuclear Information System (INIS)

Minarik, D; Ljungberg, M; Gleisner, K Sjoegreen; Segars, P

2009-01-01

With high-dose administration of 90 Y labeled antibodies, it is possible to image 90 Y without an admixture of 111 In. We have earlier shown that it is possible to perform quantitative 90 Y bremsstrahlung SPECT for dosimetry purposes with reasonable accuracy. However, whole-body (WB) activity quantification with the conjugate view method is not as time consuming as SPECT and has been the method of choice for dosimetry. We have investigated the possibility of using a conjugate view method where scatter-, backscatter- and septal-penetration compensations are performed by inverse filtering and attenuation correction is performed with a WB x-ray image, for total-body and organ activity quantification of 90 Y. The method was evaluated using both Monte Carlo simulated scintillation camera images using realistic source distributions, and by an experimental phantom study. The method was evaluated in terms of image quality and accuracy of the activity quantification. The experimental phantom study was performed using the RSD torso phantom with 90 Y activity uniformly distributed in the liver insert. A GE Discovery VH/Hawkeye system was used to acquire the image. The simulation study was performed for a realistic activity distribution in the NCAT anthropomorphic phantom where 90 Y bremsstrahlung images were generated using the SIMIND MC program. Two different phantom configurations and two activity distributions were simulated. To mimic the RSD phantom experiment one simulation study was also made with 90 Y activity located only in the liver. The SIMIND program was configured to resemble a GE Discovery VH/Hawkeye system. An x-ray projector program was used to generate whole-body x-ray images from the NCAT phantom for attenuation correction in the conjugate view method. Organ activities were calculated from ROIs that exactly covered the organs. Corrections for background activity, overlapping activity and source extension in the depth direction were applied on the ROI data

Microradiographic microsphere manipulator

International Nuclear Information System (INIS)

Singleton, R.M.

1980-01-01

A method and apparatus are provided for radiographic characterization of small hollow spherical members (microspheres), constructed of either optically transparent or opaque materials. The apparatus involves a microsphere manipulator which holds a batch of microspheres between two parallel thin plastic films for contact microradiographic characterization or projection microradiography thereof. One plastic film is translated to relative to and parallel to the other to roll the microspheres through any desired angle to allow different views of the microspheres

A PET reconstruction formulation that enforces non-negativity in projection space for bias reduction in Y-90 imaging

Science.gov (United States)

Lim, Hongki; Dewaraja, Yuni K.; Fessler, Jeffrey A.

2018-02-01

Most existing PET image reconstruction methods impose a nonnegativity constraint in the image domain that is natural physically, but can lead to biased reconstructions. This bias is particularly problematic for Y-90 PET because of the low probability positron production and high random coincidence fraction. This paper investigates a new PET reconstruction formulation that enforces nonnegativity of the projections instead of the voxel values. This formulation allows some negative voxel values, thereby potentially reducing bias. Unlike the previously reported NEG-ML approach that modifies the Poisson log-likelihood to allow negative values, the new formulation retains the classical Poisson statistical model. To relax the non-negativity constraint embedded in the standard methods for PET reconstruction, we used an alternating direction method of multipliers (ADMM). Because choice of ADMM parameters can greatly influence convergence rate, we applied an automatic parameter selection method to improve the convergence speed. We investigated the methods using lung to liver slices of XCAT phantom. We simulated low true coincidence count-rates with high random fractions corresponding to the typical values from patient imaging in Y-90 microsphere radioembolization. We compared our new methods with standard reconstruction algorithms and NEG-ML and a regularized version thereof. Both our new method and NEG-ML allow more accurate quantification in all volumes of interest while yielding lower noise than the standard method. The performance of NEG-ML can degrade when its user-defined parameter is tuned poorly, while the proposed algorithm is robust to any count level without requiring parameter tuning.

Determination of /sup 90/Sr in milk by solvent extraction of /sup 90/Y

Energy Technology Data Exchange (ETDEWEB)

Mitsuhashi, T [National Inst. of Animal Industry, Chiba (Japan); Sakanoue, M

1977-10-01

In order to replace the conventional method using violent fuming nitric acid, a new method for the determination of /sup 90/Sr in milk has been developed by using the solvent extraction with bis (2-ethylhexyl) phosphoric acid (HDEHP). The daughter nuclide /sup 90/Y in a radiochemical equilibrium with its parent /sup 90/Sr was extracted with 2:1 HDEHP-toluene from the acid solution (1M HCl) of milk ash sample prepared by dry-ashing. After stripping with 8M HCl, /sup 90/Y, together with stable yttrium added as carrier, was precipitated as oxalate to prepare ..beta..-counting source. The radiochemical purity was confirmed by decay curve. The decontamination of strontium was checked by applying non-dispersive fluorescence x-ray analysis using /sup 133/Ba as irradiating source. Bone samples of cow were also analyzed by the same method and the results were compared with those obtained by other methods. The duplicate crosschecking analyses of finely ground bone samples were carried out to examine the effectiveness of this method. This simple new method was found to be very effective for the routine analysis of /sup 90/Sr in these samples.

Development of a dosimetric system for {sup 90}Sr + {sup 90}Y betatherapy applicators; Desenvolvimento de um sistema de dosimetria para aplicadores de betaterapia de {sup 90}Sr + {sup 90}Y

Energy Technology Data Exchange (ETDEWEB)

Coelho, Talita Salles

2010-07-01

The {sup 90}Sr+{sup 90}Y applicators, used in betatherapy for prevention of keloids and pterigium, are imported and many times their dosimetric features are shown only in an illustrated form by the manufacturers. The exhaustive routine of the medical physicists in the clinic do not make possible the accomplishment of procedures for the confirmation of these parameters. This work presents the development of a methodology for the dosimetry of {sup 90}Sr+{sup 90}Y betatherapy applicators. The Monte Carlo code MCNP5 was used for the simulation of the percentage depth dose curves and dose distribution profiles produced by these applicators. The experimental measurements of the radial and axial radiation attenuation, have been done with a mini-extrapolation chamber, thermoluminescent dosimeters and radiographic films. The experimental results have been compared with the simulated values. Both percentage depth dose curves and the radial dose profiles, the theoretical and the experimental ones, have presented good agreement, which may validate the use of the MCNP5 for these simulations, confirming the viability of the usage of this method in procedures of beta emitter sources dosimetry. (author)

Enteric-coated epichlorohydrin crosslinked dextran microspheres for site-specific delivery to colon.

Science.gov (United States)

Rai, Gopal; Yadav, Awesh K; Jain, Narendra K; Agrawal, Govind P

2015-01-01

Enteric-coated epichlorohydrin crosslinked dextran microspheres containing 5-Fluorouracil (5-FU) for colon drug delivery was prepared by emulsification-crosslinking method. The formulation variables studied includes different molecular weights of dextran, volume of crosslinking agent, stirring speed, time and temperature. Dextran microspheres showed mean entrapment efficiencies ranging between 77 and 87% and mean particle size ranging between 10 and 25 µm. About 90% of drug was released from uncoated dextran microspheres within 8 h, suggesting the fast release and indicated the drug loaded in uncoated microspheres, released before they reached colon. Enteric coating (Eudragit-S-100 and Eudragit-L-100) of dextran microspheres was performed by oil-in-oil solvent evaporation method. The release study of 5-FU from coated dextran microspheres was complete retardation in simulated gastric fluid (pH 1.2) and once the coating layer of enteric polymer was dissolved at higher pH (7.4 and 6.8), a controlled release of the drug from the microspheres was observed. Further, the release of drug was found to be higher in the presence of dextranase and rat caecal contents, indicating the susceptibility of dextran microspheres to colonic enzymes. Organ distribution and pharmacokinetic study in albino rats was performed to establish the targeting potential of optimized formulation in the colon.

A Comparative Study of Production of Glass Microspheres by using Thermal Process

Science.gov (United States)

Lee, May Yan; Tan, Jully; Heng, Jerry YY; Cheeseman, Christopher

2017-06-01

Microspheres are spherical particles that can be distinguished into two categories; solid or hollow. Microspheres typical ranges from 1 to 200 μm in diameter. Microsphere are made from glass, ceramic, carbon or plastic depending on applications. Solid glass microsphere is manufactured by direct burning of glass powders while hollow glass microspheres is produced by adding blowing agent to glass powder. This paper presented the production of glass microspheres by using the vertical thermal flame (VTF) process. Pre-treated soda lime glass powder with particle sized range from 90 to 125μm was used in this work. The results showed that glass microspheres produced by two passes through the flame have a more spherical shape as compared with the single pass. Under the Scanning Electron Microscope (SEM), it is observed that there is a morphology changed from uneven surface of glass powders to smooth spherical surface particles. Qualitative analysis for density of the pre-burned and burned particles was performed. Burned particles floats in water while pre-burned particles sank indicated the change of density of the particles. Further improvements of the VTF process in terms of the VTF set-up are required to increase the transformation of glass powders to glass microspheres.

Separation of 90Y from 90Sr by solvent extraction with ionizable crown ethers

International Nuclear Information System (INIS)

Wood, D.J.; Elshani, S.; Du, H.S.; Natale, N.R.; Wai, C.M.

1993-01-01

Sym-Dibenzo-16-crown-5-oxyacetic acid and its analogues are selective for the extraction of Y 3+ over Sr 2+ from aqueous solutions into chloroform. The selectivity and the pH range of extraction are influenced by the structure of the ligand. The size of the macrocyclic cavity, the tether length of the lariat, the attachment of alkyl functional groups to the lariat, and the identity of the ionizable group can affect selectivity and extraction efficiency. When the carboxylic acid at the terminal end of the lariat is replaced by a hydroxamic acid, the selectivity for Y 3+ over Sr 2+ is significantly increased. Using these ionizable crown ethers as extractants, 90 Y fractions of greater than 99.9% purity can be obtained in a single solvent extraction step from solutions of 90 Sr. 11 refs., 5 figs., 2 tabs

{sup 90}Y -PET imaging: Exploring limitations and accuracy under conditions of low counts and high random fraction

Energy Technology Data Exchange (ETDEWEB)

Carlier, Thomas, E-mail: thomas.carlier@chu-nantes.fr [Department of Nuclear Medicine, University Hospital of Nantes, Place Alexis Ricordeau, Nantes 44093, France and CRCNA–UMR 892 INSERM 6299 CNRS, 8 quai Moncousu BP 70721, Nantes 44007 (France); Willowson, Kathy P. [Institute of Medical Physics, University of Sydney, Camperdown, New South Wales 2006 (Australia); Fourkal, Eugene [Department of Radiation Oncology, Allegheny General Hospital, Pittsburgh, Pennsylvania 15212 (United States); Bailey, Dale L. [Faculty of Health Sciences, University of Sydney, Lidcombe 2141, Australia and Department of Nuclear Medicine, Royal North Shore Hospital, St Leonards, New South Wales 2065 (Australia); Doss, Mohan [Department of Diagnostic Imaging, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 (United States); Conti, Maurizio [Siemens Healthcare Molecular Imaging, 810 Innovation Drive, Knoxville, Tennessee 37932 (United States)

2015-07-15

Purpose: {sup 90}Y -positron emission tomography (PET) imaging is becoming a recognized modality for postinfusion quantitative assessment following radioembolization therapy. However, the extremely low counts and high random fraction associated with {sup 90}Y -PET may significantly impair both qualitative and quantitative results. The aim of this work was to study image quality and noise level in relation to the quantification and bias performance of two types of Siemens PET scanners when imaging {sup 90}Y and to compare experimental results with clinical data from two types of commercially available {sup 90}Y microspheres. Methods: Data were acquired on both Siemens Biograph TruePoint [non-time-of-flight (TOF)] and Biograph microcomputed tomography (mCT) (TOF) PET/CT scanners. The study was conducted in three phases. The first aimed to assess quantification and bias for different reconstruction methods according to random fraction and number of true counts in the scan. The NEMA 1994 PET phantom was filled with water with one cylindrical insert left empty (air) and the other filled with a solution of {sup 90}Y . The phantom was scanned for 60 min in the PET/CT scanner every one or two days. The second phase used the NEMA 2001 PET phantom to derive noise and image quality metrics. The spheres and the background were filled with a {sup 90}Y solution in an 8:1 contrast ratio and four 30 min acquisitions were performed over a one week period. Finally, 32 patient data (8 treated with Therasphere{sup ®} and 24 with SIR-Spheres{sup ®}) were retrospectively reconstructed and activity in the whole field of view and the liver was compared to theoretical injected activity. Results: The contribution of both bremsstrahlung and LSO trues was found to be negligible, allowing data to be decay corrected to obtain correct quantification. In general, the recovered activity for all reconstruction methods was stable over the range studied, with a small bias appearing at extremely

90Y and 90Sr separation from hydrochloric acid solutions using TODGA as the extractant by solvent extraction and SLM methods

International Nuclear Information System (INIS)

Dutta, S.; Raut, D.R.; Mohapatra, P.K.; Manchanda, V.K.

2010-01-01

Yttrium-90 is an important radionuclide known for its therapeutic application in nuclear medicine. It is a pure β-emitter with no associated gamma rays and decays to stable daughter 90 Zr. Suitability of this isotope is because of its short half-life (t 1/2 = 64.2 hrs) and high β emissions (E max = 2.28 MeV. An important source of 90 Y is through the decay of 90 Sr, which produces carrier free isotope. 90 Sr (t 1/2 28 yrs) attains secular equilibrium with 90 Y in a short period and can serve as a long term source for the latter isotope because of relatively long half-life of the parent isotope. Solvent extraction studies with N,N,N',N'-tetra-octyldiglycolamide (TODGA) has shown that Y(III) is well extracted in 6 M HCI while at the same time, extraction of Sr(II) is very low leading to a separation factor (D Y /D Sr = 60,000). This property of TODGA can be exploited for the separation of Y from Sr. In the present work, Supported Liquid Membrane (SLM) based separation of Y and Sr has been explored using TODGA as the carrier

Practical reconstruction protocol for quantitative 90Y bremsstrahlung SPECT/CT

International Nuclear Information System (INIS)

Siman, W.; Mikell, J. K.; Kappadath, S. C.

2016-01-01

Purpose: To develop a practical background compensation (BC) technique to improve quantitative 90 Y-bremsstrahlung single-photon emission computed tomography (SPECT)/computed tomography (CT) using a commercially available imaging system. Methods: All images were acquired using medium-energy collimation in six energy windows (EWs), ranging from 70 to 410 keV. The EWs were determined based on the signal-to-background ratio in planar images of an acrylic phantom of different thicknesses (2–16 cm) positioned below a 90 Y source and set at different distances (15–35 cm) from a gamma camera. The authors adapted the widely used EW-based scatter-correction technique by modeling the BC as scaled images. The BC EW was determined empirically in SPECT/CT studies using an IEC phantom based on the sphere activity recovery and residual activity in the cold lung insert. The scaling factor was calculated from 20 clinical planar 90 Y images. Reconstruction parameters were optimized in the same SPECT images for improved image quantification and contrast. A count-to-activity calibration factor was calculated from 30 clinical 90 Y images. Results: The authors found that the most appropriate imaging EW range was 90–125 keV. BC was modeled as 0.53× images in the EW of 310–410 keV. The background-compensated clinical images had higher image contrast than uncompensated images. The maximum deviation of their SPECT calibration in clinical studies was lowest (<10%) for SPECT with attenuation correction (AC) and SPECT with AC + BC. Using the proposed SPECT-with-AC + BC reconstruction protocol, the authors found that the recovery coefficient of a 37-mm sphere (in a 10-mm volume of interest) increased from 39% to 90% and that the residual activity in the lung insert decreased from 44% to 14% over that of SPECT images with AC alone. Conclusions: The proposed EW-based BC model was developed for 90 Y bremsstrahlung imaging. SPECT with AC + BC gave improved lesion detectability and activity

Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection

Energy Technology Data Exchange (ETDEWEB)

Ali, Rehan; Riaz, Ahsun; Gabr, Ahmed; Abouchaleh, Nadine; Mora, Ronald; Al Asadi, Ali [Northwestern University, Department of Radiology, Section of Interventional Radiology, Chicago, IL (United States); Caicedo, Juan Carlos; Abecassis, Michael; Katariya, Nitin [Northwestern University, Department of Surgery, Division of Transplant Surgery, Chicago, IL (United States); Maddur, Haripriya; Kulik, Laura [Northwestern University, Department of Medicine, Division of Hepatology, Chicago, IL (United States); Lewandowski, Robert J. [Northwestern University, Department of Radiology, Section of Interventional Radiology, Chicago, IL (United States); Northwestern University, Department of Medicine, Division of Hematology and Oncology, Chicago, IL (United States); Salem, Riad [Northwestern University, Department of Radiology, Section of Interventional Radiology, Chicago, IL (United States); Northwestern University, Department of Surgery, Division of Transplant Surgery, Chicago, IL (United States); Northwestern University, Department of Medicine, Division of Hematology and Oncology, Chicago, IL (United States)

2017-12-15

To assess safety/efficacy of yttrium-90 radioembolization (Y90) in patients with recurrent hepatocellular carcinoma (HCC) following curative surgical resection. With IRB approval, we searched our prospectively acquired database for patients that were treated with Y90 for recurrent disease following resection. Baseline characteristics and bilirubin toxicities following Y90 were evaluated. Intention-to-treat overall survival (OS) and time-to-progression (TTP) from Y90 were assessed. Forty-one patients met study inclusion criteria. Twenty-six (63%) patients had undergone minor (≤3 hepatic segments) resection while 15 (37%) patients underwent major (>3 hepatic segments) resections. Two patients (5%) had biliary-enteric anastomoses created during surgical resection. The median time from HCC resection to the first radioembolization was 17 months (95% CI: 13-37). The median number of Y90 treatment sessions was 1 (range: 1-5). Ten patients received (entire remnant) lobar Y90 treatment while 31 patients received selective (≤2 hepatic segments) treatment. Grades 1/2/3/4 bilirubin toxicity were seen in nine (22%), four (10%), four (10%), and zero (0%) patients following Y90. No differences in bilirubin toxicities were identified when comparing lobar with selective approaches (P = 0.20). No post-Y90 infectious complications were identified. Median TTP and OS were 11.3 (CI: 6.5-15.5) and 22.1 months (CI: 10.3-31.3), respectively. Radioembolization is a safe and effective method for treating recurrent HCC following surgical resection, with prolonged TTP and promising survival outcomes. (orig.)

Automated characterization of glass microspheres used for laser fusion experiments

International Nuclear Information System (INIS)

Tajima, Tsuyoshi; Norimatsu, Takayoshi; Izawa, Yasukazu; Yamanaka, Chiyoe.

1985-01-01

In laser fusion experiments glass microspheres of 100 to 1000 μm in diameter and 1 to 20 μm in wall thickness are most commonly used as fuel containers. The glass microspheres should be characterized precisely to meet stringent experimental requirements. Much time is consumed to characterize and select good quality spheres among thousands of spheres. We have developed an automated system to characterize and select glass microspheres. The system consists of charger, quadrupole rail, image processing and X-Y stage control with micro-computer. Total processing time primarily depends on the time required for image analysis, which should be compromised with the accuracy of characterization. The time for simple characterization requires about 10 sec. at present. (author)

Histamine-imprinted microspheres: Comparison between conventional and raft-mediated polymerization techniques

International Nuclear Information System (INIS)

Romano, Edwin F. Jr.; So, Regina C.; Holdsworth, Clovia I.

2015-01-01

Molecularly imprinted microspheres (MIM) were synthesized via conventional free radical polymerization (CTP) and RAFT-mediated controlled radical polymerization (CRP) method using histamine as the template molecule. Optimal polymerization conditions were achieved using 4%(w/w) monomer feed concentration with 80=90% EGDMA as crosslinker, and histamine: MAA ratio of 1:4 in acetonitrile at 60°C for 24 hours. The size of CTP-M90 and CTP-M80 imprinted microspheres are comparable with that of RAFT polymer CRP-M80 at 264.5 ±12 nm in the swollen (DLS-DMSO) and collapsed state (SEM). For the CTP method, the presence of the template allows for a bigger particle size compared to the non-imprinted counterpart (NIM). Further, controlled growth was observed for the CRP technique, where the size of the imprinted microsphere, CRP-M80, is comparable to CRP-N80. The binding studies of CTP and CRP microspheres toward histamine were studied at concentrations well below biding with buffer concentration of 25mM at pH7. Results showed that the binding isotherms were found to conform to the Freundlich model. Moreover, results revealed that the difference in binding capacity (N) between MIM and NIM imparted by the imprinting process is significantly higher in CTP-80 (26 μmol/g) than both CTP-90 and CRP-80 (9 μmol/g). Non-competitive and competitive binding assays with L-histidine, imidazole, and tryptamine using CTP-80 and CRP-80 were also carried out. MIMs were shown to exhibit binding preference towards the template. (author)

Accumulation of Sr90-Y90 by the developing spawn and larvae of Coregonus lavaretus L

International Nuclear Information System (INIS)

Kulikov, N.V.; Ozhegov, L.N.

1976-01-01

The results are given of laboratory experiments aimed at studying accumulation of Sr-90 and its daughter product Y-90 in the spawn and larvae of whitefish, a representative of autumn spawning fish species. The results are of interest for predicting possible consequences of radioactive contamination of water bodies and introduction of limits for permissible concentration of radioactive substances in aqueous medium. The accumulation coefficient of Sr-90 in the spawn reaches its maximum after the first twenty four hours of the experiment. Subsequently throughout the incubation period the accumulation coefficient (AC) of radionuclide does not undergo any changes being about 3. Besides it has been established that the equilibrium distribution of Sr-90 in whitefish spawn and the surrounding solution occurs during the first two hours. Unlike Sr-90 the accumulation of Y-90 occurs during the whole incubation period and results in the AC value of 80 by the end of the spawn incubation. The experiments aimed at determining the strength of radionuclide fixation by whitefish spawn and larvae revealed that both radionuclides in the spawn are rather mobile. Strontium separates fully from it during the first twenty four hours and yttrium marked by higher fixation strength transfers completely from the spawn into surrounding aqueous medium by the end of the experiment. In larvae the radionuclides are fixed stroger than in the spawn. The approximate radiation doses of embryos by the time of their hatching have been estimated. The estimates indicate that the total radiation dose of the spawn developing in aqueous solution of Sr-90 - Y-90 with 1.1 curie/0 -5 concentration is about 500 radl

The physical and chemical stability of suspensions of sustained-release diclofenac microspheres.

Science.gov (United States)

Lewis, L; Boni, R L; Adeyeye, C M

1998-01-01

The major challenge in liquid sustained-release oral suspensions is to minimize drug diffusion into the suspending medium and to retain the original properties of the microparticles during storage. Diclofenac wax microspheres prepared by the hydrophobic congealable disperse phase method were formulated as a sustained release suspension and stored at three different temperatures (25, 37 and 45 degrees C) for 3 months, to evaluate the physical and chemical stability of the suspended microspheres. Suspensions of microspheres stored at ambient temperatures were both physically and chemically stable, but at higher temperatures, up to 45 degrees C, there was a decrease in drug release due to scaling and melting on the microsphere surface as observed by scanning electron microscopy. However, on prolonged storage, up to 90 days, especially at 45 degrees C, temperature became a dominant factor causing an increase in drug release. The suspension of diclofenac microspheres was chemically stable for 3 months, while the plain drug suspension exhibited slight degradation.

Radiolabeling, characterization and preliminary studies of 90Y-octreotate

International Nuclear Information System (INIS)

Klementyeva, O.E.; Bruskin, A.B.; Larenkov, A.A.; Kodina, G.E.; Korsunsky, V.N.

2015-01-01

Full text of publication follows. Introduction: Overexpression of the somatostatin receptors in neuroendocrine tumors has become the molecular basis for the use of somatostatin analogues in diagnosis and therapy for these neoplasms. The high energy (maximum 2.2 MeV) and penetration range (R 95 5.7 mm) of β-particles from 90 Y are advantageous, with a direct killing of somatostatin receptor positive cells and a crossfire effect which hits nearby receptor-negative tumour cells [Ref. 1]. Aim: the investigation of the reaction conditions for the preparation of 90 Y-Octreotate and its in vitro characterization. Materials and methods: DOTA-Octreotate (Farm-Syntez Ltd.) and 88 YCl 3 (V/O Isotop) were used without purification. 88 Y-Octreotate was prepared in acetate buffer solution and its radiochemical purity was controlled by ITLC. In-vitro experiments were carried out with melanoma B16. Studies of internalization were performed as described in [Ref. 2]. Results: the maximal accumulation in the cells was observed after 90 min from the beginning of incubation and was about 3.9%. In our experiments, we found high level of internalization of the surface-bound 88 Y-Octreotate into B16 cells. Maximal internalization level was 80% after 60 min of incubation. Conclusion: the optimal conditions for effective labeling (> 95%) of DOTA-Octreotate were found. The results obtained using the gamma-emitting 88 Y, provide a basis for in vivo research 90 Y octreotate as radiotherapeutic agent. References: [Ref. 1] Bodei, L.; Pepe, G.; Paganelli, G.; Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. Eur. Rev. Med. Pharmacol. Sci., 2010; v. 14: 347-351. [Ref. 2] Garcia Garayoa E., Allemann-Tannahill L., et al. In vitro and in vivo evaluation of new radiolabeled neurotensin (8-13) analogs with high affinity for NT1 receptors. Nucl. Med. Biol. 2001; 28: 75-84. (authors)

A sonochemical route for the encapsulation of drug in magnetic microspheres

International Nuclear Information System (INIS)

Wu Shixi; Jiang Wei; Zhang Xiaojuan; Sun Huan; Zhang Wenyao; Dai Junjun; Liu Li; Chen Xiaolong; Li Fengsheng

2012-01-01

This study focused on the preparation and characterization of magnetic targeted antibiotic microspheres (MTAMs). MTAMs were prepared by a sonochemical method in the presence of hydrophobic Fe 3 O 4 nanoparticles and tetracycline. The properties of MTAMs were characterized by transmission electron microscopy, Fourier-transform infrared spectrum, thermogravimetric analysis, vibration sample magnetometry, and bacteriostatic experiment. The results indicated that the superparamagnetic microspheres have ultrafine size (below 230 nm), high saturation magnetization (80.90 emu/g), high biocompatibility, biodegradability, controlled-release, and antibiotic effect. It has been proved that MTAMs can carry out the function of magnetic targeted drugs delivery system by putting together magnetic materials and antibiotics. The possible formation mechanism of MTAMs was also discussed. In summary, MTAMs had potential in medical imaging, drug targeting, and catalysis. - Highlights: → Microspheres carry out the function of magnetic targeted drugs delivery system. → Microspheres exhibit high saturation magnetization and antibiotic effect. → Microspheres have a potential application in the biomedical field. → The sonochemical method is well controlled for the synthesis.

Flexible Microsphere-Embedded Film for Microsphere-Enhanced Raman Spectroscopy.

Science.gov (United States)

Xing, Cheng; Yan, Yinzhou; Feng, Chao; Xu, Jiayu; Dong, Peng; Guan, Wei; Zeng, Yong; Zhao, Yan; Jiang, Yijian

2017-09-27

Dielectric microspheres with extraordinary microscale optical properties, such as photonic nanojets, optical whispering-gallery modes (WGMs), and directional antennas, have drawn interest in many research fields. Microsphere-enhanced Raman spectroscopy (MERS) is an alternative approach for enhanced Raman detection by dielectric microstructures. Unfortunately, fabrication of microsphere monolayer arrays is the major challenge of MERS for practical applications on various specimen surfaces. Here we report a microsphere-embedded film (MF) by immersing a highly refractive microsphere monolayer array in the poly(dimethylsiloxane) (PDMS) film as a flexible MERS sensing platform for one- to three-dimensional (1D to 3D) specimen surfaces. The directional antennas and wave-guided whispering-gallery modes (WG-WGMs) contribute to the majority of Raman enhancement by the MFs. Moreover, the MF can be coupled with surface-enhanced Raman spectroscopy (SERS) to provide an extra >10-fold enhancement. The limit of detection is therefore improved for sensing of crystal violet (CV) and Sudan I molecules in aqueous solutions at concentrations down to 10 -7 M. A hybrid dual-layer microsphere enhancer, constructed by depositing a MF onto a microsphere monolayer array, is also demonstrated, wherein the WG-WGMs become dominant and boost the enhancement ratio >50-fold. The present work opens up new opportunities for design of cost-effective and flexible MERS sensing platforms as individual or associated techniques toward practical applications in ultrasensitive Raman detection.

Multi institutional quantitative phantom study of yttrium-90 PET in PET/MRI: the MR-QUEST study.

Science.gov (United States)

Maughan, Nichole M; Eldib, Mootaz; Faul, David; Conti, Maurizio; Elschot, Mattijs; Knešaurek, Karin; Leek, Francesca; Townsend, David; DiFilippo, Frank P; Jackson, Kimberly; Nekolla, Stephan G; Lukas, Mathias; Tapner, Michael; Parikh, Parag J; Laforest, Richard

2018-04-04

Yttrium-90 ( 90 Y) radioembolization involves the intra-arterial delivery of radioactive microspheres to treat hepatic malignancies. Though this therapy involves careful pre-treatment planning and imaging, little is known about the precise location of the microspheres once they are administered. Recently, there has been growing interest post-radioembolization imaging using positron-emission tomography (PET) for quantitative dosimetry and identifying lesions that may benefit from additional salvage therapy. In this study, we aim to measure the inter-center variability of 90 Y PET measurements as measured on PET/MRI in preparation for a multi-institutional prospective phase I/II clinical trial. Eight institutions participated in this study and followed a standardized phantom filling and imaging protocol. The NEMA NU2-2012 body phantom was filled with 3 GBq of 90 Y chloride solution. The phantom was imaged for 30 min in listmode on a Siemens Biograph mMR non-TOF PET/MRI scanner at five time points across 10 days (0.3-3.0 GBq). Raw PET data were sent to a central site for image reconstruction and data analysis. Images were reconstructed with optimal parameters determined from a previous study. Volumes of interest (VOIs) matching the known sphere diameters were drawn on the vendor-provided attenuation map and propagated to the PET images. Recovery coefficients (RCs) and coefficient of variation of the RCs (COV) were calculated from these VOIs for each sphere size and activity level. Mean RCs ranged from 14.5 to 75.4%, with the lowest mean RC coming from the smallest sphere (10 mm) on the last day of imaging (0.16 MBq/ml) and the highest mean RC coming from the largest sphere (37 mm) on the first day of imaging (2.16 MBq/ml). The smaller spheres tended to exhibit higher COVs. In contrast, the larger spheres tended to exhibit lower COVs. COVs from the 37 mm sphere were  25%. Post-radioembolization dosimetry of lesions or other VOIs ≥ 22 mm in diameter can

Radiolabeling oligo nuclieotide with 90Y and its radiolysis

International Nuclear Information System (INIS)

Liu Changbin; Tian Jiahe; Zhang Jinming; Yin Dayi; Guo Zhe

2005-01-01

Objective: To evaluate labeling Morpholinos (MORF), a DNA analogue, with 90 Y using p-isothiocyanatobenzyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) as chelater and assess its stability and hybridization in vitro. Methods: A 25 mer MORF with a primary amine on the 3' equivalent end attached via a 10 member linker was conjugated with an isothiocyanate backbone derivative of DOTA. The conjugated product was labeled in various buffers over a different range of concentrations (0.5-2 mol/L) and pH(3-8.5). The labeled MORF was investigated for stability and hybridization in vitro. Results: By size exclusion high performance liquid chromatogram (HPLC) and instant thin layer chromatography (ITLC) analysis, the DOTA conjugated MORF was successfully radiolabeled, the labeling efficiency was (50 ± 12)%, the specific radioactivity was 5.05 x 10 6 MBq/mmol, radiochemistry purity >95%. The labeled MORF showed one sharp peak by HPLC that shifted completely to earlier retention times following addition of a polymer conjugated with the complementary MORF. In saline at room temperature and in serum at 37 degree C, the radioactivity profile of 90 Y showed a pronounced lower molecular weight peak which did not shifted and was shown due to 90 Y-DOTA resulting from radiolysis. Conclusion: MORF can be successfully labeled with 90 Y via DOTA as chelater, but care it must be taken to avoid the effect of radiolysis. (authors)

Oxaliplatin loaded PLAGA microspheres: design of specific release profiles.

Science.gov (United States)

Lagarce, F; Cruaud, O; Deuschel, C; Bayssas, M; Griffon-Etienne, G; Benoit, J

2002-08-21

Oxaliplatin loaded PLAGA microspheres have been prepared by solvent extraction process. Parameters affecting the release kinetics in vitro have been studied in order to design specific release profiles suitable for direct intra-tumoral injection. By varying the nature and the relative proportions of different polymers we managed to prepare microspheres with good encapsulation efficiency (75-90%) and four different release profiles: zero order kinetics (type II) and the classical sigmoïd release profile with three different sizes of plateau and burst. These results, if correlated with in vivo activity, are promising to enhance effectiveness of local tumor treatment.

Country report: India. Development of Radiopharmaceuticals Based on 188Re and 90Y for Radionuclide Therapy

International Nuclear Information System (INIS)

Venkatesh, M.; Pandey, U.; Dhami, P.S.; Chakravarty, R.; Kameswaran, M.; Subramanian, S.; Dash, A.; Samuel, G.

2010-01-01

During the past decade, our group has focused attention on the development of therapeutic radiopharmaceuticals incorporating radioisotopes such as 90 Y, 188 Re etc. As the primary source of the radioisotopes 90 Y and 188 Re are the 90 Sr/ 90 Y generators and 188 W/ 188 Re generators respectively, the local availability of these generator systems is very important for the successful development of radiopharmaceuticals incorporating these radioisotopes. In this context, 90 Sr/ 90 Y generators based on Supported Liquid Membrane (SLM) [1-3] and electrochemical techniques [4] could be designed and deployed in our laboratories for the elution of 90 Y to be used for preparation of 90 Y labeled products. This work formed a part of the IAEA co-ordinated CRP on “Development of Generator Technologies for Therapeutic Radionuclides: 90 Y and 188 Re”. In this report, work on the development of 90 Y radiopharmaceuticals for treatment of liver cancer and non-Hodgkin’s lymphoma (NHL) is reported. In addition, comparison of the Extraction Paper Chromatography technique (EPC) developed for determination of 90 Sr contamination in 90 Y samples with the US Pharmacopeia recommended method as well as the validation of the EPC technique is presented

Quantitative and qualitative assessment of Yttrium-90 PET/CT imaging.

Directory of Open Access Journals (Sweden)

Ali Asgar Attarwala

Full Text Available Yttrium-90 is known to have a low positron emission decay of 32 ppm that may allow for personalized dosimetry of liver cancer therapy with (90Y labeled microspheres. The aim of this work was to image and quantify (90Y so that accurate predictions of the absorbed dose can be made. The measurements were performed within the QUEST study (University of Sydney, and Sirtex Medical, Australia. A NEMA IEC body phantom containing 6 fillable spheres (10-37 mm ∅ was used to measure the 90Y distribution with a Biograph mCT PET/CT (Siemens, Erlangen, Germany with time-of-flight (TOF acquisition. A sphere to background ratio of 8:1, with a total (90Y activity of 3 GBq was used. Measurements were performed for one week (0, 3, 5 and 7 d. he acquisition protocol consisted of 30 min-2 bed positions and 120 min-single bed position. Images were reconstructed with 3D ordered subset expectation maximization (OSEM and point spread function (PSF for iteration numbers of 1-12 with 21 (TOF and 24 (non-TOF subsets and CT based attenuation and scatter correction. Convergence of algorithms and activity recovery was assessed based on regions-of-interest (ROI analysis of the background (100 voxels, spheres (4 voxels and the central low density insert (25 voxels. For the largest sphere, the recovery coefficient (RC values for the 30 min -2-bed position, 30 min-single bed and 120 min-single bed were 1.12 ± 0.20, 1.14 ± 0.13, 0.97 ± 0.07 respectively. For the smaller diameter spheres, the PSF algorithm with TOF and single bed acquisition provided a comparatively better activity recovery. Quantification of Y-90 using Biograph mCT PET/CT is possible with a reasonable accuracy, the limitations being the size of the lesion and the activity concentration present. At this stage, based on our study, it seems advantageous to use different protocols depending on the size of the lesion.

Radiation Safety in Production of Y-90 from an electrochemical generator. CENTIS experience

International Nuclear Information System (INIS)

Ayra Pardo, Fernando Enrique

2016-01-01

From a project with the International Atomic Energy Agency, Isotope Center installation and commissioning began operating an electrochemical generator of Sr-90 / Y-90 inside a glove box shielded. The aim was to ensure the production of Y-90 needed in the research carried out in Cuba with this radionuclide for the medical industry. Associate at the beginning of this practice, compliance with all regulatory requirements approved in the country from the radiological point of view that demonstrated the safety of this for both operators and the general public became necessary. Using the MCNPX code generator installation was simulated and the equivalent dose Hp (10) were obtained for the operator: 6.27 mSv / y Hp (0.07): 17 mSv / a for a source of 10 Ci of 90 Sr- 90 Y . Also the use of TLD dosimeters similar to those used for gamma emitting radionuclides for controlling beta exposures was evaluated. high sensitivity lithium fluoride tablets couple energy beta particles of Y-90 which ensures its use for measuring the magnitude Hp (007) was demonstrated. two possible solutions for the recovery of liquid waste 90 Sr one another by distillation and ion exchange are evaluated. To transport the Y-90 may be used the package currently used in marketing the rest of the CENTIS radiopharmaceuticals. As a final result, the practice was approved and included in the Operating License Center Isotopes. (author)

Monte Carlo simulation of PET and SPECT imaging of {sup 90}Y

Energy Technology Data Exchange (ETDEWEB)

Takahashi, Akihiko, E-mail: takahsr@hs.med.kyushu-u.ac.jp; Sasaki, Masayuki [Department of Health Sciences, Faculty of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582 (Japan); Himuro, Kazuhiko; Yamashita, Yasuo; Komiya, Isao [Division of Radiology, Department of Medical Technology, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582 (Japan); Baba, Shingo [Department of Clinical Radiology, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582 (Japan)

2015-04-15

Purpose: Yittrium-90 ({sup 90}Y) is traditionally thought of as a pure beta emitter, and is used in targeted radionuclide therapy, with imaging performed using bremsstrahlung single-photon emission computed tomography (SPECT). However, because {sup 90}Y also emits positrons through internal pair production with a very small branching ratio, positron emission tomography (PET) imaging is also available. Because of the insufficient image quality of {sup 90}Y bremsstrahlung SPECT, PET imaging has been suggested as an alternative. In this paper, the authors present the Monte Carlo-based simulation–reconstruction framework for {sup 90}Y to comprehensively analyze the PET and SPECT imaging techniques and to quantitatively consider the disadvantages associated with them. Methods: Our PET and SPECT simulation modules were developed using Monte Carlo simulation of Electrons and Photons (MCEP), developed by Dr. S. Uehara. PET code (MCEP-PET) generates a sinogram, and reconstructs the tomography image using a time-of-flight ordered subset expectation maximization (TOF-OSEM) algorithm with attenuation compensation. To evaluate MCEP-PET, simulated results of {sup 18}F PET imaging were compared with the experimental results. The results confirmed that MCEP-PET can simulate the experimental results very well. The SPECT code (MCEP-SPECT) models the collimator and NaI detector system, and generates the projection images and projection data. To save the computational time, the authors adopt the prerecorded {sup 90}Y bremsstrahlung photon data calculated by MCEP. The projection data are also reconstructed using the OSEM algorithm. The authors simulated PET and SPECT images of a water phantom containing six hot spheres filled with different concentrations of {sup 90}Y without background activity. The amount of activity was 163 MBq, with an acquisition time of 40 min. Results: The simulated {sup 90}Y-PET image accurately simulated the experimental results. PET image is visually

Dosimetry characterization of the commercial CaF2 for beta radiation of 90Sr + 90Y

International Nuclear Information System (INIS)

Oliveira, Mercia L.; Caldas, Linda V.E.

2003-01-01

This work studies the dosimetric characteristics of the CaF 2 commercial dosimetry for detection of 90 Sr + 90 Y beta radiation for using in the calibration of flat and concave appliers. Were determined the repetitiousness and linearity of answers of the samples, and their calibration curves

Clinical results of radionuclide therapy of neuroendocrine tumours with {sup 90}Y-DOTATATE and tandem {sup 90}Y/{sup 177}Lu-DOTATATE: which is a better therapy option?

Energy Technology Data Exchange (ETDEWEB)

Kunikowska, Jolanta; Krolicki, Leszek [Medical University of Warsaw, Nuclear Medicine Department, Warsaw (Poland); Hubalewska-Dydejczyk, Alicja; Sowa-Staszczak, Anna [Collegium Medicum Cracow, Cracow (Poland); Mikolajczak, Renata; Pawlak, Dariusz [Institute of Atomic Energy POLATOM, Swierk-Otwock (Poland)

2011-10-15

Peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues is a treatment option for patients with disseminated neuroendocrine tumours (NET). A combination treatment using the high-energy {sup 90}Y beta emitter for larger lesions and the lower energy {sup 177}Lu for smaller lesions has been postulated in the literature.The aim of the study was to evaluate combined {sup 90}Y/{sup 177}Lu-DOTATATE therapy in comparison to {sup 90}Y-DOTATATE alone. Fifty patients with disseminated NET were included in the study prospectively and divided into two groups: group A (n = 25) was treated with {sup 90}Y-DOTATATE, whereas group B (n = 25) received the 1:1 {sup 90}Y/{sup 177}Lu-DOTATATE. The administered activity was based on 3.7 GBq/m{sup 2} body surface area in three to five cycles, with amino acid infusion for nephroprotection. The median overall survival time in group A was 26.2 months while in group B median survival was not reached. Overall survival was significantly higher in group B (p = 0.027). Median event-free survival time in group A was 21.4 months and in group B 29.4 months (p > 0.1). At the 12-month follow-up, comparison of group A vs group B showed stable disease (SD) in 13 vs 16 patients, disease regression (RD) in 5 vs 3 patients and disease progression (PD) in 3 vs 4 patients; 4 and 2 patients died, respectively. The 24-month follow-up results were SD in nine vs ten patients, RD in one patient vs none and PD in four patients in both groups; three and four patients died, respectively. Side effects were rare and mild. The results indicate that therapy with tandem radioisotopes ({sup 90}Y/{sup 177}Lu-DOTATATE) provides longer overall survival than with a single radioisotope ({sup 90}Y-DOTATATE) and the safety of both methods is comparable. (orig.)

Practical reconstruction protocol for quantitative {sup 90}Y bremsstrahlung SPECT/CT

Energy Technology Data Exchange (ETDEWEB)

Siman, W.; Mikell, J. K.; Kappadath, S. C., E-mail: skappadath@mdanderson.org [Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 and The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas 77030 (United States)

2016-09-15

Purpose: To develop a practical background compensation (BC) technique to improve quantitative {sup 90}Y-bremsstrahlung single-photon emission computed tomography (SPECT)/computed tomography (CT) using a commercially available imaging system. Methods: All images were acquired using medium-energy collimation in six energy windows (EWs), ranging from 70 to 410 keV. The EWs were determined based on the signal-to-background ratio in planar images of an acrylic phantom of different thicknesses (2–16 cm) positioned below a {sup 90}Y source and set at different distances (15–35 cm) from a gamma camera. The authors adapted the widely used EW-based scatter-correction technique by modeling the BC as scaled images. The BC EW was determined empirically in SPECT/CT studies using an IEC phantom based on the sphere activity recovery and residual activity in the cold lung insert. The scaling factor was calculated from 20 clinical planar {sup 90}Y images. Reconstruction parameters were optimized in the same SPECT images for improved image quantification and contrast. A count-to-activity calibration factor was calculated from 30 clinical {sup 90}Y images. Results: The authors found that the most appropriate imaging EW range was 90–125 keV. BC was modeled as 0.53× images in the EW of 310–410 keV. The background-compensated clinical images had higher image contrast than uncompensated images. The maximum deviation of their SPECT calibration in clinical studies was lowest (<10%) for SPECT with attenuation correction (AC) and SPECT with AC + BC. Using the proposed SPECT-with-AC + BC reconstruction protocol, the authors found that the recovery coefficient of a 37-mm sphere (in a 10-mm volume of interest) increased from 39% to 90% and that the residual activity in the lung insert decreased from 44% to 14% over that of SPECT images with AC alone. Conclusions: The proposed EW-based BC model was developed for {sup 90}Y bremsstrahlung imaging. SPECT with AC + BC gave improved lesion

Thermoluminescent dosimetry of beta radiations of 90 Sr/ 90 Y using ZrO2: Eu

International Nuclear Information System (INIS)

Olvera T, L.; Azorin N, J.; Barrera S, M.; Soto E, A.M.; Rivera M, T.

2005-01-01

In this work the results of studying the thermoluminescent properties (TL) of the doped zirconium oxide with europium (ZrO 2 : Eu 3+ ) before beta radiations of 90 Sr/ 90 Y are presented. The powders of ZrO 2 : Eu 3+ were obtained by means of the sol-gel technique and they were characterized by means of thermal analysis and by X-ray diffraction. The powders of ZrO 2 : Eu 3+ , previously irradiated with beta particles of 90 Sr/ 90 Y, presented a thermoluminescent curve with two peaks at 204 and 292 C respectively. The TL response of the ZrO 2 : Eu 3+ as function of the absorbed dose was lineal from 2 Gy up to 90 Gy. The fading of the information of the ZrO 2 : Eu 3+ was of 10% the first 2 hours remaining almost constant the information by the following 30 days. The ZrO 2 doped with the (Eu 3+ ) ion it was found more sensitive to the beta radiation that the one of zirconium oxide without doping (ZrO 2 ) obtained by the same method. Those studied characteristics allow to propose to the doped zirconium oxide with europium like thermoluminescent dosemeter for the detection of the beta radiation. (Author)

Depth dose curves from 90Sr+90Y clinical applicators using the thermoluminescent technique

International Nuclear Information System (INIS)

Antonio, Patricia L.; Caldas, Linda V.E.; Oliveira, Mercia L.

2009-01-01

The 90 Sr+ 90 Y beta-ray sources widely used in brachytherapy applications were developed in the 1950's. Many of these sources, called clinical applicators, are still routinely used in several Brazilian radiotherapy clinics for the treatment of superficial lesions in the skin and eyes, although they are not commercialized anymore. These applicators have to be periodically calibrated, according to international recommendations, because these sources have to be very well specified in order to reach the traceability of calibration standards. In the case of beta-ray sources, the recommended quantity is the absorbed dose rate in water at a reference distance from the source. Moreover, there are other important quantities, as the depth dose curves and the source uniformity for beta-ray plaque sources. In this work, depth dose curves were obtained and studied of five dermatological applicators, using thin thermoluminescent dosimeters of CaSO 4 :Dy and phantoms of PMMA with different thicknesses (between 1.0 mm and 5.0 mm) positioned between each applicator and the TL pellets. The depth dose curves obtained presented the expected attenuation response in PMMA, and the results were compared with data obtained for a 90 Sr+ 90 Y standard source reported by the IAEA, and they were considered satisfactory. (author)

SU-G-201-12: Investigation of Beta-Emitter 90Sr-90Y Dose Distribution Using Gafchromic EBT3 Film for Application On Conformal Skin Brachytherapy Device

International Nuclear Information System (INIS)

Ferreira, C; Johnson, D; Ahmad, S; Rasmussen, K; Jung, J

2016-01-01

Purpose: To investigate 90 Sr- 90 Y as a high dose rate (HDR) source for application in a conformal skin brachytherapy (CSBT) device. The CSBT device has been previously developed to provide patient specific treatment for small inoperable lesions and irregular surfaces. Methods: A popular beta emitter, 90 Sr- 90 Y was tested for feasibility in a CSBT device. A 1 cm diameter plaque was used to deliver dose to a solid water phantom containing EBT3 Gafchromic films arranged at the surface and perpendicular to it. Additionally, a 1 cm diameter 6 MeV electron beam was used to irradiate EBT3 film at 100 cm SSD with a 0.5 cm bolus. Films were digitized with an Epson Expression 10000 XL scanner and calibrated with a 6 MeV electron specific dose curve. Normalized percent depth doses (PDD) and dose profiles for both techniques were analyzed using ImageJ. Results: Dose distributions achieved with the 90 Sr- 90 Y sources were compared with those of external electron beam radiation therapy (EBRT). Penumbra (20%- 80%) for EBRT and 90Sr-90Y were 4.3 mm and 1.6 mm, respectively. PDD values of 50% (normalized to 2 mm) were 10.1 mm and 2.8 mm for electron and 90 Sr- 90 Y, respectively. Flatness (80% of the central beam profile) was 14.1% at a 5 mm depth for EBRT and 4.0% at surface for the 90 Sr- 90 Y. Conclusion: As expected, the PDDs of 90 Sr- 90 Y in water are shallower than that of external electron beams for the same field size. 90 Sr- 90 Y can be used in CSBT to provide patient specific treatment where shallower depth doses than that provided by electron external beams may be required: e.g. eyelids, nose, lips, ears, etc. The customizability of EBRT could be replicated by using multiple adjacent 90 Sr- 90 Y plaque placements.

SU-G-201-12: Investigation of Beta-Emitter 90Sr-90Y Dose Distribution Using Gafchromic EBT3 Film for Application On Conformal Skin Brachytherapy Device

Energy Technology Data Exchange (ETDEWEB)

Ferreira, C; Johnson, D; Ahmad, S [University of Oklahoma Health Sciences Center, Oklahoma City, OK (United States); Rasmussen, K [University of Texas HSC SA, San Antonio, TX (United States); Jung, J [East Carolina University Greenville, NC (United States)

2016-06-15

Purpose: To investigate {sup 90}Sr-{sup 90}Y as a high dose rate (HDR) source for application in a conformal skin brachytherapy (CSBT) device. The CSBT device has been previously developed to provide patient specific treatment for small inoperable lesions and irregular surfaces. Methods: A popular beta emitter, {sup 90}Sr-{sup 90}Y was tested for feasibility in a CSBT device. A 1 cm diameter plaque was used to deliver dose to a solid water phantom containing EBT3 Gafchromic films arranged at the surface and perpendicular to it. Additionally, a 1 cm diameter 6 MeV electron beam was used to irradiate EBT3 film at 100 cm SSD with a 0.5 cm bolus. Films were digitized with an Epson Expression 10000 XL scanner and calibrated with a 6 MeV electron specific dose curve. Normalized percent depth doses (PDD) and dose profiles for both techniques were analyzed using ImageJ. Results: Dose distributions achieved with the {sup 90}Sr-{sup 90}Y sources were compared with those of external electron beam radiation therapy (EBRT). Penumbra (20%- 80%) for EBRT and 90Sr-90Y were 4.3 mm and 1.6 mm, respectively. PDD values of 50% (normalized to 2 mm) were 10.1 mm and 2.8 mm for electron and {sup 90}Sr-{sup 90}Y, respectively. Flatness (80% of the central beam profile) was 14.1% at a 5 mm depth for EBRT and 4.0% at surface for the {sup 90}Sr-{sup 90}Y. Conclusion: As expected, the PDDs of {sup 90}Sr-{sup 90}Y in water are shallower than that of external electron beams for the same field size. {sup 90}Sr-{sup 90}Y can be used in CSBT to provide patient specific treatment where shallower depth doses than that provided by electron external beams may be required: e.g. eyelids, nose, lips, ears, etc. The customizability of EBRT could be replicated by using multiple adjacent {sup 90}Sr-{sup 90}Y plaque placements.

90Y production of high purity by electrochemical separation

International Nuclear Information System (INIS)

Alberti Ramírez, Alejandro; Serra Águila, Rolando; Morín Zorrilla, José Antonio; Pino Peraza, Madián; Soler Iglesias, Joel; Cruz Morales, Amed

2016-01-01

In this paper 90 Y is obtained without added carrier, by electrolytic separation from a solution in secular equilibrium Sr-Y and further purification in three cycles electrolytic automated, at constant current. The process productivity was 60-80 mCi (2220-2960 MBq). The long half-life of 90 Sr to be used by virtually indefinitely ensuring the stability of the raw material for generator operation, which helps sustainability and production stability. In 18 productions to date could be found to both content of 90 Sr equal to 0.110 ± 0.004 (k = 2) kBq / g by various methods, for their ability combination with DTPA, bifunctional chelate appropriate range of concentrations and even in the presence of trace metals, resulting in excellent characteristics for use as precursor in the preparation of therapeutic radiopharmaceuticals including radioimmunotherapy. The latter being a pure beta emitter with physical half-life, comparable to the time of capture and residence of many antibodies in tumors. The influence of Fe (III) was studied by the method of addition and concluded that only affects the performance of DTPA 90 Y marking if their presence is above a concentration of 0.018 mol / L. We show that the presence of other metals such as Pb (II), Zn (II) and Cu (II) also affects performance complexation

Effect of crosslinking agents on chitosan microspheres in controlled release of diclofenac sodium

Directory of Open Access Journals (Sweden)

Vanessa L. Gonçalves

2005-03-01

Full Text Available In this work chitosan microspheres were prepared by the simple coacervation method and crosslinked using epichlorhydrin or glutaraldehyde for the controlled release of diclofenac sodium. The effects of the crosslinking agents on chitosan microspheres over a 12-hour period were assessed with regard to swelling, hydrolysis, porosity, crosslinking, impregnation of diclofenac sodium (DS, and consequently to the release of DS in buffer solutions, simulating the gastrointestinal tract. The degree of swelling varied with the pH for glutaraldehyde chitosan microspheres (GCM and epichlorhydrin chitosan microspheres (ECM. Partial acid and basic hydrolysis affected the swelling behavior of the GCM matrix. Release kinetics of diclofenac sodium from these matrices were investigated at pH 1.2, 6.8 and 9.0, simulating the gastrointestinal tract conditions. The results indicated that the release mechanism deviated slightly from Fickian transport.

Dosimetry characterization of the commercial CaF{sub 2} for beta radiation of {sup 90}Sr + {sup 90}Y; Caracterizacao dosimetrica de CaF{sub 2} comercial para radiacao beta de {sup 90}Sr + {sup 90}Y

Energy Technology Data Exchange (ETDEWEB)

Oliveira, Mercia L.; Caldas, Linda V.E. [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil)], e-mail: mlolivei@ipen.br, e-mail: lcaldas@ipen.br

2003-07-01

This work studies the dosimetric characteristics of the CaF{sub 2} commercial dosimetry for detection of {sup 90}Sr + {sup 90}Y beta radiation for using in the calibration of flat and concave appliers. Were determined the repetitiousness and linearity of answers of the samples, and their calibration curves.

An Overview of the Production, Quality Control and Feasibility of Using 90Y as a Therapeutic Radionuclide

International Nuclear Information System (INIS)

Venkatesh, M.

2009-01-01

90 Y is increasingly accepted world wide as a radionuclide for in-vivo therapy owing to attractive decay features (T1/2 2.67 d; Eβ max 2.28 MeV) and viable production feasibility in high specific activities. 90 Y is most often recommended for treatment of large tumour lesions as the hard β rays are effective in delivering therapeutic dose to large volume. However, possibility of high radiation dose to the critical organs such as bone marrow and kidneys is an important concern that is given due weightage while designing therapy using 90 Y. The best route to avail 90 Y for therapy applications is from 90 Sr, though neutron actiation of natural 89 Y(100% abundance) is feasible. The absorption cross section σ is barely 1.38 b, resulting in low specific activity 90 Y which is useful for limited applications. The possibility of obtaining 90Y through a radionuclide generator as the daughter of a long lived parent 90 Sr (T1/2 28.9 y) is a major advantage that enables access to high specific activity 90 Y. Transporting the 90Y activity to a user institution from a centralized production facility is reasonably feasible and this facilitates its wide spread use. Several generator designs have been developed and reported to access 90 Y. Solvent extraction using a chelating molecule in an organic solvent (0.3M HDEHP/n-dodecane), column chromatography using ion exchange resins (cationic as well as anionic; Dowex-50x8; AG 50x16; Aminex-A5) or inorganic exchanger, membrane based separation using chelating ligand impregnated membranes (CMPO in electrochemical separation are some of the methods reported. Limitations such as elution of 90 Y after initial elution of 90 Sr, availability of 90 Y as a chelated complex which then has to be treated to enable labeling the molecule of interest, possibility of obtaining small quantities of 90 Y owing to radiolytic damages to the separation system components, paucity of special automation gadgets for handling the high activities remotely

Radiation protection in radionuclide therapies with (90)Y-conjugates: risks and safety.

Science.gov (United States)

Cremonesi, Marta; Ferrari, Mahila; Paganelli, Giovanni; Rossi, Annalisa; Chinol, Marco; Bartolomei, Mirco; Prisco, Gennaro; Tosi, Giampiero

2006-11-01

The widespread interest in (90)Y internal radionuclide treatments has drawn attention to the issue of radiation protection for staff. Our aim in this study was to identify personnel at risk and to validate the protection devices used. (90)Y-MoAb (Zevalin, 15 cases, 1.1 GBq/patient) and (90)Y-peptide ((90)Y-DOTATOC) systemic (i.v., 50 cases, 3.0 GBq/patient) and locoregional (l.r., 50 cases, 0.4 GBq/patient) treatments were considered. Radiolabelling was carried out in a dedicated hot cell. Tele-tongs, shielded (PMMA: polymethylmethacrylate) syringes/vials and an automatic dose fractionating system were used. Operators wore anti-X-ray and anti-contamination gloves, with TLD dosimeters placed over the fingertips. For i.v. administration, activity was administered by a dedicated system; for l.r. administration, during activity infusion in the brain cavity, tongs were used and TLDs were placed over the fingertips. The air kerma-rate was measured around the patients. The use of devices provided a 75% dose reduction, with mean fingertip doses of 2.9 mGy (i.v. MoAbs), 0.6 mGy (i.v. peptides)/radiolabelling procedure and 0.5 mGy/l.r. administration. The mean effective dose to personnel was 5 microSv/patient. The air kerma-rate around the patients administered i.v. (90)Y-peptides were 3.5 (1 h) and 1.0 (48 h) microGy/h at 1 m. Patient hospitalisation of 6 h (l.r.)/48 h (i.v.) guaranteed that the recommended limits of 3 mSv/year to family members and 0.3 mSv/year to the general population (Council Directive 97/43/Euratom) were respected. When specific procedures are adopted, a substantial improvement in (90)Y manipulation is attainable, reducing doses and increasing safety. For the widespread clinical use of (90)Y-conjugates, a completely automatic labelling procedure is desirable.

Fluorescent probe encapsulated hydrogel microsphere for selective and reversible detection of Hg{sup 2+}

Energy Technology Data Exchange (ETDEWEB)

Song, Zhenhu; Wang, Fang; Qiang, Jian; Zhang, Zhijie; Chen, Yahui; Wang, Yong; Zhang, Wei; Chen, Xiaoqiang

2017-03-15

We developed a simple and sensitive hydrogel sensor in the form of microspheres by using fluorescence probe encapsulated within a hydrogel matrix for the detection of Hg{sup 2+}. The traditional fluorescence probes suspended in solution are not transportable and recoverable. To overcome these disadvantages, we devised poly(ethylene glycol) diacrylate-based hydrogel microspheres in which fluorescence probe (R19S) was embedded at high density. The functionalized hydrogel microspheres were prepared by combining a microfluidic device with UV light. The hydrogel microspheres-based sensor exhibited good selectivity to Hg{sup 2+} among various metal ions and high sensitivity with a detection limit of 90 nM. Furthermore, after binding with Hg{sup 2+}, the R19S encapsulated hydrogel microspheres can be separated from testing samples easily and treated with the solution containing KI to remove Hg{sup 2+} and realize reusable detection. The current work may offer a new method for Hg{sup 2+} recognition with a more efficient manner.

Same-day {sup 90}Y radioembolization: implementing a new treatment paradigm

Energy Technology Data Exchange (ETDEWEB)

Gabr, Ahmed; Kallini, Joseph Ralph; Gates, Vanessa L.; Hickey, Ryan; Desai, Kush; Thornburg, Bartley; Marshall, Karen; Salzig, Krystina; Williams, Melissa; Del Castillo, Carlene; Hohlastos, Elias; Lewandowski, Robert J. [Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Department of Radiology, Section of Interventional Radiology, Chicago, IL (United States); Kulik, Laura; Ganger, Daniel [Northwestern University, Department of Medicine, Division of Hepatology, Chicago, IL (United States); Baker, Talia [Northwestern University, Department of Surgery, Division of Transplantation, Comprehensive Transplant Center, Chicago, IL (United States); Salem, Riad [Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Department of Radiology, Section of Interventional Radiology, Chicago, IL (United States); Northwestern University, Department of Surgery, Division of Transplantation, Comprehensive Transplant Center, Chicago, IL (United States); Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Department of Medicine, Division of Hematology and Oncology, Chicago, IL (United States)

2016-12-15

To assess the feasibility of conducting pretreatment mesenteric angiography, coil embolization, {sup 99m}Tc macroaggregated albumin ({sup 99m}Tc-MAA) scintigraphy, and {sup 90}Y radioembolization treatment in a single, same-day, combined outpatient encounter. This was a retrospective study of 78 patients treated during the period 2008 - 2015 who were managed in a single outpatient encounter under the guidance of the Interventional Radiology Department and The Nuclear Medicine Department. Pretreatment planning was performed by reviewing baseline imaging and estimated perfused liver volume bearing the tumor. The region of interest was estimated using 3-D software; this value was used for dosimetry planning. Maximum lung shunting fractions of 10 % for hepatocellular carcinoma and 5 % for liver metastases were assumed. Subsequently, hepatic angiography and {sup 99m}Tc-MAA scintigraphy were performed followed by {sup 90}Y treatment in one outpatient encounter. Total in-room procedure time was recorded. All patients underwent same-day angiography, {sup 99m}Tc-MAA scintigraphy and {sup 90}Y radioembolization. Of the 78 patients, 16 received multiple segmental treatments to both lobes, 44 received treatment to the right lobe, and 18 received treatment to the left lobe. The median dose was 106 Gy. The median number of {sup 90}Y vials needed was two (range one to six). The median in-room time was 160 min (75 - 250 min). The residential status of the patients was as follows, 18 % (14/78) were local residents, 55 % (43/78) traveled from outside the city limits, 18 % (14/78) were from out-of-state, and 9 % (7/78) were resident abroad. Of the 78 patients, 61 (77 %) had hepatocellular carcinoma, and 17 (22 %) had liver metastases. The median lung dose was 3.5 Gy. This study demonstrated the feasibility of same-day {sup 90}Y evaluation and treatment while maintaining the principles of safe and effective {sup 90}Y infusion including tumoricidal dosimetry (lobar, segmentectomy

Comparison of positron emission tomography/CT and bremsstrahlung imaging following Y-90 radiation synovectomy

International Nuclear Information System (INIS)

Barber, Thomas W.; Yap, Kenneth S.K.; Cherk, Martin H.; Kalff, Victor; Powell, Anne

2013-01-01

The aim of this study is to compare the results of positron emission tomography (PET)/CT with bremsstrahlung imaging following Y-90 radiation synovectomy. All patients referred to our institution for Y-90 radiation synovectomy between July 2011 and February 2012 underwent both PET/CT and bremsstrahlung planar (±single photon emission computed tomography (SPECT) or SPECT/CT) imaging at 4 or 24 h following administration of Y-90 silicate colloid. PET image acquisition was performed for between 15 and 20min. In patients who underwent SPECT, side-by-side comparison with PET was performed and image quality/resolution scored using a five-point scale. The distribution pattern of Y-90 on PET and bremsstrahlung imaging was compared with the intra- or extra-articular location of Y-90 activity on fused PET/CT. Thirteen joints (11 knees and two ankles) were imaged with both PET/CT and planar bremsstrahlung imaging with 12 joints also imaged with bremsstrahlung SPECT. Of the 12 joints imaged with SPECT, PET image quality/resolution was superior in 11 and inferior in one. PET demonstrated a concordant distribution pattern compared with bremsstrahlung imaging in all scans, with the pattern classified as diffuse in 12 and predominantly focal in one. In all 12 diffuse scans, PET/CT confirmed the Y-90 activity to be located intra-articularly. In the one predominantly focal scan, the fused PET/CT images localised the Y-90 activity to mostly lie in the extra-articular space of the knee. PET/CT can provide superior image quality compared with bremsstrahlung imaging and may enable reliable detection of extra-articular Y-90 activity when there are focal patterns on planar bremsstrahlung imaging.

The exploration of nursing care for patients with benign prostatic hyperplasia treated using 90Sr-90Y

International Nuclear Information System (INIS)

Xiao Lizhen; Bai Xuemei; Zhang Bihui; Yang Xiaoling

2004-01-01

An exploration of nursing care for patients with benign prostatic hyperplasia (BPH) treated using 90 Sr- 90 Y through the rectum was carried out . The treatment result and nursing experience in 90 cases were reported in this paper. Before the therapy nurses explained the method and principle of this treatment to the patients for the sake of increasing their confidence and to help them complete the treatment course successfully. During the radiotherapy, nurses practiced strictly radiation protection principles and operating instructions. They assisted the patients to have a healthy life style and good diet . The result of treatment indicated that the total effectiveness rate was 96.7%. The symptoms of lower urinary obstruction were improved evidently and the life quality of the patients elevated. Observation of clinical system confirmed that 90 Sr- 90 Y may be a new treatment method of BPH with benefits of safe irradiation dos, easy operation, non-traumatization, painlessness, and remarkable curative effects. However, it should be stressed that nursing care plays a pivotal role in the treatment result. (authors)

Preparation and evaluation of microspheres of xyloglucan and its thiolated xyloglucan derivative.

Science.gov (United States)

Sonawane, Savita; Bhalekar, Mangesh; Shimpi, Shamkant

2014-08-01

Xyloglucan is a natural polymer reported to possess mucoadhesive properties. To enhance the mucoadhesion potential, xyloglucan was thiolated with cysteine. The microspheres of xyloglucan were prepared using a biocompatible crosslinker sodium trimetaphosphate and it was optimized for formulation variables, namely polymer concentration, internal:external phase ratio and stirring speed using a Box-Behnken experimental design. The formulation was also optimized for performance parameters like entrapment, t80 and % mucoadhesion. The microspheres were characterized by Fourier transform infrared spectroscopy, DSC and SEM for the optimum formula and then were reproduced by replacing the xyloglucan with thiomer. The microspheres formed showed entrapment efficiency of about 80%, t80 of about 400min and % mucoadhesion of 60% while same for thiomer were 90%, 500min and 80% respectively. In oral glucose tolerance test protocol the thiomer microspheres showed significant reduction in blood glucose levels. Thus thiolated xyloglucan offers a better polymer for multiparticulate drug delivery. Copyright © 2014 Elsevier B.V. All rights reserved.

Evaluation of Effective Parameters on Labeling of Hydroxyapatite Compound with 90Y and Introducing the Best Method to Produce 90Y-HAp Radiopharmaceutical for Radio synovectomy

International Nuclear Information System (INIS)

Davarpanah, M. R.; Khoshhosn, H. A.; Attar Nosrati, S.; Harati, S. M.; Aghamiri, S. M.; Ghannadi Maragheh, M.

2012-01-01

Radio synovectomy is a local intra-articular injection of radionuclides in colloidal form for treatment of articular inflammatory in rheumatoid arthritis, hemophilia or orthopedic troubles. β-emitting radionuclides can be used for various joints based on radiation energy. 90 Y is a pure β-emitter with a half-life of 64.1 hours that is used for treatment of the knee joint. β-radiation of this radionuclide possesses maximum energy of 2.281 MeV (99.98%), mean pathway of 3.6 mm in the soft tissue and maximum 11 mm. In this project, hydroxyapatite (HAp) is applied as a colloid maker agent that interacts with 90 Y 3+ ions via ion-dipole bonds and produces 90 Y-HAp. The colloidal pharmaceutical is produced by adding an acidic solution of 90 YCl 3 to an HAp suspension in saline. Effective parameters within which the colloid is applied, such as the volume of diluent, HAp particle size and sonication effect were evaluated and tested. First, these determinative parameters were optimized in the simulated conditions and then examined in the active phase. Finally, the best procedure was determined for the production of the radiopharmaceutical. Radionuclide purity of the radiopharmaceutical according to the primary 90 YCl 3 solution was over 99.9%. Labeling yield and radiochemical purity were obtained over 99% using TLC method in saline solvent up to three days after production of radiopharmaceutical. Radiochemical purity of 90 Y-HAp colloid was also evaluated in human serum albumin solution for three days at room temperature. The amount of released activity was between 0.3 to 2%.

Comparison of gas clearance and radioactive microspheres for pancreatic blood flow measurement

International Nuclear Information System (INIS)

DeMar, A.R.; Graham, L.S.; Lake, R.; Fink, A.S.

1989-01-01

Measurement of pancreatic blood flow (PBF) is technically demanding. Although radiolabeled microspheres are considered the gold standard for PBF assessment, they have practical limitations. In the current study, H 2 and xenon-133 gas clearance techniques were adapted to PBF measurement and compared to radiolabeled microsphere techniques. Simultaneous measurements of PBF were made using either hydrogen or xenon gas washout and radiolabeled microspheres. Measurements were made under basal, vasoconstricted (vasopressin 2U i.v. or nicotine 4 micrograms/kg/h) and stimulated (secretin 125 ng/kg/h or 2 U/kg i.v.) conditions (random order). Mean PBF was 26.9 +/- 5.3, 50.5 +/- 2.3 and 27.6 +/- 5.2 ml/min/100 g basally, 36.9 +/- 8.0, 90.1 +/- 18.9, and 81.7 +/- 14.5 ml/min/100 g in the stimulated state, and 24.2 +/- 7.8, 25.0 +/- 3.5, and 14.9 +/- 7.5 ml/min/100 g in the vasoconstricted state for hydrogen gas clearance, xenon gas clearance, and radiolabeled microspheres, respectively. The H 2 clearance technique resulted in tissue trauma, was complicated by frequent electrode displacement, and correlated poorly (r2 = 0.36, p greater than 0.05) with microsphere values. In contrast, xenon clearance measurement had no apparent effect on the pancreas and correlated well (r2 = 0.83, p less than 0.01) with microsphere data. We conclude that xenon clearance offers an attractive, validated alternative to radiolabeled microspheres for measuring pancreatic blood flow

The relationship between the percentage of lung shunting on Tc-99m macroaggregated albumin (Tc-99m MAA scan and the grade of hepatocellular carcinoma vascularity

Directory of Open Access Journals (Sweden)

Rania Refaat

2014-06-01

Conclusion: Tc-99m MAA scan is fundamental prior to Y-90 microsphere SIRT as it minimizes the risk of post-radioembolization complications, hence, enhancing the safety of Y-90 microsphere subsequent administration. Moreover, the percentage of lung shunting varies considerably among patients with HCC relying on the grade of tumor vascularity.

Radiochemical schemes of obtaining 89Sr and 90Y radionuclides

International Nuclear Information System (INIS)

Usarov, Z. O.

2010-03-01

Key words: strontium-89, yttrium-90, extraction and extraction-chromatographic purification of radionuclides, radiopharmaceuticals. Subjects of research: strontium-89 and yttrium-90 radionuclides and their chloride forms. Purpose of work is developing of radiochemical technologies on obtaining of 89 Sr and 90 Y on the WWR-SM reactor with high radionuclide purity. Methods of research: extraction and extraction-chromatographic methods of radionuclides separation, beta- and gamma-spectrometric methods of activity measuring. The results obtained and their novelty: Were determined the conformity to laws of Y and Sr distribution in two-phase systems TBP-HNO 3 , TBP-NH 4 NO 3 , TBP-HCI, HDEHP-NO 3 , HDEHP-NH 4 NO 3 and HDEHP-HCI. Were determined the conformity to laws of Y and Sr distribution in systems with craun ethers DB-18K-6 and DTBDB-18K-6 from water solutions of HNO 3 . Radiochemical technologies on obtaining of 89 Sr and 90 Y radionuclides including radiochemical process of yttrium target with using the systems TBP-HNO 3 and HDEHP/Teflone were developed. Practical value: the radiochemical technology of obtaining 89 Sr with high radionuclide purity was developed. The method of preparation a chloride compound of 89 SrCl 2 which is used as a drug form for preparation of 89 Sr- 'Metastron' was developed. The relatively simple method of on the way obtaining 90 Y in the reactor with high radionuclidic purity that is useful for follow using in medical practice was offered. Degree of embed and economic effectivity: the developed technologies have approbation in manufacturing conditions in Radiopreparat Enterprise of INP AS RU and were offered for receiving of domestic preparations against of import foreign analogues. The statement about using the invention by obtained patent is attached to dissertation. Field of application: the received results will be introduced in manufacture at Radiopreparat Enterprise of INP AS RU for receiving of domestic preparations

Thermoluminescent dosimetry of beta radiations of 90 Sr/ 90 Y using amorphous ZrO2

International Nuclear Information System (INIS)

Rivera M, T.; Olvera T, L.; Azorin N, J.; Barrera R, M.; Soto E, A.M.

2005-01-01

In this work the results of studying the thermoluminescent properties (Tl) of the zirconium oxide in its amorphous state (ZrO 2 -a) before beta radiations of 90 Sr/ 90 Y are presented. The amorphous powders of the zirconium oxide were synthesized by means of the sol-gel technique. The sol-gel process using alkoxides like precursors, is an efficient method to prepare a matrix of zirconium oxide by hydrolysis - condensation of the precursor to form chains of Zr-H 3 and Zr-O 2 . One of the advantages of this technique is the obtention of gels at low temperatures with very high purity and homogeneity. The powders were characterized by means of thermal analysis and by X-ray diffraction. The powders of ZrO 2 -a, previously irradiated with beta particles of 90 Sr/ 90 Y, presented a thermoluminescent curve with two peaks at 150 and 257 C. The dissipation of the information of the one ZrO 2 -a was of 40% the first 2 hours remaining constant the information for the following 30 days. The reproducibility of the information was of ± 2.5% in standard deviation. The studied characteristics allow to propose to the amorphous zirconium oxide as thermoluminescent dosemeter for the detection of beta radiation. (Author)

Comparative effects of inhaled relatively insoluble forms of 90Y, 144Ce, and 90Sr on canine peripheral lymphocyte function

International Nuclear Information System (INIS)

Benjamin, S.A.; Jones, R.K.; Snipes, M.B.; Lustgarten, C.S.

1976-01-01

Dogs that have inhaled relatively insoluble forms of either alpha- or beta-emitting radionuclides manifest a peripheral lymphopenia, the development and course of which depends on both total dose and dose rate. The remaining peripheral lymphocytes in dogs exposed to longer lived beta-emitting radionuclides showed a depressed function as measured by the ability to respond to plant mitogens in vitro. This experiment was designed to evaluate the effect of dose rate on peripheral lymphocyte function by exposing dogs to aerosols of radionuclides with varied effective half-lives in the lung: 90 Y (2.6 days), 144 Ce (170 days), and 90 Sr (650 days). Three groups of four adult beagle dogs each were exposed by inhalation to 90 Y, 144 Ce, or 90 Sr in fused-clay particles. Two controls were matched with each group. Initial lung burdens and initial dose rates to the lung were 520 to 610 μCi/kg of body weight and 2200 to 2600 rads/day in the 90 Y group, 33 to 60 μCi/kg and 200 to 350 rads/day in the 144 Ce group, and 25 to 32 μCi/kg and 130 to 170 rads/day in the 90 Sr group. Hematologic parameters and lymphocyte function as measured by the ability of lymphocytes to respond to plant mitogen stimulation were evaluated on a weekly or biweekly basis for 8 weeks after exposure and on a monthly basis thereafter. The 90 Y-exposed dogs showed a marked lymphopenia within 1 week with a return to control levels by 20 weeks after exposure. The remaining peripheral lymphocytes, however, showed no functional changes in these dogs. Animals exposed to 144 Ce or 90 Sr developed a progressive and persisent lymphopenia and showed functional depression of the remaining lymphocytes as well. The relationships among dose pattern, lymphopenia, and lymphocyte-function depression are discussed

Thermoluminescent dosimetry of beta radiations of {sup 90} Sr/ {sup 90} Y using ZrO{sub 2}: Eu; Dosimetria termoluminiscente de radiaciones beta de {sup 90} Sr/ {sup 90} Y usando ZrO{sub 2}: Eu

Energy Technology Data Exchange (ETDEWEB)

Olvera T, L.; Azorin N, J.; Barrera S, M.; Soto E, A.M. [UAM-I, 09340 Mexico D.F. (Mexico); Rivera M, T. [CICATA-IPN, Legaria 694, 11500 Mexico D.F. (Mexico)

2005-07-01

In this work the results of studying the thermoluminescent properties (TL) of the doped zirconium oxide with europium (ZrO{sub 2}: Eu{sup 3+}) before beta radiations of {sup 90}Sr/ {sup 90}Y are presented. The powders of ZrO{sub 2}: Eu{sup 3+} were obtained by means of the sol-gel technique and they were characterized by means of thermal analysis and by X-ray diffraction. The powders of ZrO{sub 2}: Eu{sup 3+}, previously irradiated with beta particles of {sup 90}Sr/ {sup 90}Y, presented a thermoluminescent curve with two peaks at 204 and 292 C respectively. The TL response of the ZrO{sub 2}: Eu{sup 3+} as function of the absorbed dose was lineal from 2 Gy up to 90 Gy. The fading of the information of the ZrO{sub 2}: Eu{sup 3+} was of 10% the first 2 hours remaining almost constant the information by the following 30 days. The ZrO{sub 2} doped with the (Eu{sup 3+}) ion it was found more sensitive to the beta radiation that the one of zirconium oxide without doping (ZrO{sub 2}) obtained by the same method. Those studied characteristics allow to propose to the doped zirconium oxide with europium like thermoluminescent dosemeter for the detection of the beta radiation. (Author)

Development of 90Y-DOTA-nimotuzumab Fab fragment for radioimmunotherapy

International Nuclear Information System (INIS)

Alonso Martinez, L.M.; Marylaine Perez-Malo Cruz; Rene Leyva Montana; Calzada Falcon, V.N.; Minely Zamora Barrabi; Alejandro Arbesu Valdivia; Ignacio Hernandez Gonzalez; Mariela Leon Perez

2014-01-01

Yttrium-90-( 90 Y) labeled monoclonal antibodies prepared with a chelating agent, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), have been used for radioimmunotherapy of cancer. In the present work, the Fab fragment of anti-EGFR monoclonal antibody nimotuzumab was prepared with high purity, integrity and biological activity. The Fab fragment with high specific recognition of EGFR in NCI-H125 human lung adenocarcinoma cells was derivatized with DOTA-NHS applying a simple procedure. DOTA-nimotuzumab Fab fragment was successfully radiolabeled with 90 Y with high radiochemical yield. The in vitro stability of labeled product was optimal over 24 h in buffered solution at 37 deg C. Biodistribution and pharmacokinetic studies correctly evaluated the in vivo non-tumor uptake, dosage regimen and excretion pathway in normal Wistar rats. (author)

Treatment of hepatocellular carcinoma (HCC) with intra-arterial Yttrium-90 microspheres for down-staging patients to transplantation

International Nuclear Information System (INIS)

De Man, K.; Defreyne, L.; Delanghe, E.; Smeets, P.; Verhelst, X.; Geerts, A.; Van Vlierberghe, H.; Rogiers, X.; Troisi, R.; Lambert, B.

2015-01-01

Full text of publication follows. Introduction and aim: in our hospital, patients are referred for intra-arterial treatment with Yttrium-90 microspheres if they present with an HCC confined to the liver, but are ineligible for curative treatment options such as liver transplantation, partial hepatectomy or radio-frequent ablation. Additional eligibility criteria for radio-embolisation consist of Child-P ugh score 90 microspheres in our hospital since 2008 and who presented at an age <70 and with a disease load exceeding the Milan criteria (single tumour ≤5 cm or ≤ 3 lesions ≤ 3 cm). We recorded whether the patient was down staged to a tumour load complying with the Milan criteria, and if so, whether transplantation was carried out. Results: 40 patients aged <70 years and with a tumour load exceeding the Milan criteria (all treated with TheraSphere, Nordion except 1 with SIR-Spheres, Sirtex) were evaluable. 35 had Barcelona Clinic Liver Cancer (BCLC) B stage disease and 5 had BCLC C. Overall median survival was 12.9 months. 16 out of 40 patients were down staged to the Milan criteria (40%, all BCLC B), of whom 8 were actually transplanted so far. Two patients are on the waiting list, 1 patient refuses to be listed and 1 patient suffers co-morbidity that excludes him from abdominal surgery. Unfortunately 4 patients died before or during work-out for transplantation: 1 unexplained sudden death, 1 lung embolism and 2 due to liver failure. The overall median survival was 30,4 months in the down staged patients. 24 out 40 patients (60%) did not have a tumour load within the Milan criteria at any point of their follow up and had a significant worse

Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities.

Science.gov (United States)

Goin, James E; Salem, Riad; Carr, Brian I; Dancey, Janet E; Soulen, Michael C; Geschwind, Jean Francois H; Goin, Kathleen; Van Buskirk, Mark; Thurston, Kenneth

2005-02-01

Intraarterial injection of yttrium 90 microspheres (TheraSpheres) is used in the treatment of hepatocellular carcinoma (HCC). This article presents an analysis of the incidence of liver toxicities (liver-related events) and pretreatment factors associated with liver toxicities after TheraSphere treatment. Eighty-eight TheraSphere-treated patients with low 90-day mortality risk were selected for analysis, with liver toxicities coded with use of standard oncology criteria. Descriptive and inferential statistical methods were applied to estimate the incidence of liver toxicities and to evaluate the influence of liver radiation dose and various pretreatment factors on the risk of their occurrence. Sixty-eight liver toxicities occurred in 37 of the 88 patients (42%). Thirty-two patients (36%) experienced 50 liver toxicities after the first treatment and nine of 23 patients (39%) who received a second treatment experienced 18 liver toxicities. Pretreatment total bilirubin and liver radiation dose were found to be associated with the risk of at least one liver toxicity and with the time to first occurrence of a liver toxicity after first treatment. Pretreatment total bilirubin also was associated with liver toxicities after the second treatment. Most of the toxicities resolved; however, those that did not resolve were attributed to tumor progression or advancing cirrhosis. The risk of liver toxicities in patients with unresectable HCC treated with TheraSpheres increases with increasing pretreatment total bilirubin level and liver radiation dose to a maximum of 150 Gy for a single administration. The toxicities attributed to treatment resolved over time, and none of the patients studied had confirmed radiation-induced liver disease. Consequently, doses as high as 150 Gy on a single administration and as high as 268 Gy on repeated administrations were well tolerated.

Mucoadhesive microspheres for gastroretentive delivery of acyclovir: in vitro and in vivo evaluation.

Science.gov (United States)

Dhaliwal, Sumeet; Jain, Subheet; Singh, Hardevinder P; Tiwary, A K

2008-06-01

The aim of the present investigation was to evaluate the potential use of mucoadhesive microspheres for gastroretentive delivery of acyclovir. Chitosan, thiolated chitosan, Carbopol 71G and Methocel K15M were used as mucoadhesive polymers. Microsphere formulations were prepared using emulsion-chemical crosslinking technique and evaluated in vitro, ex-vivo and in-vivo. Gelatin capsules containing drug powder showed complete dissolution (90.5 +/- 3.6%) in 1 h. The release of drug was prolonged to 12 h (78.8 +/- 3.9) when incorporated into mucoadhesive microspheres. The poor bioavailability of acyclovir is attributed to short retention of its dosage form at the absorption sites (in upper gastrointestinal tract to duodenum and jejunum). The results of mucoadhesion study showed better retention of thiolated chitosan microspheres (8.0 +/- 0.8 h) in duodenal and jejunum regions of intestine. The results of qualitative and quantitative GI distribution study also showed significant higher retention of mucoadhesive microspheres in upper GI tract. Pharmacokinetic study revealed that administration of mucoadhesive microspheres could maintain measurable plasma concentration of acyclovir through 24 h, as compared to 5 h after its administration in solution form. Thiolated chitosan microsphere showed superiority over the other formulations as observed with nearly 4.0-fold higher AUC(0-24) value (1,090 +/- 51 ng h/ml) in comparison to drug solution (281 +/- 28 ng h/ml). Overall, the result indicated prolonged delivery with significant improvement in oral bioavailability of acyclovir from mucoadhesive microspheres due to enhanced retention in the upper GI tract.

Y-90 PET imaging for radiation theragnosis using bootstrap event re sampling

International Nuclear Information System (INIS)

Nam, Taewon; Woo, Sangkeun; Min, Gyungju; Kim, Jimin; Kang, Joohyun; Lim, Sangmoo; Kim, Kyeongmin

2013-01-01

Surgical resection is the most effective method to recover the liver function. However, Yttrium-90 (Y-90) has been used as a new treatment due to the fact that it can be delivered to the tumors and results in greater radiation exposure to the tumors than using external radiation nowadays since most treatment is palliative in case of unresectable stage of hepatocellular carcinoma (HCC). Recently, Y-90 has been received much interest and studied by many researchers. Imaging of Y-90 has been conducted using most commonly gamma camera but PET imaging is required due to low sensitivity and resolution. The purpose of this study was to assess statistical characteristics and to improve count rate of image for enhancing image quality by using nonparametric bootstrap method. PET data was able to be improved using non-parametric bootstrap method and it was verified with showing improved uniformity and SNR. Uniformity showed more improvement under the condition of low count rate, i.e. Y-90, in case of phantom and also uniformity and SNR showed improvement of 15.6% and 33.8% in case of mouse, respectively. Bootstrap method performed in this study for PET data increased count rate of PET image and consequentially time for acquisition time can be reduced. It will be expected to improve performance for diagnosis

Country report: India. Development of Radiopharmaceuticals Based on {sup 188}Re and {sup 90}Y for Radionuclide Therapy

Energy Technology Data Exchange (ETDEWEB)

Venkatesh, M.; Pandey, U.; Dhami, P. S.; Chakravarty, R.; Kameswaran, M.; Subramanian, S.; Dash, A.; Samuel, G. [Bhabha Atomic Research Centre, Trombay, Mumbai 400 085 (India)

2010-07-01

During the past decade, our group has focused attention on the development of therapeutic radiopharmaceuticals incorporating radioisotopes such as {sup 90}Y, {sup 188}Re etc. As the primary source of the radioisotopes {sup 90}Y and {sup 188}Re are the {sup 90}Sr/{sup 90}Y generators and {sup 188}W/{sup 188}Re generators respectively, the local availability of these generator systems is very important for the successful development of radiopharmaceuticals incorporating these radioisotopes. In this context, {sup 90}Sr/{sup 90}Y generators based on Supported Liquid Membrane (SLM) [1-3] and electrochemical techniques [4] could be designed and deployed in our laboratories for the elution of {sup 90}Y to be used for preparation of {sup 90}Y labeled products. This work formed a part of the IAEA co-ordinated CRP on “Development of Generator Technologies for Therapeutic Radionuclides: {sup 90}Y and {sup 188}Re”. In this report, work on the development of {sup 90}Y radiopharmaceuticals for treatment of liver cancer and non-Hodgkin’s lymphoma (NHL) is reported. In addition, comparison of the Extraction Paper Chromatography technique (EPC) developed for determination of {sup 90}Sr contamination in {sup 90}Y samples with the US Pharmacopeia recommended method as well as the validation of the EPC technique is presented.

[Optimization of calcium alginate floating microspheres loading aspirin by artificial neural networks and response surface methodology].

Science.gov (United States)

Zhang, An-yang; Fan, Tian-yuan

2010-04-18

To investigate the preparation and optimization of calcium alginate floating microspheres loading aspirin. A model was used to predict the in vitro release of aspirin and optimize the formulation by artificial neural networks (ANNs) and response surface methodology (RSM). The amounts of the material in the formulation were used as inputs, while the release and floating rate of the microspheres were used as outputs. The performances of ANNs and RSM were compared. ANNs were more accurate in prediction. There was no significant difference between ANNs and RSM in optimization. Approximately 90% of the optimized microspheres could float on the artificial gastric juice over 4 hours. 42.12% of aspirin was released in 60 min, 60.97% in 120 min and 78.56% in 240 min. The release of the drug from the microspheres complied with Higuchi equation. The aspirin floating microspheres with satisfying in vitro release were prepared successfully by the methods of ANNs and RSM.

Prolonged amelioration of experimental postoperative pain by bupivacaine released from microsphere-coated hernia mesh.

Science.gov (United States)

Ohri, Rachit; Wang, Jeffery Chi-Fei; Pham, Lan; Blaskovich, Phillip D; Costa, Daniel; Nichols, Gary; Hildebrand, William; Scarborough, Nelson; Herman, Clifford; Strichartz, Gary R

2014-01-01

Postoperative pain alters physiological functions and delays discharge. Perioperative local anesthetics are effective analgesics in the immediate 1- to 2-day postoperative period, but acute pain often lasts longer. The goal of this work was to develop a local anesthetic formulation adhering to an intraoperative implanted device that reduces pain for at least 3 days after surgery. Six groups, each with 8 rats, were studied. In a control group (group I), one 1.2-cm-long incision of the skin was followed by blunt dissection to separate the skin away from the underlying tissues and closing with 2 sutures. In 3 of the treatment groups, the same surgical procedure was used, with the subcutaneous space formed by the blunt dissection lined with a 1-cm square patch of hernia mesh coated with poly lactide co-glycolic acid microspheres containing approximately 17 mg of bupivacaine (group II), no drug (placebo; group III), or bupivacaine free-base powder (group IV). Uncoated mesh implants (group V) served as a secondary control. A standard bupivacaine solution (0.4 mL, 0.5%; 2-mg dose) was infiltrated subcutaneously 30 minutes before the surgery and served as a standard control (group VI). Mechanosensitivity of the skin was tested by the local subcutaneous muscle responses to cutaneous tactile stimulation by von Frey hairs with forces of 4 g (for allodynia) and 15 g (for hyperalgesia) preoperatively and for 7 postoperative days. Control rats (group I) showed mechanohypersensitivity, indicative of postoperative allodynia and hyperalgesia, for all 7 postoperative days. Mechanohyperalgesia in rats that received mesh coated with bupivacaine-releasing microspheres (group II) was reduced during this period to 13% of control postoperative values (P < 0.001); mesh coated with bupivacaine base (group IV) reduced it by 50% (P = 0.034). The placebo mesh (group III) and uncoated mesh (group V) caused no significant reduction of mechanohypersensitivity, and bupivacaine solution infiltrated

Metallic coating of microspheres

International Nuclear Information System (INIS)

Meyer, S.F.

1980-01-01

Extremely smooth, uniform metal coatings of micrometer thicknesses on microscopic glass spheres (microspheres) are often needed as targets for inertial confinement fusion (ICF) experiments. The first part of this paper reviews those methods used successfully to provide metal coated microspheres for ICF targets, including magnetron sputtering, electro- and electroless plating, and chemical vapor pyrolysis. The second part of this paper discusses some of the critical aspects of magnetron sputter coating of microspheres, including substrate requirements, the sticking of microspheres during coating (preventing a uniform coating), and the difficulties in growing the desired dense, smooth, uniform microstructure on continuously moving spherical substrates

The solvent extraction of carrier-free 90Y from 90Sr with crown ethers

International Nuclear Information System (INIS)

Chuang, J.T.; Lo, J.G.

1995-01-01

A simple solvent extraction method has been developed for the separation of 90 Y from 90 Sr. Crown ether dissolved in chloroform was used as a selective reagent and organic picrate anion was chosen as a counter ion. The effect of various factors on the extraction equilibrium constant of strontium log K ex = 9.15 was obtained from the study of the distribution coefficient versus to crown ether concentration. The separation method was simple, resulted high purity (>99.9%) and quantitative yield, and took less than half an hour. (author) 27 refs.; 4 figs.; 4 tabs

Root Cause Analysis of Gastroduodenal Ulceration After Yttrium-90 Radioembolization

Energy Technology Data Exchange (ETDEWEB)

Lam, Marnix G. E. H. [Stanford University School of Medicine, Division of Interventional Radiology (United States); Banerjee, Subhas [Stanford University School of Medicine, Division of Gastroenterology and Hepatology (United States); Louie, John D.; Abdelmaksoud, Mohamed H. K. [Stanford University School of Medicine, Division of Interventional Radiology (United States); Iagaru, Andrei H. [Stanford University School of Medicine, Division of Nuclear Medicine and Molecular Imaging (United States); Ennen, Rebecca E.; Sze, Daniel Y., E-mail: dansze@stanford.edu [Stanford University School of Medicine, Division of Interventional Radiology (United States)

2013-12-15

IntroductionA root cause analysis was performed on the occurrence of gastroduodenal ulceration after hepatic radioembolization (RE). We aimed to identify the risk factors in the treated population and to determine the specific mechanism of nontarget RE in individual cases. Methods: The records of 247 consecutive patients treated with yttrium-90 RE for primary (n = 90) or metastatic (n = 157) liver cancer using either resin (n = 181) or glass (n = 66) microspheres were reviewed. All patients who developed a biopsy-proven microsphere-induced gastroduodenal ulcer were identified. Univariate and multivariate analyses were performed on baseline parameters and procedural data to determine possible risk factors in the total population. Individual cases were analyzed to ascertain the specific cause, including identification of the culprit vessel(s) leading to extrahepatic deposition of the microspheres. Results: Eight patients (3.2 %) developed a gastroduodenal ulcer. Stasis during injection was the strongest independent risk factor (p = 0.004), followed by distal origin of the gastroduodenal artery (p = 0.004), young age (p = 0.040), and proximal injection of the microspheres (p = 0.043). Prolonged administrations, pain during administration, whole liver treatment, and use of resin microspheres also showed interrelated trends in multivariate analysis. Retrospective review of intraprocedural and postprocedural imaging showed a probable or possible culprit vessel, each a tiny complex collateral vessel, in seven patients. Conclusion: Proximal administrations and those resulting in stasis of flow presented increased risk for gastroduodenal ulceration. Patients who had undergone bevacizumab therapy were at high risk for developing stasis.

Root Cause Analysis of Gastroduodenal Ulceration After Yttrium-90 Radioembolization

International Nuclear Information System (INIS)

Lam, Marnix G. E. H.; Banerjee, Subhas; Louie, John D.; Abdelmaksoud, Mohamed H. K.; Iagaru, Andrei H.; Ennen, Rebecca E.; Sze, Daniel Y.

2013-01-01

IntroductionA root cause analysis was performed on the occurrence of gastroduodenal ulceration after hepatic radioembolization (RE). We aimed to identify the risk factors in the treated population and to determine the specific mechanism of nontarget RE in individual cases. Methods: The records of 247 consecutive patients treated with yttrium-90 RE for primary (n = 90) or metastatic (n = 157) liver cancer using either resin (n = 181) or glass (n = 66) microspheres were reviewed. All patients who developed a biopsy-proven microsphere-induced gastroduodenal ulcer were identified. Univariate and multivariate analyses were performed on baseline parameters and procedural data to determine possible risk factors in the total population. Individual cases were analyzed to ascertain the specific cause, including identification of the culprit vessel(s) leading to extrahepatic deposition of the microspheres. Results: Eight patients (3.2 %) developed a gastroduodenal ulcer. Stasis during injection was the strongest independent risk factor (p = 0.004), followed by distal origin of the gastroduodenal artery (p = 0.004), young age (p = 0.040), and proximal injection of the microspheres (p = 0.043). Prolonged administrations, pain during administration, whole liver treatment, and use of resin microspheres also showed interrelated trends in multivariate analysis. Retrospective review of intraprocedural and postprocedural imaging showed a probable or possible culprit vessel, each a tiny complex collateral vessel, in seven patients. Conclusion: Proximal administrations and those resulting in stasis of flow presented increased risk for gastroduodenal ulceration. Patients who had undergone bevacizumab therapy were at high risk for developing stasis

Dose distribution following selective internal radiation therapy

International Nuclear Information System (INIS)

Fox, R.A.; Klemp, P.F.; Egan, G.; Mina, L.L.; Burton, M.A.; Gray, B.N.

1991-01-01

Selective Internal Radiation Therapy is the intrahepatic arterial injection of microspheres labelled with 90Y. The microspheres lodge in the precapillary circulation of tumor resulting in internal radiation therapy. The activity of the 90Y injected is managed by successive administrations of labelled microspheres and after each injection probing the liver with a calibrated beta probe to assess the dose to the superficial layers of normal tissue. Predicted doses of 75 Gy have been delivered without subsequent evidence of radiation damage to normal cells. This contrasts with the complications resulting from doses in excess of 30 Gy delivered from external beam radiotherapy. Detailed analysis of microsphere distribution in a cubic centimeter of normal liver and the calculation of dose to a 3-dimensional fine grid has shown that the radiation distribution created by the finite size and distribution of the microspheres results in an highly heterogeneous dose pattern. It has been shown that a third of normal liver will receive less than 33.7% of the dose predicted by assuming an homogeneous distribution of 90Y

Hierarchical Mn₂O₃ Microspheres In-Situ Coated with Carbon for Supercapacitors with Highly Enhanced Performances.

Science.gov (United States)

Gong, Feilong; Lu, Shuang; Peng, Lifang; Zhou, Jing; Kong, Jinming; Jia, Dianzeng; Li, Feng

2017-11-23

Porous Mn₂O₃ microspheres have been synthesized and in-situ coated with amorphous carbon to form hierarchical C@Mn₂O₃ microspheres by first producing MnCO₃ microspheres in solvothermal reactions, and then annealing at 500 °C. The self-assembly growth of MnCO₃ microspheres can generate hollow structures inside each of the particles, which can act as micro-reservoirs to store biomass-glycerol for generating amorphous carbon onto the surfaces of Mn₂O₃ nanorods consisting of microspheres. The C@Mn₂O₃ microspheres, prepared at 500 °C, exhibit highly enhanced pseudocapacitive performances when compared to the particles after annealed at 400 °C and 600 °C. Specifically, the C@Mn₂O₃ microspheres prepared at 500 °C show high specific capacitances of 383.87 F g -1 at current density of 0.5 A g -1 , and excellent cycling stability of 90.47% of its initial value after cycling for 5000 times. The asymmetric supercapacitors assembled with C@Mn₂O₃ microspheres after annealed at 500 °C and activated carbon (AC) show an energy density of up to 77.8 Wh kg -1 at power density of 500.00 W kg -1 , and a maximum power density of 20.14 kW kg -1 at energy density of 46.8 Wh kg -1 . We can attribute the enhanced electrochemical performances of the materials to their three-dimensional (3D) hierarchical structure in-situ coated with carbon.

Hepatic vein tumor thrombus as a risk factor for excessive pulmonary deposition of microspheres during TheraSphere therapy for unresectable hepatocellular carcinoma.

Science.gov (United States)

Fleming, Chad J; Andrews, James C; Wiseman, Gregory A; Gansen, Denise N; Roberts, Lewis R

2009-11-01

To evaluate the impact of identifiable hepatic vein tumor thrombus on the ability to safely deliver TheraSphere (yttrium 90-containing glass microspheres) for the treatment of hepatocellular carcinoma (HCC). A retrospective review was performed of 87 patients (71 men, 16 women; mean age, 64.5 years; age range, 25-83 y) referred for TheraSphere therapy for HCC during a 2-year period between April 2005 and May 2007. Evaluation included contrast-enhanced computed tomography or magnetic resonance imaging, selective mesenteric angiography, and radionuclide perfusion scintigraphy to measure the arteriovenous shunting through the tumor. Of the 87 patients, 83 underwent angiography and perfusion scintigraphy; 53 were ultimately treated with 65 glass microsphere infusions. Twelve of 83 were identified as having tumor thrombus in a hepatic vein or extending into the inferior vena cava. The mean lung shunt for the patients with hepatic vein tumor thrombus was 30% (range, 11%-60%), compared with 8.2% (range, 3%-23%) for patients without identifiable tumor thrombus. Two of the 12 patients were treated with reduced doses of glass microspheres, and the remaining 10 were offered alternative therapies. The presence of hepatic vein tumor thrombus is a risk factor for an increased lung shunt that may prohibit delivery of a therapeutic dose of TheraSphere to hepatic tumor.

Biocompatibility Research of a Novel pH Sensitive Ion Exchange Resin Microsphere.

Science.gov (United States)

Liu, Hongfei; Shi, Shuangshuang; Pan, Weisan; Sun, Changshan; Zou, Xiaomian; Fu, Min; Feng, Yingshu; Ding, Hui

2014-01-01

The main objective of this study was to investigate biocompatibility and provide in-vivo pharmacological and toxicological evidence for further investigation of the possibility of pH sensitive ion exchange resin microsphere for clinical utilizations. Acute toxicity study and general pharmacological studies were conducted on the pH sensitive ion exchange resin microsphere we prepared. The general pharmacological studies consist of the effects of the pH sensitive ion exchange resin microsphere on the nervous system of mice, the functional coordination of mice, the hypnosis of mice treated with nembutal at subliminal dose, the autonomic activities of tested mice, and the heart rate, blood pressure, ECG and breathing of the anesthetic cats. The LD50 of pH sensitive ion exchange resin microsphere after oral administration was more than 18.84 g·Kg(-1). Mice were orally administered with 16 mg·Kg(-1), 32 mg·Kg(-1) and 64 mg·Kg(-1) of pH sensitive ion exchange resin microsphere and there was no significant influence on mice nervous system, general behavior, function coordination, hypnotic effect treated with nembutal at subliminal dose and frequency of autonomic activities. Within the 90 min after 5 mg·Kg(-1), 10 mg·Kg(-1), 20 mg·Kg(-1) pH sensitive ion exchange resin microsphere was injected to cat duodenum, the heart rate, blood pressure, breathing and ECG of the cats didn't make significant changes in each experimental group compared with the control group. The desirable pharmacological and toxicological behaviors of the pH sensitive ion exchange resin microsphere exhibited that it has safe biocompatibility and is possible for clinical use.

Thermoluminescent dosimetry of beta radiations of {sup 90} Sr/ {sup 90} Y using amorphous ZrO{sub 2}; Dosimetria termoluminiscente de radiaciones beta de {sup 90} Sr/ {sup 90} Y usando ZrO{sub 2} amorfo

Energy Technology Data Exchange (ETDEWEB)

Rivera M, T. [CICATA-Legaria, IPN, Legaria Num. 694, 11500 Mexico D.F. (Mexico); Olvera T, L.; Azorin N, J.; Barrera R, M.; Soto E, A.M. [UAM-I, 09340 Mexico D.F. (Mexico)

2005-07-01

In this work the results of studying the thermoluminescent properties (Tl) of the zirconium oxide in its amorphous state (ZrO{sub 2}-a) before beta radiations of {sup 90} Sr/ {sup 90} Y are presented. The amorphous powders of the zirconium oxide were synthesized by means of the sol-gel technique. The sol-gel process using alkoxides like precursors, is an efficient method to prepare a matrix of zirconium oxide by hydrolysis - condensation of the precursor to form chains of Zr-H{sub 3} and Zr-O{sub 2}. One of the advantages of this technique is the obtention of gels at low temperatures with very high purity and homogeneity. The powders were characterized by means of thermal analysis and by X-ray diffraction. The powders of ZrO{sub 2}-a, previously irradiated with beta particles of {sup 90} Sr/{sup 90} Y, presented a thermoluminescent curve with two peaks at 150 and 257 C. The dissipation of the information of the one ZrO{sub 2}-a was of 40% the first 2 hours remaining constant the information for the following 30 days. The reproducibility of the information was of {+-} 2.5% in standard deviation. The studied characteristics allow to propose to the amorphous zirconium oxide as thermoluminescent dosemeter for the detection of beta radiation. (Author)

Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison.

Science.gov (United States)

Gnesin, Silvano; Canetti, Laurent; Adib, Salim; Cherbuin, Nicolas; Silva Monteiro, Marina; Bize, Pierre; Denys, Alban; Prior, John O; Baechler, Sebastien; Boubaker, Ariane

2016-11-01

90 Y-microsphere selective internal radiation therapy (SIRT) is a valuable treatment in unresectable hepatocellular carcinoma (HCC). Partition-model predictive dosimetry relies on differential tumor-to-nontumor perfusion evaluated on pretreatment 99m Tc-macroaggregated albumin (MAA) SPECT/CT. The aim of this study was to evaluate agreement between the predictive dosimetry of 99m Tc-MAA SPECT/CT and posttreatment dosimetry based on 90 Y time-of-flight (TOF) PET/CT. We compared the 99m Tc-MAA SPECT/CT results for 27 treatment sessions (25 HCC patients, 41 tumors) with 90 Y SIRT (7 glass spheres, 20 resin spheres) and the posttreatment 90 Y TOF PET/CT results. Three-dimensional voxelized dose maps were computed from the 99m Tc-MAA SPECT/CT and 90 Y TOF PET/CT data. Mean absorbed dose ([Formula: see text]) was evaluated to compute the predicted-to-actual dose ratio ([Formula: see text]) in tumor volumes (TVs) and nontumor volumes (NTVs) for glass and resin spheres. The Lin concordance ([Formula: see text]) was used to measure accuracy ([Formula: see text]) and precision (ρ). Administered activity ranged from 0.8 to 1.9 GBq for glass spheres and from 0.6 to 3.4 GBq for resin spheres, and the respective TVs ranged from 2 to 125 mL and from 6 to 1,828 mL. The mean dose [Formula: see text] was 240 Gy for glass and 122 Gy for resin in TVs and 72 Gy for glass and 47 Gy for resin in NTVs. [Formula: see text] was 1.46 ± 0.58 (0.65-2.53) for glass and 1.16 ± 0.41 (0.54-2.54) for resin, and the respective values for [Formula: see text] were 0.88 ± 0.15 (0.56-1.00) and 0.86 ± 0.2 (0.58-1.35). DR variability was substantially lower in NTVs than in TVs. The Lin concordance between [Formula: see text] and [Formula: see text] (resin) was significantly better for tumors larger than 150 mL than for tumors 150 mL or smaller ([Formula: see text] = 0.93 and [Formula: see text] = 0.95 vs. [Formula: see text] = 0.57 and [Formula: see text] = 0.93; P < 0.05). In 90 Y radioembolization

In vitro evaluation and intra-articular administration of biodegradable microspheres containing naproxen sodium.

Science.gov (United States)

Bozdağ, S; Caliş, S; Kaş, H S; Ercan, M T; Peksoy, I; Hincal, A A

2001-01-01

The dispersion of non-steroidal antiinflammatory drugs (NSAIDs) into biodegradable polymeric matrices have been accepted as a good approach for obtaining a therapeutic effect in a predetermined period of time meanwhile minimizing the side effects of NSAIDs. In the present study, it was aimed to prepare Naproxen Sodium (NS), (a NSAID) loaded microsphere formulation using natural Bovine Serum Albumin (BSA) and synthetic biodegradable polymers such as poly(lactide-co-glycolic acid) (PLGA) (50:50 MW 34,000 and 88,000 Da) for intra-articular administration, and to study the retention of the drug at the site of injection in the knee joint. NS incorporated microspheres were evaluated in vitro for particle size (the mean particle size; for BSA microspheres, 10.0 +/- 0.3 microm, for PLGA microspheres, 9.0 +/- 0.2 and 5.0 +/- 0.1 microm for MW 34,000 and 88,000 Da, respectively), yield value, drug loading, surface morphology and drug release. For in vivo studies, monoarticular arthritis was induced in the left knee joints of rabbits by using ovalbumin and Freund's Complete Adjuvant as antigen and adjuvant. A certain time (4 days) is allowed for the formation of arthritis in the knee joints, then the NS loaded microspheres were injected directly into the articular cavity. At specific time points, gamma scintigrams were obtained to determine the residence time of the microspheres in knee joints, in order to determine the most suitable formulation. This study indicated that PLGA, a synthetic polymer, is more promising than the natural type BSA microspheres for an effective cure of mono-articular arthritis in rabbits.

Depth dose distribution in the water for clinical applicators of 90Sr + 90Y, with a extrapolation mini chamber

International Nuclear Information System (INIS)

Antonio, Patricia de Lara; Caldas, Linda V.E.; Oliveira, Mercia L.

2009-01-01

This work determines the depth dose in the water for clinical applicators of 90 Sr + 90 Y, using a extrapolation mini chamber developed at the IPEN, Sao Paulo, Brazil, and different thickness acrylic plates. The obtained results were compared with the international recommendations and were considered satisfactory

Biocompatibility, Inflammatory Response, and Recannalization Characteristics of Nonradioactive Resin Microspheres: Histological Findings

International Nuclear Information System (INIS)

Bilbao, Jose I.; Martino, Alba de; Luis, Esther de; Diaz-Dorronsoro, Lourdes; Alonso-Burgos, Alberto; Martinez de la Cuesta, Antonio; Sangro, Bruno; Garcia de Jalon, Jose A.

2009-01-01

Intra-arterial radiotherapy with yttrium-90 microspheres (radioembolization) is a therapeutic procedure exclusively applied to the liver that allows the direct delivery of high-dose radiation to liver tumors, by means of endovascular catheters, selectively placed within the tumor vasculature. The aim of the study was to describe the distribution of spheres within the precapillaries, inflammatory response, and recannalization characteristics after embolization with nonradioactive resin microspheres in the kidney and liver. We performed a partial embolization of the liver and kidney vessels in nine white pigs. The left renal and left hepatic arteries were catheterized and filled with nonradioactive resin microspheres. Embolization was defined as the initiation of near-stasis of blood flow, rather than total occlusion of the vessels. The hepatic circulation was not isolated so that the effects of reflux of microspheres into stomach could be observed. Animals were sacrificed at 48 h, 4 weeks, and 8 weeks, and tissue samples from the kidney, liver, lung, and stomach evaluated. Microscopic evaluation revealed clusters of 10-30 microspheres (15-30 μm in diameter) in the small vessels of the kidney (the arciform arteries, vasa recti, and glomerular afferent vessels) and liver. Aggregates were associated with focal ischemia and mild vascular wall damage. Occlusion of the small vessels was associated with a mild perivascular inflammatory reaction. After filling of the left hepatic artery with microspheres, there was some evidence of arteriovenous shunting into the lungs, and one case of cholecystitis and one case of marked gastritis and ulceration at the site of arterial occlusion due to the presence of clusters of microspheres. Beyond 48 h, microspheres were progressively integrated into the vascular wall by phagocytosis and the lumen recannalized. Eight-week evaluation found that the perivascular inflammatory reaction was mild. Liver cell damage, bile duct injury, and

Failure mode and effects analysis in a dual-product microsphere brachytherapy environment.

Science.gov (United States)

Younge, Kelly Cooper; Lee, Choonik; Moran, Jean M; Feng, Mary; Novelli, Paula; Prisciandaro, Joann I

We performed a failure mode and effects analysis (FMEA) during the addition of a new microspheres product into our existing microsphere brachytherapy program to identify areas for safety improvements. A diverse group of team members from the microsphere program participated in the project to create a process map, identify and score failure modes, and discuss programmatic changes to address the highest ranking items. We developed custom severity ranking scales for staff- and institution-related failure modes to encompass possible risks that may exist outside of patient-based effects. Between both types of microsphere products, 173 failure mode/effect pairs were identified: 90 for patients, 35 for staff, and 48 for the institution. The SIR-Spheres program was ranked separately from the TheraSphere program because of significant differences in workflow during dose calculation, preparation, and delivery. High-ranking failure modes in each category were addressed with programmatic changes. The FMEA aided in identifying potential risk factors in our microsphere program and allowed a theoretically safer and more efficient design of the workflow and quality assurance for both our new SIR-Spheres program and our existing TheraSphere program. As new guidelines are made available, and our experience with the SIR-Spheres program increases, we will update the FMEA as an efficient starting point for future improvements. Copyright © 2016 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.

Chitosan Microspheres as Radiolabeled Delivery Devices

International Nuclear Information System (INIS)

Permtermsin, Chalermsin; Ngamprayad, Tippanan; Phumkhem, Sudkanung; Srinuttrakul, Wannee; Kewsuwan, Prartana

2007-08-01

Full text: This study optimized conditions for preparing, characterizing, radiolabeled of chitosan microspheres and the biodistribution of 99mTc-Chitosan microspheres after intravenous administration. Particle size distribution of the microspheres was determined by light scattering. Zeta potential was studied by dynamic light scattering and electrophoresis technique. Biodistribution studies were performed by radiolabeling using 99mTc. The results shown that geometric mean diameter of the microspheres was found to be 77.26?1.96 ?m. Microsphere surface charge of chitosan microspheres was positive charge and zeta potential was 25.80 ? 0.46 mV. The labeling efficiency for this condition was more than 95% and under this condition was stable for at least 6 h. Radioactivity

Synthesis of magnetic polymeric microspheres

Energy Technology Data Exchange (ETDEWEB)

Gervald, A Yu; Gritskova, Inessa A; Prokopov, Nikolai I [M.V. Lomonosov Moscow State Academy of Fine Chemical Technology, Moscow (Russian Federation)

2010-05-13

The key types of magnetic polymeric microspheres are considered. Methods of synthesis of different types of magnetic nanoparticles and of preparation of stable magnetic fluids on their basis are outlined. The overview of the methods for the manufacture of magnetic polymeric microspheres is presented. The effect of the synthesis conditions on the characteristics of magnetic polymeric microspheres such as the diameter and the particle size distribution and the content of magnetic material is discussed by particular examples. The application fields of magnetic polymeric microspheres are briefly surveyed.

Synthesis of magnetic polymeric microspheres

International Nuclear Information System (INIS)

Gervald, A Yu; Gritskova, Inessa A; Prokopov, Nikolai I

2010-01-01

The key types of magnetic polymeric microspheres are considered. Methods of synthesis of different types of magnetic nanoparticles and of preparation of stable magnetic fluids on their basis are outlined. The overview of the methods for the manufacture of magnetic polymeric microspheres is presented. The effect of the synthesis conditions on the characteristics of magnetic polymeric microspheres such as the diameter and the particle size distribution and the content of magnetic material is discussed by particular examples. The application fields of magnetic polymeric microspheres are briefly surveyed.

Ceramic microspheres for cementing applications

NARCIS (Netherlands)

2011-01-01

A method and apparatus for manufacturing ceramic microspheres from industrial slag. The microspheres have a particle size of about 38 microns to about 150 microns. The microspheres are used to create a cement slurry having a density of at least about 11 lbs/g. The resultant cement slurry may then be

Ceramic microspheres for cementing applications

NARCIS (Netherlands)

2010-01-01

A method and apparatus for manufacturing ceramic microspheres from industrial slag. The microspheres have a particle size of about 38 microns to about 150 microns. The microspheres are used to create a cement slurry having a density of at least about 11 lbs/g. The resultant cement slurry may then be

Ceramic microspheres for cementing applications

NARCIS (Netherlands)

2012-01-01

A method and apparatus for manufacturing ceramic microspheres from industrial slag. The microspheres have a particle size of about 38 microns to about 150 microns. The microspheres are used to create a cement slurry having a density of at least about 11 lbs/g. The resultant cement slurry may then be

Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial.

Science.gov (United States)

Gulec, Seza A; Cohen, Steven J; Pennington, Kenneth L; Zuckier, Lionel S; Hauke, Ralph J; Horne, Heather; Wegener, William A; Teoh, Nick; Gold, David V; Sharkey, Robert M; Goldenberg, David M

2011-06-15

Humanized antibody hPAM4 specifically binds a mucin glycoprotein expressed in pancreatic adenocarcinomas. This phase I study evaluated a single dose of (90)Y-clivatuzumab tetraxetan ((90)Y-labeled hPAM4) in patients with advanced pancreatic cancer. Twenty-one patients (4 stage III; 17 stage IV) received (111)In-hPAM4 for imaging and serum sampling before (90)Y-hPAM4. Study procedures evaluated adverse events, safety laboratories, computed tomography (CT) scans, biomarkers, pharmacokinetics, radiation dosimetry, and immunogenicity (HAHA). (111)In-hPAM4 showed normal biodistribution with radiation dose estimates to red marrow and solid organs acceptable for radioimmunotherapy and with tumor targeting in 12 patients. One patient withdrew before (90)Y-hPAM4; otherwise, 20 patients received (90)Y doses of 15 (n = 7), 20 (n = 9), and 25 mCi/m(2) (n = 4). Treatment was well tolerated; the only significant drug-related toxicities were (NCI CTC v.3) grade 3 to 4 neutropenia and thrombocytopenia increasing with (90)Y dose. There were no bleeding events or serious infections, and most cytopenias recovered to grade 1 within 12 weeks. Three patients at 25 mCi/m(2) encountered dose-limiting toxicity with grade 4 cytopenias more than 7 days, establishing 20 mCi/m(2) as the maximal tolerated (90)Y dose. Two patients developed HAHA of uncertain clinical significance. Most patients progressed rapidly and with CA19-9 levels increasing within 1 month of therapy, but 7 remained progression-free by CT for 1.5 to 5.6 months, including 3 achieving transient partial responses (32%-52% tumor diameter shrinkage). (90)Y-Clivatuzumab tetraxetan was well tolerated with manageable hematologic toxicity at the maximal tolerated (90)Y dose, and is a potential new therapeutic for advanced pancreatic cancer. ©2011 AACR.

111In and 90Y labelled peptide radiopharmaceuticals for diagnosis and therapy

International Nuclear Information System (INIS)

Obenaus, E.; Crudo, J.L.; Castiglia, S.G. de

2004-01-01

Full text: The application of 111In-labelled octreotide to target somatostatin receptors on tumour cells has gained acceptance as a diagnostic procedure for demonstrating neuroendocrine and other SSTR-positive tumors. A further advance in the field of somatostatin analogues is the development of macrocyclic chelators that also bind beta particle emitters like 90Y and 177Lu. [90Y-DOTA, Tyr3] octreotide and [177Lu-DOTA, Tyr3] octreotate are currently being tried as the therapeutic agents. The aim of this work was to label two somatostatin analogues (Tyr3 Octreotide and Lanreotide) with 111In and 90Y using DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) as a chelating agent. DOTA in the form of the tri-t-butyl ester was coupled to the Lys5 (BOC) protected Tyr3octreotide and Lys5 (BOC) protected lanreotide in N,N-dimethylformamide, in a three-step reaction involving conjugation, using HATU and diisopropylethylamine as coupling reagents, de-protection with trifluoroacetic and HPLC purification of the conjugates. The DOTALAN and DOTATOC were labelled with 111In and 90Y and assayed by HPLC. In both cases solutions of gentisic acid in sodium acetate 0.4M pH=5.0 and conjugated peptides were added to the 111In or 90Y chloride. The final solution was heated at 90 deg. C for 25 minutes. We tried different amounts of the two peptide complexes per mCi of 111In/90Y and quality control of the labelled products was performed with the following HPLC system: reverse phase column, flow rate 1ml-min, UV/radiometric detection and a gradient solvent: solvent A: acetonitrile, solvent B: water TFA 0.1%, gradient: 0-3min 100% B, linear increase of eluent A to 50% from 3-13 min, 13-18 min 50% A, 18-20 min linear increase of eluent A to 70%. Serum stability was determined after 4 and 24 hr. incubation of the labeled peptide in human serum at 37 deg. C. After precipitation of proteins with acetonitrile the incubation mixture was analyzed by HPLC. Normal Wistar rats were

Assessing Intra-arterial Complications of Planning and Treatment Angiograms for Y-90 Radioembolization

Energy Technology Data Exchange (ETDEWEB)

Ahmed, Osman, E-mail: osman1423@gmail.com [Rush University Medical Center, Section of Interventional Radiology, Department of Radiology (United States); Patel, Mikin V. [University of Chicago, Department of Radiology (United States); Masrani, Abdulrahman; Chong, Bradford; Osman, Mohammed; Tasse, Jordan; Soni, Jayesh; Turba, Ulku Cenk; Arslan, Bulent [Rush University Medical Center, Section of Interventional Radiology, Department of Radiology (United States)

2017-05-15

PurposeTo report hepatic arterial-related complications encountered during planning and treatment angiograms for radioembolization and understand any potential-associated risk factors.Materials and Methods518 mapping or treatment angiograms for 180 patients with primary or metastatic disease to the liver treated by Yttrium-90 radioembolization between 2/2010 and 12/2015 were retrospectively reviewed. Intra-procedural complications were recorded per SIR guidelines. Patient demographics, indication for treatment, prior exposure to chemotherapeutic agents, operator experience, and disease burden were reviewed. Technical variables including type of radioembolic (glass vs. resin microspheres), indication for angiography (mapping vs. treatment), variant anatomy, and attempts at coil embolization were also assessed.ResultsThirteen (13/518, 2.5%) arterial-related complications occurred in 13 patients. All but two complications resulted during transcatheter coil embolization to prevent non-target embolization. Complications included coil migration (n = 6), arterial dissection (n = 2), focal vessel perforation (n = 2), arterial thrombus (n = 2), and vasospasm prohibiting further arterial sub-selection (n = 1). Transarterial coiling was identified as a significant risk factor of complications on both univariate and multivariate regression analysis (odds ratio 7.8, P = 0.004). Usage of resin microspheres was also a significant risk factor (odds ratio 9.5, P = 0.042). No other technical parameters or pre-procedural variables were significant after adjusting for confounding on multivariate analysis (P > 0.05).ConclusionIntra-procedural hepatic arterial complications encountered during radioembolization were infrequent but occurred mainly during coil embolization to prevent non-target delivery to extra-hepatic arteries.

Role of diluent on the separation of {sup 90}Y from {sup 90}Sr by solvent extraction and supported liquid membrane using T2EHDGA as the extractant

Energy Technology Data Exchange (ETDEWEB)

Dutta, S. [Planning and Coordination Division, Bhabha Atomic Research Centre, Trombay, Mumbai - 400 085 (India); Raut, D.R. [Radiochemistry Division, Bhabha Atomic Research Centre, Trombay, Mumbai - 400 085 (India); Mohapatra, P.K., E-mail: mpatra@barc.gov.in [Radiochemistry Division, Bhabha Atomic Research Centre, Trombay, Mumbai - 400 085 (India)

2012-04-15

The separation behaviour of {sup 90}Y from {sup 90}Sr was investigated by diluent variation using solvent extraction and supported liquid membrane techniques employing N,N,N Prime ,N Prime -tetra-2-ethylhexyldiglycolamide (T2EHDGA) as the extractant. Both D{sub Y} (distribution ratio of Y(III)) and S.F. (separation factor) were found to be high in the solvent extraction studies when chloroform was used as the diluent. Subsequent supported liquid membrane (SLM) studies using PTFE flat sheet membranes containing 0.2 M T2EHDGA in various diluents indicated the trend of Y transport as xylene>hexone>chloroform>carbon tetrachloride>n-dodecane+30% iso-decanol mixture. However, the Sr(II) transport rates were also high with xylene, hexone, and carbon tetrachloride as the diluents which led us to carry out subsequent studies using chloroform and n-dodecane+30% iso-decanol mixture. Acid variation studies in chloroform system indicated an interesting phenomena of increasing Y(III) transport and decreasing Sr(II) transport with increasing acid concentration. Separation of {sup 90}Y from a mixture of {sup 90}Sr and {sup 90}Y was also attempted. - Highlights: Black-Right-Pointing-Pointer SLM studies using PTFE flat sheet membranes containing T2EHDGA as carrier was carried out for Y-90 separation from Sr-90. Black-Right-Pointing-Pointer The trend of Y transport as xylene>hexone>chloroform>carbon tetrachloride>n-dodecane+30% iso-decanol mixture. Black-Right-Pointing-Pointer Acid variation studies in chloroform system indicated an interesting phenomena of increasing Y(III) transport and decreasing Sr(II) transport with increasing acid concentration. Black-Right-Pointing-Pointer The present studies suggested that T2EHDGA-SLM show limited promise if coupled to another separation method such as extraction chromatography.

WE-AB-204-02: Molecular-Imaging Based Assessment of Liver Complications for Yttrium-90 Microsphere Treatments: Can Existing NTCP Models Explain Clinical Outcomes?

Energy Technology Data Exchange (ETDEWEB)

Lin, M; Choi, E; Chuong, M; Saboury, B; Moeslein, F; D’Souza, W; Guerrero, M [University of Maryland School of Medicine, Baltimore, MD (United States)

2015-06-15

Purpose: To evaluate weather the current radiobiological models can predict the normal liver complications of radioactive Yttrium-90 ({sup 90}Y) selective-internal-radiation-treatment (SIRT) for metastatic liver lesions based on the post-infusion {sup 90}Y PET images. Methods: A total of 20 patients with metastatic liver tumors treated with SIRT that received a post-infusion {sup 90}Y-PET/CT scan were analyzed in this work. The 3D activity distribution of the PET images was converted into a 3D dose distribution via a kernel convolution process. The physical dose distribution was converted into the equivalent dose (EQ2) delivered at 2 Gy based on the linear-quadratic (LQ) model considering the dose rate effect. The biological endpoint of this work was radiation-induce liver disease (RILD). The NTCPs were calculated with four different repair-times (T1/2-Liver-Repair= 0,0.5,1.0,2.0 hr) and three published NTCP models (Lyman-external-RT, Lyman 90Y-HCC-SIRT, parallel model) were compared to the incidence of RILD of the recruited patients to evaluate their ability of outcome prediction. Results: The mean normal liver physical dose (avg. 51.9 Gy, range 31.9–69.8 Gy) is higher than the suggested liver dose constraint for external beam treatment (∼30 Gy). However, none of the patients in our study developed RILD after the SIRT. The estimated probability of ‘no patient developing RILD’ obtained from the two Lyman models are 46.3% to 48.3% (T1/2-Liver-Repair= 0hr) and <1% for all other repair times. For the parallel model, the estimated probability is 97.3% (0hr), 51.7% (0.5hr), 2.0% (1.0hr) and <1% (2.0hr). Conclusion: Molecular-images providing the distribution of {sup 90}Y enable the dose-volume based dose/outcome analysis for SIRT. Current NTCP models fail to predict RILD complications in our patient population, unless a very short repair-time for the liver is assumed. The discrepancy between the Lyman {sup 90}Y-HCC-SIRT model predicted and the clinically

Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients.

Science.gov (United States)

Carr, Brian I

2004-02-01

Hepatocellular carcinoma (HCC) generally arises in a cirrhotic liver and, in most cases, is multifocal and bilobar. Although trans-hepatic artery chemoembolization (TACE) can be highly affective in shrinking tumors, it is limited by virtue of the damage that it can cause to the liver that is already damaged by chronic disease. A high priority in HCC research, after primary prevention and early detection, is to find new treatment modalities that are both effective and non-toxic to the underlying cirrhotic liver. A cohort of 65 patients with biopsy-proven unresectable HCC have been treated with hepatic arterial 90Yttrium microspheres (Therasphere), and the interim results are reported here. Only 1 cycle of Therasphere treatment ever was performed on 46 patients, 17 patients had 2 cycles, and 2 patients had 3 cycles of therapy. The median dose delivered was 134 Gy, typically as either 5 or 10 GBq (2-4 million microspheres). Clinical toxicities include 9 episodes of abdominal pain and 2 episodes of acute cholecystitis, requiring cholecystectomy. A main lab toxicity was elevated bilirubin which increased by more than 200% in 25 patients (30.5%) during 6 months of therapy, although 18 of these patients had only transient elevation. A prominent finding was prolonged and profound (>70%) lymphopenia in more than 75% of the patients, but without clinical significance. Forty-two patients (64.6%) had a substantial decrease in tumor vascularity in response to therapy, and 25 patients (38.4%) had a partial response, by computed tomography scan. Median survival for Okuda stage I patients (n=42) was 649 days (historical comparison 244) and for Okuda stage II patients (n=23) was 302 days (historical comparison 64 days). All patients were followed after therapy for a minimum of 6 months. There were 42 deaths, 21 due to liver failure, 6 from HCC progression, and 3 from metastases. Therasphere appears to be a relatively safe and effective therapy for advanced-stage unresectable HCC.

Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

International Nuclear Information System (INIS)

Wiseman, G.A.; Dunn, W.L.; White, C.A.; Berlfein, J.R.; Ding, E.; Grillo-Lopez, A.J.; Stabin, M.; Erwin, W.; Spies, S.; Dahlbom, M.; Silverman, D.H.S.; Raubitschek, A.; Karvelis, K.; Schultheiss, T.; Witzig, T.E.; Belanger, R.

2000-01-01

Dosimetry studies in patients with non-Hodgkin's lymphoma were performed to estimate the radiation absorbed dose to normal organs and bone marrow from 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) treatment in this phase I/II, multicenter trial. The trial was designed to determine the dose of Rituximab (chimeric anti-CD20, Rituxan, IDEC-C2B8, MabThera), the unlabeled antibody given prior to the radioconjugate to clear peripheral blood B cells and optimize distribution, and to determine the maximum tolerated dose of 90 Y-Zevalin [7.4, 11, or 15 MBq/kg (0.2, 0.3, or 0.4 mCi/kg)]. Patients received 111 In-Zevalin (indium-111 ibritumomab tiuxetan, IDEC-In2B8) on day 0 followed by a therapeutic dose of 90 Y-Zevalin on day 7. Both doses were preceded by an infusion of the chimeric, unlabeled antibody Rituximab. Following administration of 111 In-Zevalin, serial anterior/posterior whole-body scans were acquired. Major-organ radioactivity versus time estimates were calculated using regions of interest. Residence times were computed and entered into the MIRDOSE3 computer software program to calculate estimated radiation absorbed dose to each organ. Initial analyses of estimated radiation absorbed dose were completed at the clinical site. An additional, centralized dosimetry analysis was performed subsequently to provide a consistent analysis of data collected from the seven clinical sites. In all patients with dosimetry data (n=56), normal organ and red marrow radiation absorbed doses were estimated to be well under the protocol-defined upper limit of 20 Gy and 3 Gy, respectively. Median estimated radiation absorbed dose was 3.4 Gy to liver (range 1.2-7.8 Gy), 2.6 Gy to lungs (range 0.72-4.4 Gy), and 0.38 Gy to kidneys (range 0.07-0.61 Gy). Median estimated tumor radiation absorbed dose was 17 Gy (range 5.8-67 Gy). No correlation was noted between hematologic toxicity and the following variables: red marrow radiation absorbed dose, blood T 1/2 , blood AUC

Toxicity of 90Y in a relatively insoluble form inhaled by Beagle dogs. XIV

International Nuclear Information System (INIS)

Hahn, F.F.; Hobbs, C.H.; Kusewitt, D.F.; McClellan, R.O.; Mauderly, J.L.; Pickrell, J.A.

1982-01-01

The metabolism, dosimetry and biological effects of inhaled 90 Y in fused aluminosilicate particles in Beagle dogs are being studied. Eighty-nine dogs with initial lung burdens ranging from 80 to 5200 μCi 90 Y/kg body weight and 12 control dogs are being maintained for life span observations. The lung burdens achieved, short physical half-life and relative insolubility of the 90 Y in this vector resulted in a relatively high, rapidly decreasing radiation dose rate to the lung. To date, 69 exposed dogs have died; 38 from radiation pneumonitis, seven with pulmonary neoplasms and 24 from other causes. Four control dogs have died. Twenty-nine surviving exposed and eight control dogs are being studied for their life spans

90Sr- 90Y and 89Sr beta radioactivity measurement in milk samples using a proportional counter

International Nuclear Information System (INIS)

Mananes, A.; Perez Santos, C.; Martinez Churiaque, F.

1987-01-01

A thin window glas flow proportional counter is used to measure the 90 Sr- 90 Y and 89 Sr beta radioactivity in milk samples. A chemical procedure is used to separate strontium-yttrium from the other radionuclides present in milk. A calculation of the total efficiency of the system is performed which includes an empirical estimation of the backscattering factor. The calibration of the whole process allows the determination of the 90 Sr activity within 10% relative error in spite of uncertainties in the recovery yields of strontium and yttrium. No 89 Sr activity has been detected, and the mean value obtained for the 90 Sr activity in nine milk samples of Cantabria is 0.115 Bq/1 with a minimum detectable activity of 0.0105 Bq. (author) 18 refs

Labeling an anti-CD20 monoclonal antibody with 90Y

International Nuclear Information System (INIS)

Perera Pintado, Alejandro; Leyva Montaña, René; Prats Capote, Anaís; Góngora Bravo, Magdiel; Alberti Ramírez, Alejandro; León, Mariela; Hernández González, Ignacio; Dorvignit, Denise

2016-01-01

Lymphomas are among the 10 leading causes of death, both in Cuba and in the world, with an increasing incidence in recent years. Follicular lymphoma low-grade (indolent) is one of the most common in the Western world, representing 1/3 of all non-Hodgkin lymphomas (NHL). More than 90% of patients present with disseminated disease at diagnosis and generally have a slow evolution and good response to conventional treatment; but radically changed its forecast to relapse, resistance to therapeutic and histologic transformation can occur. The monoclonal antibody therapy has been a promising therapeutic. In this respect CD20 antigen it has been considered one of the most attractive targets in the therapy of follicular B cell lymphoma This is expressed in more than 90% of cases, while not present in stem cells and lines progenitors. Despite the success of immunotherapy, the relapse rate is still considerable. In order to increase the cytotoxic potential of immunotherapy, marked with beta emitting radionuclides alpha particles or monoclonal antibodies are used today. Despite encouraging results in patients with non-Hodgkin lymphomas refractory to other treatments, the extremely high costs of these commercial radiopharmaceuticals have greatly limited its application, even in the first world. A sustainable alternative is the marking of other anti-CD20 monoclonal antibodies, so researchers from several countries have concentrated their efforts on rituximaby other similar antibodies labeled with therapeutic radionuclides, as a possible cost-effectively to more problem. Today in Cuba it has an electrolytic generator 90 Sr- 90 Y Isotope Center, which ensures the availability of the radionuclide. In addition, the chimeric MAb rituximab is applied as part of the therapy of NHL in its health system and, recently, the Center for Molecular Immunology has obtained a chimeric monoclonal anti-CD20 antibody biosimilar rituximab, which is in phase clinical trial; which opens prospects for

Extraction and encapsulation of prodigiosin in chitosan microspheres for targeted drug delivery

Energy Technology Data Exchange (ETDEWEB)

Dozie-Nwachukwu, S.O. [Department of Materials Science and Engineering, African University of Science and Technology (AUST) Abuja, Federal Capital Territory (Nigeria); Biotechnology and Genetic Engineering Advanced Laboratory, Sheda Science and Technology Complex (SHESTCO), P.M.B 186, Garki, Abuja, Federal Capital Territory (Nigeria); Danyuo, Y. [Department of Materials Science and Engineering, African University of Science and Technology (AUST) Abuja, Federal Capital Territory (Nigeria); Department of Materials Science and Engineering, Kwara State University, Malete (Nigeria); Obayemi, J.D. [Department of Materials Science and Engineering, African University of Science and Technology (AUST) Abuja, Federal Capital Territory (Nigeria); Department of Mechanical and Aerospace Engineering, Princeton University, Princeton, NJ 08544 (United States); Odusanya, O.S. [Department of Materials Science and Engineering, African University of Science and Technology (AUST) Abuja, Federal Capital Territory (Nigeria); Biotechnology and Genetic Engineering Advanced Laboratory, Sheda Science and Technology Complex (SHESTCO), P.M.B 186, Garki, Abuja, Federal Capital Territory (Nigeria); Malatesta, K. [Department of Mechanical and Aerospace Engineering, Princeton University, Princeton, NJ 08544 (United States); Soboyejo, W.O., E-mail: soboyejo@princeton.edu [Department of Materials Science and Engineering, African University of Science and Technology (AUST) Abuja, Federal Capital Territory (Nigeria); Department of Mechanical and Aerospace Engineering, Princeton University, Princeton, NJ 08544 (United States); Princeton Institute of Science and Technology of Materials (PRISM), Bowen Hall, 70 Prospect Street, Princeton, NJ 08544 (United States)

2017-02-01

The encapsulation of drugs in polymeric materials has brought opportunities to the targeted delivery of chemotherapeutic agents. These polymeric delivery systems are capable of maximizing the therapeutic activity, as well as reducing the side effects of anti-cancer agents. Prodigiosin, a secondary metabolite extracted from the bacteria, Serratia marcescens, exhibits anti-cancer properties. Prodigiosin-loaded chitosan microspheres were prepared via water-in-oil (w/o) emulsion technique, using glutaraldehyde as a cross-linker. The morphologies of the microspheres were studied using scanning electron microscopy. The average sizes of the microspheres were between 40 μm and 60 μm, while the percentage yields ranged from 42 ± 2% to 55.5 ± 3%. The resulting encapsulation efficiencies were between 66.7 ± 3% and 90 ± 4%. The in-vitro drug release from the microspheres was characterized by zeroth order, first order and Higuchi and Korsmeyer-Peppas models. - Highlights: • Prodigiosin of ~ 92.8% purity was extracted from locally isolated Serratia marcescens. • This approach reduces the cost and ensure availability of drugs for cancer treatment. • High encapsulation efficiency which increased with increasing drug:polymer ratio • The percentage yield was generally poor due to the recovery process. • Prodigiosin greatly reduced the viability of the breast cancer cell line (MDA-MB-231).

Extraction and encapsulation of prodigiosin in chitosan microspheres for targeted drug delivery

International Nuclear Information System (INIS)

Dozie-Nwachukwu, S.O.; Danyuo, Y.; Obayemi, J.D.; Odusanya, O.S.; Malatesta, K.; Soboyejo, W.O.

2017-01-01

The encapsulation of drugs in polymeric materials has brought opportunities to the targeted delivery of chemotherapeutic agents. These polymeric delivery systems are capable of maximizing the therapeutic activity, as well as reducing the side effects of anti-cancer agents. Prodigiosin, a secondary metabolite extracted from the bacteria, Serratia marcescens, exhibits anti-cancer properties. Prodigiosin-loaded chitosan microspheres were prepared via water-in-oil (w/o) emulsion technique, using glutaraldehyde as a cross-linker. The morphologies of the microspheres were studied using scanning electron microscopy. The average sizes of the microspheres were between 40 μm and 60 μm, while the percentage yields ranged from 42 ± 2% to 55.5 ± 3%. The resulting encapsulation efficiencies were between 66.7 ± 3% and 90 ± 4%. The in-vitro drug release from the microspheres was characterized by zeroth order, first order and Higuchi and Korsmeyer-Peppas models. - Highlights: • Prodigiosin of ~ 92.8% purity was extracted from locally isolated Serratia marcescens. • This approach reduces the cost and ensure availability of drugs for cancer treatment. • High encapsulation efficiency which increased with increasing drug:polymer ratio • The percentage yield was generally poor due to the recovery process. • Prodigiosin greatly reduced the viability of the breast cancer cell line (MDA-MB-231).

Country report: Cuba. Local Production of 90Y And 188Re Radionuclides and Development of Radiopharmaceuticals for Therapy

International Nuclear Information System (INIS)

Xiques, Abmel; Hernández, Ignacio; Leyva, René; Pérez, Marylaine; Alonso, Luis Michel; Zamora, Minelys

2010-01-01

During the first period of this CRP we could test an efficient and reliable generator system based on ion-chromatography to obtain 90 Y from its parent radionuclide 90 Sr. This production scheme for 90 Y was outlined in the previous CRP related with the development of generator technologies. Quality parameters such as trace metals that can potentially interfere in the labeling of biomoléculas, 90 Y recovery, 90 Sr/ 90 Y ratio and radiation dose to bed matrix were evaluated. The results showed that high recovery and radionuclidic purity could be obtained for 90 Y during its repeated separation from the 90 Sr cow. No replacement or treatment of the cow were necessary and low waste generation and 90 Sr losses less that 0.1% after each run were also observed during the present study. A Fab’ fragment was enzimatically produced and purified from the monoclonal antibody h-R3 (Nimotuzumab®). The fragment and the parent antibody were successfully conjugated with DOTA and labeled with 90 Y. The radioinmunoconjugate thus obtained also exhibited a good 24 h in-vitro stability in an excess of DTPA. A 90 Y radiocoloid was prepared in a cromic phosphate particle for radiosynoviorthesis with promising results in animal models. Two alumina based 188 W/ 188 Re generators were prepared and their eluates were used in the labeling of hR3-DOTA conjugates. Quality control and in vivo evaluation in comparison with 99m Tc-hR3 showed very good results and similar pattern of distribution and pharmacokinetic and will be used in clinical trials for cancer patients. (author)

PLGA/alginate composite microspheres for hydrophilic protein delivery

International Nuclear Information System (INIS)

Zhai, Peng; Chen, X.B.; Schreyer, David J.

2015-01-01

Poly(lactic-co-glycolic acid) (PLGA) microspheres and PLGA/alginate composite microspheres were prepared by a novel double emulsion and solvent evaporation technique and loaded with bovine serum albumin (BSA) or rabbit anti-laminin antibody protein. The addition of alginate and the use of a surfactant during microsphere preparation increased the encapsulation efficiency and reduced the initial burst release of hydrophilic BSA. Confocal laser scanning microcopy (CLSM) of BSA-loaded PLGA/alginate composite microspheres showed that PLGA, alginate, and BSA were distributed throughout the depths of microspheres; no core/shell structure was observed. Scanning electron microscopy revealed that PLGA microspheres erode and degrade more quickly than PLGA/alginate composite microspheres. When loaded with anti-laminin antibody, the function of released antibody was well preserved in both PLGA and PLGA/alginate composite microspheres. The biocompatibility of PLGA and PLGA/alginate microspheres were examined using four types of cultured cell lines, representing different tissue types. Cell survival was variably affected by the inclusion of alginate in composite microspheres, possibly due to the sensitivity of different cell types to excess calcium that may be released from the calcium cross-linked alginate. - Highlights: • A double emulsion technique is used to prepare protein-loaded PLGA or PLGA/alginate microspheres. • PLGA, alginate and protein are distributed evenly within microsphere structure. • Addition of alginate improves loading efficiency and slows degradation and protein release. • PLGA/alginate microspheres have favorable biocompatibility

PLGA/alginate composite microspheres for hydrophilic protein delivery

Energy Technology Data Exchange (ETDEWEB)

Zhai, Peng [Department of Anatomy and Cell Biology, University of Saskatchewan, S7N5E5 (Canada); Division of Biomedical Engineering, University of Saskatchewan, S7N5A9 (Canada); Chen, X.B. [Department of Mechanical Engineering, University of Saskatchewan, S7N5A9 (Canada); Division of Biomedical Engineering, University of Saskatchewan, S7N5A9 (Canada); Schreyer, David J., E-mail: david.schreyer@usask.ca [Department of Anatomy and Cell Biology, University of Saskatchewan, S7N5E5 (Canada); Division of Biomedical Engineering, University of Saskatchewan, S7N5A9 (Canada)

2015-11-01

Poly(lactic-co-glycolic acid) (PLGA) microspheres and PLGA/alginate composite microspheres were prepared by a novel double emulsion and solvent evaporation technique and loaded with bovine serum albumin (BSA) or rabbit anti-laminin antibody protein. The addition of alginate and the use of a surfactant during microsphere preparation increased the encapsulation efficiency and reduced the initial burst release of hydrophilic BSA. Confocal laser scanning microcopy (CLSM) of BSA-loaded PLGA/alginate composite microspheres showed that PLGA, alginate, and BSA were distributed throughout the depths of microspheres; no core/shell structure was observed. Scanning electron microscopy revealed that PLGA microspheres erode and degrade more quickly than PLGA/alginate composite microspheres. When loaded with anti-laminin antibody, the function of released antibody was well preserved in both PLGA and PLGA/alginate composite microspheres. The biocompatibility of PLGA and PLGA/alginate microspheres were examined using four types of cultured cell lines, representing different tissue types. Cell survival was variably affected by the inclusion of alginate in composite microspheres, possibly due to the sensitivity of different cell types to excess calcium that may be released from the calcium cross-linked alginate. - Highlights: • A double emulsion technique is used to prepare protein-loaded PLGA or PLGA/alginate microspheres. • PLGA, alginate and protein are distributed evenly within microsphere structure. • Addition of alginate improves loading efficiency and slows degradation and protein release. • PLGA/alginate microspheres have favorable biocompatibility.

Total Lesion Glycolysis and Sequential (90)Y-Selective Internal Radiation Therapy in Breast Cancer Liver Metastases: Preliminary Results.

Science.gov (United States)

Bagni, Oreste; Filippi, Luca; Pelle, Giuseppe; Cianni, Roberto; Schillaci, Orazio

2015-12-01

To assess the prognostic role of total lesion glycolysis (TLG) in patients with breast cancer liver metastases (BCLM) after sequential lobar (90)Y-radioembolization ((90)Y-RE). Seventeen patients with bilobar BCLM underwent FDG PET/CT and TLG calculation before (90)Y-RE. The hepatic lobe with the highest TLG was treated in the first session. PET was performed 6 weeks postprocedure and decrease in TLG (ΔTLG) in the treated lobe was calculated before the second (90)Y administration. Subjects were divided in two groups (group 1: ΔTLG >50%, group 2: ΔTLG 50% and seven had a ΔTLG value 50% and ΔTLG <50% had a mean OS of 16.4 ± 0.6 and 10.3 ± 0.4 months, respectively (p < 0.001). Cox regression analysis demonstrated hepatic tumor load (p = 0.048) and ΔTLG as the only significant (p = 0.005) predictors of survival. ΔTLG after the first (90)Y administration agrees with final outcome in BCLM patients after separate sequential lobar (90)Y-RE.

The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-dPhe1,Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours

International Nuclear Information System (INIS)

Stolz, B.; Weckbecker, G.; Smith-Jones, P.M.; Albert, R.; Raulf, F.; Bruns, C.

1998-01-01

Somatostatin receptor-expressing tumours are potential targets for therapy with radiolabelled somatostatin analogues. We have synthesized a number of such analogues in the past and identified [DOTA-dPhe 1 , Tyr 3 ]octreotide (SMT 487) as the most promising candidate molecule because of its advantageous properties in cellular and in vivo tumour models. In the current paper we describe the radiotherapeutic effect of yttrium-90 labelled SMT 487 in Lewis rats bearing the somatostatin receptor-positive rat pancreatic tumour CA 20948. SMT 487 binds with nanomolar affinity to both the human and the rat somatostatin receptor subtype 2 (sst 2 ) (human sst 2 IC 50 =0.9 nM, rat sst 2 IC 50 =0.5 nM). In vivo, 90 Y-SMT 487 distributed rapidly to the sst 2 expressing CA 20948 rat pancreatic tumour, with a tumour-to-blood ratio of 49.15 at 24 h post injection. A single intravenous administration of 10 mCi/kg 90 Y-SMT 487 resulted in a complete remission of the tumours in five out of seven CA 20948 tumour-bearing Lewis rats. No regrowth of the tumours occurred 8 months post injection. Control animals that were treated with 30 μg/kg of unlabelled SMT 487 had to be sacrificed 10 days post injection due to excessive growth or necrotic areas on the tumour surface. Upon re-inoculation of tumour cells into those rats that had shown complete remission, the tumours disappeared after 3-4 weeks of moderate growth without any further treatment. The present study shows for the first time the curative potential of 90 Y-SMT 487-based radiotherapy for somatostatin receptor-expressing tumours. Clinical phase I studies with yttrium-labelled SMT 487 have started in September 1997. (orig.)

Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours

International Nuclear Information System (INIS)

Romer, A.; Seiler, D.; Brunner, P.; Ng, Q.K.T.; Mueller-Brand, J.; Marincek, N.; Walter, M.A.; Koller, M.T.; Maecke, H.R.; Rochlitz, C.; Briel, M.; Schindler, C.

2014-01-01

Somatostatin-based radiopeptide treatment is generally performed using the β-emitting radionuclides 90 Y or 177 Lu. The present study aimed at comparing benefits and harms of both therapeutic approaches. In a comparative cohort study, patients with advanced neuroendocrine tumours underwent repeated cycles of [ 90 Y-DOTA]-TOC or [ 177 Lu-DOTA]-TOC until progression of disease or permanent adverse events. Multivariable Cox regression and competing risks regression were employed to examine predictors of survival and adverse events for both treatment groups. Overall, 910 patients underwent 1,804 cycles of [ 90 Y-DOTA]-TOC and 141 patients underwent 259 cycles of [ 177 Lu-DOTA]-TOC. The median survival after [ 177 Lu-DOTA]-TOC and after [ 90 Y-DOTA]-TOC was comparable (45.5 months versus 35.9 months, hazard ratio 0.91, 95 % confidence interval 0.63-1.30, p = 0.49). Subgroup analyses revealed a significantly longer survival for [ 177 Lu-DOTA]-TOC over [ 90 Y-DOTA]-TOC in patients with low tumour uptake, solitary lesions and extra-hepatic lesions. The rate of severe transient haematotoxicities was lower after [ 177 Lu-DOTA]-TOC treatment (1.4 vs 10.1 %, p = 0.001), while the rate of severe permanent renal toxicities was similar in both treatment groups (9.2 vs 7.8 %, p = 0.32). The present results revealed no difference in median overall survival after [ 177 Lu-DOTA]-TOC and [ 90 Y-DOTA]-TOC. Furthermore, [ 177 Lu-DOTA]-TOC was less haematotoxic than [ 90 Y-DOTA]-TOC. (orig.)

Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours.

Science.gov (United States)

Romer, A; Seiler, D; Marincek, N; Brunner, P; Koller, M T; Ng, Q K T; Maecke, H R; Müller-Brand, J; Rochlitz, C; Briel, M; Schindler, C; Walter, M A

2014-02-01

Somatostatin-based radiopeptide treatment is generally performed using the β-emitting radionuclides (90)Y or (177)Lu. The present study aimed at comparing benefits and harms of both therapeutic approaches. In a comparative cohort study, patients with advanced neuroendocrine tumours underwent repeated cycles of [(90)Y-DOTA]-TOC or [(177)Lu-DOTA]-TOC until progression of disease or permanent adverse events. Multivariable Cox regression and competing risks regression were employed to examine predictors of survival and adverse events for both treatment groups. Overall, 910 patients underwent 1,804 cycles of [(90)Y-DOTA]-TOC and 141 patients underwent 259 cycles of [(177)Lu-DOTA]-TOC. The median survival after [(177)Lu-DOTA]-TOC and after [(90)Y-DOTA]-TOC was comparable (45.5 months versus 35.9 months, hazard ratio 0.91, 95% confidence interval 0.63-1.30, p = 0.49). Subgroup analyses revealed a significantly longer survival for [(177)Lu-DOTA]-TOC over [(90)Y-DOTA]-TOC in patients with low tumour uptake, solitary lesions and extra-hepatic lesions. The rate of severe transient haematotoxicities was lower after [(177)Lu-DOTA]-TOC treatment (1.4 vs 10.1%, p = 0.001), while the rate of severe permanent renal toxicities was similar in both treatment groups (9.2 vs 7.8%, p = 0.32). The present results revealed no difference in median overall survival after [(177)Lu-DOTA]-TOC and [(90)Y-DOTA]-TOC. Furthermore, [(177)Lu-DOTA]-TOC was less haematotoxic than [(90)Y-DOTA]-TOC.

Hydrogen transport and storage in engineered glass microspheres

Energy Technology Data Exchange (ETDEWEB)

Rambach, G.D.

1994-04-20

New, high-strength, hollow, glass microspheres filled with pressurized hydrogen exhibit storage densities which make them attractive for bulk hydrogen storage and transport. The hoop stress at failure of our engineered glass microspheres is about 150,000 psi, permitting a three-fold increase in pressure limit and storage capacity above commercial microspheres, which fail at wall stresses of 50,000 psi. For this project, microsphere material and structure will be optimized for storage capacity and charge/discharge kinetics to improve their commercial practicality. Microsphere production scale up will be performed, directed towards large-scale commercial use. Our analysis relating glass microspheres for hydrogen transport with infrastructure and economics` indicate that pressurized microspheres can be economically competitive with other forms of bulk rail and truck transport such as hydride beds, cryocarbons and pressurized tube transports. For microspheres made from advanced materials and processes, analysis will also be performed to identify the appropriate applications of the microspheres considering property variables, and different hydrogen infrastructure, end use, production and market scenarios. This report presents some of the recent modelling results for large beds of glass microspheres in hydrogen storage applications. It includes plans for experiments to identify the properties relevant to large-bed hydrogen transport and storage applications, of the best, currently producible, glass microspheres. This work began in March, 1994. Project successes will be manifest in the matching of cur-rent glass microspheres with a useful application in hydrogen bulk transport and storage, and in developing microsphere materials and processes that increase the storage density and reduce the storage energy requirement.

Temperature influence in crystallinity of polymer microspheres

International Nuclear Information System (INIS)

Rezende, Cristiane de P.; Novack, Katia M.

2011-01-01

Drug delivery technology is evolving through the creation of new techniques of drug delivery effectively. The new methods used in drugs administration are based in microencapsulation process. Microsphere encapsulation modifies drug delivery bringing benefits and efficiency. In this work has been evaluated the influence of temperature in microspheres preparation. Microspheres were obtained by PMMA-co-PEG (COP) copolymer with indomethacin inserted in polymer matrix. Samples were characterized by SEM, DSC and XRD. SEM micrographs confirmed the formation of different sizes of microspheres and it was verified that higher temperatures make more crystalline microspheres. (author)

Hierarchical Mn2O3 Microspheres In-Situ Coated with Carbon for Supercapacitors with Highly Enhanced Performances

Science.gov (United States)

Gong, Feilong; Lu, Shuang; Peng, Lifang; Zhou, Jing; Kong, Jinming; Jia, Dianzeng; Li, Feng

2017-01-01

Porous Mn2O3 microspheres have been synthesized and in-situ coated with amorphous carbon to form hierarchical C@Mn2O3 microspheres by first producing MnCO3 microspheres in solvothermal reactions, and then annealing at 500 °C. The self-assembly growth of MnCO3 microspheres can generate hollow structures inside each of the particles, which can act as micro-reservoirs to store biomass-glycerol for generating amorphous carbon onto the surfaces of Mn2O3 nanorods consisting of microspheres. The C@Mn2O3 microspheres, prepared at 500 °C, exhibit highly enhanced pseudocapacitive performances when compared to the particles after annealed at 400 °C and 600 °C. Specifically, the C@Mn2O3 microspheres prepared at 500 °C show high specific capacitances of 383.87 F g−1 at current density of 0.5 A g−1, and excellent cycling stability of 90.47% of its initial value after cycling for 5000 times. The asymmetric supercapacitors assembled with C@Mn2O3 microspheres after annealed at 500 °C and activated carbon (AC) show an energy density of up to 77.8 Wh kg−1 at power density of 500.00 W kg−1, and a maximum power density of 20.14 kW kg−1 at energy density of 46.8 Wh kg−1. We can attribute the enhanced electrochemical performances of the materials to their three-dimensional (3D) hierarchical structure in-situ coated with carbon. PMID:29168756

Hierarchical Mn2O3 Microspheres In-Situ Coated with Carbon for Supercapacitors with Highly Enhanced Performances

Directory of Open Access Journals (Sweden)

Feilong Gong

2017-11-01

Full Text Available Porous Mn2O3 microspheres have been synthesized and in-situ coated with amorphous carbon to form hierarchical C@Mn2O3 microspheres by first producing MnCO3 microspheres in solvothermal reactions, and then annealing at 500 °C. The self-assembly growth of MnCO3 microspheres can generate hollow structures inside each of the particles, which can act as micro-reservoirs to store biomass-glycerol for generating amorphous carbon onto the surfaces of Mn2O3 nanorods consisting of microspheres. The C@Mn2O3 microspheres, prepared at 500 °C, exhibit highly enhanced pseudocapacitive performances when compared to the particles after annealed at 400 °C and 600 °C. Specifically, the C@Mn2O3 microspheres prepared at 500 °C show high specific capacitances of 383.87 F g−1 at current density of 0.5 A g−1, and excellent cycling stability of 90.47% of its initial value after cycling for 5000 times. The asymmetric supercapacitors assembled with C@Mn2O3 microspheres after annealed at 500 °C and activated carbon (AC show an energy density of up to 77.8 Wh kg−1 at power density of 500.00 W kg−1, and a maximum power density of 20.14 kW kg−1 at energy density of 46.8 Wh kg−1. We can attribute the enhanced electrochemical performances of the materials to their three-dimensional (3D hierarchical structure in-situ coated with carbon.

Increasing sensitivity and angle-of-view of mid-wave infrared detectors by integration with dielectric microspheres

Energy Technology Data Exchange (ETDEWEB)

Allen, Kenneth W., E-mail: kenneth.allen@gtri.gatech.edu; Astratov, Vasily N., E-mail: astratov@uncc.edu [Department of Physics and Optical Science, Center for Optoelectronics and Optical Communications, University of North Carolina at Charlotte, Charlotte, North Carolina 28223-0001 (United States); Air Force Research Laboratory, Sensors Directorate, Wright Patterson AFB, Ohio 45433 (United States); UES, Dayton, Ohio 45433 (United States); Abolmaali, Farzaneh [Department of Physics and Optical Science, Center for Optoelectronics and Optical Communications, University of North Carolina at Charlotte, Charlotte, North Carolina 28223-0001 (United States); Duran, Joshua M.; Ariyawansa, Gamini; Limberopoulos, Nicholaos I. [Air Force Research Laboratory, Sensors Directorate, Wright Patterson AFB, Ohio 45433 (United States); Urbas, Augustine M. [Air Force Research Laboratory, Materials and Manufacturing Directorate, Wright-Patterson AFB, Ohio 45433 (United States)

2016-06-13

We observed up to 100 times enhancement of sensitivity of mid-wave infrared photodetectors in the 2–5 μm range by using photonic jets produced by sapphire, polystyrene, and soda-lime glass microspheres with diameters in the 90–300 μm range. By finite-difference time-domain (FDTD) method for modeling, we gain insight into the role of the microspheres refractive index, size, and alignment with respect to the detector mesa. A combination of enhanced sensitivity with angle-of-view (AOV) up to 20° is demonstrated for individual photodetectors. It is proposed that integration with microspheres can be scaled up for large focal plane arrays, which should provide maximal light collection efficiencies with wide AOVs, a combination of properties highly attractive for imaging applications.

90Y/90 Sr electron induced damages in an essential eucalyptus oil related to the absorbed dose

International Nuclear Information System (INIS)

Heredia Cardona, J.A.; Diaz Rizo, O.; Martinez Luzardo, F.; Quert, R.

2007-01-01

A good irradiation geometry was achieved in order to carry out the irradiation of an essential eucalyptus oil with a 90 Y/ 90 Sr electron source. The Monte Carlo simulation code MCNP-4C was employed to determine the absorbed doses in this particular experimental configuration. It also helped us to understand which electrons (from an energetic point of view) were responsible for the damages. In order to identify the induced damages, the irradiated samples were studied by mass spectrometry. The obtained results were related to the absorbed doses determined by the computational simulation

Absorbed doses to the main parts of eyeball due to use 90Sr + 90Y ophthalmic applicator

International Nuclear Information System (INIS)

Chen Lishu

1993-05-01

The ophthalmic radiotherapy dosimetry and some affecting factors are introduced. The distributions of absorbed doses to the main parts of a fresh eyeball such as the cornea, sclera, lens and anterior chamber, during the radiotherapy by using a 90 Sr + 90 Y ophthalmic applicator are presented. An tissue-equivalent extrapolation ionization chamber was used in the dose measurement. The reasonable doses during ophthalmic radiotherapy for different depths have been obtained. Therefore, the absorbed dose to the lens, the most sensitive organ, can be given. These data are useful for radiation protection in ophthalmic radiotherapy

Large-scale purification of 90Sr from nuclear waste materials for production of 90Y, a therapeutic medical radioisotope.

Science.gov (United States)

Wester, Dennis W; Steele, Richard T; Rinehart, Donald E; DesChane, Jaquetta R; Carson, Katharine J; Rapko, Brian M; Tenforde, Thomas S

2003-07-01

A major limitation on the supply of the short-lived medical isotope 90Y (t1/2 = 64 h) is the available quantity of highly purified 90Sr generator material. A radiochemical production campaign was therefore undertaken to purify 1,500 Ci of 90Sr that had been isolated from fission waste materials. A series of alkaline precipitation steps removed all detectable traces of 137Cs, alpha emitters, and uranium and transuranic elements. Technical obstacles such as the buildup of gas pressure generated upon mixing large quantities of acid with solid 90Sr carbonate were overcome through safety features incorporated into the custom-built equipment used for 90Sr purification. Methods are described for analyzing the chemical and radiochemical purity of the final product and for accurately determining by gravimetry the quantities of 90Sr immobilized on stainless steel filters for future use.

Large-scale purification of 90Sr from nuclear waste materials for production of 90Y, a therapeutic medical radioisotope

International Nuclear Information System (INIS)

Wester, D.W.; Steele, R.T.; Rinehart, D.E.; DesChane, J.R.; Carson, K.J.; Rapko, B.M.; Tenforde, T.S.

2003-01-01

A major limitation on the supply of the short-lived medical isotope 90 Y (t 1/2 =64 h) is the available quantity of highly purified 90 Sr generator material. A radiochemical production campaign was therefore undertaken to purify 1500 Ci of 90 Sr that had been isolated from fission waste materials. A series of alkaline precipitation steps removed all detectable traces of 137 Cs, alpha emitters, and uranium and transuranic elements. Technical obstacles such as the buildup of gas pressure generated upon mixing large quantities of acid with solid 90 Sr carbonate were overcome through safety features incorporated into the custom-built equipment used for 90 Sr purification. Methods are described for analyzing the chemical and radiochemical purity of the final product and for accurately determining by gravimetry the quantities of 90 Sr immobilized on stainless steel filters for future use

Investigation of pharmaceuticals and medical devices containing 90Y extracted from high radioactive liquid waste in spent-fuel reprocessing

International Nuclear Information System (INIS)

Hosoma, Takashi

2012-07-01

Pharmaceuticals and medical devices containing radioactive 90 Y are realized, approved and placed on the international market where three products are available in Europe and the United States, and one product in Japan. These products are used not for diagnosis but for treatment by internal irradiation. It was estimated from the deliberative report of the approval in Japan that 90 Y was extracted in Europe from high radioactive liquid waste (HALW) yielded in spent-fuel reprocessing. In this report, products placed on the market and physical properties were reviewed, reasons of the realization and conditions to realize succeeding products were estimated, extraction method was compared with other methods, technical subjects, and relevant regulations were investigated. Although a medical device containing radioactive 90 Y has been studied in Japan and one pharmaceutical product was approved, a breakthrough would be necessary to put 90 Y utilization beyond alternative treatments. The breakthrough would become be promising; for example, if conventional treatments could be supported by technical development to deliver 90 Y more sharply to the target with shorter serum half-life. Extraction of 90 Y nuclide from HALW has advantages over thermal neutron irradiation of natural nuclide, a system is envisioned where 90 Sr as a parent nuclide is separated in the reprocessing then transported to and stored in a factory of radiopharmaceuticals followed by 90 Y extraction on demand. (author)

A novel route for synthesis and growth formation of metal oxides microspheres: Insights from V_2O_3 microspheres

International Nuclear Information System (INIS)

Zhang, Yifu; Huang, Chi; Meng, Changgong; Hu, Tao

2016-01-01

Highly polydisperse V_2O_3 solid microspheres with large specific surface area were successfully synthesized via a facile hydrothermal decomposition of VOC_2O_4 solution. The morphology and composition were characterized by scanning electron microscopy (SEM), Energy dispersive spectrometer (EDS), X-ray photoelectron spectroscopy (XPS) and X-ray diffraction (XRD). V_2O_3 microspheres display an obvious Mott phase transition at −128.5 °C (cooling curve) and −114.5 °C (heating curve). Some parameters including the reaction temperature, concentration of VOC_2O_4, reaction time, surfactant, H_2C_2O_4 and precursor were briefly discussed to reveal the formation of V_2O_3 microspheres. It was found that the precursor is crucial for the fabrication of microsphere. A self-assembly growth mechanism was suggested to explain the growth process of microspheres and the autogenic CO and CO_2 gas served as the soft templates. Furthermore, this route was developed to synthesize different metal oxides microspheres, and it was found that AlO(OH), Fe_3O_4, Fe_2O_3, Co_3O_4, Cr_2O_3, MoO_2 and WO_3 microspheres were obtained. All the results showed this process was successfully explored as a methodology to synthesize different metal oxides microspheres using the gas as the templates by this facile hydrothermal route. - Highlights: • Highly uniform V_2O_3 solid microspheres were synthesized. • V_2O_3 microspheres display an obvious Mott phase transition. • The autogenic CO and CO_2 gas served as the soft templates for designed synthesis. • AlO(OH), Fe_3O_4, Fe_2O_3, Co_3O_4, Cr_2O_3, MoO_2 and WO_3 microspheres were obtained. • A methodology to synthesize different metal oxides microspheres was developed.

Utility of Quantitative 99mTc-MAA SPECT/CT for 90yttrium-Labelled Microsphere Treatment Planning: Calculating Vascularized Hepatic Volume and Dosimetric Approach

Science.gov (United States)

Garin, Etienne; Rolland, Yan; Lenoir, Laurence; Pracht, Marc; Mesbah, Habiba; Porée, Philippe; Laffont, Sophie; Clement, Bruno; Raoul, Jean-Luc; Boucher, Eveline

2011-01-01

Objectives. The aim of this study was to assess the effectiveness of SPECT/CT for volume measurements and to report a case illustrating the major impact of SPECT/CT in calculating the vascularized liver volume and dosimetry prior to injecting radiolabelled yttrium-90 microspheres (Therasphere). Materials and Methods. This was a phantom study, involving volume measurements carried out by two operators using SPECT and SPECT/CT images. The percentage of error for each method was calculated, and interobserver reproducibility was evaluated. A treatment using Therasphere was planned in a patient with three hepatic arteries, and the quantitative analysis of SPECT/CT for this patient is provided. Results. SPECT/CT volume measurements proved to be accurate (mean error Therasphere used. Conclusions. MAA SPECT/CT is accurate for vascularized liver volume measurements, providing a valuable contribution to the therapeutic planning of patients with complex hepatic vascularization. PMID:21822489

Magnetic susceptibility characterisation of superparamagnetic microspheres

Science.gov (United States)

Grob, David Tim; Wise, Naomi; Oduwole, Olayinka; Sheard, Steve

2018-04-01

The separation of magnetic materials in microsystems using magnetophoresis has increased in popularity. The wide variety and availability of magnetic beads has fuelled this drive. It is important to know the magnetic characteristics of the microspheres in order to accurately use them in separation processes integrated on a lab-on-a-chip device. To investigate the magnetic susceptibility of magnetic microspheres, the magnetic responsiveness of three types of Dynabeads microspheres were tested using two different approaches. The magnetophoretic mobility of individual microspheres is studied using a particle tracking system and the magnetization of each type of Dynabeads microsphere is measured using SQUID relaxometry. The magnetic beads' susceptibility is obtained at four different applied magnetic fields in the range of 38-70 mT for both the mobility and SQUID measurements. The susceptibility values in both approaches show a consistent magnetic field dependence.

Radiolabeling optimization and reduced staff radiation exposure for high-dose 90Y-ibritumomab tiuxetan (HD-Zevalin)

International Nuclear Information System (INIS)

Papi, Stefano; Martano, Luigi; Garaboldi, Lucia; Rossi, Annalisa; Cremonesi, Marta; Grana, Chiara Maria; Paolucci, Daniele; Sansovini, Maddalena; Paganelli, Giovanni; Chinol, Marco

2010-01-01

Introduction: 90 Y-Zevalin labeling may cause severe finger radiation exposure, especially in high-dose protocols (HD-Zevalin), where up to 7.4 GBq could be injected. In this work, we optimized the labeling of HD-Zevalin with special regard to simplicity, speed, safety and radiation protection. Methods: Factors influencing labeling outcome (activity, specific activity, time, final volume, stability) were studied separately. The critical steps of a standard radiolabeling procedure were optimized to reduce finger exposure, developing an alternative labeling procedure and including a different 90 Y supplier. Finger doses were monitored by thermoluminescent dosimeters at each fingertip under anti-X gloves, considering both absolute values and values after normalization to 1.48 GBq. Results: Labeling of 90 Y-Zevalin was safe and reproducible up to 7.4 GBq with a simple and single-step procedure offering good stability for several hours. Radiolabeling specific activity was found critical, being kept at 740 MBq.mg -1 . Radiochemical purity values ≥98% were routinely achieved. The alternative procedure allowed a sensible reduction of finger dose, due to both the different 90 Y vial and the handling. Finger exposure was reduced from 6.6±4.3 to 3.1±0.8 mSv/1.48 GBq in the case of the original 90 Y vial and from 1.5±0.9 to 0.3±0.1 mSv/1.48 GBq using a shielded 90 Y vial. Conclusions: HD-Zevalin can be prepared in a safe and reproducible way, giving high radiochemical purity values, good stability and low finger exposure. This study may improve the safety of nuclear medicine professionals involved in the preparation of Zevalin.

Method for sizing hollow microspheres

Science.gov (United States)

Farnum, E.H.; Fries, R.J.

1975-10-29

Hollow Microspheres may be effectively sized by placing them beneath a screen stack completely immersed in an ultrasonic bath containing a liquid having a density at which the microspheres float and ultrasonically agitating the bath.

Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus 90Y-radioembolization for hepatocellular carcinoma

International Nuclear Information System (INIS)

Ludwig, Johannes M.; Xing, Minzhi; Zhang, Di; Kim, Hyun S.

2017-01-01

To investigate comparative effectiveness of drug-eluting bead transarterial chemoembolization (DEB-TACE) versus Yttrium-90 ( 90 Y)-radioembolization for hepatocellular carcinoma (HCC). Studies comparing conventional (c)TACE versus 90 Y-radioembolization or DEB-TACE for HCC treatment were identified using PubMed/Medline, Embase, and Cochrane databases. The adjusted indirect meta-analytic method for effectiveness comparison of DEB-TACE versus 90 Y-radioembolization was used. Wilcoxon rank-sum test was used to compare baseline characteristics. A priori defined sensitivity analysis of stratified study subgroups was performed for primary outcome analyses. Publication bias was tested by Egger's and Begg's tests. Fourteen studies comparing DEB-TACE or 90 Y-radioembolization with cTACE were included. Analysis revealed a 1-year overall survival benefit for DEB-TACE over 90 Y-radioembolization (79 % vs. 54.8 %; OR: 0.57; 95 %CI: 0.355-0.915; p = 0.02; I-squared: 0 %; p > 0.5), but not for the 2-year (61 % vs. 34 %; OR: 0.65; 95%CI: 0.294-1.437; p = 0.29) and 3-year survival (56.4 % vs. 20.9 %; OR: 0.713; 95 % CI: 0.21-2.548; p = 0.62). There was significant heterogeneity in the 2- and 3-year survival analyses. The pooled median overall survival was longer for DEB-TACE (22.6 vs. 14.7 months). There was no significant difference in tumour response rate. DEB-TACE and 90 Y-radioembolization are efficacious treatments for patients suffering from HCC; DEB-TACE demonstrated survival benefit at 1-year compared to 90 Y-radioembolization but direct comparison is warranted for further evaluation. (orig.)

Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model.

Directory of Open Access Journals (Sweden)

Johnnie J Orozco

Full Text Available Radioimmunotherapy (RIT for treatment of hematologic malignancies has primarily employed monoclonal antibodies (Ab labeled with 131I or 90Y which have limitations, and alternative radionuclides are needed to facilitate wider adoption of RIT. We therefore compared the relative therapeutic efficacy and toxicity of anti-CD45 RIT employing 90Y and 177Lu in a syngeneic, disseminated murine myeloid leukemia (B6SJLF1/J model. Biodistribution studies showed that both 90Y- and 177Lu-anti-murine CD45 Ab conjugates (DOTA-30F11 targeted hematologic tissues, as at 24 hours 48.8 ± 21.2 and 156 ± 14.6% injected dose per gram of tissue (% ID/g of 90Y-DOTA-30F11 and 54.2 ± 9.5 and 199 ± 11.7% ID/g of 177Lu-DOTA-30F11 accumulated in bone marrow (BM and spleen, respectively. However, 90Y-DOTA-30F11 RIT demonstrated a dose-dependent survival benefit: 60% of mice treated with 300 µCi 90Y-DOTA-30F11 lived over 180 days after therapy, and mice treated with 100 µCi 90Y-DOTA-30F11 had a median survival 66 days. 90Y-anti-CD45 RIT was associated with transient, mild myelotoxicity without hepatic or renal toxicity. Conversely, 177Lu- anti-CD45 RIT yielded no long-term survivors. Thus, 90Y was more effective than 177Lu for anti-CD45 RIT of AML in this murine leukemia model.

In vitro evaluation of biodegradable microspheres with surface-bound ligands.

Science.gov (United States)

Keegan, Mark E; Royce, Sara M; Fahmy, Tarek; Saltzman, W Mark

2006-02-21

Protein ligands were conjugated to the surface of biodegradable microspheres. These microsphere-ligand conjugates were then used in two in vitro model systems to evaluate the effect of conjugated ligands on microsphere behavior. Microsphere retention in agarose columns was increased by ligands on the microsphere surface specific for receptors on the agarose matrix. In another experiment, conjugating the lectin Ulex europaeus agglutinin 1 to the microsphere surface increased microsphere adhesion to Caco-2 monolayers compared to control microspheres. This increase in microsphere adhesion was negated by co-administration of l-fucose, indicating that the increase in adhesion is due to specific interaction of the ligand with carbohydrate receptors on the cell surface. These results demonstrate that the ligands conjugated to the microspheres maintain their receptor binding activity and are present on the microsphere surface at a density sufficient to target the microspheres to both monolayers and three-dimensional matrices bearing complementary receptors.

Evaluation of a pyrex glass shield for the dose reduction in extremities to manipulate a 90 Sr- 90 Y generator

International Nuclear Information System (INIS)

Ayra P, F.E.; Xiques C, A.; Torres B, M.B.

2006-01-01

The production of Y-90 of high activity it specifies (free of payee) for their use in radioimmunotherapy uses the Strontium 90 as isotope source. Depending on the method employee for the separation of both isotopes several types of generators are described in different bibliographies. The column generator used in the facilities of the Center of Isotopes requires of a frequent manipulation causing significant dose in the skin of the extremities due to the exhibition to the radiation beta of high energy. The properties of the shieldings for this radiation type have been well studied Y they consist in several publications. To be in correspondence with requirements of radiological protection in the Cuban legislation, the column was covered with a tube of glass pyrex of 5 mm of thickness and it was monitored the exposure with an ionization chamber. At the own time, the shielding using the Monte Carlo method was evaluated. It was used the MCNP 4C code to simulate the absorption of the beta particles generated in the process of disintegration of the Sr-90 and Y-90 in the glass shielding. The column generator and the fluence of beta particles were modeled in different points inside the shielding to determine if the experimentally measured values correspond to electrons that were not absorbed or to the weak stopping radiation generated in the glass due to the deceleration of these particles. A cylinder of 4 mm of diameter simulates the source (it dilutes) and a tube of walls of 6 mm of thickness simulates the shielding more the wall of the column around the generator. This it was divided in cells of 1 mm of thickness and the energy deposited in them was evaluated. The results show that all the electrons generated in the source are absorbed in the shielding and the exposure rates decrease in more of 78 times using the 5 mm of pyrex glass. The doses in extremities to the operators of the generator don't surpass the 70 mSv by year that is the dose restriction imposed in the

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.

Science.gov (United States)

Vilgrain, Valérie; Pereira, Helena; Assenat, Eric; Guiu, Boris; Ilonca, Alina Diana; Pageaux, Georges-Philippe; Sibert, Annie; Bouattour, Mohamed; Lebtahi, Rachida; Allaham, Wassim; Barraud, Hélène; Laurent, Valérie; Mathias, Elodie; Bronowicki, Jean-Pierre; Tasu, Jean-Pierre; Perdrisot, Rémy; Silvain, Christine; Gerolami, René; Mundler, Olivier; Seitz, Jean-Francois; Vidal, Vincent; Aubé, Christophe; Oberti, Frédéric; Couturier, Olivier; Brenot-Rossi, Isabelle; Raoul, Jean-Luc; Sarran, Anthony; Costentin, Charlotte; Itti, Emmanuel; Luciani, Alain; Adam, René; Lewin, Maïté; Samuel, Didier; Ronot, Maxime; Dinut, Aurelia; Castera, Laurent; Chatellier, Gilles

2017-12-01

Sorafenib is the recommended treatment for patients with advanced hepatocellular carcinoma. We aimed to compare the efficacy and safety of sorafenib to that of selective internal radiotherapy (SIRT) with yttrium-90 ( 90 Y) resin microspheres in patients with hepatocellular carcinoma. SARAH was a multicentre, open-label, randomised, controlled, investigator-initiated, phase 3 trial done at 25 centres specialising in liver diseases in France. Patients were eligible if they were aged at least 18 years with a life expectancy greater than 3 months, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, Child-Pugh liver function class A or B score of 7 or lower, and locally advanced hepatocellular carcinoma (Barcelona Clinic Liver Cancer [BCLC] stage C), or new hepatocellular carcinoma not eligible for surgical resection, liver transplantation, or thermal ablation after a previously cured hepatocellular carcinoma (cured by surgery or thermoablative therapy), or hepatocellular carcinoma with two unsuccessful rounds of transarterial chemoembolisation. Patients were randomly assigned (1:1) by a permutated block method with block sizes two and four to receive continuous oral sorafenib (400 mg twice daily) or SIRT with 90 Y-loaded resin microspheres 2-5 weeks after randomisation. Patients were stratified according to randomising centre, ECOG performance status, previous transarterial chemoembolisation, and presence of macroscopic vascular invasion. The primary endpoint was overall survival. Analyses were done on the intention-to-treat population; safety was assessed in all patients who received at least one dose of sorafenib or underwent at least one of the SIRT work-up exams. This study has been completed and the final results are reported here. The trial is registered with ClinicalTrials.gov, number NCT01482442. Between Dec 5, 2011, and March 12, 2015, 467 patients were randomly assigned; after eight patients withdrew consent, 237 were assigned to

Measurement of blood flow through surgical anastomosis using the radioactive microsphere technique

Energy Technology Data Exchange (ETDEWEB)

Hummel, S.J.; Delgado, G.; Butterfield, A.; Dritschilo, A.; Harbert, J.

1985-10-01

Two different radioactive microspheres ( U Ce and UWSc) were used to measure blood flow to an area of the large intestine in dogs before and after a surgical resection was performed with surgical staples. The healing of an anastomosis is theoretically related to the blood flow to the anastomotic site. Blood flow studies were conducted in three dogs using this technique. The average blood flow preoperatively was 0.558 mL/minute per gram and 1.04 mL/minute per gram postoperatively. These results indicate a statistically significant increase in blood flow at the anastomotic site six days after anastomosis when compared with the blood flow to the same area before any surgical procedures.

Measurement of blood flow through surgical anastomosis using the radioactive microsphere technique

International Nuclear Information System (INIS)

Hummel, S.J.; Delgado, G.; Butterfield, A.; Dritschilo, A.; Harbert, J.

1985-01-01

Two different radioactive microspheres ( 141 Ce and 46 Sc) were used to measure blood flow to an area of the large intestine in dogs before and after a surgical resection was performed with surgical staples. The healing of an anastomosis is theoretically related to the blood flow to the anastomotic site. Blood flow studies were conducted in three dogs using this technique. The average blood flow preoperatively was 0.558 mL/minute per gram and 1.04 mL/minute per gram postoperatively. These results indicate a statistically significant increase in blood flow at the anastomotic site six days after anastomosis when compared with the blood flow to the same area before any surgical procedures

Two-stage supported liquid membrane method for the separation of carrier-free {sup 90}Y from {sup 90}Sr using KSM-17 and CMPO as carriers

Energy Technology Data Exchange (ETDEWEB)

Dhami, P S; Naik, P W; Dudwadkar, N L; Kannan, R; Achuthan, P V; Dakshinamoorthy, A; Jambunathan, U; Munshi, S K; Dey, P K [Fuel Reprocessing Division, Bhabha Atomic Research Centre, Mumbai (India); Pandey, Usha; Venkatesh, Meera [Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai (India)

2007-07-01

A two stage supported liquid membrane system is developed for the separation of carrier free {sup 90}Y from {sup 90}Sr for therapeutic applications. The feed containing {sup 90}Sr-{sup 90}Y in nitric acid solution at pH 2 is placed in the feed compartment and transported across a polytetrafluoroethylene membrane containing 2-ethyhexyl2ethylhexyl phosphonic acid to a 4M HNO{sub 3} receiver phase. This is then transported across another polytetrafluoroethylene membrane containing octyl phenyl N,N-diisobutylcarbamoyl methylphosphene oxide to another receiving phase, 1 M acetic acid. This has been implemented on simultaneous and sequential modes with very good yield. The second stage will act as a barrier for {sup 90}Sr, and will improve the product purity. (author)

Intestinal absorption of PLAGA microspheres in the rat.

Science.gov (United States)

Damgé, C; Aprahamian, M; Marchais, H; Benoit, J P; Pinget, M

1996-12-01

Rhodamine B-labelled poly (DL-lactide-co-glycolide) (PLAGA) microspheres of 2 different sizes, 1-5 microns and 5-10 microns, were administered as a single dose (1.44 x 10(9) and 1.83 x 10(8) particles, respectively) into the ileal lumen of adult rats. The content of rhodamine in the mesenteric vein and ileal lumen was analysed periodically from 10 min to 48 h as well as the distribution of microspheres in the intestinal mucosa and various other tissues. The concentration of rhodamine decreased progressively in the intestinal lumen and was negligible after 24 h. The number of microspheres in the mesenteric vein increased rapidly and reached a maximum after 4 h whatever the size of the particles. It then decreased progressively, but more rapidly with microspheres > 5 microns than with microspheres PLAGA microspheres mainly crossed the intestinal mucosa at the site of Peyer's patches where microspheres of 5 microns were retained in the ileal lumen. A few small microspheres were occasionally observed in the epithelial cells. Only the smallest particles were recovered in the liver, lymph nodes and spleen while basement membranes were always labelled. It is concluded that PLAGA microspheres could be useful for the oral delivery of antigens if their size is between 1 and 5 microns.

Gastroretentive Floating Microspheres of Silymarin: Preparation and ...

African Journals Online (AJOL)

Methods: Cellulose microspheres – formulated with hydroxylpropyl methylcellulose (HPMC) and ethyl cellulose (EC) – and Eudragit microspheres – formulated with Eudragit® S 100 (ES) and Eudragit® RL (ERL) - were prepared by an emulsion-solvent evaporation method. The floating microspheres were evaluated for flow ...

Time optimization of 90Sr measurements: Sequential measurement of multiple samples during ingrowth of 90Y

International Nuclear Information System (INIS)

Holmgren, Stina; Tovedal, Annika; Björnham, Oscar; Ramebäck, Henrik

2016-01-01

The aim of this paper is to contribute to a more rapid determination of a series of samples containing 90 Sr by making the Cherenkov measurement of the daughter nuclide 90 Y more time efficient. There are many instances when an optimization of the measurement method might be favorable, such as; situations requiring rapid results in order to make urgent decisions or, on the other hand, to maximize the throughput of samples in a limited available time span. In order to minimize the total analysis time, a mathematical model was developed which calculates the time of ingrowth as well as individual measurement times for n samples in a series. This work is focused on the measurement of 90 Y during ingrowth, after an initial chemical separation of strontium, in which it is assumed that no other radioactive strontium isotopes are present. By using a fixed minimum detectable activity (MDA) and iterating the measurement time for each consecutive sample the total analysis time will be less, compared to using the same measurement time for all samples. It was found that by optimization, the total analysis time for 10 samples can be decreased greatly, from 21 h to 6.5 h, when assuming a MDA of 1 Bq/L and at a background count rate of approximately 0.8 cpm. - Highlights: • An approach roughly a factor of three more efficient than an un-optimized method. • The optimization gives a more efficient use of instrument time. • The efficiency increase ranges from a factor of three to 10, for 10 to 40 samples.

Hydrogen transport and storage in engineered glass microspheres

Energy Technology Data Exchange (ETDEWEB)

Rambach, G.D.

1995-02-28

New, high strength glass microspheres filled with pressurized hydrogen exhibit densities which make them attractive for bulk hydrogen storage and transport. The membrane tensile stress at failure for engineered glass microspheres is about 150,000 psi, permitting a three-fold increase in pressure limit and storage capacity above commercial microspheres, which have been studied a decade ago and have been shown to fail at membrane stresses of 50,000 psi. This analysis relating glass microspheres for hydrogen transport with infrastructure and economics, indicate that pressurized microspheres can be economically competitive with other forms of bulk rail and truck transport such as pressurized tube transports and liquid hydrogen trailers. This paper will describe the matching of current glass microspheres with the useful application in commercial hydrogen bulk transport and storage.

Investigation on the influence of metal ion impurities on the complexation behavior of generator produced {sup 90}Y with bifunctional chelators

Energy Technology Data Exchange (ETDEWEB)

Pandey, Usha; Gamre, Naresh; Dash, Ashutosh [Isotope Applications and Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai (India)

2014-05-01

The {sup 90}Sr/ {sup 90}Y generator is the exclusive source of 'no carrier added' {sup 90}Y for targeted therapy. However, the concomitant presence of trace metals diminishes the complexation of {sup 90}Y with bifunctional chelators (BFCs). A systematic investigation was performed to evaluate the influence of trace metals on the complexation of {sup 90}Y (from an electrochemical generator) with BFCs such as p-SCN-Bn-PCTA, p-SCN-Bn-DTPA and p-SCN-Bn-DOTA. Our study indicates that while p-SCN-Bn-DTPA was least affected by most of the trace metals studied, p-SCN-Bn-PCTA was most sensitive to their presence and hence could be the ligand of choice for assessing the chemical purity of generator derived {sup 90}Y. (author)

A data acquisition system for indentification of 90Sr/ 90Y in environmental samples

International Nuclear Information System (INIS)

Medin, G.; Brajnik, D.; Starcic, M.; Stanovnik, A.

1996-01-01

Often, in the stage of research and development of new techniques for detection of ionizing radiation, elaborate electronic systems are required. In this paper, we describe the relatively complex detector and electronic system used for a relatively simple but nevertheless demanding measurement of the beta emitting radionuclides 90 Sr/ 90 Y in environmental samples. The detection limit of 1 Bq in a thin, disc-shaped sample, was obtained by careful elimination of background. Contribution of other radionuclides in the sample, were eliminated or at least considerably reduced by using a silica aerogel as Cherenkov radiator and thin multiwire chamber in coincidence. Cosmic ray signals were reduced by large scintillation counters in anticoincidence. Finally, persisting RF pick-up signals were eliminated by using the signal from a wire antenna and identical MWPC preamplifier and discriminator for a veto to the master coincidence. For each accepted event, both timing and pulse height information was recorded with a personal computer

Characterization of an extrapolation chamber in a 90Sr/90Y beta radiation field

International Nuclear Information System (INIS)

Oramas Polo, I.; Tamayo Garcia, J. A.

2015-01-01

The extrapolation chamber is a parallel plate chamber and variable volume based on the Bragg-Gray theory. It determines in absolute mode, with high accuracy the dose absorbed by the extrapolation of the ionization current measured for a null distance between the electrodes. This camera is used for dosimetry of external beta rays for radiation protection. This paper presents the characterization of an extrapolation chamber in a 90 Sr/ 90 Y beta radiation field. The absorbed dose rate to tissue at a depth of 0.07 mm was calculated and is (0.13206±0.0028) μGy. The extrapolation chamber null depth was determined and its value is 60 μm. The influence of temperature, pressure and humidity on the value of the corrected current was also evaluated. Temperature is the parameter that has more influence on this value and the influence of pressure and the humidity is not very significant. Extrapolation curves were obtained. (Author)

Successful Preoperative Chemoembolization in the Treatment of a Giant Malignant Phyllodes Tumor

Energy Technology Data Exchange (ETDEWEB)

Hashimoto, Kazuki, E-mail: kazkik1980@gmail.com; Mimura, Hidefumi; Arai, Yasunori [St. Marianna University School of Medicine, Department of Radiology (Japan); Doi, Masatomo [St. Marianna University School of Medicine, Department of Pathology (Japan); Kojima, Yasuyuki; Tsugawa, Koichiro [St. Marianna University School of Medicine, Division of Breast and Endocrine Surgery, Department of Surgery (Japan); Nakajima, Yasuo [St. Marianna University School of Medicine, Department of Radiology (Japan)

2016-07-15

The malignant phyllodes tumor is a relatively rare neoplasm and has not previously been a therapeutic target of interventional radiology. Herein, we report a successful case of preoperative chemoembolization of a giant malignant phyllodes tumor. The objective was to achieve sufficient tumor shrinkage before surgery to avoid the requirement for skin grafting after resection. Intra-arterial epirubicin infusion and subsequent embolization with Embosphere Microspheres (BioSphere Medical, Rockland, MA, USA) was undertaken three times over the course of 6 weeks and was well tolerated. The patient underwent surgery without skin grafting. Neither local recurrence nor distant metastasis was observed at 6 months after surgery.

Successful Preoperative Chemoembolization in the Treatment of a Giant Malignant Phyllodes Tumor

International Nuclear Information System (INIS)

Hashimoto, Kazuki; Mimura, Hidefumi; Arai, Yasunori; Doi, Masatomo; Kojima, Yasuyuki; Tsugawa, Koichiro; Nakajima, Yasuo

2016-01-01

The malignant phyllodes tumor is a relatively rare neoplasm and has not previously been a therapeutic target of interventional radiology. Herein, we report a successful case of preoperative chemoembolization of a giant malignant phyllodes tumor. The objective was to achieve sufficient tumor shrinkage before surgery to avoid the requirement for skin grafting after resection. Intra-arterial epirubicin infusion and subsequent embolization with Embosphere Microspheres (BioSphere Medical, Rockland, MA, USA) was undertaken three times over the course of 6 weeks and was well tolerated. The patient underwent surgery without skin grafting. Neither local recurrence nor distant metastasis was observed at 6 months after surgery.

Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus {sup 90}Y-radioembolization for hepatocellular carcinoma

Energy Technology Data Exchange (ETDEWEB)

Ludwig, Johannes M.; Xing, Minzhi [Yale School of Medicine, Division of Interventional Radiology, Department of Radiology and Biomedical Imaging, New Haven, CT (United States); Zhang, Di [University of Pittsburgh Graduate School of Public Health, Department of Biostatistics, Pittsburgh, PA (United States); Kim, Hyun S. [Yale School of Medicine, Division of Interventional Radiology, Department of Radiology and Biomedical Imaging, New Haven, CT (United States); Yale School of Medicine, Yale Cancer Center, New Haven, CT (United States)

2017-05-15

To investigate comparative effectiveness of drug-eluting bead transarterial chemoembolization (DEB-TACE) versus Yttrium-90 ({sup 90}Y)-radioembolization for hepatocellular carcinoma (HCC). Studies comparing conventional (c)TACE versus {sup 90}Y-radioembolization or DEB-TACE for HCC treatment were identified using PubMed/Medline, Embase, and Cochrane databases. The adjusted indirect meta-analytic method for effectiveness comparison of DEB-TACE versus {sup 90}Y-radioembolization was used. Wilcoxon rank-sum test was used to compare baseline characteristics. A priori defined sensitivity analysis of stratified study subgroups was performed for primary outcome analyses. Publication bias was tested by Egger's and Begg's tests. Fourteen studies comparing DEB-TACE or {sup 90}Y-radioembolization with cTACE were included. Analysis revealed a 1-year overall survival benefit for DEB-TACE over {sup 90}Y-radioembolization (79 % vs. 54.8 %; OR: 0.57; 95 %CI: 0.355-0.915; p = 0.02; I-squared: 0 %; p > 0.5), but not for the 2-year (61 % vs. 34 %; OR: 0.65; 95%CI: 0.294-1.437; p = 0.29) and 3-year survival (56.4 % vs. 20.9 %; OR: 0.713; 95 % CI: 0.21-2.548; p = 0.62). There was significant heterogeneity in the 2- and 3-year survival analyses. The pooled median overall survival was longer for DEB-TACE (22.6 vs. 14.7 months). There was no significant difference in tumour response rate. DEB-TACE and {sup 90}Y-radioembolization are efficacious treatments for patients suffering from HCC; DEB-TACE demonstrated survival benefit at 1-year compared to {sup 90}Y-radioembolization but direct comparison is warranted for further evaluation. (orig.)

Efficiency calibration of a liquid scintillation counter for 90Y Cherenkov counting

International Nuclear Information System (INIS)

Vaca, F.; Garcia-Leon, M.

1998-01-01

In this paper a complete and self-consistent method for 90 Sr determination in environmental samples is presented. It is based on the Cherenkov counting of 90 Y with a conventional liquid scintillation counter. The effects of color quenching on the counting efficiency and background are carefully studied. A working curve is presented which allows to quantify the correction in the counting efficiency depending on the color quenching strength. (orig.)

Innovative hydrogen storage in hollow glass-microspheres

Energy Technology Data Exchange (ETDEWEB)

Keding, M.; Schmid, G.; Tajmar, M. [Austrian Research Centers, Vienna (Austria)

2009-07-01

Hydrogen storage technologies are becoming increasingly important for a number of future applications. The Austrian Research Centers (ARC) are developing a unique hydrogen storage system that combines the advantages of both hollow glass microsphere and chemical compound hydrogen storage, but eliminates their respective drawbacks. Water is utilized as a functional liquid to carry the hollow glass microspheres that are loaded with up to 700 bar of hydrogen gas. Sodium borohydride (NaBH{sub 4}) is then injected together with the glass microspheres into a reaction chamber where the water reacts catalytically with the NaBH{sub 4} producing hydrogen and heat. The heat is then utilized to release the hydrogen from the hollow glass microspheres providing a double hydrogen generation process without any external energy or heat during storage or gas release. The paper described this hydrogen storage system with particular reference to microspheres, the coating process, the experimental facility and NaBH{sub 4} test results. It was concluded that hydrogen storage and production on demand is possible with microspheres and sodium borohydride solution. 9 refs., 16 figs.

Country report: Cuba. Local Production of {sup 90}Y And {sup 188}Re Radionuclides and Development of Radiopharmaceuticals for Therapy

Energy Technology Data Exchange (ETDEWEB)

Xiques, Abmel; Hernández, Ignacio; Leyva, René; Pérez, Marylaine; Alonso, Luis Michel; Zamora, Minelys [Centro de Isotopos (CENTIS) (Cuba)

2010-07-01

During the first period of this CRP we could test an efficient and reliable generator system based on ion-chromatography to obtain {sup 90}Y from its parent radionuclide {sup 90}Sr. This production scheme for {sup 90}Y was outlined in the previous CRP related with the development of generator technologies. Quality parameters such as trace metals that can potentially interfere in the labeling of biomoléculas, {sup 90}Y recovery, {sup 90}Sr/{sup 90}Y ratio and radiation dose to bed matrix were evaluated. The results showed that high recovery and radionuclidic purity could be obtained for {sup 90}Y during its repeated separation from the {sup 90}Sr cow. No replacement or treatment of the cow were necessary and low waste generation and {sup 90}Sr losses less that 0.1% after each run were also observed during the present study. A Fab’ fragment was enzimatically produced and purified from the monoclonal antibody h-R3 (Nimotuzumab®). The fragment and the parent antibody were successfully conjugated with DOTA and labeled with {sup 90}Y. The radioinmunoconjugate thus obtained also exhibited a good 24 h in-vitro stability in an excess of DTPA. A {sup 90}Y radiocoloid was prepared in a cromic phosphate particle for radiosynoviorthesis with promising results in animal models. Two alumina based {sup 188}W/{sup 188}Re generators were prepared and their eluates were used in the labeling of hR3-DOTA conjugates. Quality control and in vivo evaluation in comparison with {sup 99m}Tc-hR3 showed very good results and similar pattern of distribution and pharmacokinetic and will be used in clinical trials for cancer patients. (author)

Preparation of microspheres for slow release drug by radiation-induced suspension polymerization and their properties

International Nuclear Information System (INIS)

Yoshida, Masaru; Asano, Masaharu; Kaetsu, Isao

1982-01-01

The polymer microspheres containing drugs as drug delivery system were made by means of suspension-polymerization by radiation at low temperature by using glass-forming monomers which have stable supercooling properties and large polymerizability at low temperature. The particle distribution depended on the kind of monomer. It was found that the entrapping yield of drug in polymer microspheres increased with increasing viscosity of monomer and that the maximum value on the particle size distribution curve was also shifted to large particle diameter side. In the case of trimethylolpropane trimethacrylate monomer (43 cps), TMPT, the entrapping yield of drug reached 74% and the maximum value in particle size distribution curve appeared in the neighborhood of 105 to 210 mu m ranges. On the other hand, those values in neopentyl glycol dimethacrylate monomer (4 cps) were 12% in former and 44 -- 105 mu m in the latter. The release phenomenon of drugs from polymer microspheres was investigated. for example, the cumulative amount of mitomycin C (water soluble drug) released from TMPT polymer microsphere was about 90% after 30-day dissolution, while in the case of water-insoluble drug such as testosterone the amount of release was about 49% after 40-day dissolution. In all cases, the release rate is constant during the experimental period. Therefore, it was concluded that the release of drugs from polymer microspheres obtained in this study is possible over the long periods. (author)

Microsphere estimates of blood flow: Methodological considerations

International Nuclear Information System (INIS)

von Ritter, C.; Hinder, R.A.; Womack, W.; Bauerfeind, P.; Fimmel, C.J.; Kvietys, P.R.; Granger, D.N.; Blum, A.L.

1988-01-01

The microsphere technique is a standard method for measuring blood flow in experimental animals. Sporadic reports have appeared outlining the limitations of this method. In this study the authors have systematically assessed the effect of blood withdrawals for reference sampling, microsphere numbers, and anesthesia on blood flow estimates using radioactive microspheres in dogs. Experiments were performed on 18 conscious and 12 anesthetized dogs. Four blood flow estimates were performed over 120 min using 1 x 10 6 microspheres each time. The effects of excessive numbers of microspheres pentobarbital sodium anesthesia, and replacement of volume loss for reference samples with dextran 70 were assessed. In both conscious and anesthetized dogs a progressive decrease in gastric mucosal blood flow and cardiac output was observed over 120 min. This was also observed in the pancreas in conscious dogs. The major factor responsible for these changes was the volume loss due to the reference sample withdrawals. Replacement of the withdrawn blood with dextran 70 led to stable blood flows to all organs. The injection of excessive numbers of microspheres did not modify hemodynamics to a greater extent than did the injection of 4 million microspheres. Anesthesia exerted no influence on blood flow other than raising coronary flow. The authors conclude that although blood flow to the gastric mucosa and the pancreas is sensitive to the minor hemodynamic changes associated with the microsphere technique, replacement of volume loss for reference samples ensures stable blood flow to all organs over a 120-min period

Microsphere based improved sunscreen formulation of ethylhexyl methoxycinnamate.

Science.gov (United States)

Gogna, Deepak; Jain, Sunil K; Yadav, Awesh K; Agrawal, G P

2007-04-01

Polymethylmethacrylate (PMMA) microspheres of ethylhexyl methoxycinnamate (EHM) were prepared by emulsion solvent evaporation method to improve its photostability and effectiveness as sunscreening agent. Process parameters like stirring speed and aqueous polyvinyl alcohol (PVA) concentration were analyzed in order to optimize the formulations. Shape and surface morphology of the microspheres were examined using scanning electron microscopy. Particle size of the microspheres was determined using laser diffraction particle size analyzer. The PMMA microspheres of EHM were incorporated in water-removable cream base. The in vitro drug release of EHM in pH 7.4 was performed using dialysis membrane. Thin layer chromatography was performed to determine photostability of EHM inside the microspheres. The formulations were evaluated for sun protection factor (SPF) and minimum erythema dose (MED) in albino rats. Cream base formulation containing microspheres prepared using EHM:PMMA in ratio of 1:3 (C(3)) showed slowest drug (EHM) release and those prepared with EHM: PMMA in ratio of 1:1 showed fastest release. The cream base formulations containing EHM loaded microspheres had shown better SPF (more than 16.0) as compared to formulation C(d) that contained 3% free EHM as sunscreen agent and showed SPF 4.66. These studies revealed that the incorporation of EHM loaded PMMA microspheres into cream base had greatly increased the efficacy of sunscreen formulation approximately four times. Further, photostability was also shown to be improved in PMMA microspheres.

Preparation and Characterization of Sugar Cane Wax Microspheres ...

African Journals Online (AJOL)

... and characterize indomethacin (IM) microspheres prepared with sugar cane wax microsperes. Methods: Microspheres were prepared by melt-emulsified dispersion and cooling-induced solidification method. The microspheres were characterized by scanning electron microscopy (SEM) and differntial scanning calorimetry ...

Preparation of mesoporous zirconia microspheres as inert matrix

Energy Technology Data Exchange (ETDEWEB)

Guo, Ting [State Key Laboratory of New Ceramics and Fine Processing, Institute of Nuclear and New Energy Technology, Tsinghua University, Beijing, 100084 (China); Wang, Chen; Lv, Jinlong [Beijing Key Laboratory of Fine Ceramics, Institute of Nuclear and New Energy Technology, Tsinghua University, Beijing, 100084 (China); Liang, Tongxiang, E-mail: txliang@tsinghua.edu.cn [State Key Laboratory of New Ceramics and Fine Processing, Institute of Nuclear and New Energy Technology, Tsinghua University, Beijing, 100084 (China)

2016-12-01

Mesoporous zirconia microspheres, with a diameter of 900 μm, were prepared as an inert accelerator driven system (ADS) transmutation element matrix by the sol-gel method. The purpose of mesopores is to improve the adsorption capacity of inert matrix fuel (IMF) for minor actinides. The study indicated that the mesoporous zirconia performance was improved after the microspheres were hydrothermally treated at 150 °C, the specific surface area increased from 28.29 m{sup 2}/g to 61.28 m{sup 2}/g, and hydrothermal treatment avoided the cracking of the microspheres. Pre-decomposition of the organics during the hydrothermal process stabilized the mesoporous structure. The average pore diameter of mesoporous microsphere was 14.3 nm. - Highlights: • Mesoporous zirconia microspheres with a diameter of 900 μm were prepared as ADS transmutation element inert matrix. • The mesoporous performance was improved after the microspheres were hydrothermally treated at 150 °C. • The specific surface area increased from 28.29 m{sup 2}/g to 61.28 m{sup 2}/g. • The hydrothermal treatment could avoid the cracking of the microspheres. • The specific surface area of mesoporous microsphere was 61.28 m{sup 2}/g and the average pore diameter was 14.3 nm.

Insulin delivery through nasal route using thiolated microspheres.

Science.gov (United States)

Nema, Tarang; Jain, Ashish; Jain, Aviral; Shilpi, Satish; Gulbake, Arvind; Hurkat, Pooja; Jain, Sanjay K

2013-01-01

The aim of the present study was to investigate the potential of developed thiolated microspheres for insulin delivery through nasal route. In the present study, cysteine was immobilized on carbopol using EDAC. A total of 269.93 µmol free thiol groups per gram polymer were determined. The prepared nonthiolated and thiolated microspheres were studied for particle shape, size, drug content, swellability, mucoadhesion and in vitro insulin release. The thiolated microspheres exhibited higher mucoadhesion due to formation of covalent bonds via disulfide bridges with the mucus gel layer. Drug permeation through goat nasal mucosa of nonthiolated and thiolated microspheres were found as 52.62 ± 2.4% and 78.85 ± 3.1% in 6 h, respectively. Thiolated microspheres bearing insulin showed better reduction in blood glucose level (BGL) in comparison to nonthiolated microspheres as 31.23 ± 2.12% and 75.25 ± 0.93% blood glucose of initial BGL were observed at 6 h after nasal delivery of thiolated and nonthiolated microspheres in streptozotocin-induced diabetic rabbits.

Current knowledge on biodegradable microspheres in drug delivery.

Science.gov (United States)

Prajapati, Vipul D; Jani, Girish K; Kapadia, Jinita R

2015-08-01

Biodegradable microspheres have gained popularity for delivering a wide variety of molecules via various routes. These types of products have been prepared using various natural and synthetic biodegradable polymers through suitable techniques for desired delivery of various challenging molecules. Selection of biodegradable polymers and technique play a key role in desired drug delivery. This review describes an overview of the fundamental knowledge and status of biodegradable microspheres in effective delivery of various molecules via desired routes with consideration of outlines of various compendial and non-compendial biodegradable polymers, formulation techniques and release mechanism of microspheres, patents and commercial biodegradable microspheres. There are various advantages of using biodegradable polymers including promise of development with different types of molecules. Biocompatibility, low dosage and reduced side effects are some reasons why usage biodegradable microspheres have gained in popularity. Selection of biodegradable polymers and formulation techniques to create microspheres is the biggest challenge in research. In the near future, biodegradable microspheres will become the eco-friendly product for drug delivery of various genes, hormones, proteins and peptides at specific site of body for desired periods of time.

Optimization of preparation method for ketoprofen-loaded microspheres consisting polymeric blends using simplex lattice mixture design

Energy Technology Data Exchange (ETDEWEB)

Das, Sanjoy Kumar, E-mail: sanjoydasju@gmail.com; Khanam, Jasmina; Nanda, Arunabha

2016-12-01

In the present investigation, simplex lattice mixture design was applied for formulation development and optimization of a controlled release dosage form of ketoprofen microspheres consisting polymers like ethylcellulose and Eudragit{sup ®}RL 100; when those were formed by oil-in-oil emulsion solvent evaporation method. The investigation was carried out to observe the effects of polymer amount, stirring speed and emulsifier concentration (% w/w) on percentage yield, average particle size, drug entrapment efficiency and in vitro drug release in 8 h from the microspheres. Analysis of variance (ANOVA) was used to estimate the significance of the models. Based on the desirability function approach numerical optimization was carried out. Optimized formulation (KTF-O) showed close match between actual and predicted responses with desirability factor 0.811. No adverse reaction between drug and polymers were observed on the basis of Fourier transform infrared (FTIR) spectroscopy and Differential scanning calorimetric (DSC) analysis. Scanning electron microscopy (SEM) was carried out to show discreteness of microspheres (149.2 ± 1.25 μm) and their surface conditions during pre and post dissolution operations. The drug release pattern from KTF-O was best explained by Korsmeyer-Peppas and Higuchi models. The batch of optimized microspheres were found with maximum entrapment (~ 90%), minimum loss (~ 10%) and prolonged drug release for 8 h (91.25%) which may be considered as favourable criteria of controlled release dosage form. - Graphical abstract: Optimization of preparation method for ketoprofen-loaded microspheres consisting polymeric blends using simplex lattice mixture design. - Highlights: • Simplex lattice design was used to optimize ketoprofen-loaded microspheres. • Polymeric blend (Ethylcellulose and Eudragit® RL 100) was used. • Microspheres were prepared by oil-in-oil emulsion solvent evaporation method. • Optimized formulation depicted favourable

Hydrogen transport and storage in engineered glass microspheres

Energy Technology Data Exchange (ETDEWEB)

Rambach, G.D.

1995-04-18

New, high strength glass microspheres filled with pressurized hydrogen exhibit densities which make them attractive for bulk hydrogen storage and transport. The membrane tensile stress at failure for our engineered glass microspheres is about 150,000 psi, permitting a threefold increase in pressure limit and storage capacity above commercial microspheres, which have been studied a decade ago and have been shown to fail at membrane stresses of 50,000 psi. Our analysis relating glass microspheres for hydrogen transport with infrastructure and economics, indicate that pressurized microspheres can be economically competitive with other forms of bulk rail and truck transport such as pressurized tube transports and liquid hydrogen trailers.

Evaluation of radiolabelled microspheres as digesta markers

International Nuclear Information System (INIS)

Young, B.A.; Turner, B.V.; Dixon, A.E.; Exley, D.M.; Young, S.B.; Abidin, Z.

1991-01-01

The suitability of microspheres as markers for measuring digesta kinetics in sheep was examined. Microspheres offer advantages of uniformity of size and density, and stability during passage through the gastrointestinal tract. They are commercially available labelled with the choice of one of eleven different radionuclides and can be easily measured in digesta and faecal material. Tests comparing several types of digesta markers gave different measures of kinetic parameters when the measurements were made concurrently in the same sheep. However, concurrent measurements derived from use of microspheres were consistent. Microspheres offer a new alternative for digestive studies. (author). 19 refs, 4 tabs

Glass microspheres for brachytherapy

International Nuclear Information System (INIS)

Prado, Miguel O.; Prastalo, Simon; Blaumann, Herman; Longhino, Juan M.; Repetto Llamazares, A.H.V.

2007-01-01

We developed the capacity to produce glass microspheres containing in their structure one or more radioactive isotopes useful for brachytherapy. We studied the various facts related with their production: (Rare earth) alumino silicate glass making, glass characterization, microspheres production, nuclear activation through (n,γ) nuclear reactions, mechanical characterization before and after irradiation. Corrosion tests in simulated human plasma and mechanical properties characterization were done before and after irradiation. (author) [es

Toxicity of inhaled 90Y in fused clay particles in beagle dogs. VI

International Nuclear Information System (INIS)

Hobbs, C.H.; Chiffelle, T.L.; Hahn, F.F.; Jones, R.K.; Mauderly, J.L.; McClellan, R.O.; Pickrell, J.A.

1974-01-01

Studies on the metabolism, dosimetry, and effects of inhaled 90 Y in fused clay in the Beagle dog are being continued to assess the consequences of inhalation of an energetic beta emitter that has a short effective half-life in the lung. A radiation dose pattern study in which 12 dogs were sacrificed in pairs at 0, 2, 4, 6, 8, and 12 days post-inhalation exposure has been completed. A longevity study in which 89 dogs have been exposed to 90 Y fused clay with initial lung burdens ranging from 80 to 5200 μCi/kg body weight and 12 control dogs were exposed to stable yttrium in fused clay is in progress. The 90 Y was retained in lung with a half-life similar to its physical half-life (64 hours) and with only small quantities translocated to tracheobronchial lymph nodes, skeleton, and liver. The infinite radiation doses to lung, tracheobronchial lymph nodes, skeleton, and liver for an initial lung burden of 100 μCi 90 Y/kg of body weight were estimated to be 1600, 170, 0.54, and 0.38 rads, respectively. Thirty-eight of 39 dogs with doses to lung from 9300 to 70,000 rads have died at 7.5 to 903 days post-exposure. The one surviving dog in this dose range has radiographic evidence of pulmonary fibrosis at 1316 days post-exposure. All the dogs that died had radiation pneumonitis. The dog that died at 903 days post-exposure with a dose to lung of 11,000 rads also had 2 small pulmonary adenomas. Fifty exposed dogs with doses to lung of 1300 to 7900 rads are surviving with no significant abnormalities at 1278 to 1834 days post-exposure and will be studied for the remainder of their lifespan. (U.S.)